|
IperionX Limited is a U.S.-based titanium metal and critical minerals company that develops and operates an integrated supply chain for titanium production. The company produces titanium powder, mill products, and near-net-shape components using proprietary technologies, including Hydrogen Assisted Metallothermic Reduction (HAMR), Granulation Sintering Deoxygenation, and Hydrogen Sintering and Phase Transformation. Its operations are centered on the Titanium Manufacturing Campus in Virginia, the Industrial Pilot Facility in Utah, and the Atlas-Titan platform in Tennessee, which includes the Titan critical minerals project. IperionX serves advanced industries such as aerospace, defense, consumer electronics, automotive, medical, and additive manufacturing. The company holds exclusive global licenses to its titanium and metal alloy production technologies and establishes a domestic U.S. supply chain from recycled scrap and mineral feedstocks. Summarised from the company's own disclosures, fiscal year ended Jun 2026 |
Industry Materials | Homepage iperionx.com |
| Sector Basic Materials | IR page iperionx.com/investor-center | |
|
Tags
titanium production, critical minerals, metal recycling, powder metallurgy, additive manufacturing, rare earths, zircon, defense materials, aerospace materials, sustainable manufacturing, HAMR, Granulation Sintering Deoxygenation, Hydrogen Sintering and Phase Transformation, Alkaline Roasting and Hydrolysis, Titanium Manufacturing Campus, Atlas-Titan, Industrial Pilot Facility, Titan, Atlas, Advanced Manufacturing Center, Titanium Production Facility, SACMI press, GenX, THRM
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | A$ 5.708B |
| Market cap (USD) | $ 3.843B |
| P/E | -8.41 |
| PEG | — |
| P/BV | 64.65 |
| P/S | — |
| P/OCF | -126.98 |
| P/FCF | -90.99 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -73.9% |
| ROI | -72.7% |
| ROIC | -72.7% |
| Profit margin | — |
| Growth | |
|---|---|
| Revenue growing | — |
| Profits growing | No |
| Revenue up 3y | — |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | — |
| Buying back stock | No |
| Diluting (TTM) | — |
| Debt/Equity | 4.0% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 65 |
| Quality score | -72.7% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
Podcast Mentions
Material events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Announcements lodged with ASX, newest first, routine forms (director and substantial-holding notices, daily buy-back and quotation notices) included. The link opens the announcement on ASX. Press releases from the company's own website, newest first.
Appendix 2A - Application for quotation of securities
Announcement Summary
Entity name IPERIONX LIMITED Announcement Type New announcement Date of this announcement Thursday November 05, 2026 The +securities to be quoted are: +Securities issued, transferred or re-classified as a result of options being exercised or other +convertible securities being converted Total number of +securities to be quoted ASX +security code
Security description
IPX
ORDINARY FULLY PAID
Number of +securities to be quoted
Issue date
63,377
05/11/2026
Refer to next page for full details of the announcement
Appendix 2A - Application for quotation of securities
1/8
Appendix 2A - Application for quotation of securities
Part 1 - Entity and announcement details
1.1 Name of entity IPERIONX LIMITED We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules. 1.2 Registered number type
Registration number
ABN
84618935372
1.3 ASX issuer code IPX 1.4 The announcement is New announcement 1.5 Date of this announcement 5/11/2026
Appendix 2A - Application for quotation of securities
2/8
Appendix 2A - Application for quotation of securities
Part 2 - Type of Issue
2.1 The +securities to be quoted are: +Securities issued, transferred or re-classified as a result of options being exercised or other +convertible securities being converted 2.2 The +class of +securities to be quoted is: Additional +securities in a class that is already quoted on ASX ("existing class")
Appendix 2A - Application for quotation of securities
3/8
Appendix 2A - Application for quotation of securities
Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B
Existing +securities converting into additional +securities in an existing class FROM (Existing Class) ASX +security code and description IPXAP : RESTRICTED STOCK UNITS
TO (Existing Class) ASX +security code and description IPX : ORDINARY FULLY PAID Please state the number of options that were exercised or other +convertible securities that were converted
The first date the options were exercised or other +convertible securities were converted
The last date the options were exercised or other +convertible securities were converted
4/11/2026
4/11/2026
48,377 Is this all of the options or other +convertible securities on issue of that type (ie have all of those options now been exercised or have all of those convertible securities now been converted)? No The right of the holder of the options or other +convertible securities to receive the +underlying securities is being satisfied by: An issue of new +securities The underlying +securities being received by the holder are: Intended to be, but are not yet, quoted by ASX Were the options being exercised or other +convertible securities being converted issued under an +employee incentive scheme? No
Issue date 5/11/2026 Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class? Yes
Appendix 2A - Application for quotation of securities
4/8
Appendix 2A - Application for quotation of securities Issue details
Number of +securities to be quoted 48,377 Are the +securities being issued for a cash consideration? No Please describe the consideration being provided for the +securities Conversion of RSUs upon satisfaction of relevant service condition Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted 2.190000 Any other information the entity wishes to provide about the +securities to be quoted
Existing +securities converting into additional +securities in an existing class FROM (Existing Class) ASX +security code and description IPXAW : PERFORMANCE RIGHTS EXPIRING 31-DEC-2026
TO (Existing Class) ASX +security code and description IPX : ORDINARY FULLY PAID Please state the number of options that were exercised or other +convertible securities that were converted
The first date the options were exercised or other +convertible securities were converted
The last date the options were exercised or other +convertible securities were converted
4/11/2026
4/11/2026
15,000 Is this all of the options or other +convertible securities on issue of that type (ie have all of those options now been exercised or have all of those convertible securities now been converted)? No The right of the holder of the options or other +convertible securities to receive the +underlying securities is being satisfied by: An issue of new +securities The underlying +securities being received by the holder are: Intended to be, but are not yet, quoted by ASX Were the options being exercised or other +convertible securities being converted issued under an +employee incentive scheme? No
Issue date 5/11/2026 Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class? Yes
Appendix 2A - Application for quotation of securities
5/8
Appendix 2A - Application for quotation of securities Issue details
Number of +securities to be quoted 15,000 Are the +securities being issued for a cash consideration? No Please describe the consideration being provided for the +securities Conversion of performance rights upon satisfaction of relevant performance condition Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted 2.190000 Any other information the entity wishes to provide about the +securities to be quoted
Appendix 2A - Application for quotation of securities
6/8
Appendix 2A - Application for quotation of securities
Part 4 - Issued capital following quotation
Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise: The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing. 4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application) ASX +security code and description
Total number of +securities on issue
IPX : ORDINARY FULLY PAID
362,303,540
4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX) ASX +security code and description
Total number of +securities on issue
IPXAB : OPTION EXPIRING 02-APR-2030 EX $11.00
511,972
IPXAC : OPTION EXPIRING 02-APR-2031 EX $18.00
1,566,690
IPXAD : OPTION EXPIRING 02-APR-2031 EX $22.00
1,773,209
IPXAE : PERFORMANCE RIGHTS EXPIRING 02-APR-2031
660,077
IPXAF : OPTION EXPIRING 05-AUG-2030 EX $11.00
947,062
IPXAAC : OPTION EXPIRING 30-JUN-2027 EX $8.00
1,305,000
IPXAAD : OPTION EXPIRING 10-APR-2029 EX $5.00
1,374,746
IPXAAE : PERFORMANCE RIGHTS EXPIRING 10-APR-2031
3,473,409
IPXAAA : PERFORMANCE RIGHTS EXPIRING 21-DEC-2028
2,440,000
IPXAAB : PERFORMANCE RIGHTS EXPIRING 31-DEC-2027
445,000
IPXAW : PERFORMANCE RIGHTS EXPIRING 31-DEC-2026
15,000
IPXAA : OPTION EXPIRING 01-APR-2027 EX $10.00
235,000
IPXAP : RESTRICTED STOCK UNITS
Appendix 2A - Application for quotation of securities
4,120,875
7/8
Appendix 2A - Application for quotation of securities
Appendix 2A - Application for quotation of securities
8/8
IperionX Limited (NASDAQ: IPX, ASX: IPX) (“IperionX” or “Company”) has today issued 63,377 fully paid ordinary shares in relation to the conversion of performance rights and restricted stock units. The issued securities are part of a class of securities quoted on the Australian Securities Exchange ("ASX"). The Company hereby notifies ASX under paragraph 708A(5)(e) of the Corporations Act 2001 (Cth) (the "Act") that:
- the Company issued the securities without disclosure to investors under Part 6D.2 of the Act;
- as at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company, and sections 674 and 674A of the Act; and
- as at the date of this notice, there is no information that is “excluded information” within the meaning of sections 708A(7) and 708A(8) of the Act. This announcement has been authorized for release by the Company Secretary.
Investor Webinar A breakthrough in titanium production, made in America
November 2026
IperionX Limited NASDAQ and ASX: IPX
Disclaimers Forward Looking Statements Information included in this release constitutes forward
- looking statements. Often, but not always, forward looking statements c “anticipate”, “continue”, and “guidance”, or other similar words and may include, without limitation, statements regarding pl or production outputs.
an generally be identified by the use of forward looking words such as “may”, “will”, “expect”, “intend”, “plan”, “estimate”, ans , strategies and objectives of management, anticipated production or construction commencement dates and expected costs
Forward looking statements inherently involve known and unknown risks, uncertainties and other factors that may cause Iperion results, performance or achievements. Relevant factors may include, but are not limited to, changes in commodity prices, fore nature of exploration and project development, including the risks of obtaining necessary licenses and permits and diminishin technologies, commercially scale its closed
- loop titanium production process, or protect its intellectual property rights environmental conditions including extreme weather conditions, recruitment and retention of personnel, industrial relations i
X L imited’s (the “Company”) actual results, performance, and achievements to differ materially from any forecast future ign exchange fluctuations and general economic conditions, increased costs and demand for production inputs, the speculative g q uantities or grades of mineralization, the Company’s ability to comply with the relevant contractual terms to access the , political and social risks, changes to the regulatory framework within which the company operates or may in the future operat ssu es and litigation.
Forward looking statements are based on the Company and its management’s good faith assumptions relating to the financial, ma future. The Company does not give any assurance that the assumptions on which forward looking statements are based will prove factors not foreseen or foreseeable by the Company or management or beyond the Company’s control.
rke t, regulatory and other relevant environments that will exist and affect the Company’s business and operations in the to be correct, or that the Company’s business or operations will not be affected in any material manner by these or other
e,
Although the Company attempts and has attempted to identify factors that would cause actual actions, events or results to dif fer materially from those disclosed in forward looking statements, there may be other factors that could cause actual results, performance, achievements or events not to be as anticipated, estimated or intended, and many events are beyond the reasonabl e c ontrol of the Company. Accordingly, readers are cautioned not to place undue reliance on forward looking statements. Forward looking statements in these materials speak only at the date of issue. Subject to any continuing obligations under ap pli cable law or any relevant stock exchange listing rules, in providing this information the company does not undertake any obligation to publicly update or revise any of the forward looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based. Cautionary Statements and Important Information This presentation has been prepared by the Company as a summary only and does not contain all information about assets and li securities. Any investment in the Company should be considered speculative and there is no guarantee that they will make a re future.
abi lities, financial position and performance, profits and losses, prospects, and the rights and liabilities attaching to turn on capital invested, that dividends would be paid, or that there will be an increase in the value of the investment in the
The Company does not purport to give financial or investment advice. No account has been taken of the objectives, financial s ituation or needs of any recipient of this presentation. Recipients of this presentation should carefully consider whether the securities issued by the Company are an appropriate investment for them in light of their personal circumstances, including their financial and taxation position. Compliance Statement This presentation contains information relating to a Mineral Resource Estimate and an Ore Reserve Estimate for the Titan depo sit (where the Mineral Resource Estimate was prepared by Mr. John Eckman, a Competent Person, and the Ore Reserve Estimate was prepared by Mr. Justin Douthat, also a Competent Person) extracted from an ASX market announcement titled “Iperi onX Titan DFS Confirms High
- Return U.S. Rare Earths and Critical Minerals Project” and published on the ASX platform (www.asx.com.au) on June 4, 2026. The Company confirms that it is not aware of any new information or data that materially af fec ts the information included in the original market announcement and that all material assumptions and technical parameters underpinning the estimates in the release of June 4, 2026 continue to apply and have not materially changed. The Company confirms that the form and context in which the Competent Pers on s' findings are presented have not been materially modified from the original market announcement. This presentation contains exploration results relating to the Atlas deposit extracted from an ASX market announcement titled Company confirms that it is not aware of any new information or data that materially affects the information included in the presented have not been materially modified from the original market announcement. The Competent Person was Mr. Adam Karst.
“A cquisition Delivers High Value Critical Minerals” and published on the ASX platform (www.asx.com.au) on July 2, 2026. The ori ginal market announcement. The Company confirms that the form and context in which the Competent Persons’ findings are
This presentation contains information relating to the Company's production targets and financial forecasts for the Titan Pro Critical Minerals Project" and published on the ASX platform (www.asx.com.au) on June 4, 2026. The Company confirms that all production target in the original ASX announcement continue to apply and have not materially changed.
jec t extracted from the Company's ASX announcement titled "IperionX Titan DFS Confirms High
- Return U.S. Rare Earths and the material assumptions underpinning the production target and the forecast financial information derived from the
Not an offer in the United States This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the re
or any other jurisdiction. Any securities described in this presentation have not been, and will not be, registered under the US gis tration requirements of the US Securities Act and applicable US state securities laws.
S ecurities
This presentation has been authorized for release by the CEO and Managing Director.
IPERIONX LIMITED ABN 84 618 935 372
2
Capacity built, products delivering 19 t inventory
200 tpa
4 products
finished powder inventory
HAMR
delivering to U.S. defense
19 t titanium powder in existing inventory
1.6 t in 63 hours of back
- toback runs, above nameplate
Army fasteners x2, ballistic plate, Navy pump components
US$18.5m
6x
US$96.7m
new Army Task Order 2
GenX
funds industrial fastener and track - pin production
with >75% less power per kilogram than batch HAMR
furnace validated
throughput validated
available liquidity US$63.0m cash plus US$33.7m obligated U.S. Government funding
MATERIAL DEVELOPMENTS
Powder capacity is no longer the constraint; qualified products and funded orders are the focus
3
Six years from idea to production DEVELOPMENT · 2020
– 2023
CONSTRUCTION · 2024
– 2025
PRODUCTION · 2026
2020 –2021
2022
2023
2024
2025
2026
• Company founded
• Nasdaq listing
• Titan Project acquired
• Serial production at Utah pilot plant
• Won U.S. Air Force Titanium Recycling Challenge
• HAMR and HSPT technologies acquired outright
• Virginia campus built and commissioned
• Furnace validated above 200 tpa
• US$12.7m DoW DPA Title III award
• First furnace run
• US$47.1m IBAS award for 1,400 tpa & $99m SBIR Phase III
• University of Utah titanium R&D • First titanium metal from Tennessee minerals • Aerospace, defense and luxury engagement
• First UL - validated 100% recycled titanium; first commercial contract
• Virginia site selected
• Receipt of key permits for Titan Project development
• First automotive contract
• 24/7 operations; first defense purchase orders
• Parts delivered to Army and Navy; US$18.5m Task Order 2 • Titan DFS, Atlas, GenX validated
4
The U.S. cannot make its own titanium Titanium is in every fighter jet, missile, naval vessel and armored vehicle. The United States stopped making primary titanium in 2020, and the incumbent supply chain is now sold out.
0
~80%
~20 months
U.S. titanium sponge capacity
controlled by China and Russia
lead time for premium titanium
Last plant closed in 2020; every U.S. titanium part starts with imported metal
Chinese sponge capacity now exceeds 500,000 tpa
Peer reports of backlog a record US$4.3bn; forgings out two years; buyers paying more for capacity
Sources: U.S. Geological Survey; Argus Metals; ATI Q3 2026 results and call, Oct 29, 2026
5
IperionX’s HAMR and HSPT technologies provide a step change in the overall efficiency of titanium manufacturing Incumbent industry case study
– production of
a 0.50” hex head bolt (highly simplified
HAMR and HSPT significantly improve the efficiency and cost of the supply chain
100% Import Reliant Titanium Minerals
Carbothermic Chlorination
Kroll Process
Titanium Sponge
Primary titanium
Titanium Scrap
Vacuum Arc Remelting
Titanium 36” Ingot
1st intermediate product
Titanium Powders
Forging
Titanium 16” Billet
Intermediate product
Cold Drawing
Titanium 0.50” Bar
Intermediate product
CNC Machining
Titanium Blank
Semi - finished product
Titanium Blank
HSPT
Thread Rolling
Titanium Bolt
Final product
Titanium Bolt
Thread Rolling
HAMR
Process Product
Rolling
- Case study based on Company management’s internal analysis
6
Proven technology operating at commercial scale HAMR + HSPT County, Virginia
DEMAND
is commercially proven for primary titanium at the Titanium Manufacturing Campus in Halifax
200 tpa
HAMR furnace validated: 1.6 t in 63 h (>200 tpa). Full system rating by year
- end
Grade 5
Aerospace - grade quality met consistently; spherical powder within Grade 23 oxygen
3x
Forming capacity from the 300
- ton SACMI press; ~11 million single - cavity parts a year
3 furnaces
New Elnik HSPT sintering furnaces: one commissioned, the second in the December quarter, plus existing furnace
8.7 t / 15.9 t
Finished powder / HAMR powder quarterly production 1, up from 1.4 t / 5.1 t in the June quarter
- LED FROM HERE
19 t of powder and 207 t of scrap in hand; output is now scheduled to customer orders
- Finished powder basis (after leaching, drying and other final steps). HAMR powder basis
(furnace deoxygenation throughput,
i.e. work in process).
7
Sales process:
parts, then powder, then mill products
One platform, three product families. Parts first: fastest to qualify, highest value per kilogram
Engineered products · now
Titanium powders · test prints
Mill products · qualifying
Fasteners, track pins, impellers, brackets, gears. Pressed and sintered to near
- net shape in Virginia
Spherical and angular powder for additive manufacturing and consumer electronics
Billet, bar, plate and sheet from the CIP line, into a market with 20 - month lead times
Product family Engineered products
Indicative pricing US$200
– 1,000+ per kg
Sales cycle
Target market entry
Products in development
Lead customers
<6 to 18 months
2026
~19
U.S. Army, U.S. Navy, automotive
Titanium powders
US$60 – 120 per kg
6 – 12 months
2027
~5
Consumer electronics, defense
Mill products
US$50 – 80 per kg
12+ months
2028
~5
Aerospace and mill customers
8
The platform is built Most of the Phase 1 capital is now sunk; each additional ton of product spreads it further
PHASE 1 COMPLETE
RAMP
IS
UNDERWAY
SCAL
ING IS
NEXT
A complete platform in place
Spend shift ing from construction to production
Fixed costs are sunk; volume reduces costs
• Six years of investment created the Virginia campus with HAMR and HSPT at commercial scale .
• Phase 1 capital is complete.
• The cost of the platform has already been paid.
• P ressing and sintering capacity to turn powder into parts is in place.
• The next tranche of Virginia capacity is supported with funding by the U.S. Government , and operating spend is scheduled to customer orders.
scaling
• Each additional ton of product carries less capital and less overhead, so cost per ton falls as output scales.
FROM BUILD TO STEADY STATE
Most of the capital is sunk; its benefit arrives as production scales
9
GenX
: continuous titanium production, validated
The next - generation HAMR batch cycle
platform runs continuously, eliminating the heat
- up, cool - down and reloading of every
6x
75%
higher throughput on a like run time
- for - like
45% From batch furnaces to one continuous line
less power per kilogram of titanium powder
60%
less magnesium, HAMR reagent cost
’s largest
less hydrogen per kilogram of titanium powder
GENX CAMPAIGN
GENX QUALITY
Over 500 kg of powder across four continuous runs totalling 41 hours, at a rate equivalent to ~100 tpa
100% of valid samples met ASTM oxygen specifications; all spherical powder within Grade 23
10
Titan DFS: strong economics, strategic products and shovel Leading U.S. rare earth and critical minerals project with strong economics and near
- term development pathway POTENTIAL MARKET OPPORTUNITY
SITE ECONOMICS
After - tax NPV
- ready
Life of Mine EBITDA and FCF
37,000
Development Capex
BOEING 787 s 2
US$813M
US$2.8B
US$381M
39.4% IRR
US$1.9B FCF
Phase 1: US$228M Phase 2: US$153M
Heavy Rare Earth Concentrate 1
Titanium Minerals
~5,300 tpa
~143,300 tpa
~65,700 tpa
Heavy rare earth concentrate
Rutile: ~24,700 tpa Ilmenite: ~118,700 tpa
Zircon concentrate
Refer to ASX Announcement dated June 4 2026 for details. 1. Phase 2 production rates shown, rounded. All production values stated in metric tons throughout presentation. 2. Equivalent product figures shown are rounded. Based on Titan’s LOM projected production of titanium in ilmenite and rutile, a Resources, Conservation & Recycling (2025) 107966
1
Zircon Concentrate
nd NdPr in HREC oxides. IPX estimates for material intensities for various end
13,000,000 Electric Vehicles
2
1
5,700,000
Humanoid Robots
- use applications. Sources: Adamas Intelligence; Benc
2
hmark Minerals; ORNL; DoE; MDPI Minerals 2023, 13, 1274;
11
Atlas acquisition: unlocking ultra support U.S. supply chains
- high - grade critical minerals to
1, positioning IperionX to support strategic titanium, Atlas surface stockpiles return exceptional grades up to 23% THM zircon, and heavy rare earth feedstocks to the U.S. defense and advanced technology sectors
The Atlas acquisition combines value
- drivers that are not readily available together in a U.S. critical minerals development pro
Scale: Adjacent mineral sands position increases the scale potential of the combined Atlas
Ultra - high - grade stockpiles:
Pre - mined, pre - processed critical mineral stockpiles of approximately 70 acres at surface.
Pre - stripped mineralization:
approximately 180 acres of near
Established, turnkey infrastructure:
-
Titan project.
-
zero - overburden access to the rich Lower McNairy seam.
Ready - to- use industrial assets, utilities and rail infrastructure. 2
U.S. rare earths supply chain components and associated U.S. Government funding Heavy rare earths minerals
Refining / Processing & Separation
MP Materials
N/A
Mountain Pass California
Energy Fuels
Various Madagascar Brazil Australia
White Mesa Utah
ASM South Korea
Vacuumschmelze Germany
USA Rare Earths
Serra Verde Brazil
Wheat Ridge Colorado
Less Common Metals, UK
Blacksburg South Carolina
Company
IperionX
- Refer to ASX announcement dated July 2,
2026 2. Source: MP Materials (
link ), Energy Fuels (
ject:
link ), USA Rare Earths (
link )
Titan / Camden Tennessee
Magnet Production
Metallization
U.S. Government rare earths funding 2025 package incl. $400m preferred equity + $150m loan + 10 - yr NdPr floor & magnet offtake.
Fort Worth Texas
2026 conditional commitment for up to US$725m senior - secured debt. Supports White Mesa expansion + planned U.S. metals / alloy capacity. 2026 $277m federal funding + up to $1.3bn CHIPS loan capacity
Titan / Camden is a potential near
- term domestic source of heavy rare earth minerals, with key permits already in place
12
High value catalysts are imminent
✓
Corporate Overview
✓
Test powders and/or prototype parts with prospective customers
✓
Prototype orders secured
✓
Convert qualification programs into commercial
– U.S. Army GVSC, Carver Pump
- scale orders
Scale up production of titanium powder and products
✓
HAMR
✓
300 - ton SACMI press commissioned; fasteners made in
✓
Additional HSPT
✓
GenX
✓
~200 tpa titanium powder run
✓
1,400 tpa expansion under US$47.1m IBAS award (underway)
furnace commissioned; 24/7 operations in Virginia
HAMR
Progress Atlas
- house
sintering furnaces delivered to Virginia validated – 6x throughput, >75% lower power use
(US$)
✓
Secure strategic partners for our titanium metal products
ADS Price
✓
(NASDAQ / ASX Ticker Symbol: IPX)
$65.00 $60.00 $55.00 $50.00 $45.00 $40.00 $35.00 $30.00 $25.00 $20.00 $15.00 $10.00 $5.00 $0.00
-
rate capacity by end CY2026 Ordinary Shares / ADR’s (1:10) Outstanding
-
Titan Project to be construction ready
Market Capitalization (30
- Oct - 2026)
✓
Definition of largest known titanium mineral resource in U.S.
✓
State Mine and NPDES permits granted
Fidelity Management and Research (FMR)
✓
Titan DFS completed
State Street
✓
Atlas acquisition completed
✓
Atlas - Titan integrated study, offtake, U.S. funding and FID
- JORC and SK - 1300 code compliant
- Last disclosed
– after - tax NPV 8 US$813m, IRR 39% – ultra - high - grade stockpiles
1
362.2 million / 36.2 million
~US$0.54 billion
Cash (30 - Sep - 2026)
Vanguard
2
2
Insider/management Ownership
~US$63 million 2
~9% ~8% ~5% ~16% 13
604
Page 1 of 4
Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder
To Company Name/Scheme
IPERIONX LTD
ACN/ARSN/ABN
84 618 935 372
- Details of substantial holder (1) Name
JPMorgan Chase & Co. and its affiliates
ACN/ARSN (if applicable)
NA
There was a change in the interests of the substantial holder on
28/October/2026
The previous notice was given to the company on
22/October/2026 DD/MMM/YYYY
The previous notice was dated 20/October/2026 2. Previous and present voting power The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:
Class of securities (4)
Previous notice Person’s votes
Ordinary
31,541,153.52
Present notice Voting power (5)
Person’s votes
8.71%
27,466,768
Voting power (5) 7.58%
- Changes in relevant interests Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows: Date of change
See Appendix
Person whose relevant interest Nature of change (6) changed
Consideration given Class and number of Person's in relation to securities affected votes change (7) affected
JPMORGAN CHASE BANK, N.A.
Securities on Loan as Agent Lender
See Appendix
2,570,321 (Ordinary)
2,570,321 (Ordinary)
See Appendix
J.P. MORGAN SECURITIES PLC
Holder of securities subject to an obligation to return under a securities lending agreement
See Appendix
616,907 (Ordinary)
616,907 (Ordinary)
See Appendix
J.P. MORGAN SECURITIES Purchase and sales of securities in its capacity PLC as Principal/Proprietary
See Appendix
511 (Ordinary)
511 (Ordinary)
J.P. MORGAN SECURITIES LLC
Holder of securities subject to an obligation to return under a securities lending agreement
See Appendix
88,000 (Ordinary)
88,000 (Ordinary)
See Appendix
J.P. MORGAN SECURITIES LLC
Rehypothecation of client securities under a Prime Brokerage Agreement
See Appendix
966,049 (Ordinary)
966,049 (Ordinary)
See Appendix
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
Holder of securities subject to an obligation to return under a securities lending agreement
See Appendix
234,645 (Ordinary)
234,645 (Ordinary)
See Appendix
604
Page 2 of 4
See Appendix
J.P. MORGAN SECURITIES Purchase and sales of securities in its capacity AUSTRALIA LIMITED as Principal/Proprietary
See Appendix
16,064 (Ordinary)
16,064 (Ordinary)
See Appendix
J.P. MORGAN PRIME INC.
Rehypothecation of client securities under a Prime Brokerage Agreement
See Appendix
251,630 (Ordinary)
251,630 (Ordinary)
See Appendix
J.P. MORGAN INVESTMENT MANAGEMENT INC.
securities received as collateral due to securities lending
See Appendix
0.52 (Ordinary)
0.52 (Ordinary)
J.P. MORGAN INVESTMENT MANAGEMENT INC.
In its capacity as investment manager or in various other related capacities
See Appendix
10,540 (Ordinary)
10,540 (Ordinary)
See Appendix
- Present relevant interests Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows: Holder of relevant interest
Registered holder of securities
Person entitled to be registered as holder (8)
Nature of relevant interest (6)
Class and number of securities
Person's votes
Securities on Loan as Agent Lender
12,528,386 (Ordinary)
12,528,386 (Ordinary)
JPMORGAN CHASE BANK, N.A.
JPM Nominees Australia Pty Limited
Various Borrowers under the Securities Lending Agreement
JPMORGAN ASSET MANAGEMENT (UK) LIMITED
Citibank, N.A., Hong Kong Branch
Various Clients and Custodians
In its capacity as investment manager or in various other related capacities
58,584 (Ordinary)
58,584 (Ordinary)
JPMORGAN ASSET MANAGEMENT (UK) LIMITED
BNP Paribas (Sydney Branch)
Various Clients and Custodians
In its capacity as investment manager or in various other related capacities
145,791 (Ordinary)
145,791 (Ordinary)
J.P. MORGAN SECURITIES PLC
JPM Nominees Australia Pty Limited
JPM Nominees Australia Pty Limited
Holder of securities subject to an obligation to return under a securities lending agreement
798,712 (Ordinary)
798,712 (Ordinary)
J.P. MORGAN SECURITIES PLC
JPM Nominees Australia Pty Limited
J.P. MORGAN SECURITIES PLC
Purchase and sales of securities in its capacity as Principal/Proprietary
155,073 (Ordinary)
155,073 (Ordinary)
J.P. MORGAN SECURITIES LLC
Citi Australia
Various Clients and Custodians
Rehypothecation of client securities under a Prime Brokerage Agreement
3,984,907 (Ordinary)
3,984,907 (Ordinary)
J.P. MORGAN SECURITIES LLC
Citi Australia
Citi Australia
Holder of securities subject to an obligation to return under a securities lending agreement
3,755,000 (Ordinary)
3,755,000 (Ordinary)
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
Ecapital Nominees Pty Ltd
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
Purchase and sales of securities in its capacity as Principal/Proprietary
1,206,875 (Ordinary)
1,206,875 (Ordinary)
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
Ecapital Nominees Pty Ltd
Ecapital Nominees Pty Ltd
Holder of securities subject to an obligation to return under a securities lending agreement
1,550,000 (Ordinary)
1,550,000 (Ordinary)
J.P. MORGAN PRIME INC.
Citi Australia
Various Clients and Custodians
Rehypothecation of client securities under a Prime Brokerage Agreement
3,283,440 (Ordinary)
3,283,440 (Ordinary)
604
Page 3 of 4
- Changes in association The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows: Name and ACN/ARSN (if applicable)
Nature of association
J.P. MORGAN SECURITIES LLC
Subsidiary of JPMorgan Chase & Co.
J.P. MORGAN SECURITIES PLC
Subsidiary of JPMorgan Chase & Co.
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
Subsidiary of JPMorgan Chase & Co.
JPMORGAN CHASE BANK, N.A.
Subsidiary of JPMorgan Chase & Co.
J.P. MORGAN PRIME INC.
Subsidiary of JPMorgan Chase & Co.
J.P. MORGAN INVESTMENT MANAGEMENT INC.
Subsidiary of JPMorgan Chase & Co.
- Addresses The addresses of persons named in this form are as follows: Name
Address JPMorgan Chase & Co.
270 Park Avenue, New York, New York, NY, 10017, United States
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
LEVEL 18, 83-85 CASTLEREAGH STREET, SYDNEY, NSW 2000, Australia
J.P. MORGAN SECURITIES LLC
270 Park Avenue, New York, New York, NY, 10017, United States
J.P. MORGAN SECURITIES PLC
25 Bank Street, Canary Wharf, London, E14 5JP, England
JPMORGAN CHASE BANK, N.A.
1111 Polaris Parkway, Columbus, Delaware, OH, 43240, United States
J.P. MORGAN PRIME INC.
270 Park Avenue, New York, New York, NY, 10017, United States
J.P. MORGAN INVESTMENT MANAGEMENT INC.
270 Park Avenue, New York, New York, NY, 10017, United States
JPMORGAN ASSET MANAGEMENT (UK) LIMITED
60 Victoria Embankment, London, EC4Y0JP, England
Signature print name sign here
Vasim Pathan
Capacity Date
Compliance Officer 30/October/2026
604
Page 4 of 4
DIRECTIONS (1)
If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 6 of the form.
(2)
See the definition of "associate" in section 9 of the Corporations Act 2001.
(3)
See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
(4)
The voting shares of a company constitute one class unless divided into separate classes.
(5)
The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.
(6)
Include details of: (a)
any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
(b)
any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).
See the definition of "relevant agreement" in section 9 of the Corporations Act 2001. (7)
Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
(8)
If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown".
(9)
Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.
TRADES FOR RELEVANT PERIOD Transaction Date Balance at start of relevant period 21-Oct-26 21-Oct-26 21-Oct-26 21-Oct-26 21-Oct-26 21-Oct-26 21-Oct-26 21-Oct-26 21-Oct-26 21-Oct-26 21-Oct-26 21-Oct-26 21-Oct-26 21-Oct-26 21-Oct-26 21-Oct-26 21-Oct-26 21-Oct-26 22-Oct-26 22-Oct-26 22-Oct-26 22-Oct-26 22-Oct-26 22-Oct-26 22-Oct-26 22-Oct-26 22-Oct-26 22-Oct-26 22-Oct-26 23-Oct-26 23-Oct-26 23-Oct-26 23-Oct-26 23-Oct-26 26-Oct-26 26-Oct-26 26-Oct-26 26-Oct-26 26-Oct-26 26-Oct-26 26-Oct-26 26-Oct-26 27-Oct-26 27-Oct-26 27-Oct-26 27-Oct-26 27-Oct-26 27-Oct-26 27-Oct-26 27-Oct-26 27-Oct-26 27-Oct-26 27-Oct-26 27-Oct-26 27-Oct-26 27-Oct-26 28-Oct-26 28-Oct-26 28-Oct-26 28-Oct-26 28-Oct-26 28-Oct-26 28-Oct-26 28-Oct-26 28-Oct-26 28-Oct-26 28-Oct-26 28-Oct-26 28-Oct-26 28-Oct-26 Balance at end of relevant period
Appendix Entity
Product Type
Type of Transaction
J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN INVESTMENT MANAGEMENT INC. J.P. MORGAN INVESTMENT MANAGEMENT INC. J.P. MORGAN INVESTMENT MANAGEMENT INC. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC J.P. MORGAN INVESTMENT MANAGEMENT INC. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES PLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN PRIME INC. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A.
Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity Equity Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity Equity Equity
Buy Buy Sell Sell Sell Buy Sell Buy Buy Buy Sell Sell Sell Collateral Out Collateral Out Collateral Out Borrow Return Borrow Return Buy Sell Borrow Return Borrow Return Borrow Return Borrow Return Borrow Return Borrow Borrow Return Borrow Return Borrow Return Buy Sell Borrow Sell Borrow Return Sell Buy Sell Sell Buy Sell Borrow Return Borrow Return Buy Sell Sell Buy Buy Sell Borrow Return Borrow Return Borrow Return Borrow Borrow Return Borrow Borrow Return Borrow On-Lend Adjustment On-Lend Return On-Lend Return Adjustment Sell Buy Buy Sell Sell Borrow Return Borrow Return Borrow Return Borrow Return
Quantity 31,541,153.52 4,907 25 (5,727) (162) (16,833) 254 (6) 6 10 13,058 (767) (10) (1,561) (0.02) (0.49) (0.01) (45,562) (303,635) 381 (746) (9,819) (24,000) (29,645) (101,211) (82,747) 2 (14,000) (1) (26,595) 26 (27,979) 148,000 (10,540) (2,000,000) (5) 5 (354) (2,106) 254 (20,950) (7,663) (60,142) 5,333 (708) (551) 497 810 (810) (400,000) (200,000) (5,000) 868 (238,000) 238,000 (51,682) 51,682 251,630 25,875 (355,279) (610,770) 511 (5) 5 17,742 (131) (5,841) (46,000) (69,000) (4,668) (53,055) 27,466,768
Price (AUD) 1.96 1.96 1.96 1.94 1.94 1.98 1.92 1.92 1.92 1.92 1.96 1.92 1.92 1.87 1.87 1.87 1.87 1.76 1.81 1.81 1.78 1.83 1.81 1.81 1.94 1.84 1.94 1.94 1.94 1.94 2.10 2.10 2.10 2.06 2.12
Consideration $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $
9,617.72 49.00 11,210.60 313.47 32,646.31 501.65 11.52 11.52 19.20 25,071.36 1,503.32 19.20 2,997.12 712.47 1,392.84 48.62 52,320.73 18,500.92 9.03 9.03 631.35 3,856.34 458.47 37,814.75 10,346.02 1,303.23 1,068.94 964.18 1,571.40 1,571.40 10.50 10.50 37,258.20 269.86 12,360.96
1/1
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX. Date:
30-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant interests: Schedule
28-Oct-2026
Type of agreement
Global Master Securities Lending Agreement (“GMSLA”)
Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and BARCLAYS CAPITAL SECURITIES LIMITED ( “Borrower”) Settlement Date: 02-Jun-2025 29-Jan-2026 30-Jan-2026
Transfer date Holder of voting rights Are there any restriction on voting rights If yes, detail Scheduled return date (if any) Does the borrower have the right to return early?
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA. None Yes
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
30-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 28-Oct-2026 interests: Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and BNP Paribas Financial Markets (Borrower)
Transfer date
Settlement Date 02-Sep-2026 03-Sep-2026 07-Sep-2026 17-Sep-2026 18-Sep-2026 21-Sep-2026 30-Sep-2026 01-Oct-2026 02-Oct-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX. Date:
30-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant interests: Schedule
28-Oct-2026
Type of agreement
Master Securities Lending Agreement (“MSLA”)
Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Bofa Securities, Inc. ( “Borrower”)
Transfer date
Settlement date 07-Aug-2026 11-Aug-2026 21-Aug-2026 26-Aug-2026 28-Aug-2026
Holder of voting rights Are there any restriction on voting rights If yes, detail Scheduled return date (if any) Does the borrower have the right to return early?
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out as per the rights of the borrower as stated in the MSLA. None Yes
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
30-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 28-Oct-2026 interests: Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Citigroup Global Markets Limited (Borrower)
Transfer date
Settlement Date 10-Aug-2026 29-Sep-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX. Date:
30-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant interests: Schedule
28-Oct-2026
Type of agreement
Master Securities Lending Agreement (“MSLA”)
Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Citigroup Global Markets Inc. ( “Borrower”) Settlement date 02-Oct-2026
Transfer date Holder of voting rights Are there any restriction on voting rights If yes, detail Scheduled return date (if any) Does the borrower have the right to return early?
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out as per the rights of the borrower as stated in the MSLA. None Yes
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX. Date:
30-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant interests: Schedule
28-Oct-2026
Type of agreement
Master Securities Lending Agreement (“MSLA”)
Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Goldman Sachs & Co. LLC ( “Borrower”)
Transfer date
Settlement Date 08-Sep-2026 29-Sep-2026
Holder of voting rights Are there any restriction on voting rights If yes, detail Scheduled return date (if any) Does the borrower have the right to return early?
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out as per the rights of the borrower as stated in the MSLA. None Yes
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
30-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 28-Oct-2026 interests: Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Goldman Sachs International (Borrower)
Transfer date
Settlement Date 07-Sep-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
30-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 28-Oct-2026 interests: Schedule Type of agreement Australian Master Securities Lending Agreement (“AMSLA”) Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Macquarie Bank Limited(Borrower)
Transfer date
Settlement Date 16-Oct-2026 19-Oct-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4.3 of the standard form AMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender’s instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
30-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 28-Oct-2026 interests: Schedule Type of agreement Australian Master Securities Lending Agreement (“AMSLA”) Parties to agreement
Transfer date
Holder of voting rights Are there any restriction on voting rights
If yes, detail
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Merrill Lynch Equities (Australia) Limited(Borrower) Settlement Date 05-Jun-2026 13-Jul-2026 12-Aug-2026 25-Aug-2026 16-Sep-2026 Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4.3 of the standard form AMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender’s instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
30-Oct-2026
Company’s name: IPERIONX LTD ISIN:
AU0000208910
Date of change of relevant interests:
28-Oct-2026
Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Merrill Lynch International(Borrower)
Transfer date
Settlement Date 09-Jun-2026 16-Jun-2026 26-Jun-2026 14-Jul-2026 15-Jul-2026 17-Jul-2026 21-Jul-2026 22-Jul-2026 23-Jul-2026 24-Jul-2026 29-Jul-2026 30-Jul-2026 31-Jul-2026 03-Aug-2026 15-Sep-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions.
Will the securities be returned on Yes settlement?
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
30-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 28-Oct-2026 interests: Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
Transfer date
Holder of voting rights Are there any restriction on voting rights
If yes, detail
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Morgan Stanley & Co. International PLC (Borrower) Settlement Date 24-Aug-2026 23-Sep-2026 08-Oct-2026 20-Oct-2026 Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
30-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 28-Oct-2026 interests: Schedule Type of agreement Australian Master Securities Lending Agreement (“AMSLA”) Parties to agreement
Transfer date
Holder of voting rights Are there any restriction on voting rights
If yes, detail
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Morgan Stanley Australia Securities Limited (Borrower) Settlement Date 31-Oct-2025 18-Mar-2026 10-Jul-2026 15-Jul-2026 22-Sep-2026 01-Oct-2026 05-Oct-2026 07-Oct-2026 Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4.3 of the standard form AMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender’s instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
30-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 28-Oct-2026 interests: Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Societe Generale Paris Branch (Borrower)
Transfer date
Settlement Date 15-Oct-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
30-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 28-Oct-2026 interests: Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and UBS AG London Branch (Borrower)
Transfer date
Settlement Date 28-Aug-2026 31-Aug-2026 17-Sep-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX. Date:
30-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of 28-Oct-2026 relevant interests: Schedule Type of agreement Australian Master Securities Lending Agreement (“AMSLA”) Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and UBS Securities Australia Ltd (Borrower)
Transfer date
Settlement Date 18-Jun-2026 25-Jun-2026 26-Jun-2026 29-Jun-2026 14-Sep-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4.3 of the standard form AMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s If yes, detail instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX. Date:
30-Oct-2026
Company’s name:
IPERIONX LTD
ISIN: Date of change of relevant interests: Schedule
AU0000208910
Type of agreement
Master Securities Lending Agreement (“MSLA”)
Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and UBS SECURITIES LLC ( “Borrower”)
Transfer date
Settlement Date 15-Sep-2026 14-Oct-2026 21-Oct-2026
Holder of voting rights Are there any restriction on voting rights If yes, detail Scheduled return date (if any) Does the borrower have the right to return early?
28-Oct-2026
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out as per the rights of the borrower as stated in the MSLA. None Yes
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX. Date:
30-Oct-2026
Company’s name:
IPERIONX LTD
ISIN: Date of change of relevant interests: Schedule
AU0000208910
Type of agreement Parties to agreement
Australian Master Securities Lending Agreement ("AMSLA")
28-Oct-2026
JPMorgan Chase Bank, N.A. (acting as agent) ("lender"), J.P. Morgan Securities Australia Limited ('borrower')
Transfer date
Settlement Date 20-Mar-2026
Holder of voting rights
Borrower
Are there any restriction on voting Yes rights
If yes, detail
The borrower undertakes to use its best endeavours to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavours to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4.3 of the standard form AMSLA.
Scheduled return date (if any)
None
Does the borrower have the right to return early?
Yes
If yes, detail
Borrower has right to return all and any securities or equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities on any business day by giving such notice as agreed by the parties. The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exception
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX. Date:
30-Oct-2026
Company’s name:
IPERIONX LTD
ISIN: Date of change of relevant interests: Schedule
AU0000208910
Type of agreement
Global Master Securities Lending Agreement ("GMSLA")
Parties to agreement Transfer date Holder of voting rights Are there any restriction on voting rights If yes, detail
28-Oct-2026
State Street Bank and Trust Company ("lender") and J.P. Morgan Securities Australia Limited ("borrower") Settlement Date 23-Feb-2026 07-Jul-2026 Borrower Yes The borrower shall have no obligation to arrange for voting rights to be exercised in accordance with the instructions of the other party, unless otherwise agreed between the parties.
Scheduled return date (if None any) Does the borrower have the right to return early?
Yes
If yes, detail
Borrower has the right to terminate a loan and redeliver all and any equivalent securities due and outstanding to the lender in accordance with lender's instructions and lender shall accept such redelivery.
Does the lender have the Yes right to recall early? Lender has right to recall all or any equivalent securities on any business day by giving such notice as If yes, detail agreed by the parties. The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions. Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX.
Date: Company’s name: ISIN: Date of change of relevant interests: Schedule Type of agreement
30-Oct-2026 IPERIONX LTD AU0000208910
28-Oct-2026 Institutional Account Agreement
Parties to agreement
JP Morgan Securities LLC for itself and as agent and trustee for the other J.P. Morgan Entities and VANGUARD GROUP INC (AS AGT),CHARLES SCHWAB & CO., INC,INTERACTIVE BROKERS LLC,ROBINHOOD SECURITIES, LLC (herein referred to as “JPMS”). “ J.P. Morgan Entities” means, as the context may require or permit, any and all of JPMSL, JPMorgan Chase Bank, N.A., J.P. Morgan Securities LLC., J.P. Morgan Markets Limited, J.P. Morgan Securities Australia Limited, J.P. Morgan Securities (Asia Pacific) Limited, J.P. Morgan Securities Japan Co., Ltd and J.P. Morgan Prime Nominees Limited and any additional entity notified to the Company from time to time.
Transfer date
Settlement Date 25-Jun-2026 30-Jun-2026 31-Jul-2026 03-Aug-2026 06-Aug-2026 28-Aug-2026 01-Sep-2026 02-Sep-2026 30-Sep-2026 01-Oct-2026 13-Oct-2026 15-Oct-2026 16-Oct-2026 19-Oct-2026 23-Oct-2026
Holder of voting rights
JPMS is the holder of the voting rights from the time at which it exercises its right to borrow. Notwithstanding this, please note that the Company has the right to recall equivalent securities if it wishes to exercise its voting rights in respect of the securities.
Are there any restriction on voting Yes rights JPMS will not be able to exercise voting rights in circumstances where the Company has recalled If yes, detail equivalent securities from JPMS before the voting rights have been exercised. In these circumstances, JPMS must return the securities to the Company and the Company holds the voting rights. Scheduled return N/A. There is no term to the loan of securities. date (if any) Does the borrower have the right to Yes. return early? If yes, detail
JPMS has the right to return all and any securities or equivalent securities early at any time.
Does the lender have the right to recall early?
Yes.
If yes, detail
The Company has the right to recall all or any equivalent securities on demand.
Will the securities be Yes. Settlement of the loan will occur when JPMS returns equivalent securities to the Company. There returned on is no term to the loan of securities. settlement? If yes, detail any exceptions Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX. Date:
30-Oct-2026
Company’s name:
IPERIONX LTD
ISIN: Date of change of relevant interests: Schedule
AU0000208910
Type of agreement
Global Master Securities Lending Agreement ("GMSLA")
Parties to agreement
BANK JULIUS BAER & CO. AG vs JPMS PLC
Transfer date
Settlement Date 01-Jul-2026 02-Jul-2026 06-Jul-2026 09-Jul-2026 13-Jul-2026 16-Oct-2026 19-Oct-2026
Holder of voting rights
28-Oct-2026
Borrower
Are there any Yes restriction on voting rights If yes, detail Scheduled return date (if any) Does the borrower have the right to return early?
If yes, detail
Does the lender have the right to recall early?
If yes, detail
The borrower shall have no obligation to arrange for voting rights to be exercised in accordance with the instructions of the other party, unless otherwise agreed between the parties. None
Yes
Borrower has the right to terminate a loan and redeliver all and any equivalent securities due and outstanding to the lender in accordance with lender's instructions and lender shall accept such redelivery on a business day if notice of redelivery has been given within the standard market settlement period.
Yes
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time provided notification is given by the lender within standard market settlement period for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered. The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX.
Date: Company’s name:
30-Oct-2026
ISIN: Date of change of relevant interests: Schedule
AU0000208910
Type of agreement Parties to agreement Transfer date Holder of voting rights
IPERIONX LTD
28-Oct-2026
Global Master Securities Lending Agreement ("GMSLA") Blackrock Advisors (UK) Limited ("lender") and J.P. Morgan Securities plc ("borrower") Settlement Date 26-Oct-2026 29-Oct-2026
Borrower
Are there any restriction on voting Yes rights
If yes, detail
The borrower shall have no obligation to arrange for voting rights to be exercised in accordance with the instructions of the other party, unless otherwise agreed between the parties.
Scheduled return date (if any)
None
Does the borrower have the right to return early?
Yes
If yes, detail
Borrower has the right to terminate a loan and redeliver all and any equivalent securities due and outstanding to the lender in accordance with lender's instructions and lender shall accept such redelivery.
Does the lender have the right to recall early?
Yes.
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant
borrowed securities were originally delivered. The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions. Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX.
Date: Company’s name:
30-Oct-2026
ISIN: Date of change of relevant interests: Schedule
AU0000208910
Type of agreement
IPERIONX LTD
28-Oct-2026 Overseas Securities Lender's Agreement ("OSLA")
Parties to agreement
J.P. Morgan Securities Plc ("borrower") and Citibank N.A. acting as Agent ("lender")
Transfer date
Settlement Date 07-Aug-2026
Holder of voting rights Borrower Are there any restriction on voting rights
Yes
If yes, detail
The borrower undertakes to use its best endeavours to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavours to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4(B)(vi) of the standard form OSLA.
Scheduled return date None (if any) Does the borrower have the right to return early?
Yes
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered. The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX. Date:
30-Oct-2026
Company’s name:
IPERIONX LTD
ISIN: Date of change of relevant interests:
AU0000208910
28-Oct-2026
Schedule Type of agreement Parties to agreement Transfer date
Overseas Securities Lender’s Agreement (“OSLA”) JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) J.P. Morgan Securities plc (“borrower”) Settlement Date 30-Mar-2026 20-Oct-2026
Holder of voting rights
Borrower
Are there any restriction on voting rights
Yes
If yes, detail
The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4(B)(vi) of the standard form OSLA.
Scheduled return date (if any)
None
Does the borrower have the right to Yes return early?
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX.
Date: Company’s name:
30-Oct-2026
ISIN: Date of change of relevant interests: Schedule
AU0000208910
Type of agreement
IPERIONX LTD
28-Oct-2026
Global Master Securities Lending Agreement ("GMSLA")
Parties to agreement
J.P. Morgan Securities plc ("borrower") and State St Bank and Trust Company as agent ("lender")
Transfer date
Settlement Date 29-Jul-2026
Holder of voting rights
Borrower
Are there any restriction on voting Yes rights
If yes, detail
The borrower shall have no obligation to arrange for voting rights to be exercised in accordance with the instructions of the other party, unless otherwise agreed between the parties.
Scheduled return date (if any)
None
Does the borrower have the right to return early?
Yes
If yes, detail
Borrower has the right to terminate a loan and redeliver all and any equivalent securities due and outstanding to the lender in accordance with lender's instructions and lender shall accept such redelivery.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered. The borrower must return the
securities not later than the expiry of such notice in accordance with the lender’s instructions. Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
IperionX Limited (Nasdaq | ASX: IPX) is pleased to present its quarterly report for the period ended September 30, 2026. Highlights during and subsequent to the end of the quarter include:
Operations – Titanium powder and product manufacturing
• HAMR™ Furnace Capacity Validated Above 200 tpa: HAMR™ titanium powder production continued to ramp on a 24/7 schedule, completing 1.6 tons of back-to-back deoxygenation runs in 63 hours and validated furnace capacity above the 200 tpa target annualized run-rate.
• Aerospace-Grade Quality: HAMR™ powder consistently met or exceeded Grade 5 titanium quality specifications, confirming HAMR™ as a commercially proven process for primary titanium metal production.
• Production & Inventory Volumes: Produced 8.7 tons of titanium HAMR™ powder during the quarter (June quarter: 1.4 tons), closing the period with 19 tons of finished titanium powder inventory and 207 tons of titanium scrap feedstock.
• Near-term Commercial Programs: With titanium powder capacity validated and inventory established, downstream manufacturing and near-term commercial program execution are now the operational priorities, supported by increased customer qualification.
PRESS RELEASE | NASDAQ: IPX | ASX: IPX
October 29, 2026
IPERIONX – SEPTEMBER 2026 QUARTERLY REPORT IperionX Limited (Nasdaq | ASX: IPX) is pleased to present its quarterly report for the period ended September 30, 2026. Highlights during and subsequent to the end of the quarter include: Operations – Titanium powder and product manufacturing
• HAMR™ Furnace Capacity Validated Above 200 tpa: HAMR™ titanium powder production continued to ramp on a 24/7 schedule, completing 1.6 tons of back-to-back deoxygenation runs in 63 hours and validated furnace capacity above the 200 tpa target annualized run-rate.
• Aerospace-Grade Quality: HAMR™ powder consistently met or exceeded Grade 5 titanium quality specifications, confirming HAMR™ as a commercially proven process for primary titanium metal production.
• Production & Inventory Volumes: Produced 8.7 tons of titanium HAMR™ powder during the quarter (June quarter: 1.4 tons), closing the period with 19 tons of finished titanium powder inventory and 207 tons of titanium scrap feedstock.
• Near-term Commercial Programs: With titanium powder capacity validated and inventory established, downstream manufacturing and near-term commercial program execution are now the operational priorities, supported by increased customer qualification.
• Titanium Fastener Manufacturing: Optimized the 300-ton, six-axis SACMI powder metallurgy press tooling and pressing parameters for a large range of titanium fastener geometries across defense and commercial applications.
• Domestic Billet & Bar Products: Dedicated wet-bag cold isostatic press (CIP) production to large titanium billet and bar production for internal fastener manufacturing and as a domestic alternative to conventional titanium bar and wire mill products.
• Sintering Bottleneck Relieved: Commissioned the first of two additional Elnik HSPT™ sintering furnaces, with the second furnace now installed and scheduled for commissioning in the December quarter, removing a key downstream manufacturing constraint and increasing finished titanium product output.
• In-House Virginia Fastener Manufacturing: Expanded in-house finish machining and thread-rolling capabilities. Fastener production now runs largely in-house in Virginia to meet current needs, spanning uniaxial pressing, HSPT™ sintering, THRM™ heat treatment, finish machining, and thread rolling, with centerless grinding to be brought in-house under Task Order 2. Produced 1,500 fasteners with further production now scaling for U.S. Army and commercial programs.
• Multi-Sector Component Development: Advanced additive manufacturing and powder-to-product programs across defense, aerospace, consumer electronics, and industrial applications, alongside advancing titanium plate and large-format titanium component manufacturing. GenX™ continuous titanium production
• Breakthrough Continuous Validation: Validated the next-generation GenX™ continuous HAMR™ production platform, processing over 500 kg of titanium powder across four continuous runs (41 hours), with 100% of valid samples meeting ASTM oxygen specifications.
• Step-Change in Unit Economics: Compared to batch HAMR™ on a like-for-like run-time basis, GenX™ delivered 6x higher throughput while reducing power consumption by >75%, magnesium usage by >45%, and hydrogen consumption by >60% per kilogram of titanium powder.
• 100 tpa Titanium Powder Production Capacity: Validated the current GenX™ platform at an equivalent run-rate of ~100 tpa; engineering is underway to integrate the full production line and bring this incremental capacity online. Virginia
Tennessee
Utah
1092 Confroy Drive South Boston, VA 24592
279 West Main Street Camden, TN 38320
1782 W 2300 S West Valley City, UT 84119
IperionX Limited ABN 84 618 935 372
Customers and product development
• U.S. Navy + Carver Pump: Completed manufacturing of all titanium components under the Carver Pump purchase order; components are now undergoing final customer testing to support commercial-scale orders for U.S. Navy pump contractors.
• U.S. Army + American Rheinmetall Vehicles: Advanced manufacturing of large format titanium track pins under the U.S. Army prototype order, leveraging new Elnik HSPT™ sintering capacity to support larger follow-on production orders across U.S. Army ground combat platforms.
• U.S. Army GVSC Titanium Fasteners: Secured a follow-on purchase order from the U.S. Army Ground Vehicle Systems Center (GVSC) for titanium fasteners for the Joint Light Tactical Vehicle (JLTV) and trailer. Independent test work validated that IperionX titanium fasteners exceed SAE Grade 8 steel torque-to-yield performance.
• Targeting Mill Markets: U.S. titanium mill product supply remains constrained, underscored by the sectors’ record order backlog and near 20-month lead times for premium titanium products. IperionX’s CIP billet and bar program directly targets this supply gap.
• Commercial Pipeline Maturation: Advanced the customer pipeline from material validation to component testing, prototype orders, and funded scale-up, targeting recurring, higher-value revenue across four core verticals: o
Titanium mill products for established mill and aerospace customers;
o
Aerospace defense primes, with an emphasis on missile systems;
o
Ground and naval defense contractors, building on active U.S. Army and U.S. Navy programs; and
o
Spherical titanium powder for consumer goods and electronics.
Atlas-Titan Critical Minerals Development
• Tier-1 Project Economics: The U.S. Government-supported Titan Definitive Feasibility Study (DFS), completed in June, demonstrated an after-tax NPV8 of US$813 million, an after-tax IRR of 39.4%, a 3.6-year payback period, and US$1.9 billion in cumulative after-tax free cash flow over an initial 14-year mine life.
• Strategic Atlas Acquisition Closed: Completed the US$3 million acquisition of the adjacent Atlas critical mineral and infrastructure assets on July 1, 2026 (following the June agreement).
• Immediate Infrastructure & Resource Synergies: Atlas adds ~70 acres of at-surface stockpiles, 180 acres of pre-stripped critical mineral mineralization, and established power, water, natural gas, and rail infrastructure. The full integrated Atlas-Titan economic assessment is underway. U.S. Department of War (DoW) programs
• US$18.5M Task Order 2 Award: The U.S. Army awarded Task Order 2 under IperionX’s US$99 million SBIR Phase III IDIQ contract, with an US$18.5 million base value (US$11.5 million initially funded) and scoped options bringing the total potential value to US$25.4 million.
• Remaining Contract Ceiling: Task Order 2 funding for continuous HSPT™ and dehydride furnaces alongside in-house fastener finishing in Virginia. Combined awards under Task Orders 1 and 2 total ~US$19.8 million, leaving US$79.2 million available under the existing US$99 million contract ceiling.
• U.S. titanium Supply Chain Funding Proposal Submitted: Submitted a formal proposal under Defense Industrial Base Consortium solicitation RPP-CM-26-02 (Domestic Processing Capabilities of Critical Minerals), which designates titanium, including titanium sponge substitutes, as a priority defense material.
• 1,400 tpa Expansion: Continued execution of the 1,400 tpa titanium capacity expansion under the fully obligated US$47.1 million IBAS award, the US$12.7 million DPA Title III award, and ~290 metric tons of no-cost U.S. Government titanium scrap transfers.
2
Corporate and liquidity
• Strong Balance Sheet & Liquidity: Closed the quarter with US$63.0 million in cash (June 30, 2026: US$35.2 million), supplemented by US$33.7 million in remaining obligated, reimbursable U.S. Government funding (including US$0.5 million in incurred expenditure pending reimbursement for IBAS and another $0.3m pending reimbursement from SBIR) - providing approximately US$96.7 million in total available liquidity. Net operating cash outflow was US$12.6 million, deployed across the Virginia production ramp, product qualification, and GenX™ R&D.
• US$50M U.S. Public Offering: Priced an underwritten U.S. public offering on July 7, 2026, issuing 2,275,000 ADSs at US$21.98 per ADS for gross proceeds of ~US$50.0 million (net proceeds of ~US$46.1 million).
• Director On-Market Purchases: Directors acquired ~US$1.9 million of IperionX shares via on-market purchases in July, underscoring strong board alignment with shareholders.
• Proposed U.S. Redomiciliation: Announced plans on August 3, 2026, to redomicile to a Texas parent company with common stock listed directly on Nasdaq (replacing the current ADS structure), subject to shareholder, court, and regulatory approvals.
• Board Strengthened: Appointed Michael J. Loparco as an Independent Non-Executive Director on August 3, 2026, bringing over 25 years of global advanced manufacturing and supply-chain leadership at Jabil and Symbotic.
IperionX Limited (NASDAQ: IPX, ASX: IPX) (IperionX) is pleased to invite shareholders and investors to a webinar on Tuesday November 3, 2026 at 10:00 am Australian Eastern Daylight Time / Monday November 2, 2026 at 18:00 pm U.S. Eastern Standard Time, where Founder and CEO, Taso Arima will provide a company update. Details of the event are as follows: • • • • •
Event: Presenter: Time: Where: Registration link:
IperionX Webinar Founder and CEO, Taso Arima Tue. Nov 3, 2026 at 10:00 am AEDT / Mon. Nov 2, 2026 at 18:00 pm U.S. EST Zoom webinar https://us06web.zoom.us/webinar/register/WN_0ZcrgMM3SzG2qzhwPZbzlw
After registering your interest, you will receive a confirmation email with information about joining the webinar. This announcement has been authorized for release by the CEO and Managing Director.
604
Page 1 of 4
Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder
To Company Name/Scheme
IPERIONX LTD
ACN/ARSN/ABN
84 618 935 372
- Details of substantial holder (1) Name
JPMorgan Chase & Co. and its affiliates
ACN/ARSN (if applicable)
NA
There was a change in the interests of the substantial holder on
20/October/2026
The previous notice was given to the company on
29/September/2026 DD/MMM/YYYY
The previous notice was dated 25/September/2026 2. Previous and present voting power The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:
Class of securities (4)
Previous notice Person’s votes
Ordinary
27,809,067
Present notice Voting power (5) 7.68%
Person’s votes 31,541,153.52
Voting power (5) 8.71%
- Changes in relevant interests Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows: Date of change
Person whose relevant interest Nature of change (6) changed
Consideration given Class and number of Person's in relation to securities affected votes change (7) affected
See Appendix
JPMORGAN CHASE BANK, N.A.
Securities on Loan as Agent Lender
See Appendix
527,194 (Ordinary)
527,194 (Ordinary)
See Appendix
J.P. MORGAN SECURITIES PLC
Holder of securities subject to an obligation to return under a securities lending agreement
See Appendix
443,917 (Ordinary)
443,917 (Ordinary)
See Appendix
J.P. MORGAN SECURITIES PLC
Purchase and sales of securities in its capacity as Principal/Proprietary
See Appendix
7,493 (Ordinary)
7,493 (Ordinary)
See Appendix
J.P. MORGAN SECURITIES LLC
Holder of securities subject to an obligation to return under a securities lending agreement
See Appendix
539,000 (Ordinary)
539,000 (Ordinary)
See Appendix
J.P. MORGAN SECURITIES LLC
Rehypothecation of client securities under a Prime Brokerage Agreement
See Appendix
2,464,142 (Ordinary)
2,464,142 (Ordinary)
See Appendix
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
Holder of securities subject to an obligation to return under a securities lending agreement
See Appendix
500,355 (Ordinary)
500,355 (Ordinary)
604
Page 2 of 4
See Appendix
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
Purchase and sales of securities in its capacity as Principal/Proprietary
See Appendix
40,689 (Ordinary)
40,689 (Ordinary)
See Appendix
J.P. MORGAN PRIME INC.
Rehypothecation of client securities under a Prime Brokerage Agreement
See Appendix
306,420 (Ordinary)
306,420 (Ordinary)
See Appendix
J.P. MORGAN INVESTMENT MANAGEMENT INC.
securities received as collateral due to securities lending
See Appendix
0.52 (Ordinary)
0.52 (Ordinary)
See Appendix
ALMEA 2 SEGREGATED PORTFOLIO COMPANY
Purchase and sales of securities in its capacity as Principal/Proprietary
See Appendix
50 (Ordinary)
50 (Ordinary)
- Present relevant interests Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows: Holder of relevant interest
Registered holder of securities
Person entitled to be registered as holder (8)
Nature of relevant interest (6)
Class and number of securities
Person's votes
Securities on Loan as Agent Lender
15,098,707 (Ordinary)
15,098,707 (Ordinary)
JPMORGAN CHASE BANK, N.A.
JPM Nominees Australia Pty Limited
Various Borrowers under the Securities Lending Agreement
J.P. MORGAN SECURITIES PLC
JPM Nominees Australia Pty Limited
JPM Nominees Australia Pty Limited
Holder of securities subject to an obligation to return under a securities lending agreement
1,415,619 (Ordinary)
1,415,619 (Ordinary)
J.P. MORGAN SECURITIES PLC
JPM Nominees Australia Pty Limited
J.P. MORGAN SECURITIES PLC
Purchase and sales of securities in its capacity as Principal/Proprietary
154,562 (Ordinary)
154,562 (Ordinary)
J.P. MORGAN SECURITIES LLC
Citi Australia
Various Clients and Custodians
Rehypothecation of client securities under a Prime Brokerage Agreement
4,950,956 (Ordinary)
4,950,956 (Ordinary)
J.P. MORGAN SECURITIES LLC
Citi Australia
Citi Australia
Holder of securities subject to an obligation to return under a securities lending agreement
3,667,000 (Ordinary)
3,667,000 (Ordinary)
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
Ecapital Nominees Pty Ltd
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
Purchase and sales of securities in its capacity as Principal/Proprietary
1,222,939 (Ordinary)
1,222,939 (Ordinary)
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
Ecapital Nominees Pty Ltd
Ecapital Nominees Pty Ltd
Holder of securities subject to an obligation to return under a securities lending agreement
1,784,645 (Ordinary)
1,784,645 (Ordinary)
J.P. MORGAN PRIME INC.
Citi Australia
Various Clients and Custodians
Rehypothecation of client securities under a Prime Brokerage Agreement
3,031,810 (Ordinary)
3,031,810 (Ordinary)
J.P. MORGAN INVESTMENT MANAGEMENT INC.
Not Available
Various Clients and Custodians
In its capacity as investment manager or in various other related capacities
10,540 (Ordinary)
10,540 (Ordinary)
604
Page 3 of 4
J.P. MORGAN INVESTMENT MANAGEMENT INC.
Brown Brothers Harriman Trustee Services (Ireland ) Limited
Brown Brothers Harriman Trustee Services (Ireland ) Limited
securities received as collateral due to securities lending
0.52 (Ordinary)
0.52 (Ordinary)
JPMORGAN ASSET MANAGEMENT (UK) LIMITED
BNP Paribas (Sydney Branch)
Various Clients and Custodians
In its capacity as investment manager or in various other related capacities
145,791 (Ordinary)
145,791 (Ordinary)
JPMORGAN ASSET MANAGEMENT (UK) LIMITED
Citibank, N.A., Hong Kong Branch
Various Clients and Custodians
In its capacity as investment manager or in various other related capacities
58,584 (Ordinary)
58,584 (Ordinary)
- Changes in association The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows: Name and ACN/ARSN (if applicable)
Nature of association
J.P. MORGAN SECURITIES LLC
Subsidiary of JPMorgan Chase & Co.
J.P. MORGAN SECURITIES PLC
Subsidiary of JPMorgan Chase & Co.
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
Subsidiary of JPMorgan Chase & Co.
JPMORGAN CHASE BANK, N.A.
Subsidiary of JPMorgan Chase & Co.
J.P. MORGAN PRIME INC.
Subsidiary of JPMorgan Chase & Co.
ALMEA 2 SEGREGATED PORTFOLIO COMPANY
Subsidiary of JPMorgan Chase & Co.
J.P. MORGAN INVESTMENT MANAGEMENT INC.
Subsidiary of JPMorgan Chase & Co.
- Addresses The addresses of persons named in this form are as follows: Name
Address JPMorgan Chase & Co.
270 Park Avenue, New York, New York, NY, 10017, United States
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
LEVEL 18, 83-85 CASTLEREAGH STREET, SYDNEY, NSW 2000, Australia
J.P. MORGAN SECURITIES LLC
270 Park Avenue, New York, New York, NY, 10017, United States
J.P. MORGAN SECURITIES PLC
25 Bank Street, Canary Wharf, London, E14 5JP, England
JPMORGAN CHASE BANK, N.A.
1111 Polaris Parkway, Columbus, Delaware, OH, 43240, United States
J.P. MORGAN PRIME INC.
270 Park Avenue, New York, New York, NY, 10017, United States
ALMEA 2 SEGREGATED PORTFOLIO COMPANY
270 Park Avenue, New York, New York, NY, 10017, United States
J.P. MORGAN INVESTMENT MANAGEMENT INC.
270 Park Avenue, New York, New York, NY, 10017, United States
JPMORGAN ASSET MANAGEMENT (UK) LIMITED
60 Victoria Embankment, London, EC4Y0JP, England
Signature print name sign here
Vasim Pathan
Capacity Date
Compliance Officer 22/October/2026
604
Page 4 of 4
DIRECTIONS (1)
If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 6 of the form.
(2)
See the definition of "associate" in section 9 of the Corporations Act 2001.
(3)
See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
(4)
The voting shares of a company constitute one class unless divided into separate classes.
(5)
The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.
(6)
Include details of: (a)
any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
(b)
any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).
See the definition of "relevant agreement" in section 9 of the Corporations Act 2001. (7)
Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
(8)
If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown".
(9)
Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.
TRADES FOR RELEVANT PERIOD Transaction Date Balance at start of relevant period 28-Sep-26 28-Sep-26 28-Sep-26 28-Sep-26 28-Sep-26 28-Sep-26 28-Sep-26 28-Sep-26 28-Sep-26 28-Sep-26 28-Sep-26 28-Sep-26 28-Sep-26 28-Sep-26 28-Sep-26 28-Sep-26 29-Sep-26 29-Sep-26 29-Sep-26 29-Sep-26 29-Sep-26 29-Sep-26 29-Sep-26 29-Sep-26 29-Sep-26 29-Sep-26 29-Sep-26 29-Sep-26 29-Sep-26 29-Sep-26 29-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 30-Sep-26 1-Oct-26 1-Oct-26 1-Oct-26 1-Oct-26 1-Oct-26 1-Oct-26 1-Oct-26 1-Oct-26 1-Oct-26 1-Oct-26 1-Oct-26 1-Oct-26 1-Oct-26 2-Oct-26 2-Oct-26 2-Oct-26 2-Oct-26 2-Oct-26 2-Oct-26 2-Oct-26 2-Oct-26 2-Oct-26 2-Oct-26 2-Oct-26 2-Oct-26 5-Oct-26 5-Oct-26 5-Oct-26 5-Oct-26 5-Oct-26 5-Oct-26 5-Oct-26 5-Oct-26 5-Oct-26 5-Oct-26 5-Oct-26 6-Oct-26 6-Oct-26 6-Oct-26 6-Oct-26 6-Oct-26 6-Oct-26 6-Oct-26 6-Oct-26 6-Oct-26 6-Oct-26 6-Oct-26 6-Oct-26 6-Oct-26 6-Oct-26 6-Oct-26 7-Oct-26 7-Oct-26 7-Oct-26 7-Oct-26 7-Oct-26 7-Oct-26 7-Oct-26 7-Oct-26 7-Oct-26 7-Oct-26 7-Oct-26 7-Oct-26 8-Oct-26 8-Oct-26 8-Oct-26 8-Oct-26 8-Oct-26 8-Oct-26
Appendix Entity
Product Type
Type of Transaction
J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES AUSTRALIA LIMITED JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES AUSTRALIA LIMITED JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A.
Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity Equity
Adjustment Buy Sell Sell Sell Borrow Sell Sell Borrow Return Borrow Return Borrow Borrow Borrow Borrow Return Borrow Return Borrow Return Buy Buy Buy Sell Borrow Return Borrow Return Borrow Return Borrow Return Borrow Return Borrow Return Borrow Return Borrow Return Borrow Borrow Borrow Buy Sell Sell Buy Sell Sell Sell Sell Buy Buy Sell Sell Sell Sell Sell Sell Sell Borrow Return Borrow Return Borrow Return Borrow Return Borrow Return Borrow Return Borrow Return Borrow Borrow Borrow Return Borrow Return Borrow Return Borrow Borrow Borrow Borrow Return Borrow Borrow Return Buy Sell Buy Sell Buy Borrow Return Borrow Return Borrow Return Borrow Borrow Borrow Return Borrow Borrow Buy Buy Buy Buy Sell Sell Sell Borrow Borrow Borrow Borrow Return Borrow Return Sell Sell Sell Sell Borrow Return Borrow Return Borrow Borrow Borrow Return Borrow Return Borrow Return Buy Buy Sell Sell Sell Sell Buy Borrow Return Borrow Return Borrow Return Borrow Borrow Return Borrow Return Borrow Return Borrow Return Sell Buy Sell Borrow Return Borrow Return Borrow Return Borrow Borrow Return Borrow Return Borrow Return Borrow Return Borrow Return Buy Sell Sell Borrow Return Borrow Return Borrow Return
Quantity 27,809,067 (385) 643 (1,984) (6,451) (5,915) 420,000 (3,986) (39) (1,000) (35,000) 50,000 9,392 7,509 (2) (272,720) (11,230) 13,603 45 5,856 (28) (9,000) (35,000) (10,000) (3,000) (25,000) (38,000) (22,000) (9,000) 2,000 31,067 70,000 2,075 (23) (289) 5,718 (7,340) (258) (107) (11) 11 6,236 (625) (1,096) (298) (20) (10) (10) (10) (6,000) (2,000) (4,000) (4,000) (22,000) (41,000) (11,000) 151,000 600,000 (640,482) (229,511) (1) 1 1,196 157,100 (6,082) 210 (210) 3,989 (8) 1,390 (968) 3,055 (20,000) (11,000) (18,000) 89,000 1,000 (57,665) 47,592 26,000 869 5,109 274 235 (1,802) (1,538) (732) 50,000 187,521 16,596 (16,596) (200) (11,115) (5,109) (7,142) (4,163) (14,000) (750,222) 200 69,800 (2) (1,196) (482,100) 1,674 127 (16,795) (131) (4,473) (684) 684 (420,000) (500,000) (34,000) 1,060,488 (66,513) (26,000) (8,240) (5,760) (12,190) 95 (902) (41,000) (57,460) (160,000) 89,645 (8,404) (4) (2) (15) (33,715) 1,982 (97) (167) (1,000) (170,000) (100,000)
Price (AUD) 2.69 2.76 2.76 2.69 2.72 2.71 2.65 2.63 2.63 2.69 2.54 2.47 2.51 2.52 2.51 2.52 2.52 2.52 2.52 2.51 2.63 2.63 2.63 2.42 2.42 2.42 2.42 2.35 2.36 2.31 2.51 2.31 2.40 2.40 2.40 2.40 2.31 2.31 2.31 2.41 2.39 2.40 2.40 2.39 2.40 2.39 2.39 2.39 2.40 2.40 2.32 2.33 2.40 2.22 2.24 2.35
Consideration $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $
1,729.67 5,475.84 17,804.76 15,911.35 10,835.60 105.69 36,024.31 118.35 15,402.51 75.32 5,273.02 56.81 725.39 14,411.67 18,423.40 650.16 269.64 27.72 27.72 15,653.61 1,643.75 2,882.48 783.74 48.48 24.23 24.20 24.21 9,381.31 18.88 3,211.16 2,429.68 7,057.05 2,085.77 12,281.58 657.60 564.00 4,162.62 3,552.78 1,690.92 26,742.39 12,219.79 17,140.80 9,991.20 4,004.87 304.80 40,140.05 313.09 10,690.47 1,641.60 1,641.60 28,280.80 221.35 2,164.80 4,400.04 217.28 392.45
1/2
TRADES FOR RELEVANT PERIOD 8-Oct-26 8-Oct-26 8-Oct-26 8-Oct-26 9-Oct-26 9-Oct-26 9-Oct-26 9-Oct-26 9-Oct-26 9-Oct-26 9-Oct-26 9-Oct-26 12-Oct-26 12-Oct-26 12-Oct-26 12-Oct-26 12-Oct-26 12-Oct-26 12-Oct-26 12-Oct-26 12-Oct-26 12-Oct-26 12-Oct-26 12-Oct-26 13-Oct-26 13-Oct-26 13-Oct-26 13-Oct-26 13-Oct-26 13-Oct-26 13-Oct-26 13-Oct-26 13-Oct-26 13-Oct-26 13-Oct-26 13-Oct-26 13-Oct-26 13-Oct-26 13-Oct-26 14-Oct-26 14-Oct-26 14-Oct-26 14-Oct-26 14-Oct-26 14-Oct-26 14-Oct-26 14-Oct-26 14-Oct-26 14-Oct-26 14-Oct-26 15-Oct-26 15-Oct-26 15-Oct-26 15-Oct-26 15-Oct-26 15-Oct-26 15-Oct-26 15-Oct-26 15-Oct-26 16-Oct-26 16-Oct-26 16-Oct-26 16-Oct-26 16-Oct-26 16-Oct-26 16-Oct-26 16-Oct-26 16-Oct-26 16-Oct-26 16-Oct-26 16-Oct-26 16-Oct-26 16-Oct-26 16-Oct-26 16-Oct-26 16-Oct-26 16-Oct-26 16-Oct-26 19-Oct-26 19-Oct-26 19-Oct-26 19-Oct-26 19-Oct-26 19-Oct-26 19-Oct-26 19-Oct-26 19-Oct-26 19-Oct-26 19-Oct-26 19-Oct-26 19-Oct-26 19-Oct-26 20-Oct-26 20-Oct-26 20-Oct-26 20-Oct-26 20-Oct-26 20-Oct-26 20-Oct-26 20-Oct-26 20-Oct-26 20-Oct-26 20-Oct-26 20-Oct-26 20-Oct-26 20-Oct-26 20-Oct-26 20-Oct-26 20-Oct-26 Balance at end of relevant period
JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES PLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES PLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES AUSTRALIA LIMITED JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN PRIME INC. J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN INVESTMENT MANAGEMENT INC. J.P. MORGAN INVESTMENT MANAGEMENT INC. J.P. MORGAN INVESTMENT MANAGEMENT INC. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A.
Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity - Depository Receipt Equity Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity
Borrow Return Borrow Return Borrow Return Borrow Return Buy Buy Sell Sell Borrow Return Borrow Borrow Return Borrow Return Sell Sell Buy Sell Borrow Return Borrow Borrow Borrow Borrow Return Borrow Borrow Borrow Sell Buy Sell Buy Sell Sell Borrow Borrow Borrow Borrow Borrow Return Borrow Return Borrow Return Borrow Return Borrow Sell Buy Buy Sell Buy Borrow Borrow Return Borrow Return Borrow Borrow Borrow Return Borrow Sell Sell Borrow Return Borrow Return Borrow Return Borrow Return Borrow Return Borrow Return Buy Buy Sell Buy Buy Buy Buy Sell Buy Sell Buy Borrow Borrow Borrow Borrow Borrow Borrow Borrow Borrow Buy Buy Sell Sell Buy Buy Borrow Borrow Borrow Borrow Return Borrow Borrow Borrow Return Borrow On-Lend On-Lend On-Lend Buy Buy Buy Sell Buy Sell Sell Buy Sell Collateral In Collateral In Collateral In Borrow Borrow
(202,932) (904,778) (95,222) (247,772) 5,908 3,893 (3,949) (12,420) (1,000) 84,198 (2,000) (42,657) (6,396) (32) 2,283 (5,648) (60,000) 482,747 220,000 9,091 (153,779) 1,196 267,404 293,000 (6,396) 5,649 (5,649) 3,018 (83) (434) 5,000 9,819 39,000 97,978 (125,391) (101,471) (3,472) (38,576) 85,000 (2,067) 2,067 477 (101) 3,823 101,211 (220,000) (64,274) 2,276 11,000 (201,210) 6,000 (48) (5,047) (10,000) (33,704) (2,276) (22,381) (1,196) (267,404) 253 180 (27) 27 40 309 577 (26) 5,000 (3,261) 6,743 75,000 24,000 8,000 6,000 395,000 146,569 4,668 395,332 1,779 152 (1,016) (3) 3 149 1,600 98,000 46,000 (53,000) 49,954 1 (19,278) 200,000 306,420 1,007,032 1,457,110 2,944 2,557 6,443 (256) 152 (1,552) (4,004) 767 (1,779) 0.02 0.49 0.01 2,000,000 21,500 31,541,153.52
2.24 2.20 2.20 2.24 2.36 2.37 2.36 2.20 2.17 2.19 2.14 2.13 2.13 2.33 2.11 2.18 2.11 2.09 2.09 1.94 2.09 2.05 2.03 2.02 2.02 2.03 2.07 2.07 2.08 2.06 2.06 2.08 2.04 2.04 2.08 2.04 2.04 2.04 1.96 1.96 1.96 1.96 2.00 1.96 1.96 1.95 2.04
Appendix $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $
13,233.92 8,564.60 8,687.80 27,820.80 15,072.62 75.84 5,388.31 12,425.60 13,867.12 12,371.31 12,067.31 6,428.52 176.79 1,011.22 4,361.37 4,506.06 1,007.39 211.09 7,990.71 92.88 10,548.23 518.65 365.40 54.54 54.54 81.00 638.09 1,191.51 54.08 10,300.00 6,728.66 14,026.56 3,629.75 310.08 2,113.28 6.12 6.12 303.96 5,770.24 5,011.72 12,628.28 501.76 304.00 3,034.86 7,838.73 1,497.55 3,629.16
2/2
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX. Date:
22-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant interests: Schedule
20-Oct-2026
Type of agreement
Global Master Securities Lending Agreement (“GMSLA”)
Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and BARCLAYS CAPITAL SECURITIES LIMITED ( “Borrower”) Settlement Date: 02-Jun-2025 29-Jan-2026 30-Jan-2026
Transfer date Holder of voting rights Are there any restriction on voting rights If yes, detail Scheduled return date (if any) Does the borrower have the right to return early?
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA. None Yes
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
22-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 20-Oct-2026 interests: Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and BNP Paribas Financial Markets (Borrower)
Transfer date
Settlement Date 02-Sep-2026 03-Sep-2026 07-Sep-2026 17-Sep-2026 18-Sep-2026 21-Sep-2026 30-Sep-2026 01-Oct-2026 02-Oct-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX. Date:
22-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant interests: Schedule
20-Oct-2026
Type of agreement
Master Securities Lending Agreement (“MSLA”)
Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Bofa Securities, Inc. ( “Borrower”)
Transfer date
Settlement date 07-Aug-2026 11-Aug-2026 21-Aug-2026 26-Aug-2026 28-Aug-2026
Holder of voting rights Are there any restriction on voting rights If yes, detail Scheduled return date (if any) Does the borrower have the right to return early?
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out as per the rights of the borrower as stated in the MSLA. None Yes
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
22-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 20-Oct-2026 interests: Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Citigroup Global Markets Limited (Borrower)
Transfer date
Settlement Date 10-Aug-2026 29-Sep-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX. Date:
22-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant interests: Schedule
20-Oct-2026
Type of agreement
Master Securities Lending Agreement (“MSLA”)
Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Citigroup Global Markets Inc. ( “Borrower”) Settlement date 02-Oct-2026
Transfer date Holder of voting rights Are there any restriction on voting rights If yes, detail Scheduled return date (if any) Does the borrower have the right to return early?
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out as per the rights of the borrower as stated in the MSLA. None Yes
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX. Date:
22-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant interests: Schedule
20-Oct-2026
Type of agreement
Master Securities Lending Agreement (“MSLA”)
Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Goldman Sachs & Co. LLC ( “Borrower”)
Transfer date
Settlement Date 08-Sep-2026 29-Sep-2026
Holder of voting rights Are there any restriction on voting rights If yes, detail Scheduled return date (if any) Does the borrower have the right to return early?
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out as per the rights of the borrower as stated in the MSLA. None Yes
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
22-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 20-Oct-2026 interests: Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Goldman Sachs International (Borrower)
Transfer date
Settlement Date 07-Sep-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
22-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 20-Oct-2026 interests: Schedule Type of agreement Australian Master Securities Lending Agreement (“AMSLA”) Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Macquarie Bank Limited(Borrower)
Transfer date
Settlement Date 16-Oct-2026 19-Oct-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4.3 of the standard form AMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender’s instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
22-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 20-Oct-2026 interests: Schedule Type of agreement Australian Master Securities Lending Agreement (“AMSLA”) Parties to agreement
Transfer date
Holder of voting rights Are there any restriction on voting rights
If yes, detail
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Merrill Lynch Equities (Australia) Limited(Borrower) Settlement Date 05-Jun-2026 13-Jul-2026 12-Aug-2026 25-Aug-2026 16-Sep-2026 Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4.3 of the standard form AMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender’s instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
22-Oct-2026
Company’s name: IPERIONX LTD ISIN:
AU0000208910
Date of change of relevant interests:
20-Oct-2026
Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Merrill Lynch International(Borrower)
Transfer date
Settlement Date 09-Jun-2026 16-Jun-2026 26-Jun-2026 14-Jul-2026 15-Jul-2026 17-Jul-2026 21-Jul-2026 22-Jul-2026 23-Jul-2026 24-Jul-2026 29-Jul-2026 30-Jul-2026 31-Jul-2026 03-Aug-2026 15-Sep-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions.
Will the securities be returned on Yes settlement?
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
22-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 20-Oct-2026 interests: Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
Transfer date
Holder of voting rights Are there any restriction on voting rights
If yes, detail
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Morgan Stanley & Co. International PLC (Borrower) Settlement Date 24-Aug-2026 23-Sep-2026 08-Oct-2026 20-Oct-2026 Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
22-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 20-Oct-2026 interests: Schedule Type of agreement Australian Master Securities Lending Agreement (“AMSLA”) Parties to agreement
Transfer date
Holder of voting rights Are there any restriction on voting rights
If yes, detail
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Morgan Stanley Australia Securities Limited (Borrower) Settlement Date 31-Oct-2025 18-Mar-2026 10-Jul-2026 15-Jul-2026 22-Sep-2026 01-Oct-2026 05-Oct-2026 07-Oct-2026 Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4.3 of the standard form AMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender’s instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
22-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 20-Oct-2026 interests: Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Societe Generale Paris Branch (Borrower)
Transfer date
Settlement Date 15-Oct-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
22-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 20-Oct-2026 interests: Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and UBS AG London Branch (Borrower)
Transfer date
Settlement Date 28-Aug-2026 31-Aug-2026 17-Sep-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX. Date:
22-Oct-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of 20-Oct-2026 relevant interests: Schedule Type of agreement Australian Master Securities Lending Agreement (“AMSLA”) Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and UBS Securities Australia Ltd (Borrower)
Transfer date
Settlement Date 18-Jun-2026 25-Jun-2026 26-Jun-2026 29-Jun-2026 27-Aug-2026 14-Sep-2026 19-Oct-2026 21-Oct-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4.3 of the standard form AMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s If yes, detail instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX. Date:
22-Oct-2026
Company’s name:
IPERIONX LTD
ISIN: Date of change of relevant interests: Schedule
AU0000208910
Type of agreement
Master Securities Lending Agreement (“MSLA”)
Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and UBS SECURITIES LLC ( “Borrower”)
Transfer date
Settlement Date 15-Sep-2026 14-Oct-2026 21-Oct-2026
Holder of voting rights Are there any restriction on voting rights If yes, detail Scheduled return date (if any) Does the borrower have the right to return early?
20-Oct-2026
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out as per the rights of the borrower as stated in the MSLA. None Yes
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX.
Date: Company’s name:
22-Oct-2026
ISIN: Date of change of relevant interests: Schedule Type of agreement Parties to agreement
AU0000208910
Transfer date Holder of voting rights Are there any restriction on voting rights
If yes, detail
Scheduled return date (if any) Does the borrower have the right to return early?
IPERIONX LTD
20-Oct-2026 Australian Master Securities Lending Agreement ("AMSLA") BNP Paribas Fund Securities Services S.C.A.(“lender”), J.P. Morgan Securities Australia Limited (“borrower”) Settlement Date 09-Oct-2026
Borrower Yes The borrower undertakes to use its best endeavours to arrange for the voting rights to be exercised in accordance with the instructions of the other lender, provided that the lender uses its best endeavours to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4.3 of the standard form AMSLA. None Yes
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day as agreed by the parties. The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX. Date:
22-Oct-2026
Company’s name:
IPERIONX LTD
ISIN: Date of change of relevant interests: Schedule
AU0000208910
Type of agreement Parties to agreement
Australian Master Securities Lending Agreement ("AMSLA")
20-Oct-2026
JPMorgan Chase Bank, N.A. (acting as agent) ("lender"), J.P. Morgan Securities Australia Limited ('borrower')
Transfer date
Settlement Date 20-Mar-2026 28-Apr-2026 14-Oct-2026
Holder of voting rights
Borrower
Are there any restriction on voting Yes rights
If yes, detail
The borrower undertakes to use its best endeavours to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavours to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4.3 of the standard form AMSLA.
Scheduled return date (if any)
None
Does the borrower have the right to return early?
Yes
If yes, detail
Borrower has right to return all and any securities or equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities on any business day by giving such notice as agreed by the parties. The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exception
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX. Date:
22-Oct-2026
Company’s name:
IPERIONX LTD
ISIN: Date of change of relevant interests: Schedule
AU0000208910
Type of agreement
Global Master Securities Lending Agreement ("GMSLA")
Parties to agreement Transfer date Holder of voting rights Are there any restriction on voting rights If yes, detail
20-Oct-2026
State Street Bank and Trust Company ("lender") and J.P. Morgan Securities Australia Limited ("borrower") Settlement Date 23-Feb-2026 07-Jul-2026 Borrower Yes The borrower shall have no obligation to arrange for voting rights to be exercised in accordance with the instructions of the other party, unless otherwise agreed between the parties.
Scheduled return date (if None any) Does the borrower have the right to return early?
Yes
If yes, detail
Borrower has the right to terminate a loan and redeliver all and any equivalent securities due and outstanding to the lender in accordance with lender's instructions and lender shall accept such redelivery.
Does the lender have the Yes right to recall early? Lender has right to recall all or any equivalent securities on any business day by giving such notice as If yes, detail agreed by the parties. The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions. Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX.
Date: Company’s name: ISIN: Date of change of relevant interests: Schedule Type of agreement
22-Oct-2026 IPERIONX LTD AU0000208910
20-Oct-2026 Institutional Account Agreement
Parties to agreement
JP Morgan Securities LLC for itself and as agent and trustee for the other J.P. Morgan Entities and VANGUARD GROUP INC (AS AGT),CHARLES SCHWAB & CO., INC,INTERACTIVE BROKERS LLC,ROBINHOOD SECURITIES, LLC (herein referred to as “JPMS”). “ J.P. Morgan Entities” means, as the context may require or permit, any and all of JPMSL, JPMorgan Chase Bank, N.A., J.P. Morgan Securities LLC., J.P. Morgan Markets Limited, J.P. Morgan Securities Australia Limited, J.P. Morgan Securities (Asia Pacific) Limited, J.P. Morgan Securities Japan Co., Ltd and J.P. Morgan Prime Nominees Limited and any additional entity notified to the Company from time to time.
Transfer date
Settlement Date 25-Jun-2026 30-Jun-2026 31-Jul-2026 03-Aug-2026 06-Aug-2026 28-Aug-2026 01-Sep-2026 02-Sep-2026 30-Sep-2026 01-Oct-2026 02-Oct-2026 13-Oct-2026 15-Oct-2026 16-Oct-2026 19-Oct-2026
Holder of voting rights
JPMS is the holder of the voting rights from the time at which it exercises its right to borrow. Notwithstanding this, please note that the Company has the right to recall equivalent securities if it wishes to exercise its voting rights in respect of the securities.
Are there any restriction on voting Yes rights JPMS will not be able to exercise voting rights in circumstances where the Company has recalled If yes, detail equivalent securities from JPMS before the voting rights have been exercised. In these circumstances, JPMS must return the securities to the Company and the Company holds the voting rights. Scheduled return N/A. There is no term to the loan of securities. date (if any) Does the borrower have the right to Yes. return early? If yes, detail
JPMS has the right to return all and any securities or equivalent securities early at any time.
Does the lender have the right to recall early?
Yes.
If yes, detail
The Company has the right to recall all or any equivalent securities on demand.
Will the securities be Yes. Settlement of the loan will occur when JPMS returns equivalent securities to the Company. There returned on is no term to the loan of securities. settlement? If yes, detail any exceptions Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX. Date:
22-Oct-2026
Company’s name:
IPERIONX LTD
ISIN: Date of change of relevant interests: Schedule
AU0000208910
Type of agreement
Global Master Securities Lending Agreement ("GMSLA")
Parties to agreement
BANK JULIUS BAER & CO. AG vs JPMS PLC
Transfer date
Settlement Date 01-Jul-2026 02-Jul-2026 06-Jul-2026 09-Jul-2026 13-Jul-2026 16-Oct-2026 19-Oct-2026
Holder of voting rights
20-Oct-2026
Borrower
Are there any Yes restriction on voting rights If yes, detail Scheduled return date (if any) Does the borrower have the right to return early?
If yes, detail
Does the lender have the right to recall early?
If yes, detail
The borrower shall have no obligation to arrange for voting rights to be exercised in accordance with the instructions of the other party, unless otherwise agreed between the parties. None
Yes
Borrower has the right to terminate a loan and redeliver all and any equivalent securities due and outstanding to the lender in accordance with lender's instructions and lender shall accept such redelivery on a business day if notice of redelivery has been given within the standard market settlement period.
Yes
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time provided notification is given by the lender within standard market settlement period for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered. The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX.
Date: Company’s name:
22-Oct-2026
ISIN: Date of change of relevant interests: Schedule
AU0000208910
Type of agreement
IPERIONX LTD
20-Oct-2026 Overseas Securities Lender's Agreement ("OSLA")
Parties to agreement
J.P. Morgan Securities Plc ("borrower") and Citibank N.A. acting as Agent ("lender")
Transfer date
Settlement Date 07-Aug-2026
Holder of voting rights Borrower Are there any restriction on voting rights
Yes
If yes, detail
The borrower undertakes to use its best endeavours to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavours to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4(B)(vi) of the standard form OSLA.
Scheduled return date None (if any) Does the borrower have the right to return early?
Yes
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered. The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX. Date:
22-Oct-2026
Company’s name:
IPERIONX LTD
ISIN: Date of change of relevant interests:
AU0000208910
20-Oct-2026
Schedule Type of agreement Parties to agreement
Transfer date
Overseas Securities Lender’s Agreement (“OSLA”) JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) J.P. Morgan Securities plc (“borrower”) Settlement Date 30-Mar-2026 14-Oct-2026 15-Oct-2026 16-Oct-2026 20-Oct-2026
Holder of voting rights
Borrower
Are there any restriction on voting rights
Yes
If yes, detail
The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4(B)(vi) of the standard form OSLA.
Scheduled return date (if any)
None
Does the borrower have the right to Yes return early?
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX.
Date: Company’s name:
22-Oct-2026
ISIN: Date of change of relevant interests: Schedule
AU0000208910
Type of agreement
IPERIONX LTD
20-Oct-2026
Global Master Securities Lending Agreement ("GMSLA")
Parties to agreement
J.P. Morgan Securities plc ("borrower") and State St Bank and Trust Company as agent ("lender")
Transfer date
Settlement Date 29-Jul-2026
Holder of voting rights
Borrower
Are there any restriction on voting Yes rights
If yes, detail
The borrower shall have no obligation to arrange for voting rights to be exercised in accordance with the instructions of the other party, unless otherwise agreed between the parties.
Scheduled return date (if any)
None
Does the borrower have the right to return early?
Yes
If yes, detail
Borrower has the right to terminate a loan and redeliver all and any equivalent securities due and outstanding to the lender in accordance with lender's instructions and lender shall accept such redelivery.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered. The borrower must return the
securities not later than the expiry of such notice in accordance with the lender’s instructions. Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
604
Page 1 of 2 15 July 2001
Form 604 Corporations Act 2001 Section 671B
Notice of change of interests of substantial holder To Company Name/Scheme
IperionX Ltd
ACN/ARSN
618 935 372
- Details of substantial holder (1)
The Bank of New York Mellon Corporation (BNY) and each Group Entity listed in Annexure A (Group Entity),(together BNY)
Name ACN/ARSN (if applicable)
There was a change in the interests of the substantial holder on
15/October/2026
The previous notice was given to the company on
10/July/2026
The previous notice was dated
09/July/2026
- Previous and present voting power The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows: Class of securities (4)
Ordinary shares
Previous notice
Present notice
Person’s votes
Voting power (5)
Person’s votes
Voting power (5)
96,768,001
26.72%
100,737,812*
27.81%*
*See Note 1 in Annexure C
- Changes in relevant interests Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows: Date of change
Person whose relevant interest changed
Nature of change (6)
Consideration given in relation to change (7)
Class and number of securities affected
Person's votes affected
See Annexure B
- Present relevant interests Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows: Holder of relevant interest
See Annexure C
Registered holder of securities
Person entitled to be registered as holder (8)
Nature of relevant interest (6)
Class and number of securities
Person's votes
604
Page 2 of 2 15 July 2001
- Changes in association The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows: Name and ACN/ARSN (if applicable)
Nature of association
BNY and each Group Entity
Each Group Entity is an associate of BNY pursuant to section 12(2)(a) of the Corporations Act 2001 (Cth) as each entity is directly or indirectly owned and controlled by BNY.
- Addresses The addresses of persons named in this form are as follows: Name
Address
The Bank of New York Mellon Corporation
240 Greenwich Street, New York, NY 10286 USA
Each Group Entity
240 Greenwich Street, New York, NY 10286 USA
Signature print name
sign here
Andrew Weiser
capacity
Attorney-In-Fact
date
16/October/2026
Annexure A This is Annexure A of 1 page referred to in Form 604 Notice of Change of Interests of Substantial Holder given by The Bank of New York Mellon Corporation and its related bodies corporate The Bank of New York Mellon Corporation is the ultimate parent company of a corporate group comprised of a large number of operating and holding companies. Details of the entities directly owned and controlled by The Bank of New York Mellon Corporation are listed below.
The Bank of New York Mellon Pershing Group LLC Pershing LLC BNY Mellon IHC, LLC MBC Investments Corporation Mellon Investments Corporation BNY Mellon Advisors, Inc.
print name Andrew Weiser
capacity______ Attorney-In-Fact
sign here
date
16/October/2026_____________
Annexure B This is Annexure B of 2 pages referred to in Form 604 Notice of Change of Interests of Substantial Holder given by The Bank of New York Mellon Corporation and its related bodies corporate Changes in relevant interest Date of change 10-Jul-2026 10-Jul-2026 10-Jul-2026 13-Jul-2026 13-Jul-2026 14-Jul-2026 15-Jul-2026 15-Jul-2026 15-Jul-2026 16-Jul-2026 16-Jul-2026 16-Jul-2026 16-Jul-2026 16-Jul-2026 17-Jul-2026 17-Jul-2026 17-Jul-2026 20-Jul-2026 20-Jul-2026 20-Jul-2026 20-Jul-2026 21-Jul-2026 21-Jul-2026 22-Jul-2026 22-Jul-2026 22-Jul-2026 22-Jul-2026 23-Jul-2026 24-Jul-2026 24-Jul-2026 24-Jul-2026 27-Jul-2026 28-Jul-2026 29-Jul-2026 29-Jul-2026 29-Jul-2026 30-Jul-2026 30-Jul-2026 31-Jul-2026 31-Jul-2026 03-Aug-2026 03-Aug-2026 03-Aug-2026 05-Aug-2026 06-Aug-2026 06-Aug-2026 07-Aug-2026 07-Aug-2026 10-Aug-2026 10-Aug-2026 12-Aug-2026 13-Aug-2026 14-Aug-2026 14-Aug-2026 17-Aug-2026 17-Aug-2026 18-Aug-2026 18-Aug-2026 18-Aug-2026 19-Aug-2026 20-Aug-2026 20-Aug-2026 21-Aug-2026 21-Aug-2026 24-Aug-2026 24-Aug-2026 25-Aug-2026 26-Aug-2026 27-Aug-2026 28-Aug-2026 31-Aug-2026 01-Sep-2026 01-Sep-2026 02-Sep-2026 03-Sep-2026 04-Sep-2026 08-Sep-2026 10-Sep-2026 11-Sep-2026 14-Sep-2026 14-Sep-2026 14-Sep-2026 15-Sep-2026
Person whose relevant interest changed The Bank of New York Mellon The Bank of New York Mellon BNY Mellon Advisors, Inc. The Bank of New York Mellon The Bank of New York Mellon The Bank of New York Mellon The Bank of New York Mellon BNY Mellon Advisors, Inc. BNY Mellon Advisors, Inc. The Bank of New York Mellon The Bank of New York Mellon The Bank of New York Mellon The Bank of New York Mellon BNY Mellon Advisors, Inc. The Bank of New York Mellon The Bank of New York Mellon BNY Mellon Advisors, Inc. The Bank of New York Mellon The Bank of New York Mellon The Bank of New York Mellon BNY Mellon Advisors, Inc. The Bank of New York Mellon The Bank of New York Mellon The Bank of New York Mellon The Bank of New York Mellon The Bank of New York Mellon BNY Mellon Advisors, Inc. The Bank of New York Mellon The Bank of New York Mellon BNY Mellon Advisors, Inc. BNY Mellon Advisors, Inc. The Bank of New York Mellon BNY Mellon Advisors, Inc. The Bank of New York Mellon The Bank of New York Mellon BNY Mellon Advisors, Inc. The Bank of New York Mellon Mellon Investments Corporation The Bank of New York Mellon BNY Mellon Advisors, Inc. The Bank of New York Mellon The Bank of New York Mellon BNY Mellon Advisors, Inc. The Bank of New York Mellon The Bank of New York Mellon BNY Mellon Advisors, Inc. BNY Mellon Advisors, Inc. BNY Mellon Advisors, Inc. The Bank of New York Mellon BNY Mellon Advisors, Inc. The Bank of New York Mellon The Bank of New York Mellon The Bank of New York Mellon The Bank of New York Mellon The Bank of New York Mellon BNY Mellon Advisors, Inc. The Bank of New York Mellon The Bank of New York Mellon BNY Mellon Advisors, Inc. BNY Mellon Advisors, Inc. The Bank of New York Mellon BNY Mellon Advisors, Inc. BNY Mellon Advisors, Inc. BNY Mellon Advisors, Inc. Mellon Investments Corporation BNY Mellon Advisors, Inc. The Bank of New York Mellon BNY Mellon Advisors, Inc. BNY Mellon Advisors, Inc. BNY Mellon Advisors, Inc. BNY Mellon Advisors, Inc. The Bank of New York Mellon The Bank of New York Mellon BNY Mellon Advisors, Inc. BNY Mellon Advisors, Inc. BNY Mellon Advisors, Inc. The Bank of New York Mellon BNY Mellon Advisors, Inc. The Bank of New York Mellon The Bank of New York Mellon The Bank of New York Mellon The Bank of New York Mellon The Bank of New York Mellon
Nature of Change Transfer Out of Securities Securities Lent (Agent Lender) Transfer Out of Securities Transfer Out of Securities Securities Lent (Agent Lender) Transfer Out of Securities Transfer Out of Securities Purchase of Securities Sale of Securities Transfer Out of Securities Sale of securities Transfer In of Securities Return of Lent securities (Agent Lender) Purchase of Securities Transfer Out of Securities Return of Lent securities (Agent Lender) Purchase of Securities Transfer Out of Securities Transfer In of Securities Securities Lent (Agent Lender) Purchase of Securities Transfer In of Securities Securities Lent (Agent Lender) Deposit of Securities Transfer In of Securities Return of Lent securities (Agent Lender) Transfer In of Securities Transfer Out of Securities Transfer Out of Securities Sale of Securities Purchase of Securities Transfer Out of Securities Purchase of Securities Transfer Out of Securities Securities Lent (Agent Lender) Purchase of Securities Return of Lent securities (Agent Lender) Purchase of Securities Return of Lent securities (Agent Lender) Purchase of Securities Transfer Out of Securities Return of Lent securities (Agent Lender) Purchase of Securities Securities Lent (Agent Lender) Deposit of Securities Purchase of Securities Purchase of Securities Sale of Securities Securities Lent (Agent Lender) Purchase of Securities Return of Lent securities (Agent Lender) Deposit of Securities Transfer Out of Securities Return of Lent securities (Agent Lender) Return of Lent securities (Agent Lender) Sale of Securities Deposit of Securities Return of Lent securities (Agent Lender) Purchase of Securities Transfer Out of Securities Transfer Out of Securities Sale of Securities Purchase of Securities Sale of Securities Purchase of Securities Purchase of Securities Transfer Out of Securities Purchase of Securities Sale of Securities Sale of Securities Sale of Securities Deposit of Securities Transfer Out of Securities Purchase of Securities Purchase of Securities Sale of Securities Securities Lent (Agent Lender) Purchase of Securities Deposit of Securities Deposit of Securities Transfer Out of Securities Return of Lent securities (Agent Lender) Deposit of Securities
Consideration given in relation to change N/A N/A N/A N/A N/A N/A N/A USD 24.6111 USD 24.56 N/A AUD 3.54 N/A N/A USD 23.3604 N/A N/A USD 22.795 N/A N/A N/A USD 22.3933 N/A N/A N/A N/A N/A N/A N/A N/A USD 21.685 USD 21.685 N/A USD 22.3114 N/A N/A USD 20.615 N/A USD 20.83 N/A USD 20.845 N/A N/A USD 21.445 N/A N/A USD 23.64 USD 25.3099 USD 25.12 N/A USD 25.735 N/A N/A N/A N/A N/A USD 24.63 N/A N/A USD 22.72 N/A N/A USD 20.7319 USD 22.1933 USD 22.245 USD 22.56 USD 21.58 N/A USD 21.21 USD 21.4 USD 21.0164 USD 21.55 N/A N/A USD 20.69 USD 21.807 USD 21.29 N/A USD 19.8606 N/A N/A N/A N/A N/A
Class and number of securities affected (Ordinary Shares) (197,500) 74,000 (11) ADR = Converted (110) shares (461,120) 34,759 (112,330) (21,570) 21 ADR = Converted 210 shares (1) ADR = Converted (10) shares (309,870) (1,348) 56,902 (19,787) 24 ADR = Converted 240 shares (30,000) (12,855) 1 ADR = Converted 10 shares (28,380) 62,759 55,224 22 ADR = Converted 220 shares 100,866 18,987 10,780 12,667 (10,121) 11 ADR = Converted 110 shares (425,110) (459,420) (4) ADR = Converted (40) shares 14 ADR = Converted 140 shares (87,420) 4 ADR = Converted 40 shares (26,750) 48,529 9 ADR = Converted 90 shares (13,053) 28 ADR = Converted 280 shares (110,874) 5 ADR = Converted 50 shares (15,750) (5,510) 1 ADR = Converted 10 shares 60,000 744,000 6 ADR = Converted 60 shares 5 ADR = Converted 50 shares (4) ADR = Converted (40) shares 140,000 3 ADR = Converted 30 shares (5,465) 270,000 (2,000) (16,862) (721) (3) ADR = Converted (30) shares 98,930 (13,236) 7 ADR = Converted 70 shares (7) ADR = Converted (70) shares (79,170) (40) ADR = Converted (400) shares 7 ADR = Converted 70 shares (1) ADR = Converted (10) shares 24 ADR = Converted 240 shares 1 ADR = Converted 10 shares (73,890) 1 ADR = Converted 10 shares (1) ADR = Converted (10) shares (9) ADR = Converted (90) shares (2) ADR = Converted (20) shares 665,000 (24,170) 1 ADR = Converted 10 shares 4 ADR = Converted 40 shares (3) ADR = Converted (30) shares 47,000 9 ADR = Converted 90 shares 3,800 511,800 (90,950) (47,000) 50,000
Person's votes affected (197,500) 74,000 (110) (461,120) 34,759 (112,330) (21,570) 210 (10) (309,870) (1,348) 56,902 (19,787) 240 (30,000) (12,855) 10 (28,380) 62,759 55,224 220 100,866 18,987 10,780 12,667 (10,121) 110 (425,110) (459,420) (40) 140 (87,420) 40 (26,750) 48,529 90 (13,053) 280 (110,874) 50 (15,750) (5,510) 10 60,000 744,000 60 50 (40) 140,000 30 (5,465) 270,000 (2,000) (16,862) (721) (30) 98,930 (13,236) 70 (70) (79,170) (400) 70 (10) 240 10 (73,890) 10 (10) (90) (20) 665,000 (24,170) 10 40 (30) 47,000 90 3,800 511,800 (90,950) (47,000) 50,000
15-Sep-2026 16-Sep-2026 17-Sep-2026 21-Sep-2026 24-Sep-2026 24-Sep-2026 25-Sep-2026 28-Sep-2026 29-Sep-2026 30-Sep-2026 01-Oct-2026 02-Oct-2026 02-Oct-2026 05-Oct-2026 05-Oct-2026 05-Oct-2026 05-Oct-2026 6-Oct-2026 06-Oct-2026 06-Oct-2026 07-Oct-2026 07-Oct-2026 08-Oct-2026 08-Oct-2026 08-Oct-2026 12-Oct-2026 13-Oct-2026 13-Oct-2026 13-Oct-2026 14-Oct-2026 14-Oct-2026 15-Oct-2026 15-Oct-2026 15-Oct-2026
BNY Mellon Advisors, Inc. The Bank of New York Mellon Mellon Investments Corporation The Bank of New York Mellon BNY Mellon Advisors, Inc. BNY Mellon Advisors, Inc. BNY Mellon Advisors, Inc. BNY Mellon Advisors, Inc. The Bank of New York Mellon The Bank of New York Mellon BNY Mellon Advisors, Inc. The Bank of New York Mellon BNY Mellon Advisors, Inc. The Bank of New York Mellon The Bank of New York Mellon BNY Mellon Advisors, Inc. BNY Mellon Advisors, Inc. Mellon Investments Corporation BNY Mellon Advisors, Inc. BNY Mellon Advisors, Inc. The Bank of New York Mellon BNY Mellon Advisors, Inc. The Bank of New York Mellon The Bank of New York Mellon BNY Mellon Advisors, Inc. BNY Mellon Advisors, Inc. The Bank of New York Mellon BNY Mellon Advisors, Inc. BNY Mellon Advisors, Inc. The Bank of New York Mellon BNY Mellon Advisors, Inc. The Bank of New York Mellon BNY Mellon Advisors, Inc. BNY Mellon Advisors, Inc.
Print Name -Andrew Weiser
Sign Here
Purchase of Securities Deposit of Securities Transfer In of Securities Deposit of Securities Purchase of Securities Sale of Securities Purchase of Securities Sale of Securities Deposit of Securities Deposit of Securities Sale of Securities Transfer In of Securities Sale of Securities Securities Lent (Agent Lender) Transfer Out of Securities Sale of Securities Purchase of Securities Transfer Out of Securities Purchase of Securities Sale of Securities Securities Lent (Agent Lender) Transfer Out of Securities Deposit of Securities Return of Lent securities (Agent Lender) Sale of Securities Sale of Securities Deposit of Securities Sale of Securities Purchase of Securities Securities Lent (Agent Lender) Purchase of Securities Deposit of Securities Sale of Securities Purchase of Securities
USD 17.905 N/A N/A N/A USD 19.37 USD 19.3596 USD 19.35 USD 19.0012 N/A N/A USD 15.815 N/A USD 17.1644 N/A N/A USD 16.9825 USD 16.99 N/A USD 17.16 USD 17.155 N/A N/A N/A N/A USD 15.26 USD 15.7025 N/A USD 14.755 USD 14.748 N/A USD 13.9606 N/A USD 14.0875 USD 14.09
Capacity - Attorney - In - Fact
Date - 16 October 2026
1 ADR = Converted 10 shares 610,000 237 ADR = Converted 2,370 shares 600,000 10 ADR = Converted 100 shares (27) ADR = Converted (270) shares 7 ADR = Converted 70 shares (1) ADR = Converted (10) shares 466,950 200,000 (6) ADR = Converted (60) shares 69 ADR = Converted 690 shares (5) ADR = Converted (50) shares 32,000 (69) ADR = Converted (690) shares (4) ADR = Converted (40) shares 3 ADR = Converted 30 shares (464) ADR = Converted (4,640) shares 1 ADR = Converted 10 shares (11) ADR = Converted (110) shares 30,000 (1) ADR = Converted (10) shares 443,500 (30,000) (9) ADR = Converted (90) shares (23) ADR = Converted (230) shares 699,580 (9) ADR = Converted (90) shares 4 ADR = Converted 40 shares 30,000 3 ADR = Converted 30 shares 525,690 (3) ADR = Converted (30) shares 7 ADR = Converted 70 shares
10 610,000 2,370 600,000 100 (270) 70 (10) 466,950 200,000 (60) 690 (50) 32,000 (690) (40) 30 (4,640) 10 (110) 30,000 (10) 443,500 (30,000) (90) (230) 699,580 (90) 40 30,000 30 525,690 (30) 70
Annexure C
This is Annexure C of 3 pages referred to in Form 604 Notice of Change of Interests of Substantial Holder given by The Bank of New York Mellon Corporation and its related bodies corporate Holder of relevant interest
The Bank of New York Mellon (BNYM)
Nature of relevant interest
Remote Interest Held Under Deposit Agreement
Class and number of securities
100,010,170 ordinary shares
Relevant interest under section 608(1)(c) of the Corporations Act 2001 (Cth) arising from BNYM having the limited power to dispose of, or control the exercise of a power to dispose of, securities deposited with or held by BNYM (or its custodian or agent) in its capacity as depositary administering an ADR program for IperionX Ltd (Company) under the Deposit Agreement dated June 15, 2022, between the Company, holders of American depositary receipts (ADRs) and BNYM (Deposit Agreement), [*See Note 1 below].
BNY (other than BNYM)
Relevant interest under section 608(3)(a) and/or 100,010,170 ordinary shares section 608(3)(b) of the Corporations Act 2001 (Cth) being a relevant interest held through a body corporate (namely BNYM) in which the voting power of each other entity in the BNY is above 20%, or that each other entity in the BNY controls. [*See Note 1 and Note 2 below]
BNYM
Relevant interest under section 608(8) of the Corporations Act 2001 (Cth) arising from BNYM acting as Principal Lender. These securities are subject to an obligation to return under a securities lending agreement.
BNY Group (other than BNYM)
Relevant interest under section 608(3)(a) and/or 233,194 ordinary shares section 608(3)(b) of the Corporations Act 2001 (Cth) being a relevant interest held through a body corporate (namely BNYM) in which the voting power of each other entity in the BNY Group is above 20%, or that each other entity in the BNY Group controls. [*See Note 2 below]
BNYM
Relevant interest under sections 608(1)(b) and 3,907 ordinary shares 608(1)(c) of the Corporations Act 2001 (Cth) arising from having the power to control the exercise of the right to vote attached to securities and control the exercise of the power to dispose of securities in its capacity as discretionary asset/investment manager in accordance with its investment mandates.
BNY (other than BNYM)
Relevant interest under section 608(3)(a) and/or 3,907 ordinary shares section 608(3)(b) of the Corporations Act 2001 (Cth) being a relevant interest held through a body corporate (namely BNYM) in which the voting power of each other entity in the BNY is above 20%, or that each other entity in the BNY controls. [*See Note 2 below]
233,194 ordinary shares
BNYM
Relevant interest under section 608(8) of the 447,805 ordinary shares Corporations Act 2001 (Cth) arising from BNYM, acting as Agent Lender. These securities are subject to an obligation to return under a securities lending agreement.
BNY (other than BNYM)
Relevant interest under section 608(3)(a) and/or 447,805 ordinary shares section 608(3)(b) of the Corporations Act 2001 (Cth) being a relevant interest held through a body corporate (namely BNYM) in which the voting power of each other entity in the BNY is above 20%, or that each other entity in the BNY controls. [*See Note 2 below]
Pershing LLC
Relevant interest under sections 608(1) of the Corporations Act 2001 (Cth) arising from Pershing LLC being the registered owner of the securities.
BNY (other than Pershing LLC)
Relevant interest under section 608(3)(a) and/or 16 ordinary shares section 608(3)(b) of the Corporations Act 2001 (Cth) being a relevant interest held through a body corporate (namely Pershing LLC) in which the voting power of each other entity in the BNY is above 20%, or that each other entity in the BNY controls. [*See Note 2 below]
Mellon Investments Corporation
Relevant interest under sections 608(1)(b) and 9,790 ordinary shares 608(1)(c) of the Corporations Act 2001 (Cth) arising from having the power to control the exercise of the right to vote attached to securities and control the exercise of the power to dispose of securities in its capacity as discretionary asset/investment manager in accordance with its investment mandates.
BNY (other than Mellon Investments Corporation)
Relevant interest under section 608(3)(a) and/or 9,790 ordinary shares section 608(3)(b) of the Corporations Act 2001 (Cth) being a relevant interest held through a body corporate (namely Mellon Investments Corporation) in which the voting power of each other entity in the BNY is above 20%, or that each other entity in the BNY controls. [*See Note 2 below]
BNY Mellon Advisors, Inc
Relevant interest under sections 608(1)(b) and 32,930 ordinary shares 608(1)(c) of the Corporations Act 2001 (Cth) arising from having the power to control the exercise of the right to vote attached to securities and control the exercise of the power to dispose of securities in its capacity as discretionary asset/investment manager in accordance with its investment mandates.
16 ordinary shares
BNY (other than BNY Mellon Relevant interest under section 608(3)(a) and/or 32,930 ordinary shares Advisors, Inc) section 608(3)(b) of the Corporations Act 2001 (Cth) being a relevant interest held through a body corporate (namely BNY Mellon Advisors, Inc) in which the voting power of each other entity in the BNY is above 20%, or that each other entity in the BNY controls. [*See Note 2 below]
NOTES: *Note 1: Of the total of 100,737,812 securities in which the BNY has a relevant interest, BNYM has a relevant interest in 100,010,170 securities as depositary for IperionX Ltd ADR program administered under the Deposit Agreement. BNYM's relevant interest in these securities arises as a result of the Deposit Agreement containing rights for BNYM to dispose of securities held under the ADR program in limited circumstances. Under the Deposit Agreement, ADR holders retain their rights to dispose of those securities and to give voting instructions for the exercise of voting rights attached to the securities. BNY's power to vote or dispose of these securities is qualified accordingly. *Note 2: Each Group Entity is a direct or indirect wholly owned subsidiary of BNYM, the ultimate parent company. Other than BNYM in respect of 100,695,076 securities (of which BNYM's power to only dispose of 100,010,170 securities is limited – see Note 1) Pershing LLC in respect of 16 securities, BNY Mellon Advisors, Inc in respect of 32,930 securities and Mellon Investments Corporation in respect of 9,790 securities, none of the BNY entities are entitled to be registered as holder of the securities and their power to vote or dispose of the securities is qualified accordingly.
s print name Andrew Weiser
capacity_ Attorney-In-Fact
sign here
date
16/October/2026__
October 15, 2026 Dear Shareholder
IperionX Limited – Notice of Annual General Meeting IperionX Limited (ASX:IPX, NASDAQ:IPX) (Company) advises that its Annual General Meeting (Meeting) will be held on November 25, 2026 at 11:00am (AEDT) at Level 5, 56 Pitt Street, Sydney NSW 2000. In accordance with 110D of the Corporations Act 2001 (Cth) (Corporations Act), the Company will not be dispatching physical copies of the Notice of Meeting (unless a shareholder has elected to receive documents in hard copy in accordance with the timeframe specified in section 110E(8) of the Corporations Act). A copy of the Meeting materials can be viewed and downloaded online as follows: •
You can access the Meeting materials online at the Company’s website: https://iperionx.com/investorcenter/asx-announcements/;
•
A complete copy of the Meeting materials has been posted to the Company’s ASX Market Announcements page at www.asx.com.au under the Company’s ASX code “IPX”; or
•
If you have provided an email address and have elected to receive electronic communications from the Company, you will receive an email to your nominated email address with a link to an electronic copy of the Meeting materials and the voting instruction form.
A copy of your Proxy Form is enclosed for convenience. The Company intends to hold a physical meeting. The Company will notify any changes to this by way of an announcement on ASX and the details will also be made available on our website. The Meeting materials are important and should be read in their entirety. If you are in doubt as to the course of action you should follow, you should consult your stockbroker, investment advisor, accountant, solicitor, or other professional adviser. How do I update my communications preference? Shareholders can still elect to receive some or all of their communications in physical or electronic form or elect not to receive certain documents such as annual reports. To review your communications preferences or sign up to receive your shareholder communications via email, please update your communication preferences at https://investor.automic.com.au. Yours sincerely Louisa Martino Company Secretary
Virginia
Tennessee
Utah
1092 Confroy Drive South Boston, VA 24592
279 West Main Street Camden, TN 38320
1782 W 2300 S West Valley City, UT 84119
IperionX Limited ABN 84 618 935 372
IPERIONX LIMITED ACN 618 935 372
NOTICE OF ANNUAL GENERAL MEETING The Annual General Meeting of the Company will be held at Level 5, 56 Pitt Street, Sydney NSW 2000 on Wednesday, 25 November 2026 at 11.00am (AEDT).
If the above arrangements with respect to the Meeting change, Shareholders will be updated via the ASX Market Announcements Platform. This Notice should be read in its entirety. If Shareholders are in doubt as to how they should vote, they should seek advice from their accountant, solicitor or other professional adviser prior to voting. Should you wish to discuss any matter, please do not hesitate to contact the Company by telephone on +61 2 8823 3179
IPERIONX LIMITED ACN 618 935 372 NOTICE OF ANNUAL GENERAL MEETING Notice is hereby given that the annual general meeting of shareholders of IperionX Limited (Company) will be held at Level 5, 56 Pitt Street, Sydney NSW 2000 on Wednesday, 25 November 2026 at 11.00am (AEDT) (Meeting). If it becomes necessary or appropriate to make alternative arrangements to those detailed in this Notice, Shareholders will be updated via the ASX announcements platform and on the Company’s website at www.iperionx.com. The Explanatory Memorandum provides additional information on matters to be considered at the Meeting. The Explanatory Memorandum and the Proxy Form form part of this Notice. The Directors have determined pursuant to regulation 7.11.37 of the Corporations Regulations 2001 (Cth) that the persons eligible to vote at the Meeting are those who are registered as Shareholders on Monday, 23 November 2026 at 5:00pm (AEDT). The Company advises that a poll will be conducted for all Resolutions. Terms and abbreviations used in this Notice (including the Explanatory Memorandum) are defined in Schedule 1.
AGENDA
Annual Report To consider the Annual Report of the Company and its controlled entities for the year ended 30 June 2026, which includes the Financial Report, the Directors' Report and the Auditor's Report.
1
Resolution 1 – Remuneration Report To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution the following: "That, pursuant to and in accordance with section 250R(2) of the Corporations Act and for all other purposes, approval is given by the Shareholders for the adoption of the Remuneration Report on the terms and conditions in the Explanatory Memorandum." Voting Prohibition A vote on this Resolution must not be cast: (a)
by or on behalf of a member of the Key Management Personnel or a Closely Related Party of such member, regardless of the capacity in which the vote is cast; or
(b)
by a person appointed as a proxy, where that person is either a member of the Key Management Personnel or a Closely Related Party of such member.
However, a vote may be cast by such persons if the vote is not cast on behalf of a person who is excluded from voting on this Resolution, and: (a)
the person is appointed as a proxy that specifies the way the proxy is to vote on this Resolution; or
(b)
the person is the Chairperson and the appointment of the Chairperson as proxy does not specify the way the proxy is to vote on this Resolution, but expressly authorises the Chairperson to exercise the proxy even if this Resolution is connected with the remuneration of a member of the Key Management Personnel.
Page 1
2
Resolution 2 – Re-election of Mr Todd Hannigan as Director To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution the following: "That, pursuant to and in accordance with the Constitution and for all other purposes, Mr Todd Hannigan, Director, retires and being eligible pursuant to the Constitution, is re-elected as a Director on the terms and conditions in the Explanatory Memorandum."
3
Resolution 3 – Re-election of Ms Beverly Wyse as Director To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution the following: "That, pursuant to and in accordance with the Constitution and for all other purposes, Ms Beverly Wyse, Director, retires and being eligible pursuant to the Constitution, is re-elected as a Director on the terms and conditions in the Explanatory Memorandum."
4
Resolution 4 – Re-election of Ms Melissa Waller as Director To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution the following: "That, pursuant to and in accordance with the Constitution and for all other purposes, Ms Melissa Waller, Director, retires and being eligible pursuant to the Constitution, is re-elected as a Director on the terms and conditions in the Explanatory Memorandum."
5
Resolution 5 – Re-election of Mr Vaughn Taylor as Director To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution the following: "That, pursuant to and in accordance with the Constitution and for all other purposes, Mr Vaughn Taylor, Director, retires and being eligible pursuant to the Constitution, is re-elected as a Director on the terms and conditions in the Explanatory Memorandum."
6
Resolution 6 – Re-election of Ms Lorraine Martin as Director To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution the following: "That, pursuant to and in accordance with the Constitution and for all other purposes, Ms Lorraine Martin, Director, retires and being eligible pursuant to the Constitution, is re-elected as a Director on the terms and conditions in the Explanatory Memorandum."
7
Resolution 7 – Re-election of Mr Tony Tripeny as Director To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution the following: "That, pursuant to and in accordance with the Constitution and for all other purposes, Mr Tony Tripeny, Director, retires and being eligible pursuant to the Constitution, is re-elected as a Director on the terms and conditions in the Explanatory Memorandum."
8
Resolution 8 – Election of Mr Michael Loparco as Director To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution the following: "That, pursuant to and in accordance with Listing Rule 14.4 and clause 7.3(j) of the Constitution and for all other purposes, Mr Michael Loparco, a Director who was appointed on 3 August 2026, retires and being eligible, is elected as a non-executive Director on the terms and conditions in the Explanatory Memorandum."
Page 2
9
Resolution 9 – Issue of RSUs to Non-Executive Director Ms Lorraine Martin To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution the following: "That, pursuant to and in accordance with Listing Rule 10.11, Chapter 2E of the Corporations Act (including section 208 of the Corporations Act), and for all other purposes, Shareholders approve the issue of up to 77,228 RSUs to Ms Lorraine Martin (and/or her nominee(s)) on the terms and conditions in the Explanatory Memorandum." Voting Exclusion Listing Rules The Company will disregard any votes cast in favour of this Resolution by or on behalf of Ms Lorraine Martin (and/or her nominee(s)) and any other person who will obtain a material benefit as a result of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of those persons. However, this does not apply to a vote cast in favour of this Resolution by: (a)
a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with the directions given to the proxy or attorney to vote on this Resolution in that way; or
(b)
the Chairperson as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the Chairperson to vote on this Resolution as the Chairperson decides; or
(c)
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: (i)
the beneficiary provides written confirmation to the Shareholder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting on this Resolution; and
(ii)
the Shareholder votes on this Resolution in accordance with the directions given by the beneficiary to the Shareholder to vote in that way.
Voting Prohibition Corporations Act In accordance with section 224 of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by or on behalf of Ms Lorraine Martin or any associate of Ms Lorraine Martin. However, a person described above may cast a vote on this Resolution if: (a)
it is cast as a proxy appointed by writing that specifies how the proxy is to vote on the Resolution; and
(b)
it is not cast on behalf of Ms Lorraine Martin or any associate of Ms Lorraine Martin.
Further, in accordance with section 250BD of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by a person appointed as a proxy, where that person is either a member of the Key Management Personnel or a Closely Related Party of such member. However, a vote may be cast by such person if the vote is not cast on behalf of a person who is otherwise excluded from voting, and:
10
(a)
the person is appointed as a proxy and the appointment specifies how the proxy is to vote on the Resolution; or
(b)
the person appointed as proxy is the Chairperson and the appointment does not specify how the Chairperson is to vote, but expressly authorises the Chairperson to exercise the proxy even if the Resolution is connected with the remuneration of a member of the Key Management Personnel.
Resolution 10 – Issue of RSUs to Non-Executive Director Mr Vaughn Taylor To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution the following: Page 3
"That, pursuant to and in accordance with Listing Rule 10.11, Chapter 2E of the Corporations Act (including section 208 of the Corporations Act), and for all other purposes, Shareholders approve the issue of up to 62,281 RSUs to Mr Vaughn Taylor (and/or his nominee(s)) on the terms and conditions in the Explanatory Memorandum." Voting Exclusion Listing Rules The Company will disregard any votes cast in favour of this Resolution by or on behalf of Mr Vaughn Taylor (and/or his nominee(s)) and any other person who will obtain a material benefit as a result of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of those persons. However, this does not apply to a vote cast in favour of this Resolution by: (a)
a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with the directions given to the proxy or attorney to vote on this Resolution in that way; or
(b)
the Chairperson as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the Chairperson to vote on this Resolution as the Chairperson decides; or
(c)
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: (i)
the beneficiary provides written confirmation to the Shareholder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting on this Resolution; and
(ii)
the Shareholder votes on this Resolution in accordance with the directions given by the beneficiary to the Shareholder to vote in that way.
Voting Prohibition Corporations Act In accordance with section 224 of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by or on behalf of Mr Vaughn Taylor or any associate of Mr Vaughn Taylor. However, a person described above may cast a vote on this Resolution if: (a)
it is cast as a proxy appointed by writing that specifies how the proxy is to vote on the Resolution; and
(b)
it is not cast on behalf of Mr Vaughn Taylor or any associate of Mr Vaughn Taylor.
Further, in accordance with section 250BD of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by a person appointed as a proxy, where that person is either a member of the Key Management Personnel or a Closely Related Party of such member. However, a vote may be cast by such person if the vote is not cast on behalf of a person who is otherwise excluded from voting, and:
11
(a)
the person is appointed as a proxy and the appointment specifies how the proxy is to vote on the Resolution; or
(b)
the person appointed as proxy is the Chairperson and the appointment does not specify how the Chairperson is to vote, but expressly authorises the Chairperson to exercise the proxy even if the Resolution is connected with the remuneration of a member of the Key Management Personnel.
Resolution 11 – Issue of RSUs to Non-Executive Director Ms Melissa Waller To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution the following: "That, pursuant to and in accordance with Listing Rule 10.11, Chapter 2E of the Corporations Act (including section 208 of the Corporations Act), and for all other purposes, Shareholders approve the issue of up to 62,281 RSUs to Ms Melissa Waller (and/or her nominee(s)) on the terms and conditions in the Explanatory Memorandum."
Page 4
Voting Exclusion Listing Rules The Company will disregard any votes cast in favour of this Resolution by or on behalf of Ms Melissa Waller (and/or her nominee(s)) and any other person who will obtain a material benefit as a result of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of those persons. However, this does not apply to a vote cast in favour of this Resolution by: (a)
a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with the directions given to the proxy or attorney to vote on this Resolution in that way; or
(b)
the Chairperson as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the Chairperson to vote on this Resolution as the Chairperson decides; or
(c)
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: (i)
the beneficiary provides written confirmation to the Shareholder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting on this Resolution; and
(ii)
the Shareholder votes on this Resolution in accordance with the directions given by the beneficiary to the Shareholder to vote in that way.
Voting Prohibition Corporations Act In accordance with section 224 of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by or on behalf of Ms Melissa Waller or any associate of Ms Melissa Waller. However, a person described above may cast a vote on this Resolution if: (a)
it is cast as a proxy appointed by writing that specifies how the proxy is to vote on the Resolution; and
(b)
it is not cast on behalf of Ms Melissa Waller or any associate of Ms Melissa Waller.
Further, in accordance with section 250BD of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by a person appointed as a proxy, where that person is either a member of the Key Management Personnel or a Closely Related Party of such member. However, a vote may be cast by such person if the vote is not cast on behalf of a person who is otherwise excluded from voting, and:
12
(a)
the person is appointed as a proxy and the appointment specifies how the proxy is to vote on the Resolution; or
(b)
the person appointed as proxy is the Chairperson and the appointment does not specify how the Chairperson is to vote, but expressly authorises the Chairperson to exercise the proxy even if the Resolution is connected with the remuneration of a member of the Key Management Personnel.
Resolution 12 – Issue of RSUs to Non-Executive Director Ms Beverly Wyse To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution the following: "That, pursuant to and in accordance with Listing Rule 10.11, Chapter 2E of the Corporations Act (including section 208 of the Corporations Act), and for all other purposes, Shareholders approve the issue of up to 62,281 RSUs to Ms Beverly Wyse (and/or her nominee(s)) on the terms and conditions in the Explanatory Memorandum." Voting Exclusion Listing Rules The Company will disregard any votes cast in favour of this Resolution by or on behalf of Ms Beverly Wyse (and/or her nominee(s)) and any other person who will obtain a material benefit as a result Page 5
of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of those persons. However, this does not apply to a vote cast in favour of this Resolution by: (a)
a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with the directions given to the proxy or attorney to vote on this Resolution in that way; or
(b)
the Chairperson as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the Chairperson to vote on this Resolution as the Chairperson decides; or
(c)
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: (i)
the beneficiary provides written confirmation to the Shareholder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting on this Resolution; and
(ii)
the Shareholder votes on this Resolution in accordance with the directions given by the beneficiary to the Shareholder to vote in that way.
Voting Prohibition Corporations Act In accordance with section 224 of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by or on behalf of Ms Beverly Wyse or any associate of Ms Beverly Wyse. However, a person described above may cast a vote on this Resolution if: (a)
it is cast as a proxy appointed by writing that specifies how the proxy is to vote on the Resolution; and
(b)
it is not cast on behalf of Ms Beverly Wyse or any associate of Ms Beverly Wyse.
Further, in accordance with section 250BD of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by a person appointed as a proxy, where that person is either a member of the Key Management Personnel or a Closely Related Party of such member. However, a vote may be cast by such person if the vote is not cast on behalf of a person who is otherwise excluded from voting, and:
13
(a)
the person is appointed as a proxy and the appointment specifies how the proxy is to vote on the Resolution; or
(b)
the person appointed as proxy is the Chairperson and the appointment does not specify how the Chairperson is to vote, but expressly authorises the Chairperson to exercise the proxy even if the Resolution is connected with the remuneration of a member of the Key Management Personnel.
Resolution 13 – Issue of RSUs to Non-Executive Director Mr Tony Tripeny To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution the following: "That, pursuant to and in accordance with Listing Rule 10.11, Chapter 2E of the Corporations Act (including section 208 of the Corporations Act), and for all other purposes, Shareholders approve the issue of up to 62,281 RSUs to Mr Tony Tripeny (and/or his nominee(s)) on the terms and conditions in the Explanatory Memorandum." Voting Exclusion Listing Rules The Company will disregard any votes cast in favour of this Resolution by or on behalf of Mr Tony Tripeny (and/or his nominee(s)) and any other person who will obtain a material benefit as a result of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of those persons. However, this does not apply to a vote cast in favour of this Resolution by:
Page 6
(a)
a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with the directions given to the proxy or attorney to vote on this Resolution in that way; or
(b)
the Chairperson as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the Chairperson to vote on this Resolution as the Chairperson decides; or
(c)
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: (i)
the beneficiary provides written confirmation to the Shareholder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting on this Resolution; and
(ii)
the Shareholder votes on this Resolution in accordance with the directions given by the beneficiary to the Shareholder to vote in that way.
Voting Prohibition Corporations Act In accordance with section 224 of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by or on behalf of Mr Tony Tripeny or any associate of Mr Tony Tripeny. However, a person described above may cast a vote on this Resolution if: (a)
it is cast as a proxy appointed by writing that specifies how the proxy is to vote on the Resolution; and
(b)
it is not cast on behalf of Mr Tony Tripeny or any associate of Mr Tony Tripeny.
Further, in accordance with section 250BD of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by a person appointed as a proxy, where that person is either a member of the Key Management Personnel or a Closely Related Party of such member. However, a vote may be cast by such person if the vote is not cast on behalf of a person who is otherwise excluded from voting, and:
14
(a)
the person is appointed as a proxy and the appointment specifies how the proxy is to vote on the Resolution; or
(b)
the person appointed as proxy is the Chairperson and the appointment does not specify how the Chairperson is to vote, but expressly authorises the Chairperson to exercise the proxy even if the Resolution is connected with the remuneration of a member of the Key Management Personnel.
Resolution 14 – Issue of RSUs to Non-Executive Director Mr Michael Loparco To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution the following: "That, pursuant to and in accordance with Listing Rule 10.11, Chapter 2E of the Corporations Act (including section 208 of the Corporations Act), and for all other purposes, Shareholders approve the issue of up to 62,281 RSUs to Mr Michael Loparco (and/or his nominee(s)) on the terms and conditions in the Explanatory Memorandum." Voting Exclusion Listing Rules The Company will disregard any votes cast in favour of this Resolution by or on behalf of Mr Michael Loparco (and/or his nominee(s)) and any other person who will obtain a material benefit as a result of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of those persons. However, this does not apply to a vote cast in favour of this Resolution by: (a)
a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with the directions given to the proxy or attorney to vote on this Resolution in that way; or
Page 7
(b)
the Chairperson as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the Chairperson to vote on this Resolution as the Chairperson decides; or
(c)
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: (i)
the beneficiary provides written confirmation to the Shareholder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting on this Resolution; and
(ii)
the Shareholder votes on this Resolution in accordance with the directions given by the beneficiary to the Shareholder to vote in that way.
Voting Prohibition Corporations Act In accordance with section 224 of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by or on behalf of Mr Michael Loparco or any associate of Mr Michael Loparco. However, a person described above may cast a vote on this Resolution if: (a)
it is cast as a proxy appointed by writing that specifies how the proxy is to vote on the Resolution; and
(b)
it is not cast on behalf of Mr Michael Loparco or any associate of Mr Michael Loparco.
Further, in accordance with section 250BD of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by a person appointed as a proxy, where that person is either a member of the Key Management Personnel or a Closely Related Party of such member. However, a vote may be cast by such person if the vote is not cast on behalf of a person who is otherwise excluded from voting, and: (a) (b)
15
the person is appointed as a proxy and the appointment specifies how the proxy is to vote on the Resolution; or the person appointed as proxy is the Chairperson and the appointment does not specify how the Chairperson is to vote, but expressly authorises the Chairperson to exercise the proxy even if the Resolution is connected with the remuneration of a member of the Key Management Personnel.
Resolution 15 – Increase in Aggregate Fee Pool for NonExecutive Directors To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution the following: “That, pursuant to and in accordance with Listing Rule 10.17, clause 7.5 of the Constitution and for all other purposes, the maximum total fees payable to Non-Executive Directors be increased from US$300,000 per annum to US$700,000 per annum (being an increase of US$400,000) on the terms and conditions in the Explanatory Memorandum.” Voting Exclusion Listing Rules The Company will disregard any votes cast in favour of this Resolution by or on behalf of the NonExecutive Directors or an associate of the Non-Executive Directors. However, this does not apply to a vote cast in favour of this Resolution by: (a)
a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with the directions given to the proxy or attorney to vote on this Resolution in that way; or
(b)
the Chairperson as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the Chairperson to vote on this Resolution as the Chairperson decides; or
(c)
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
Page 8
(i)
the beneficiary provides written confirmation to the Shareholder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting on this Resolution; and
(ii)
the Shareholder votes on this Resolution in accordance with the directions given by the beneficiary to the Shareholder to vote in that way.
Voting Prohibition Corporations Act In accordance with section 250BD of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by a person appointed as a proxy, where that person is either a member of the Key Management Personnel or a Closely Related Party of such member. However, a vote may be cast by such person if the vote is not cast on behalf of a person who is otherwise excluded from voting, and: (a) (b)
16
the person is appointed as a proxy and the appointment specifies how the proxy is to vote on the Resolution; or the person appointed as proxy is the Chairperson and the appointment does not specify how the Chairperson is to vote, but expressly authorises the Chairperson to exercise the proxy even if the Resolution is connected with the remuneration of a member of the Key Management Personnel.
Resolution 16 – Ratification of Placement Shares To consider and, if thought fit, to pass with or without amendment, the following resolution as an ordinary resolution: "That, pursuant to and in accordance with Listing Rule 7.4 and for all other purposes, Shareholders ratify the prior issue of 22,750,000 Placement Shares at an issue price of A$3.19 per Share to Institutional Placement Participants under Listing Rule 7.1 on the terms and conditions in the Explanatory Memorandum." Voting Exclusion Listing Rules The Company will disregard any votes cast in favour of this Resolution by or on behalf of a person who participated in the issue of shares or any associates of those persons. However, this does not apply to a vote cast in favour of this Resolution by: (a)
a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with the directions given to the proxy or attorney to vote on this Resolution in that way; or
(b)
the Chairperson as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the Chairperson to vote on this Resolution as the Chairperson decides; or
(c)
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: (i)
the beneficiary provides written confirmation to the Shareholder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting on this Resolution; and
(ii)
the Shareholder votes on this Resolution in accordance with the directions given by the beneficiary to the Shareholder to vote in that way.
BY ORDER OF THE BOARD
Louisa Anne Martino Company Secretary Dated: 15 October 2026 Page 9
IPERIONX LIMITED ACN 618 935 372 EXPLANATORY MEMORANDUM 1
Introduction This Explanatory Memorandum has been prepared for the information of Shareholders in connection with the business to be conducted at the Meeting. This Explanatory Memorandum should be read in conjunction with and forms part of the Notice. The purpose of this Explanatory Memorandum is to provide information to Shareholders in deciding whether or not to pass the Resolutions. This Explanatory Memorandum includes the following information to assist Shareholders in deciding how to vote on the Resolutions: Section 1
Introduction
Section 2
Action to be taken by Shareholders
Section 3
Annual Report
Section 4
Resolution 1 – Remuneration Report
Section 5
Resolution 2 – Re-election of Mr Todd Hannigan as Director
Section 6
Resolution 3 – Re-election of Ms Beverly Wyse as Director
Section 7
Resolution 4 – Re-election of Ms Melissa Waller as Director
Section 8
Resolution 5 – Re-election of Mr Vaughn Taylor as Director
Section 9
Resolution 6 – Re-election of Ms Lorraine Martin as Director
Section 10
Resolution 7 – Re-election of Mr Tony Tripeny as Director
Section 11
Resolution 8 – Election of Mr Michael Loparco as Director
Section 12
Resolutions 9 to 14 (inclusive) – Issue of RSUs to Non-Executive Directors Ms Lorraine Martin, Mr Vaughn Taylor, Ms Melissa Waller, Ms Beverly Wyse, Mr Tony Tripeny and Mr Michael Loparco
Section 13
Resolution 15 – Increase in Aggregate Fee Pool for Non-Executive Directors
Section 14
Resolution 16 – Ratification of Placement Shares
Schedule 1
Definitions
Schedule 2
Terms and Conditions of RSUs
A Proxy Form is located at the end of this Explanatory Memorandum.
2
Action to be taken by Shareholders Shareholders should read the Notice including this Explanatory Memorandum carefully before deciding how to vote on the Resolutions. The Company advises that a poll will be conducted for all Resolutions.
2.1
Proxies A Proxy Form is attached to the Notice. This is to be used by Shareholders if they wish to appoint a representative (a 'proxy') to vote in their place. All Shareholders are invited and encouraged to attend the Meeting or, if they are unable to attend in person, sign and return the Proxy Form to the Company in accordance with the instructions thereon. Returning the Proxy Form will not preclude a Shareholder from attending and voting at the Meeting in person. Please note that: (a)
a member of the Company entitled to attend and vote at the Meeting is entitled to appoint a proxy; Page 10
(b)
a proxy need not be a member of the Company; and
(c)
a member of the Company entitled to cast two or more votes may appoint two proxies and may specify the proportion or number of votes each proxy is appointed to exercise. Where the proportion or number is not specified, each proxy may exercise half of the votes.
Proxy Forms must be received by the Company no later than 11.00am (AEDT) on Monday, 23 November 2026, being at least 48 hours before the Meeting. The Proxy Form provides further details on appointing proxies and lodging Proxy Forms. If the Chairperson is appointed as your proxy and you have not specified the way the Chairperson is to vote on Resolutions 1, 9, 10, 11, 12, 13, 14 and 15, by signing and returning the Proxy Form, you are considered to have provided the Chairperson with an express authorisation for the Chairperson to vote the proxy in accordance with the Chairperson's intention, even though the Resolutions are connected directly or indirectly with the remuneration of a member of the Key Management Personnel. 2.2
Attendance at Meeting To vote in person, Shareholders are able to attend the Meeting at the time, date and place set out above. Based on the best information available to the Board at the time of the Notice, the Board considers it will be in a position to hold an 'in-person' meeting to provide Shareholders with a reasonable opportunity to participate in and vote at the Meeting. If it becomes necessary or appropriate to make alternative arrangements to those detailed in this Notice, Shareholders will be updated via the ASX announcements platform and on the Company’s website at www.iperionx.com.
3
Annual Report In accordance with section 317(1) of the Corporations Act, the Annual Report must be laid before the annual general meeting. There is no requirement for Shareholders to approve the Annual Report. At the Meeting, Shareholders will be offered the opportunity to: (a)
discuss the Annual Report which is available online at www.iperionx.com;
(b)
ask questions about, or comment on, the management of the Company; and
(c)
ask the auditor questions about the conduct of the audit and the preparation and content of the Auditor's Report.
In addition to taking questions at the Meeting, written questions to the Chairperson about the management of the Company, or to the Company's auditor about: (a)
the preparation and the content of the Auditor's Report;
(b)
the conduct of the audit;
(c)
accounting policies of the Company in relation to the preparation of the financial statements;
(d)
the independence of the auditor in relation to the conduct of the audit,
and may be submitted no later than five business days before the Meeting to the Company Secretary at the Company's registered office.
4
Resolution 1 – Remuneration Report In accordance with section 250R(2) of the Corporations Act, the Company must put the Remuneration Report to the vote of Shareholders. The Directors' Report contains the Remuneration Report which sets out the remuneration policy for the Company and the remuneration arrangements in place for the executive Directors, specified executives and Non-Executive Directors. In accordance with section 250R(3) of the Corporations Act, Resolution 1 is advisory only and does not bind the Directors. If Resolution 1 is not passed, the Directors will not be required to alter any of the arrangements in the Remuneration Report. Shareholders will have the opportunity to remove the whole Board except the Managing Director if the Remuneration Report receives a 'no' vote of 25% or more (Strike) at two consecutive annual general meetings. Where a resolution on the Remuneration Report receives a Strike at two consecutive annual general meetings, the Company will be required to put to Shareholders at the second annual general meeting Page 11
a resolution on whether another meeting should be held (within 90 days) at which all Directors (other than the Managing Director) who were in office at the date of approval of the applicable Directors' Report must stand for re-election. The Remuneration Report did not receive a Strike at the 2025 annual general meeting. Please note if the Remuneration Report receives a Strike at this Meeting and if a second Strike is received at the 2027 annual general meeting, this may result in the re-election of the Board. The Chairperson will allow reasonable opportunity for Shareholders to ask questions about or comment on the Remuneration Report. Resolution 1 is an ordinary resolution. The Chairperson intends to exercise all available proxies in favour of Resolution 1.
5
Resolution 2 – Re-election of Mr Todd Hannigan as Director Under the Constitution of the Company, Directors are required to retire by rotation, and may seek reelection, every three years. However, having regard to feedback from Shareholders, all Directors (excluding Mr Anastasios Arima) will retire at the Meeting and present themselves for re-election. Resolution 2 provides that Mr Todd Hannigan retires and seeks re-election as a Director. Details of Mr Todd Hannigan’s qualifications and experience are set out in the Annual Report. Resolution 2 is an ordinary resolution. The Chairperson intends to exercise all available proxies in favour of Resolution 2. The Board (excluding Mr Todd Hannigan) supports the re-election of Mr Todd Hannigan and recommends that Shareholders vote in favour of Resolution 2.
6
Resolution 3 – Re-election of Ms Beverly Wyse as Director Under the Constitution of the Company, Directors are required to retire by rotation, and may seek reelection, every three years. However, having regard to feedback from Shareholders, all Directors (excluding Mr Anastasios Arima) will retire at the Meeting and present themselves for re-election. Resolution 3 provides that Ms Beverly Wyse retires and seeks re-election as a Director. Details of Ms Beverly Wyse’s qualifications and experience are set out in the Annual Report. Resolution 3 is an ordinary resolution. The Chairperson intends to exercise all available proxies in favour of Resolution 3. The Board (excluding Ms Beverly Wyse) supports the re-election of Ms Beverly Wyse and recommends that Shareholders vote in favour of Resolution 3.
7
Resolution 4 – Re-election of Ms Melissa Waller as Director Under the Constitution of the Company, Directors are required to retire by rotation, and may seek reelection, every three years. However, having regard to feedback from Shareholders, all Directors (excluding Mr Anastasios Arima) will retire at the Meeting and present themselves for re-election. Resolution 4 provides that Ms Melissa Waller retires and seeks re-election as a Director. Details of Ms Melissa Waller’s qualifications and experience are set out in the Annual Report. Resolution 4 is an ordinary resolution. The Chairperson intends to exercise all available proxies in favour of Resolution 4. The Board (excluding Ms Melissa Waller) supports the re-election of Ms Melissa Waller and recommends that Shareholders vote in favour of Resolution 4.
8
Resolution 5 – Re-election of Mr Vaughn Taylor as Director Under the Constitution of the Company, Directors are required to retire by rotation, and may seek reelection, every three years. However, having regard to feedback from Shareholders, all Directors (excluding Mr Anastasios Arima) will retire at the Meeting and present themselves for re-election. Page 12
Resolution 5 provides that Mr Vaughn Taylor retires and seeks re-election as a Director. Details of Mr Vaughn Taylor’s qualifications and experience are set out in the Annual Report. Resolution 5 is an ordinary resolution. The Chairperson intends to exercise all available proxies in favour of Resolution 5. The Board (excluding Mr Vaughn Taylor) supports the re-election of Mr Vaughn Taylor and recommends that Shareholders vote in favour of Resolution 5.
9
Resolution 6 – Re-election of Ms Lorraine Martin as Director Under the Constitution of the Company, Directors are required to retire by rotation, and may seek reelection, every three years. However, having regard to feedback from Shareholders, all Directors (excluding Mr Anastasios Arima) will retire at the Meeting and present themselves for re-election. Resolution 6 provides that Ms Lorraine Martin retires and seeks re-election as a Director. Details of Ms Lorraine Martin’s qualifications and experience are set out in the Annual Report. Resolution 6 is an ordinary resolution. The Chairperson intends to exercise all available proxies in favour of Resolution 6. The Board (excluding Ms Lorraine Martin) supports the re-election of Ms Lorraine Martin and recommends that Shareholders vote in favour of Resolution 6.
10
Resolution 7 – Re-election of Mr Tony Tripeny as Director Under the Constitution of the Company, Directors are required to retire by rotation, and may seek reelection, every three years. However, having regard to feedback from Shareholders, all Directors (excluding Mr Anastasios Arima) will retire at the Meeting and present themselves for re-election. Resolution 7 provides that Mr Tony Tripeny retires and seeks re-election as a Director. Details of Mr Tony Tripeny’s qualifications and experience are set out in the Annual Report. Resolution 7 is an ordinary resolution. The Chairperson intends to exercise all available proxies in favour of Resolution 7. The Board (excluding Mr Tony Tripeny) supports the re-election of Mr Tony Tripeny and recommends that Shareholders vote in favour of Resolution 7.
11
Resolution 8 – Election of Mr Michael Loparco as Director
11.1
General Under the Constitution, the Board may at any time appoint any person as a Director. The Constitution provides that a Director so appointed must retire at the next annual general meeting of the Company and is then eligible for election by Shareholders at that meeting. In addition, Listing Rule 14.4 provides that a Director appointed as an addition to the Board must not hold office (without re-election) past the next annual general meeting. On 3 August 2026, Mr Michael Loparco was appointed as a Non-Executive Director of the Company. Accordingly, Mr Michael Loparco retires as a Director at the Meeting and, being eligible, seeks approval to be elected as a Director pursuant to Resolution 8. Details of Mr Michael Loparco's qualifications and experience are set out in the Annual Report. The Chairperson intends to exercise all available proxies in favour of Resolution 8. Resolution 8 is an ordinary resolution. The Board (excluding Mr Michael Loparco) supports the election of Mr Michael Loparco and recommends that Shareholders vote in favour of Resolution 8.
Page 13
12
Resolutions 9, 10, 11, 12, 13 and 14 – Issue of RSUs to NonExecutive Directors
12.1
General Resolutions 9, 10, 11, 12, 13 and 14 seek Shareholder approval, pursuant to Listing Rule 10.11 and Chapter 2E of the Corporations Act, for the issue of up to an aggregate of 388,633 RSUs to the NonExecutive Directors as follows: (a)
up to 77,228 RSUs to Ms Lorraine Martin (and/or her nominee(s)) pursuant to Resolution 9;
(b)
up to 62,281 RSUs to Mr Vaughn Taylor (and/or his nominee(s)) pursuant to Resolution 10;
(c)
up to 62,281 RSUs to Ms Melissa Waller (and/or her nominee(s)) pursuant to Resolution 11;
(d)
up to 62,281 RSUs to Ms Beverly Wyse (and/or her nominee(s)) pursuant to Resolution 12;
(e)
up to 62,281 RSUs to Mr Tony Tripeny (and/or his nominee(s)) pursuant to Resolution 13; and
(f)
up to 62,281 RSUs to Mr Michael Loparco (and/or his nominee(s)) pursuant to Resolution 14.
Subject to shareholder approval, the Company has agreed, on an annual basis commencing from the Meeting: (a) to grant Ms Lorraine Martin (the lead independent Director) such number of RSUs calculated by dividing US$155,000 (converted into AUD using a US$1/A$1.42 exchange rate) by the VWAP of a Share on ASX over the 5 Trading Days immediately prior to 28 September 2026; and (b)
to grant all other Non-Executive Directors such number of RSUs calculated by dividing US$125,000 (converted into AUD using a US$1/A$1.42 exchange rate) by the VWAP of a Share on ASX over the 5 Trading Days immediately prior to 28 September 2026.
The VWAP of a Share on ASX over the five (5) Trading Days immediately prior to 28 September 2026 was A$2.85 (equal to US$2.01 based on an exchange rate of US$1/A$1.42). In the Company’s present circumstances, the Board considers that the grant of the RSUs to the NonExecutive Directors is a cost effective and efficient reward for the Company to make as part of its NonExecutive Director compensation arrangements to appropriately incentivise the continued performance of Non-Executive Directors and is consistent with the strategic goals and targets of the Company. The terms and conditions of the RSUs to be granted to the Non-Executive Directors (and/or their respective nominee(s)) are summarised in Schedule 2. Resolutions 9, 10, 11, 12, 13 and 14 are each an ordinary resolution. The Chairperson intends to exercise all available proxies in favour of Resolutions 9, 10, 11, 12, 13 and 14. 12.2
Chapter 2E of the Corporations Act Chapter 2E of the Corporations Act requires that for a public company, or an entity that the public company controls, to give a financial benefit to a related party of the public company, the public company or entity must: (a)
obtain the approval of the public company's members in the manner set out in sections 217 to 227 of the Corporations Act; and
(b)
give the benefit within 15 months following such approval,
unless the giving of the financial benefit falls within an exception set out in sections 210 to 216 of the Corporations Act. A "related party" includes a director of a company and "giving a financial benefit" is interpreted broadly. The RSUs to be granted (subject to Shareholder approval) constitute the giving of a financial benefit as Ms Lorraine Martin, Mr Vaughn Taylor, Ms Melissa Waller, Ms Beverly Wyse, Mr Tony Tripeny and Mr Michael Loparco are related parties of the Company by reason of being a Director.
Page 14
The Company has determined to seek Shareholder approval for the purposes of Chapter 2E for the issue of up to an aggregate of 388,633 RSUs to the Non-Executive Directors (and/or their respective nominee(s)). 12.3
Specific Information required by section 219 of the Corporations Act The following information is provided to Shareholders for the purposes of obtaining Shareholder approval for the purposes of section 219 of the Corporations Act for the financial benefits associated with the issue of the RSUs to Non-Executive Directors: (a)
(b)
the financial benefits relating to the issue of the RSUs are being provided to: (i)
Ms Lorraine Martin (and/or her nominee(s)) pursuant to Resolution 9;
(ii)
Mr Vaughn Taylor (and/or his nominee(s)) pursuant to Resolution 10;
(iii)
Ms Melissa Waller (and/or her nominee(s)) pursuant to Resolution 11;
(iv)
Ms Beverly Wyse (and/or her nominee(s)) pursuant to Resolution 12;
(v)
Mr Tony Tripeny (and/or his nominee(s)) pursuant to Resolution 13; and
(vi)
Mr Michael Loparco (and/or his nominee(s)) pursuant to Resolution 14.
the maximum number of RSUs to be granted to: (i)
Ms Lorraine Martin (and/or her nominee(s)) is 77,228 RSUs;
(ii)
Mr Vaughn Taylor (and/or his nominee(s)) is 62,281 RSUs;
(iii)
Ms Melissa Waller (and/or her nominee(s)) is 62,281 RSUs;
(iv)
Ms Beverly Wyse (and/or her nominee(s)) is 62,281 RSUs;
(v)
Mr Tony Tripeny (and/or his nominee(s)) is 62,281 RSUs; and
(vi)
Mr Michael Loparco (and/or his nominee(s)) is 62,281 RSUs. Director
Number of RSUs
Expiry Date
Lorraine Martin
77,228
Two years from date of issue
Vaughn Taylor
62,281
Two years from date of issue
Melissa Waller
62,281
Two years from date of issue
Beverly Wyse
62,281
Two years from date of issue
Tony Tripeny
62,281
Two years from date of issue
Michael Loparco
62,281
Two years from date of issue
(c)
Ms Lorraine Martin, Mr Vaughn Taylor, Ms Melissa Waller, Ms Beverly Wyse, Mr Tony Tripeny and Mr Michael Loparco are being issued the RSUs as a cost-effective and efficient reward to incentivise their performance. The RSUs will be granted to Ms Lorraine Martin, Mr Vaughn Taylor, Ms Melissa Waller, Ms Beverly Wyse, Mr Tony Tripeny and Mr Michael Loparco (and/or their respective nominee(s)) on the terms and conditions in Schedule 2;
(d)
Ms Lorraine Martin, Mr Vaughn Taylor, Ms Melissa Waller, Ms Beverly Wyse, Mr Tony Tripeny and Mr Michael Loparco each have a material personal interest in the outcome of Resolutions 9, 10, 11, 12, 13 and 14 (respectively) and believe it inappropriate to make recommendations;
(e)
the RSUs have an estimated value of A$2.85 per RSU (based on the underlying Share price of A$2.85, being the VWAP of a Share on ASX over the five (5) Trading Days immediately prior to 28 September 2026). As a result, the total value attributed to the RSUs to be issued to Ms Lorraine Martin (and/or her respective nominee(s)) would be approximately A$220,100 (US$155,000) and the total value attributed to the RSUs to be issued to Mr Vaughn Taylor, Ms Melissa Waller, Ms Beverly Wyse, Mr Tony Tripeny and Mr Michael Loparco (and/or their respective nominee(s)) would be approximately A$177,500 (US$125,000) each;
(f)
the current remuneration package for each of the Non-Executive Directors consists of: (i) fees of US$60,000 per annum for director and committee fees (excluding Mr Michael Loparco, who recently became a Non-Executive Director). However, pursuant to Resolution 15, the Company is seeking to increase the aggregate Non-Executive Page 15
Director fee pool to US$700,000. If Resolution 15 is approved and the fee pool is increased, adjustments to the Non-Executive Directors fees will be made; and (ii)
(g)
apart from the RSUs proposed to be issued to the Non-Executive Directors pursuant to Resolutions 9 to 14, in the previous financial year each of the Non-Executive Directors were issued the following securities as part of their remuneration package: Name
Number of securities
Lorraine Martin
28,131 RSUs
Vaughn Taylor
22,686 RSUs
Melissa Waller
22,686 RSUs
Beverly Wyse
22,686 RSUs
Tony Tripeny
22,686 RSUs
Michael Loparco
Nil
the current security holdings of Ms Lorraine Martin, Mr Vaughn Taylor, Ms Melissa Waller, Ms Beverly Wyse, Mr Tony Tripeny and Mr Michael Loparco (and/or their respective nominee(s)) in the Company are as follows: Non-Executive Director Lorraine Martin Vaughn Taylor Melissa Waller Beverly Wyse Tony Tripeny Michael Loparco
12.4
Shares 1,177,138 973,457 486,318 745,868 38,777
Options
American Depositary Shares
Performance Rights
RSUs
8,855
90,216
84,771
84,771
84,771
8,033
51,010
58,584
(h)
if all the RSUs, subject to Resolutions 9, 10, 11, 12, 13 and 14 are converted into Shares, a total of 388,633 Shares would be issued. This will increase the number of Shares on issue from 362,240,163 (being the total number of Shares on issue as at 28 September 2026) to 362,628,796 (assuming no further issues of Shares and no convertible securities vest or are exercised) with the effect that the shareholding of existing Shareholders would be diluted by an aggregate of 0.11%;
(i)
voting prohibition and voting exclusion statements are included in the Notice for the purposes of Resolutions 9, 10, 11, 12, 13 and 14; and
(j)
other than the information above and otherwise set out in the Notice, the Company believes that there is no other information that would be reasonably required by Shareholders to pass Resolutions 9, 10, 11, 12, 13 and 14.
Listing Rule 10.11 The Company is proposing to issue up to 388,633 RSUs to Non-Executive Directors (and/or their nominees) without using up the Company's 15% Placement Capacity under Listing Rule 7.1. Listing Rule 10.11.1 provides that unless one of the exceptions in Listing Rule 10.12 applies, a listed company must not issue or agree to issue Equity Securities to a related party unless it obtains the approval of its shareholders. The issue of up to 388,633 RSUs to Non-Executive Directors (and/or their nominees) falls within Listing Rule 10.11.1 and does not fall within any of the exceptions in Listing Rule 10.12. It therefore requires the approval of the Company's Shareholders under Listing Rule 10.11. As Shareholder approval is sought under Listing Rule 10.11, Shareholder approval is not required under Listing Rule 7.1. Accordingly, the issue of up to 388,633 RSUs to Non-Executive Directors (and/or their nominees) will not reduce the Company's 15% Placement Capacity for the purposes of Listing Rule 7.1 Exception 14. Page 16
If Resolutions 9, 10, 11, 12, 13 and 14 are passed, the Company will be able to proceed with the issuance of 77,228 RSUs to Ms Lorraine Martin and 62,281 RSUs to each of Mr Vaughn Taylor, Ms Melissa Waller, Ms Beverly Wyse, Mr Tony Tripeny and Mr Michael Loparco (respectively). If Resolutions 9, 10, 11, 12, 13 and 14 are not passed, the Company will not be able to proceed with the issuance of 77,228 RSUs to Ms Lorraine Martin and 62,281 RSUs to each of Mr Vaughn Taylor, Ms Melissa Waller, Ms Beverly Wyse, Mr Tony Tripeny and Mr Michael Loparco (respectively) as part of their Non-Executive Director compensation arrangements and the Company will need to find alternative measures to compensate its Non-Executive Directors. 12.5
Specific Information required by Listing Rule 10.13 Listing Rule 10.13 requires that the following information be provided to Shareholders for the purpose of obtaining Shareholder approval for the grant of the RSUs: (a)
12.6
the RSUs will be granted to: (i)
Ms Lorraine Martin (and/or her nominee(s)) pursuant to Resolution 9;
(ii)
Mr Vaughn Taylor (and/or his nominee(s)) pursuant to Resolution 10;
(iii)
Ms Melissa Waller (and/or her nominee(s)) pursuant to Resolution 11;
(iv)
Ms Beverly Wyse (and/or her nominee(s)) pursuant to Resolution 12;
(v)
Mr Tony Tripeny (and/or his nominee(s)) pursuant to Resolution 13; and
(vi)
Mr Michael Loparco (and/or his nominee(s)) pursuant to Resolution 14;
(b)
Ms Lorraine Martin, Mr Vaughn Taylor, Ms Melissa Waller, Ms Beverly Wyse, Mr Tony Tripeny and Mr Michael Loparco are Directors of the Company and therefore, are related parties under Listing Rule 10.11.1;
(c)
the maximum number of RSUs to be granted to the Non-Executive Directors is set out in Section 12.3(b) of this Notice;
(d)
the material terms of the RSUs are detailed in Schedule 2;
(e)
the Company will grant the RSUs no later than 1 month after the date of the Meeting;
(f)
the RSUs will be granted for nil consideration (and accordingly no funds will be raised by the issue);
(g)
the RSUs are being issued to Ms Lorraine Martin, Mr Vaughn Taylor, Ms Melissa Waller, Ms Beverly Wyse, Mr Tony Tripeny and Mr Michael Loparco as part of their Non-Executive Director compensation arrangements. The Company considers the issuance of RSUs to be a cost-effective way to provide compensation benefits to directors, and it assists to align the interests of shareholders and Directors;
(h)
the current remuneration package of the Non-Executive Directors is set out in Section 12.3(f) of this Notice;
(i)
the RSUs are being issued pursuant to appointment letters for the Non-Executive Directors on usual terms which provide for an annual grant of RSUs or other securities to Non-Executive Directors, subject to Shareholder approval; and
(j)
voting exclusion statements are included in the Notice for the purposes of Resolutions 9, 10, 11, 12, 13 and 14.
Board Recommendation The Board (excluding Ms Lorraine Martin) recommends that Shareholders vote in favour of Resolution 9. The Board (excluding Mr Vaughn Taylor) recommends that Shareholders vote in favour of Resolution 10. The Board (excluding Ms Melissa Waller) recommends that Shareholders vote in favour of Resolution 11. The Board (excluding Ms Beverly Wyse) recommends that Shareholders vote in favour of Resolution 12. Page 17
The Board (excluding Mr Tony Tripeny) recommends that Shareholders vote in favour of Resolution 13. The Board (excluding Mr Michael Loparco) recommends that Shareholders vote in favour of Resolution 14.
13
Resolution 15 – Increase in Aggregate Fee Pool for Non-Executive Directors
13.1
General In accordance with Listing Rule 10.17 and clause 7.5 of the Constitution, the Company must not increase the total amount of Non-Executive Directors' fees payable by it and any of its child entities without the approval of holders of its ordinary securities. Listing Rule 10.17 also provides that the Notice must include the amount of the increase, the maximum amount that may be paid to the Directors as a whole, and a voting exclusion statement. Resolution 15 seeks Shareholder approval to set the maximum aggregate remuneration payable to Non-Executive Directors at US$700,000 per annum. The Board believes that the remuneration of the Directors must be maintained at a level consistent with similarly sized ASX listed companies, taking into account the time commitment of the role and Company performance. The increase in the aggregate remuneration pool sought by Resolution 15 is designed to: (a)
accommodate an increase in the number of non-executive Directors, if such an increase is considered appropriate; and
(b)
allow for future increases in remuneration to current or future non-executive Directors, should this be considered appropriate.
The maximum aggregate amount does not include any matters excluded from Directors' fees pursuant to the Listing Rules governing the total aggregate amount of Directors' fees payable to the NonExecutive Directors and any Equity Securities issued to Non-Executive Directors as permitted by the Listing Rules. If Resolution 15 is passed, it will ensure the Company has adequate flexibility to increase the size of the Board or the remuneration of Non-executive Directors, as and when the business of the Company requires. If Resolution 15 is not passed, the Company will not have additional flexibility to increase the remuneration of Non-Executive Directors beyond the current maximum aggregate remuneration pool of US$300,000. Resolution 15 is an ordinary resolution. The Chairperson intends to exercise all available proxies in favour of Resolution 15. The Board (excluding Mr Anastasios Arima and Mr Todd Hannigan) does not make a recommendation on Resolution 15 in view of the personal interest of those Directors in the Resolution. Mr Anastasios Arima and Mr Todd Hannigan recommend that Shareholders vote in favour of Resolution 15. 13.2
Clause 7.5 of the Constitution and Listing Rule 10.17 Clause 7.5 of the Constitution provides that the remuneration of the Directors shall not be increased except pursuant to a resolution passed at a general meeting of the Company. Listing Rule 10.17 provides that Shareholder approval is required to increase the total amount of Directors' fees payable by the Company. Listing Rule 10.17 does not apply to the salary of an executive Director. Listing Rule 10.17 requires that the following information be provided to Shareholders:
Page 18
(a)
Shareholder approval is being sought to increase the fee pool by US$400,000, which would increase the annual remuneration pool from US$300,000 to US$700,000 (equivalent to approximately A$994,000).
(b)
Subject to Shareholders approving Resolution 15, the maximum aggregate amount of Directors fees that may be paid to all of the Company’s Non-Executive Directors will be US$700,000 per annum.
(c)
In the last 3 years prior to the date of this Notice, the following securities have been issued to Non-Executive Directors under Listing Rule 10.11 or 10.14 (with Shareholder approval, where applicable): Name
Lorraine Martin
Vaughn Taylor
Melissa Waller
Beverly Wyse
Tony Tripeny Michael Loparco (d)
Number
Type of Security
Date of issue
101,281
RSUs
22 Dec 2023
158,655
Shares
3 Aug 2024
42,486
RSUs
22 Dec 2024
24,615
Shares
3 Nov 2025
28,131
RSUs
28 Dec 2025
101,281
RSUs
22 Dec 2023
42,486
RSUs
22 Dec 2024
16,000
Shares
3 Nov 2025
22,686
RSUs
28 Dec 2025
101,281
RSUs
22 Dec 2023
42,486
RSUs
22 Dec 2024
22,686
RSUs
28 Dec 2025
101,281
RSUs
22 Dec 2023
42,486
RSUs
22 Dec 2024
52,000
Shares
3 Nov 2025
22,686
RSUs
28 Dec 2025
24,615
Shares
3 Nov 2025
22,686
RSUs
28 Dec 2025
58,584
RSUs
3 Aug 2026
A voting exclusion statement is included in the Notice for Resolution 15.
Directors may be entitled to further remuneration if they are called upon to perform additional services or make special exertions on behalf of the Company or the business of the Company.
14
Resolution 16 – Ratification of Placement Shares
14.1
General On 8 July 2026, the Company announced a capital raising comprising a placement to institutional, professional and sophisticated investors (Institutional Placement Participants) of 2,275,000 of its american depositary shares (ADSs), with each ADS representing 10 of its ordinary shares. The ADSs were issued to the Institutional Placement Participants. The Placement represents the issue of 22,750,000 ordinary shares underlying the ADSs, which were issued using the Company's 15% Placement Capacity under Listing Rule 7.1, at an issue price of US$21.98 per ADS (converted into AUD using a US$0.69/A$1 exchange rate and with an underlying price per Share of A$3.19) (Placement Shares). Proceeds raised pursuant to the Placement will be used to continue the commercialization and scaleup of certain of the Company's titanium and metal alloy production technologies, including continued scale-up and expansion of the Company’s Titanium Manufacturing Campus in Virginia and associated
Page 19
titanium metal research and development activities, continued development of the Camden-Titan Project in Tennessee, and for general corporate purposes. Cantor Fitzgerald acted as sole book-running manager for the Placement. Roth Capital Partners and B. Riley Securities acted as co-managers for the Placement. Refer to the Company's ASX announcement dated 8 July 2026 for further details regarding the Placement. Resolution 16 seeks Shareholder ratification, pursuant to and in accordance with Listing Rule 7.4 and for all other purposes, for the prior issue of the Placement Shares to the Institutional Placement Participants pursuant to the Company's placement capacity under Listing Rule 7.1. Resolution 16 is an ordinary resolution. The Chairperson intends to exercise all available proxies in favour of Resolution 16. 14.2
Listing Rule 7.1 Subject to a number of exceptions, Listing Rule 7.1 limits the amount of Equity Securities that a listed company can issue without the approval of its shareholders over any 12 month period to 15% of the fully paid ordinary securities it had on issue at the start of that period (15% Placement Capacity). The issue of the Placement Shares did not fit within any of the exceptions to Listing Rule 7.1 and, as it has not yet been approved by Shareholders, it effectively uses up part of the Company's 15% Placement Capacity under Listing Rule 7.1, thereby reducing the Company’s capacity to issue further Equity Securities without Shareholder approval under Listing Rule 7.1 for the 12 month period following the issue of the Placement Shares. Listing Rule 7.4 provides that if the Company in general meeting ratifies the previous issue of or agreement to issue Equity Securities pursuant to Listing Rule 7.1 (and provided that the previous issue did not breach Listing Rule 7.1), those Equity Securities will be deemed to have been made with Shareholder approval for the purposes of Listing Rule 7.1. If Resolution 16 is passed, the issue of the Placement Shares will be excluded in calculating the Company's 15% Placement Capacity under Listing Rule 7.1, effectively increasing the number of Equity Securities it can issue without Shareholder approval over the 12 month period following 8 July 2026. If Resolution 16 is not passed, the Placement Shares will be included in calculating the Company's 15% Placement Capacity under Listing Rule 7.1, effectively decreasing the number of Equity Securities it can issue without Shareholder approval for the 12 month period following 8 July 2026.
14.3
Specific information required by Listing Rule 7.5 For the purposes of Shareholder ratification of the prior issue of Placement Shares to the Institutional Placement Participants and the requirements of Listing Rule 7.5, the following information is provided: (a)
the Placement Shares were issued to professional and sophisticated investors who were identified through a bookbuild process, which involved Cantor Fitzgerald, in consultation with the Company, seeking expressions of interest from non-related and related parties of the Company to participate in the Placement. None of the participants in the Placement are related parties or associates of related parties of the Company;
(b)
22,750,000 Shares were issued pursuant to Listing Rule 7.1 on 8 July 2026;
(c)
the Placement Shares are fully paid ordinary shares of the Company and rank equally with the existing Shares on issue;
(d)
the Placement Shares were issued at US$21.98 per ADS (converted into A$ using a US$0.69/A$1 exchange rate, with the underlying Shares at an issue price of A$3.19 (being US$2.20) per Share) (to raise A$72.5 million (before costs));
Page 20
14.4
(e)
proceeds raised from the Placement will be used as detailed in Section 14.1;
(f)
the Placement Shares were issued under short form subscription letters pursuant to which the Institutional Placement Participants received ADSs at an issue price of US$21.98 per ADS (converted into A$ using a US$0.69/A$1 exchange rate, with the underlying Shares at an issue price of A$3.19 per Placement Share (being US$2.20 per Share));
(g)
Cantor Fitzgerald acted as sole book-running manager for the Placement, and Roth Capital Partners and B. Riley Securities acted as co-managers for the Placement. Cantor Fitzgerald will receive a fee of 6% of gross proceeds raised from the Placement; and
(h)
a voting exclusion statement is included in the Notice for Resolution 16.
Board recommendation The Board recommends that Shareholders vote in favour of Resolution 16.
Page 21
Schedule 1 Definitions In the Notice and this Explanatory Memorandum, words importing the singular include the plural and vice versa. 15% Placement Capacity has the meaning given in Section 14.2. A$ means Australian Dollars. ADSs has the meaning given in Section 14.1. AEDT means Australian Eastern Daylight Time, being the time in Sydney, New South Wales. Annual Report means the Directors' Report, the Financial Report and the Auditor's Report in respect of the financial year ended 30 June 2026. ASIC means the Australian Securities and Investments Commission. ASX means ASX Limited (ACN 008 624 691) and, where the context permits, the Australian Securities Exchange operated by ASX. Auditor's Report means the auditor's report on the Financial Report. Board means the board of Directors. Chairperson means the person appointed to chair the Meeting, or any part of the Meeting, convened by the Notice. Closely Related Party means: (a)
a spouse or child of the member; or
(b)
has the meaning given in section 9 of the Corporations Act.
Company means IperionX Limited (ACN 618 935 372). Constitution means the constitution of the Company as at the commencement of the Meeting. Corporations Act means the Corporations Act 2001 (Cth). Director means a director of the Company. Directors' Report means the annual directors' report prepared under chapter 2M of the Corporations Act for the Company and its controlled entities. Equity Security has the same meaning as in the Listing Rules. Explanatory Memorandum means the explanatory memorandum which forms part of the Notice. Financial Report means the annual financial report prepared under chapter 2M of the Corporations Act of the Company and its controlled entities. Institutional Placement Participants has the meaning given in Section 14.1. Key Management Personnel means persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly, including any Director (whether executive or otherwise) of the Company. Listing Rules means the listing rules of ASX. Managing Director means the managing director of the Company. Meeting has the meaning in the introductory paragraph of the Notice.
Page 22
Non-Executive Directors means the non-executive directors of the Company. Notice means the notice of meeting which comprises of the notice, agenda, Explanatory Memorandum and Proxy Form. Option means an option which entitles the holder to subscribe for a Share in the capital of the Company. Performance Right means a right to be issued a Share on the satisfaction of a specified vesting condition. Placement Shares has the meaning given in Section 14.1. Proxy Form means the proxy form attached to the Notice. Remuneration Report means the remuneration report of the Company contained in the Directors' Report. Resolution means a resolution contained in the Notice. RSU means an unquoted restricted stock unit that converts into a Share in the capital of the Company. Schedule means a schedule to this Explanatory Memorandum. Section means a section of this Explanatory Memorandum. Security means a security in the Company. Share means a fully paid ordinary share in the capital of the Company. Shareholder means a shareholder of the Company. Strike has the meaning given in Section 4. Trading Day means a day determined by ASX to be a trading day in accordance with the Listing Rules. US$ means United States Dollars. VWAP means volume weighted average price.
Page 23
Schedule 2 Terms and Conditions of RSUs Offer of RSUs 1.1
Each RSU confers an entitlement to the holder (Holder) (and/or his or her nominee(s)) to be provided with one fully paid ordinary Share of the Company (Share) at no cost, upon the satisfaction of the Vesting Conditions (described below) specified by the Board in relation to that RSU. Number of RSUs and Expiry Date
1.2
The Number of RSUs and Expiry Date for each are as follows: Holder
Number of RSUs
Expiry Date
Ms Lorraine Martin
77,228
Two years from date of issue
Ms Melissa Waller
62,281
Two years from date of issue
Ms Beverly Wyse
62,281
Two years from date of issue
Mr Vaughn Taylor
62,281
Two years from date of issue
Mr Tony Tripeny
62,281
Two years from date of issue
Mr Michael Loparco
62,281
Two years from date of issue
Vesting Conditions 1.3
Subject to the Holder's continuous service to the Company (Vesting Condition), all RSUs issued to the Holder will vest one year from the date of issue (Vesting Period).
1.4
Subject to clauses 1.5 and 1.6, RSUs will only vest and entitle the Holder to be issued Shares if the applicable Vesting Condition has been satisfied on or before the Expiry Date.
1.5
If a Holder ceases to be a Director during the Vesting Period due to: (a)
their resignation for any reason, other than the Holder having become disqualified or prohibited by law from being or acting as a director or from being involved in the management of a company;
(b)
being either removed as a director of the Company, or is not re-elected as a director of the Company after having notified the Board of his or her willingness to be re-elected, in either case for any reason other than the Holder having become disqualified or prohibited by law from being or acting as a director or from being involved in the management of a company;
(c)
their death or total and permanent disability; or
(d)
their retirement or redundancy,
then: (e)
a pro-rata proportion of their unvested RSUs (calculated as a percentage of the Vesting Period that has elapsed on the date the holder ceases to be a Director) will automatically vest; and
(f)
the remainder of the Holder's unvested RSUs will lapse,
unless the Board determines in its absolute discretion that another treatment of the Holder's RSUs will apply. Page 24
1.6
If a Holder ceases to be a Director during the Vesting Period due to any other reason, all of the Holder's unvested RSUs will lapse, unless the Board determines in its absolute discretion that another treatment of the RSUs will apply. In exercising its discretion, the Board may (but is not obliged to) have regard to the proportion of the Vesting Period in relation to the relevant RSUs that has elapsed on the date the Holder ceases to be a Director. Satisfaction of Vesting Condition
1.7
The Board will determine in its sole discretion whether (and, where applicable, to what extent) the Holder has satisfied the Vesting Conditions applicable to the RSUs. As soon as practicable after making that determination the Board must allot and issue, or transfer, the number of Shares for which the Holder is entitled to acquire upon satisfaction of the Vesting Conditions for the relevant number of RSUs held in accordance with clause 1.10. Lapse of RSUs
1.8
The Expiry Date for each RSU is as detailed in clause 1.2.
1.9
Where RSUs have not satisfied the Vesting Condition on or before the Expiry Date, those RSUs will automatically lapse. Timing of the Issue of Shares and Quotation
1.10
The Company must within twenty (20) business days after the later of the following: (a)
the satisfaction of the Vesting Conditions applicable to the RSUs; and
(b)
when excluded information in respect of the Company (as defined in section 708A(7) of the Corporations Act) (if any) ceases to be excluded information, provided that in no event will the shares be issued to a Holder subject to section 409A of the US Internal Revenue Code be issued later than 15 March of the year following the year that includes satisfaction of the Vesting Conditions. If there is no such information, the relevant date will be the date the relevant Vesting Conditions are satisfied;
the Company will:
1.11
(c)
allot and issue the Shares pursuant to the vesting of the RSUs;
(d)
as soon as reasonably practicable and if required, give ASX a notice that complies with section 708A(5)(e) of the Corporations Act, or, if the Company is unable to issue such a notice, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors; and
(e)
apply for official quotation on ASX of Shares issued pursuant to the vesting of the RSUs.
Notwithstanding clause 1.10 above, solely with respect to Holders who are not U.S. residents or to the extent such does not otherwise violate section 409A of the US Internal Revenue Code, the Company’s obligation to issue such Shares pursuant to clause 1.10(c) shall be postponed if such Holder at any time after the relevant Vesting Conditions are satisfied pursuant to clause 1.3 elects for the Shares to be issued to be subject to a holding lock for a period of twelve (12) months. Following any such election: (a)
the Shares to be issued or transferred will be held by such Holder on the Company's issuer sponsored sub-register (and not in a CHESS sponsored holding);
(b)
the Company will apply a holding lock on the Shares to be issued or transferred and such Holder is taken to have agreed to that application of that holding lock;
(c)
the Company shall release the holding lock on the Shares on the earlier to occur of:
(i)
the date that is twelve (12) months from the date of issue of the Share; or
(ii)
the date the Company issues a disclosure document that qualifies the Shares for trading in accordance with section 708A(11) of the Corporations Act; or Page 25
(iii) (d)
the date a transfer of the Shares occurs pursuant to clause 1.11(d) of these terms and conditions; and
Shares shall be transferable by such Holder and the holding lock will be lifted provided that the transfer of the Share complies with section 707(3) of the Corporations Act and, if requested by the Company, the transferee of the Shares agrees by way of a deed poll in favour of the Company to the holding lock applying to the Shares following its transfer for the balance of the period in clause 1.11(c).
Shares Issued 1.12
Shares issued on the satisfaction of the Vesting Conditions attaching to the RSUs rank equally with all existing Shares. Quotation of the Shares Issued on Exercise
1.13
If admitted to the official list of ASX at the time, application will be made by the Company to ASX for quotation of the Shares issued upon the vesting of the RSUs. Reorganisation
1.14
If there is any reorganisation of the issued share capital of the Company, the terms of RSUs and the rights of the Holder who holds such RSUs will be varied, including an adjustment to the number of RSUs, in accordance with the ASX Listing Rules that apply to the reorganisation at the time of the reorganisation. Holder Rights
1.15
A Holder who holds RSUs is not entitled to: (a)
notice of, or to vote or attend at, a meeting of the Shareholders;
(b)
receive any dividends declared by the Company;
(c)
any right to a return of capital, whether in winding up of the Company, upon a reduction of capital in the Company or otherwise;
(d)
participate in any new issues of securities offered to Shareholders such as bonus issues or entitlement issues during the term of the RSUs; or
(e)
cash for the RSUs or any right to participate in surplus assets of profits of the Company on winding up,
unless and until the RSUs vest and the Holder holds Shares. Pro Rata Issue of Securities 1.16
If during the term of any RSU, the Company makes a pro rata issue of securities to the Shareholders by way of a rights issue, a Holder shall not be entitled to participate in the rights issue in respect of any RSUs, only in respect of Shares issued in respect of vested RSUs.
1.17
A Holder will not be entitled to any adjustment to the number of Shares they are entitled to or adjustment to any Vesting Conditions which is based, in whole or in part, upon the Company’s share price, as a result of the Company undertaking a rights issue. Adjustment for Bonus Issue
1.18
If, during the term of any RSU, securities are issued pro rata to Shareholders generally by way of bonus issue, the number of Shares to which the Holder is then entitled, shall be increased by that
Page 26
number of securities which the Holder would have been issued if the RSUs then held by the Holder were vested immediately prior to the record date for the bonus issue. Change of Control 1.19
1.20
For the purposes of these terms and conditions, a "Change of Control Event" occurs if: (a)
the Company announces that its Shareholders have at a Court convened meeting of Shareholders voted in favour, by the necessary majority, of a proposed scheme of arrangement (excluding a merger by way of scheme of arrangement for the purposes of a corporate restructure (including change of domicile, or any reconstruction, consolidation, subdivision, reduction or return) of the issued capital of the Company) and the Court, by order, approves the scheme of arrangement;
(b)
a Takeover Bid (as defined in the Corporations Act):
(i)
is announced;
(ii)
has become unconditional; and
(iii)
the person making the Takeover Bid has a Relevant Interest (as defined in the Corporations Act) in fifty percent (50%) or more of the issued Shares;
(c)
any person acquires a Relevant Interest in fifty and one-tenths percent (50.1%) or more of the issued Shares by any other means; or
(d)
the announcement by the Company that a sale or transfer (in one transaction or a series of related transactions) of the whole or substantially the whole of the undertaking and business of the Company has been completed.
Where a Change of Control Event has (i) occurred or (ii) been announced by the Company and, in the opinion of the Board, will or is likely to occur, all granted RSUs which have not yet vested or lapsed shall automatically and immediately vest, regardless of whether any Vesting Conditions have been satisfied. Quotation
1.21
The Company will not seek official quotation of any RSUs. RSUs Not Property
1.22
A Holder's RSUs are personal contractual rights granted to the Holder only and do not constitute any form of property. No Transfer of RSUs
1.23
Unless otherwise determined by the Board, RSUs cannot be transferred to or vest in any person other than the Holder, provided that upon the death of the Holder, any shares that have not yet been issued with respect to vested RSUs (including RSUs that vest on the Holder’s death) shall be issued to the representative of the Holder’s estate.
Page 27
Proxy Voting Form If you are attending the Meeting in person, please bring this with you for Securityholder registration. IperionX Limited | ABN 84 618 935 372
Your proxy voting instruction must be received by 11:00am (AEDT) on Monday, 23 November 2026, being not later than 48 hours before the commencement of the Meeting. Any Proxy Voting instructions received after that time will not be valid for the scheduled Meeting.
SUBMIT YOUR PROXY Complete the form overleaf in accordance with the instructions set out below. YOUR NAME AND ADDRESS The name and address shown above is as it appears on the Company’s share register. If this information is incorrect, and you have an Issuer Sponsored holding, you can update your address through the investor portal: https://investor.automic.com.au/#/home Shareholders sponsored by a broker should advise their broker of any changes. STEP 1 - APPOINT A PROXY If you wish to appoint someone other than the Chair of the Meeting as your proxy, please write the name of that Individual or body corporate. A proxy need not be a Shareholder of the Company. Otherwise if you leave this box blank, the Chair of the Meeting will be appointed as your proxy by default.
Lodging your Proxy Voting Form: Online Use your computer or smartphone to appoint a proxy at https://portal.automic.com.au/investor/home or
scan the QR code below using your smartphone Login & Click on ‘Meetings’. Use the Holder Number as shown at the top of this Proxy Voting Form.
DEFAULT TO THE CHAIR OF THE MEETING Any directed proxies that are not voted on a poll at the Meeting will default to the Chair of the Meeting, who is required to vote these proxies as directed. Any undirected proxies that default to the Chair of the Meeting will be voted according to the instructions set out in this Proxy Voting Form, including where the Resolutions are connected directly or indirectly with the remuneration of Key Management Personnel. STEP 2 - VOTES ON ITEMS OF BUSINESS You may direct your proxy how to vote by marking one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as he or she chooses. If you mark more than one box on an item your vote on that item will be invalid.
BY MAIL: Automic GPO Box 5193 Sydney NSW 2001
APPOINTMENT OF SECOND PROXY You may appoint up to two proxies. If you appoint two proxies, you should complete two separate Proxy Voting Forms and specify the percentage or number each proxy may exercise. If you do not specify a percentage or number, each proxy may exercise half the votes. You must return both Proxy Voting Forms together. If you require an additional Proxy Voting Form, contact Automic Registry Services.
IN PERSON: Automic Level 5, 126 Phillip Street Sydney NSW 2000
SIGNING INSTRUCTIONS Individual: Where the holding is in one name, the Shareholder must sign. Joint holding: Where the holding is in more than one name, all Shareholders should sign. Power of attorney: If you have not already lodged the power of attorney with the registry, please attach a certified photocopy of the power of attorney to this Proxy Voting Form when you return it. Companies: To be signed in accordance with your Constitution. Please sign in the appropriate box which indicates the office held by you. Email Address: Please provide your email address in the space provided. By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible) such as a Notice of Meeting, Proxy Voting Form and Annual Report via email.
BY EMAIL: [email protected]
BY FACSIMILE: +61 2 8583 3040 All enquiries to Automic: WEBSITE: https://automicgroup.com.au
PHONE: CORPORATE REPRESENTATIVES 1300 288 664 (Within Australia) If a representative of the corporation is to attend the Meeting the appropriate ‘Appointment of Corporate +61 2 9698 5414 (Overseas) Representative’ should be produced prior to admission. A form may be obtained from the Company’s share registry online at https://automicgroup.com.au.
STEP 1 - How to vote APPOINT A PROXY: I/We being a Shareholder entitled to attend and vote at the Annual General Meeting of IperionX Limited, to be held at 11:00am (AEDT) on Wednesday, 25 November 2026 at Level 5, 56 Pitt Street, Sydney NSW 2000 hereby: Appoint the Chair of the Meeting (Chair) to vote in accordance with the following directions (or if no directions have been given, and subject to the relevant laws, as the Chair sees fit) at this meeting and at any adjournment thereof.
Please note: If you are not appointing the Chair of the Meeting as your proxy, please write in the box provided below the name of the person or body corporate you are appointing as your proxy. If the person so named is absent from the meeting, or if no person is named, the Chair will act on your behalf.
The Chair intends to vote undirected proxies in favour of all Resolutions in which the Chair is entitled to vote. Unless indicated otherwise by marking the “for”, “against” or “abstain” box you will be authorising the Chair to vote in accordance with the Chair’s voting intention. AUTHORITY FOR CHAIR TO VOTE UNDIRECTED PROXIES ON REMUNERATION RELATED RESOLUTIONS Where I/we have appointed the Chair as my/our proxy (or where the Chair becomes my/our proxy by default), I/we expressly authorise the Chair to exercise my/our proxy on Resolutions 1, 9, 10, 11, 12, 13, 14 and 15 (except where I/we have indicated a different voting intention below) even though Resolutions 1, 9, 10, 11, 12, 13, 14 and 15 are connected directly or indirectly with the remuneration of a member of the Key Management Personnel, which includes the Chair.
STEP 2 - Your voting direction For
Against Abstain Resolutions
For
Remuneration Report
9
Issue of RSUs to Non-Executive Director Ms Lorraine Martin
2
Re-election of Mr Todd Hannigan as Director
10
Issue of RSUs to Non-Executive Director Mr Vaughn Taylor
3
Re-election of Ms Beverly Wyse as Director
11
Issue of RSUs to Non-Executive Director Ms Melissa Waller
4
Re-election of Ms Melissa Waller as Director
12
Issue of RSUs to Non-Executive Director Ms Beverly Wyse
5
Re-election of Mr Vaughn Taylor as Director
13
Issue of RSUs to Non-Executive Director Mr Tony Tripeny
6
Re-election of Ms Lorraine Martin as Director
14
Issue of RSUs to Non-Executive Director Mr Michael Loparco
7
Re-election of Mr Tony Tripeny as Director
15
Increase in Aggregate Fee Pool for NonExecutive Directors
8
Election of Mr Michael Loparco as Director
16
Ratification of Placement Shares
Against Abstain
Please note: If you mark the abstain box for a particular Resolution, you are directing your proxy not to vote on that Resolution and your votes will not be counted in computing the required majority on a poll.
STEP 3 – Signatures and contact details Individual or Securityholder 1
Sole Director and Sole Company Secretary
604
Page 1 of 5
Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder
To Company Name/Scheme
IPERIONX LTD
ACN/ARSN/ABN
84 618 935 372
- Details of substantial holder (1) Name
JPMorgan Chase & Co. and its affiliates
ACN/ARSN (if applicable)
NA
There was a change in the interests of the substantial holder on
25/September/2026
The previous notice was given to the company on
03/September/2026
The previous notice was dated
01/September/2026
- Previous and present voting power The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:
Class of securities (4)
Previous notice Person’s votes
Ordinary
24,126,965
Present notice Voting power (5)
Person’s votes
6.66%
27,809,067
Voting power (5) 7.68%
- Changes in relevant interests Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows: Date of change
Person whose relevant interest Nature of change (6) changed
See Appendix
JPMORGAN CHASE BANK, N.A.
See Appendix
Consideration given Class and number of Person's in relation to securities affected votes change (7) affected
See Appendix
2,969,924 (Ordinary)
2,969,924 (Ordinary)
J.P. MORGAN SECURITIES Purchase and sales of securities in its capacity PLC as Principal/Proprietary
See Appendix
5,292 (Ordinary)
5,292 (Ordinary)
See Appendix
J.P. MORGAN SECURITIES LLC
Holder of securities subject to an obligation to return under a securities lending agreement
See Appendix
104,000 (Ordinary)
104,000 (Ordinary)
See Appendix
J.P. MORGAN SECURITIES LLC
Rehypothecation of client securities under a Prime Brokerage Agreement
See Appendix
1,493,349 (Ordinary)
1,493,349 (Ordinary)
See Appendix
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
Holder of securities subject to an obligation to return under a securities lending agreement
See Appendix
35,000 (Ordinary)
35,000 (Ordinary)
Securities on Loan as Agent Lender
604
Page 2 of 5
See Appendix
J.P. MORGAN SECURITIES Purchase and sales of securities in its capacity AUSTRALIA LIMITED as Principal/Proprietary
See Appendix
1,764,725 (Ordinary)
1,764,725 (Ordinary)
See Appendix
J.P. MORGAN PRIME INC.
Rehypothecation of client securities under a Prime Brokerage Agreement
See Appendix
1,001,940 (Ordinary)
1,001,940 (Ordinary)
See Appendix
ALMEA 2 SEGREGATED PORTFOLIO COMPANY
Purchase and sales of securities in its capacity as Principal/Proprietary
See Appendix
50 (Ordinary)
50 (Ordinary)
See Appendix
JPMORGAN ASSET MANAGEMENT (UK) LIMITED
In its capacity as investment manager or in various other related capacities
See Appendix
162,728 (Ordinary)
162,728 (Ordinary)
- Present relevant interests Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows: Holder of relevant interest
Registered holder of securities
JPMORGAN CHASE BANK, N.A.
JPM Nominees Australia Pty Limited
J.P. MORGAN SECURITIES PLC
Person entitled to be registered as holder (8)
Nature of relevant interest (6)
Class and number of securities
Person's votes
Various Borrowers under the Securities Lending Agreement
Securities on Loan as Agent Lender
14,571,513 (Ordinary)
14,571,513 (Ordinary)
JPM Nominees Australia Pty Limited
JPM Nominees Australia Pty Limited
Holder of securities subject to an obligation to return under a securities lending agreement
971,702 (Ordinary)
971,702 (Ordinary)
J.P. MORGAN SECURITIES PLC
JPM Nominees Australia Pty Limited
J.P. MORGAN SECURITIES PLC
Purchase and sales of securities in its capacity as Principal/Proprietary
162,055 (Ordinary)
162,055 (Ordinary)
J.P. MORGAN SECURITIES LLC
Citi Australia
Various Clients and Custodians
Rehypothecation of client securities under a Prime Brokerage Agreement
2,486,814 (Ordinary)
2,486,814 (Ordinary)
J.P. MORGAN SECURITIES LLC
Citi Australia
Citi Australia
Holder of securities subject to an obligation to return under a securities lending agreement
3,128,000 (Ordinary)
3,128,000 (Ordinary)
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
Ecapital Nominees Pty Ltd
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
Purchase and sales of securities in its capacity as Principal/Proprietary
1,263,628 (Ordinary)
1,263,628 (Ordinary)
604
Page 3 of 5
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
Ecapital Nominees Pty Ltd
Ecapital Nominees Pty Ltd
Holder of securities subject to an obligation to return under a securities lending agreement
2,285,000 (Ordinary)
2,285,000 (Ordinary)
J.P. MORGAN PRIME INC.
Citi Australia
Various Clients and Custodians
Rehypothecation of client securities under a Prime Brokerage Agreement
2,725,390 (Ordinary)
2,725,390 (Ordinary)
ALMEA 2 SEGREGATED PORTFOLIO COMPANY
Various clients
ALMEA 2 SEGREGATED PORTFOLIO COMPANY
Purchase and sales of securities in its capacity as Principal/Proprietary
50 (Ordinary)
50 (Ordinary)
J.P. MORGAN INVESTMENT MANAGEMENT INC.
Not Available
Various Clients and Custodians
In its capacity as investment manager or in various other related capacities
10,540 (Ordinary)
10,540 (Ordinary)
JPMORGAN ASSET MANAGEMENT (UK) LIMITED
Citibank, N.A., Hong Kong Branch
Various Clients and Custodians
In its capacity as investment manager or in various other related capacities
58,584 (Ordinary)
58,584 (Ordinary)
JPMORGAN ASSET MANAGEMENT (UK) LIMITED
BNP Paribas (Sydney Branch)
Various Clients and Custodians
In its capacity as investment manager or in various other related capacities
145,791 (Ordinary)
145,791 (Ordinary)
- Changes in association The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows: Name and ACN/ARSN (if applicable)
Nature of association
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
Subsidiary of JPMorgan Chase & Co.
J.P. MORGAN SECURITIES LLC
Subsidiary of JPMorgan Chase & Co.
J.P. MORGAN SECURITIES PLC
Subsidiary of JPMorgan Chase & Co.
JPMORGAN CHASE BANK, N.A.
Subsidiary of JPMorgan Chase & Co.
J.P. MORGAN PRIME INC.
Subsidiary of JPMorgan Chase & Co.
ALMEA 2 SEGREGATED PORTFOLIO COMPANY
Subsidiary of JPMorgan Chase & Co.
JPMORGAN ASSET MANAGEMENT (UK) LIMITED
Subsidiary of JPMorgan Chase & Co.
- Addresses The addresses of persons named in this form are as follows: Name
Address
JPMorgan Chase & Co.
270 Park Avenue, New York, New York, NY, 10017, United States
604
Page 4 of 5
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
LEVEL 18, 83-85 CASTLEREAGH STREET, SYDNEY, NSW 2000, Australia
J.P. MORGAN SECURITIES LLC
270 Park Avenue, New York, New York, NY, 10017, United States
J.P. MORGAN SECURITIES PLC
25 Bank Street, Canary Wharf, London, E14 5JP, England
JPMORGAN CHASE BANK, N.A.
1111 Polaris Parkway, Columbus, Delaware, OH, 43240, United States
J.P. MORGAN PRIME INC.
270 Park Avenue, New York, New York, NY, 10017, United States
ALMEA 2 SEGREGATED PORTFOLIO COMPANY
270 Park Avenue, New York, New York, NY, 10017, United States
J.P. MORGAN INVESTMENT MANAGEMENT INC.
270 Park Avenue, New York, New York, NY, 10017, United States
JPMORGAN ASSET MANAGEMENT (UK) LIMITED
60 Victoria Embankment, London, EC4Y0JP, England
Signature print name sign here
Vasim Pathan
Capacity Date
Compliance Officer 29/September/2026
604
Page 5 of 5
DIRECTIONS (1)
If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 6 of the form.
(2)
See the definition of "associate" in section 9 of the Corporations Act 2001.
(3)
See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
(4)
The voting shares of a company constitute one class unless divided into separate classes.
(5)
The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.
(6)
Include details of: (a)
any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
(b)
any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).
See the definition of "relevant agreement" in section 9 of the Corporations Act 2001. (7)
Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
(8)
If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown".
(9)
Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.
TRADES FOR RELEVANT PERIOD Transaction Date Balance at start of relevant period 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 2-Sep-26 3-Sep-26 3-Sep-26 3-Sep-26 3-Sep-26 3-Sep-26 3-Sep-26 3-Sep-26 3-Sep-26 3-Sep-26 3-Sep-26 3-Sep-26 3-Sep-26 3-Sep-26 3-Sep-26 3-Sep-26 3-Sep-26 4-Sep-26 4-Sep-26 4-Sep-26 4-Sep-26 4-Sep-26 4-Sep-26 4-Sep-26 4-Sep-26 4-Sep-26 4-Sep-26 4-Sep-26 4-Sep-26 4-Sep-26 4-Sep-26 7-Sep-26 7-Sep-26 7-Sep-26 7-Sep-26 7-Sep-26 7-Sep-26 7-Sep-26 7-Sep-26 7-Sep-26 8-Sep-26 8-Sep-26 8-Sep-26 8-Sep-26 8-Sep-26 8-Sep-26 8-Sep-26 8-Sep-26 8-Sep-26 8-Sep-26 8-Sep-26 8-Sep-26 8-Sep-26 8-Sep-26 8-Sep-26 8-Sep-26 8-Sep-26 8-Sep-26 8-Sep-26 9-Sep-26 9-Sep-26 9-Sep-26 9-Sep-26 9-Sep-26 9-Sep-26 9-Sep-26 9-Sep-26 9-Sep-26 9-Sep-26 9-Sep-26 10-Sep-26 10-Sep-26 10-Sep-26 10-Sep-26 10-Sep-26 10-Sep-26 10-Sep-26 10-Sep-26 10-Sep-26 10-Sep-26 10-Sep-26 10-Sep-26 10-Sep-26 10-Sep-26 10-Sep-26 10-Sep-26 11-Sep-26 11-Sep-26 11-Sep-26
Appendix Entity
Product Type
Type of Transaction
J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES PLC ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED
Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity
Adjustment Adjustment Buy Buy Buy Buy Buy Sell Buy Buy Buy Sell Buy Sell Sell Sell Sell Sell Borrow Return Borrow Return Borrow Borrow Borrow Return Borrow Borrow Borrow Borrow Borrow Return Borrow Borrow Borrow Return Borrow Return Sell Sell Sell Buy Buy Sell Buy Buy Borrow Return Borrow Return Borrow Borrow Borrow Borrow Borrow Return Borrow Return Sell Buy Buy Buy Buy Sell Sell Sell Buy Sell Sell Buy Borrow Borrow Buy Sell Buy Buy Buy Sell Borrow Borrow Borrow Return Buy Buy Buy Buy Buy Buy Buy Sell Sell Sell Buy Buy Sell Sell Borrow Return Borrow Borrow Borrow Borrow Return Buy Sell Sell Buy Buy Sell Sell Borrow Borrow Return Borrow Return Borrow Sell Buy Sell Buy Sell Sell Sell Sell Sell Borrow Borrow Return Borrow Return Borrow Borrow Borrow Borrow Sell Buy Buy
Quantity 24,126,965 (182) (56) 40 20 210 40 2,130 (1,639) 1,033 488 2,230 (12,482) 7 (488) (2,375) (2) (3,002) (153,383) (26,000) (2,000) 3,000 28,000 (120,000) 53,000 63 3,000 10,000 (74,265) 72,016 3,471 (68,394) (9,700) (326) (21,599) (4,391) 2,697 4,391 (645) 12,327 211 (17,000) (2,000) 15,000 147,000 3,423 6,229 (60,512) (298,000) (23) 184 325 475 3,226 (41,361) (12,330) (1,758) 904 (215) (5,476) 24 10,000 505,100 487 (10,785) 4,250 12,729 32,999 (307) 70,000 2,000 (2,581) 40 30 30 30 50 50 470 (4,250) (30,733) (173) 4,367 2,455 (280) (611) (31,080) 45,000 14,900 16,485 (17,003) 981 (6) (24,183) 5,561 14,944 (449) (205,975) 4,000 (14,900) (15,233) 222,000 (497) 1,169 (38,826) 3,681 (3,681) (160) (3,173) (6,267) (691,798) 100,000 (17,965) (1) 1 269,400 2,249 576,351 (3) 436 1,448
Price (AUD) 2.98 2.95 2.94 2.96 2.95 2.89 2.91 2.89 2.91 2.85 2.86 3.10 3.10 3.10 3.10 3.10 3.01 2.99 2.98 2.96 2.97 2.89 3.01 2.96 3.01 2.96 2.96 2.99 3.00 2.98 2.98 2.97 2.99 3.01 3.01 2.96 3.12 3.09 3.11 3.11 3.11 2.96 3.14 3.13 3.14 3.11 3.12 3.13 3.12 3.08 3.03 3.02 3.04 3.05 3.12 3.12 3.11 3.11 3.09 3.11 3.10 3.03 3.03 2.85 2.97 2.84 2.92 2.81 3.11 3.11 3.11 2.85 2.64 2.64 2.64
Consideration $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $
119.38 58.98 617.36 118.38 6,286.99 4,736.71 3,006.27 1,409.99 6,489.82 35,584.11 20.02 1,512.80 7,362.50 6.20 9,306.20 475,487.30 981.26 64,492.02 13,083.57 7,983.12 13,041.27 1,864.05 37,045.59 625.15 69.23 544.64 962.00 1,417.99 9,670.39 123,162.01 36,725.45 5,222.12 2,706.18 647.15 16,482.76 71.04 1,519.44 33,347.57 13,215.68 39,592.59 102,618.61 908.72 125.51 93.97 94.15 93.33 155.98 156.64 1,466.96 13,090.00 93,266.17 522.98 13,281.98 7,492.73 873.60 1,906.32 3,050.91 18.66 74,710.52 17,296.09 46,316.66 1,360.47 624,104.25 1,416.45 3,472.21 110,293.60 10,765.76 10,335.74 497.60 9,868.03 19,490.37 1,971,624.30 7.92 1,148.86 3,823.32
1/3
TRADES FOR RELEVANT PERIOD 11-Sep-26 11-Sep-26 11-Sep-26 11-Sep-26 11-Sep-26 11-Sep-26 11-Sep-26 11-Sep-26 11-Sep-26 11-Sep-26 11-Sep-26 14-Sep-26 14-Sep-26 14-Sep-26 14-Sep-26 14-Sep-26 14-Sep-26 14-Sep-26 14-Sep-26 14-Sep-26 14-Sep-26 14-Sep-26 14-Sep-26 14-Sep-26 14-Sep-26 14-Sep-26 14-Sep-26 14-Sep-26 14-Sep-26 14-Sep-26 14-Sep-26 14-Sep-26 14-Sep-26 14-Sep-26 15-Sep-26 15-Sep-26 15-Sep-26 15-Sep-26 15-Sep-26 15-Sep-26 15-Sep-26 15-Sep-26 15-Sep-26 15-Sep-26 15-Sep-26 15-Sep-26 15-Sep-26 15-Sep-26 16-Sep-26 16-Sep-26 16-Sep-26 16-Sep-26 16-Sep-26 16-Sep-26 16-Sep-26 16-Sep-26 16-Sep-26 16-Sep-26 16-Sep-26 16-Sep-26 16-Sep-26 16-Sep-26 16-Sep-26 16-Sep-26 16-Sep-26 16-Sep-26 16-Sep-26 16-Sep-26 17-Sep-26 17-Sep-26 17-Sep-26 17-Sep-26 17-Sep-26 17-Sep-26 17-Sep-26 17-Sep-26 17-Sep-26 17-Sep-26 17-Sep-26 17-Sep-26 17-Sep-26 17-Sep-26 17-Sep-26 17-Sep-26 17-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 18-Sep-26 21-Sep-26 21-Sep-26 21-Sep-26 21-Sep-26 21-Sep-26 21-Sep-26 21-Sep-26
J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY ALMEA 2 SEGREGATED PORTFOLIO COMPANY J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED JPMORGAN ASSET MANAGEMENT (UK) LIMITED JPMORGAN ASSET MANAGEMENT (UK) LIMITED JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC
Equity Equity Equity Equity Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt
Sell Buy Buy Sell Borrow Return Borrow Return Borrow Return Borrow Return Borrow Borrow Return Borrow Sell Sell Sell Sell Sell Sell Buy Buy Sell Sell Buy Sell Sell Sell Borrow Borrow Borrow Return Borrow Borrow Borrow Return Borrow Borrow Borrow Sell Sell Buy Buy Buy Buy Sell Sell Sell Sell Borrow Borrow Return Borrow Return Borrow Buy Sell Sell Sell Buy Sell Sell Borrow Return Borrow Borrow Borrow Borrow Borrow Return Borrow Return Borrow Borrow Return Borrow Borrow Return Borrow Return Borrow Return Sell Buy Buy Sell Buy Buy Sell Sell Sell Borrow Borrow Borrow Return Borrow Return Borrow Borrow Return Borrow Borrow Sell Sell Sell Sell Sell Sell Sell Sell Sell Sell Buy Sell Buy Buy Sell Buy Buy Sell Sell Sell Sell Sell Borrow Borrow Return Borrow Borrow Borrow Return Borrow Borrow Borrow Return Borrow Return Sell Buy Sell Buy Sell Sell Borrow
(18,651) 532 5,842 (21,167) (6,000) (30) (13,822) (32,307) 4 (4) 45,000 (40) (50) (820) (200) (90) (800) 505 165 (11,909) (12,163) 745 (2,716) (745) (372,932) 8,998 487 (487) 42,000 100,000 (5) 5 2,000 384,000 (1,296) (2) 2,030 2,664 60 4 (2,382) (7) (60) (2,437) 3,000 (17,199) (2) 2 161 (12,032) (2,030) (26,037) 1,833 (2,382) (236) (100,000) 293 28,707 84,200 2,249 (5,741) (10,000) 10,000 (2) 2 (2,249) (313,902) (11,256) (18,071) 790 3,757 (3,613) 4,386 290 (9,492) (424) (290) 50,000 22,626 (19,147) (2) 1 (45,705) 9,030 4,970 (40) (70) (690) (30) (10) (30) (70) (50) (20) (40) 462 (535) 11,115 782 (634) 5,324 788 (46) (742) (31,147) (45,537) (117,191) 5,757 (93,391) 93 344,844 (4) 4 200 (142,045) (9,513) (22,393) 10,729 (681) 5,605 (1,755) (184) 88,000
2.65 2.64 2.65 2.85 2.56 2.56 2.56 2.56 2.56 2.56 2.55 2.55 2.57 2.57 2.59 2.64 2.64 2.64 2.50 2.50 2.54 2.50 2.54 2.54 2.55 2.55 2.55 2.55 2.63 2.55 2.57 2.57 2.58 2.50 2.50 2.57 2.72 2.72 2.57 2.64 2.69 2.69 2.56 2.56 2.91 2.92 2.93 2.92 2.91 2.91 2.92 2.92 2.91 2.90 3.00 3.00 2.93 2.94 2.91 3.00 2.98 2.72 2.72 2.72 2.88 2.88 2.95 2.95 2.92 2.92 3.00 3.00
$ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $
Appendix 49,506.00 1,402.73 15,483.41 60,325.95 102.48 128.22 2,096.49 511.75 230.72 2,051.72 1,287.75 420.75 30,597.75 31,277.77 1,929.55 7,170.24 1,966.80 984,540.48 3,240.00 5.00 5,156.20 6,660.16 152.40 10.16 6,074.10 17.85 153.00 6,214.35 423.46 30,705.00 5,214.52 66,803.57 4,723.46 5,955.00 590.00 46,442.47 2,148.80 10,219.86 9,285.41 11,598.17 779.38 25,504.17 1,085.44 742.40 116.37 204.66 2,019.20 87.48 29.10 87.30 204.38 146.08 58.12 116.11 1,386.00 1,605.00 32,563.28 2,299.08 1,844.94 15,972.00 2,344.80 125.12 2,018.24 84,719.84 131,237.63 337,744.46 66,025.56 31,653.72 1,988.52 16,367.91 5,265.00 552.00
2/3
TRADES FOR RELEVANT PERIOD 21-Sep-26 21-Sep-26 21-Sep-26 21-Sep-26 21-Sep-26 22-Sep-26 22-Sep-26 22-Sep-26 22-Sep-26 22-Sep-26 22-Sep-26 22-Sep-26 22-Sep-26 22-Sep-26 22-Sep-26 22-Sep-26 22-Sep-26 22-Sep-26 22-Sep-26 23-Sep-26 23-Sep-26 23-Sep-26 23-Sep-26 23-Sep-26 23-Sep-26 23-Sep-26 23-Sep-26 24-Sep-26 24-Sep-26 24-Sep-26 24-Sep-26 24-Sep-26 24-Sep-26 24-Sep-26 24-Sep-26 24-Sep-26 24-Sep-26 24-Sep-26 24-Sep-26 24-Sep-26 24-Sep-26 24-Sep-26 24-Sep-26 25-Sep-26 25-Sep-26 25-Sep-26 25-Sep-26 25-Sep-26 25-Sep-26 25-Sep-26 25-Sep-26 25-Sep-26 25-Sep-26 25-Sep-26 25-Sep-26 25-Sep-26 25-Sep-26 25-Sep-26 25-Sep-26 25-Sep-26 25-Sep-26 Balance at end of relevant period
J.P. MORGAN SECURITIES AUSTRALIA LIMITED JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. ALMEA 2 SEGREGATED PORTFOLIO COMPANY J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN PRIME INC. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A.
Equity Equity Equity Equity Equity Equity - Depository Receipt Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity - Depository Receipt Equity Equity Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt
Borrow Borrow Borrow Borrow Borrow Return Sell Sell Buy Buy Sell Borrow Return Borrow Return Borrow Borrow Borrow Borrow Return Borrow Return Borrow Return Borrow Return Buy Sell Buy Sell Sell Borrow Borrow Borrow Return Sell Buy Sell Buy Buy Sell Sell Sell Borrow Return Borrow Borrow Borrow Return Borrow Return Borrow Return Borrow Return Borrow On-Lend Adjustment On-Lend On-Lend Sell Buy Sell Buy Sell Sell Borrow Return Borrow Borrow Borrow Return Borrow Borrow Borrow Return Borrow
35,000 478,434 1 79,580 (2,000) (40) (162) 15,070 829 (31,919) (44,000) (9,000) 12,061 205,054 2 (141,411) (1,616) (2) (332,613) 9,902 (31,919) 117 (11,057) (2,598) 64,000 2 (7,967) (6) 179 (664) 3,986 6,096 (32,886) (544) (94) (4,000) 11,000 11,000 (147,000) (84,200) (1) (174,113) 225,000 1,001,940 13,840 844,729 648,620 (255) 40 (17,741) 17,741 (670) (6,235) (1,000) 400,000 370,000 (1) 1 348,000 (1,000) 1,000 27,809,067
3.02 2.98 3.01 3.02 3.00 3.05 2.98 3.05 3.03 3.03 2.76 2.78 2.82 2.77 2.82 2.93 2.93 2.93 2.76 2.79 2.76 2.76 2.82 2.82
$ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $
Appendix
120.65 482.76 45,430.64 2,504.30 95,678.58 30,218.37 95,089.19 356.85 33,502.71 7,871.94 16.56 497.62 1,872.48 11,037.58 17,188.63 96,355.98 1,593.92 275.42 703.80 111.61 48,965.16 48,965.16 1,889.40 17,582.70
3/3
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX. Date:
29-Sep-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant interests: Schedule
25-Sep-2026
Type of agreement
Global Master Securities Lending Agreement (“GMSLA”)
Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and BARCLAYS CAPITAL SECURITIES LIMITED ( “Borrower”) Settlement Date: 02-Jun-2025 29-Jan-2026 30-Jan-2026 10-Apr-2026 16-Jun-2026 08-Sep-2026
Transfer date
Holder of voting rights Are there any restriction on voting rights If yes, detail Scheduled return date (if any) Does the borrower have the right to return early?
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA. None Yes
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
29-Sep-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 25-Sep-2026 interests: Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and BNP Paribas Financial Markets (Borrower)
Transfer date
Settlement Date 14-Aug-2026 17-Aug-2026 19-Aug-2026 20-Aug-2026 27-Aug-2026 28-Aug-2026 31-Aug-2026 01-Sep-2026 02-Sep-2026 03-Sep-2026 04-Sep-2026 07-Sep-2026 17-Sep-2026 18-Sep-2026 21-Sep-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions. Yes No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX. Date:
29-Sep-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant interests: Schedule
25-Sep-2026
Type of agreement
Master Securities Lending Agreement (“MSLA”)
Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Bofa Securities, Inc. ( “Borrower”)
Transfer date
Settlement date 07-Aug-2026 11-Aug-2026 21-Aug-2026 26-Aug-2026 28-Aug-2026 17-Sep-2026
Holder of voting rights Are there any restriction on voting rights If yes, detail Scheduled return date (if any) Does the borrower have the right to return early?
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out as per the rights of the borrower as stated in the MSLA. None Yes
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
29-Sep-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 25-Sep-2026 interests: Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Citigroup Global Markets Limited (Borrower)
Transfer date
Settlement Date 10-Aug-2026 29-Sep-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX. Date:
29-Sep-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant interests: Schedule
25-Sep-2026
Type of agreement
Master Securities Lending Agreement (“MSLA”)
Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Goldman Sachs & Co. LLC ( “Borrower”)
Transfer date
Settlement Date 08-Sep-2026 29-Sep-2026
Holder of voting rights Are there any restriction on voting rights If yes, detail Scheduled return date (if any) Does the borrower have the right to return early?
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out as per the rights of the borrower as stated in the MSLA. None Yes
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
29-Sep-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 25-Sep-2026 interests: Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Goldman Sachs International (Borrower)
Transfer date
Settlement Date 07-Sep-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
29-Sep-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 25-Sep-2026 interests: Schedule Type of agreement Australian Master Securities Lending Agreement (“AMSLA”) Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Macquarie Bank Limited(Borrower)
Transfer date
Settlement Date 02-Sep-2026 03-Sep-2026 04-Sep-2026 07-Sep-2026 09-Sep-2026 10-Sep-2026 15-Sep-2026 21-Sep-2026 22-Sep-2026 24-Sep-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4.3 of the standard form AMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender’s instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
29-Sep-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 25-Sep-2026 interests: Schedule Type of agreement Australian Master Securities Lending Agreement (“AMSLA”) Parties to agreement
Transfer date
Holder of voting rights Are there any restriction on voting rights
If yes, detail
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Merrill Lynch Equities (Australia) Limited(Borrower) Settlement Date 05-Jun-2026 13-Jul-2026 12-Aug-2026 25-Aug-2026 16-Sep-2026 Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4.3 of the standard form AMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender’s instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
29-Sep-2026
Company’s name: IPERIONX LTD ISIN:
AU0000208910
Date of change of relevant interests:
25-Sep-2026
Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Merrill Lynch International(Borrower)
Transfer date
Settlement Date 09-Jun-2026 16-Jun-2026 26-Jun-2026 14-Jul-2026 15-Jul-2026 17-Jul-2026 21-Jul-2026 22-Jul-2026 23-Jul-2026 24-Jul-2026 29-Jul-2026 30-Jul-2026 31-Jul-2026 03-Aug-2026 15-Sep-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions.
Will the securities be returned on Yes settlement?
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
29-Sep-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 25-Sep-2026 interests: Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
Transfer date
Holder of voting rights Are there any restriction on voting rights
If yes, detail
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Morgan Stanley & Co. International PLC (Borrower) Settlement Date 30-Oct-2025 14-Jul-2026 15-Jul-2026 21-Aug-2026 24-Aug-2026 03-Sep-2026 22-Sep-2026 23-Sep-2026 Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
29-Sep-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 25-Sep-2026 interests: Schedule Type of agreement Australian Master Securities Lending Agreement (“AMSLA”) Parties to agreement
Transfer date
Holder of voting rights Are there any restriction on voting rights
If yes, detail
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Morgan Stanley Australia Securities Limited (Borrower) Settlement Date 31-Oct-2025 05-Nov-2025 18-Mar-2026 10-Jul-2026 15-Jul-2026 22-Sep-2026 Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4.3 of the standard form AMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender’s instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
29-Sep-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 25-Sep-2026 interests: Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and UBS AG London Branch (Borrower)
Transfer date
Settlement Date 28-Aug-2026 31-Aug-2026 11-Sep-2026 14-Sep-2026 15-Sep-2026 16-Sep-2026 17-Sep-2026 18-Sep-2026 24-Sep-2026 25-Sep-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX. Date:
29-Sep-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of 25-Sep-2026 relevant interests: Schedule Type of agreement Australian Master Securities Lending Agreement (“AMSLA”) Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and UBS Securities Australia Ltd (Borrower)
Transfer date
Settlement Date 18-Jun-2026 25-Jun-2026 26-Jun-2026 29-Jun-2026 16-Jul-2026 27-Aug-2026 14-Sep-2026 24-Sep-2026 25-Sep-2026 28-Sep-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4.3 of the standard form AMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s If yes, detail instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX. Date:
29-Sep-2026
Company’s name:
IPERIONX LTD
ISIN: Date of change of relevant interests: Schedule
AU0000208910
Type of agreement
Master Securities Lending Agreement (“MSLA”)
Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and UBS SECURITIES LLC ( “Borrower”)
Transfer date
Settlement Date 14-Sep-2026 15-Sep-2026
Holder of voting rights Are there any restriction on voting rights If yes, detail Scheduled return date (if any) Does the borrower have the right to return early?
25-Sep-2026
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out as per the rights of the borrower as stated in the MSLA. None Yes
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX.
Date: Company’s name:
29-Sep-2026
ISIN: Date of change of relevant interests: Schedule Type of agreement Parties to agreement
AU0000208910
Transfer date Holder of voting rights Are there any restriction on voting rights
If yes, detail
Scheduled return date (if any) Does the borrower have the right to return early?
IPERIONX LTD
25-Sep-2026 Australian Master Securities Lending Agreement ("AMSLA") BNP Paribas Fund Securities Services S.C.A.(“lender”), J.P. Morgan Securities Australia Limited (“borrower”) Settlement Date 21-Sep-2026
Borrower Yes The borrower undertakes to use its best endeavours to arrange for the voting rights to be exercised in accordance with the instructions of the other lender, provided that the lender uses its best endeavours to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4.3 of the standard form AMSLA. None Yes
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day as agreed by the parties. The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX. Date:
29-Sep-2026
Company’s name:
IPERIONX LTD
ISIN: Date of change of relevant interests: Schedule
AU0000208910
Type of agreement Parties to agreement
Australian Master Securities Lending Agreement ("AMSLA")
25-Sep-2026
JPMorgan Chase Bank, N.A. (acting as agent) ("lender"), J.P. Morgan Securities Australia Limited ('borrower')
Transfer date
Settlement Date 20-Mar-2026 28-Apr-2026
Holder of voting rights
Borrower
Are there any restriction on voting Yes rights
If yes, detail
The borrower undertakes to use its best endeavours to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavours to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4.3 of the standard form AMSLA.
Scheduled return date (if any)
None
Does the borrower have the right to return early?
Yes
If yes, detail
Borrower has right to return all and any securities or equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities on any business day by giving such notice as agreed by the parties. The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exception
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX. Date:
29-Sep-2026
Company’s name:
IPERIONX LTD
ISIN: Date of change of relevant interests: Schedule
AU0000208910
Type of agreement
Global Master Securities Lending Agreement ("GMSLA")
Parties to agreement Transfer date Holder of voting rights Are there any restriction on voting rights If yes, detail
25-Sep-2026
State Street Bank and Trust Company ("lender") and J.P. Morgan Securities Australia Limited ("borrower") Settlement Date 23-Feb-2026 07-Jul-2026 Borrower Yes The borrower shall have no obligation to arrange for voting rights to be exercised in accordance with the instructions of the other party, unless otherwise agreed between the parties.
Scheduled return date (if None any) Does the borrower have the right to return early?
Yes
If yes, detail
Borrower has the right to terminate a loan and redeliver all and any equivalent securities due and outstanding to the lender in accordance with lender's instructions and lender shall accept such redelivery.
Does the lender have the Yes right to recall early? Lender has right to recall all or any equivalent securities on any business day by giving such notice as If yes, detail agreed by the parties. The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions. Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX.
Date: Company’s name: ISIN: Date of change of relevant interests: Schedule Type of agreement
Parties to agreement
29-Sep-2026
IPERIONX LTD AU0000208910
25-Sep-2026 Institutional Account Agreement JP Morgan Securities LLC for itself and as agent and trustee for the other J.P. Morgan Entities and VANGUARD GROUP INC (AS AGT),CHARLES SCHWAB & CO., INC,INTERACTIVE BROKERS LLC,NATIONAL FINANCIAL SERVICES LLC - AS AGENT,ROBINHOOD SECURITIES, LLC (herein referred to as “JPMS”). “ J.P. Morgan Entities” means, as the context may require or permit, any and all of JPMSL, JPMorgan Chase Bank, N.A., J.P. Morgan Securities LLC., J.P. Morgan Markets Limited, J.P. Morgan Securities Australia Limited, J.P. Morgan Securities (Asia Pacific) Limited, J.P. Morgan Securities Japan Co., Ltd and J.P. Morgan Prime Nominees Limited and any additional entity notified to the Company from time to time.
Transfer date
Settlement Date 25-Jun-2026 30-Jun-2026 17-Jul-2026 31-Jul-2026 03-Aug-2026 05-Aug-2026 06-Aug-2026 07-Aug-2026 27-Aug-2026 28-Aug-2026 31-Aug-2026 01-Sep-2026 02-Sep-2026 04-Sep-2026 21-Sep-2026 23-Sep-2026 24-Sep-2026
Holder of voting rights
JPMS is the holder of the voting rights from the time at which it exercises its right to borrow. Notwithstanding this, please note that the Company has the right to recall equivalent securities if it wishes to exercise its voting rights in respect of the securities.
Are there any restriction on voting Yes rights JPMS will not be able to exercise voting rights in circumstances where the Company has recalled If yes, detail equivalent securities from JPMS before the voting rights have been exercised. In these circumstances, JPMS must return the securities to the Company and the Company holds the voting rights. Scheduled return N/A. There is no term to the loan of securities. date (if any) Does the borrower have the right to Yes. return early? If yes, detail
JPMS has the right to return all and any securities or equivalent securities early at any time.
Does the lender have the right to recall early? If yes, detail Will the securities be returned on settlement?
Yes. The Company has the right to recall all or any equivalent securities on demand. Yes. Settlement of the loan will occur when JPMS returns equivalent securities to the Company. There is no term to the loan of securities.
If yes, detail any exceptions Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX. Date:
29-Sep-2026
Company’s name:
IPERIONX LTD
ISIN: Date of change of relevant interests: Schedule
AU0000208910
Type of agreement
Global Master Securities Lending Agreement ("GMSLA")
Parties to agreement
BANK JULIUS BAER & CO. AG vs JPMS PLC
Transfer date
Settlement Date 01-Jul-2026 02-Jul-2026 06-Jul-2026 09-Jul-2026 13-Jul-2026
Holder of voting rights
25-Sep-2026
Borrower
Are there any Yes restriction on voting rights If yes, detail Scheduled return date (if any) Does the borrower have the right to return early?
If yes, detail
Does the lender have the right to recall early?
If yes, detail
The borrower shall have no obligation to arrange for voting rights to be exercised in accordance with the instructions of the other party, unless otherwise agreed between the parties. None
Yes
Borrower has the right to terminate a loan and redeliver all and any equivalent securities due and outstanding to the lender in accordance with lender's instructions and lender shall accept such redelivery on a business day if notice of redelivery has been given within the standard market settlement period.
Yes
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time provided notification is given by the lender within standard market settlement period for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered. The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX.
Date: Company’s name:
29-Sep-2026
ISIN: Date of change of relevant interests: Schedule
AU0000208910
Type of agreement
IPERIONX LTD
25-Sep-2026 Overseas Securities Lender's Agreement ("OSLA")
Parties to agreement
J.P. Morgan Securities Plc ("borrower") and Citibank N.A. acting as Agent ("lender")
Transfer date
Settlement Date 07-Aug-2026
Holder of voting rights Borrower Are there any restriction on voting rights
Yes
If yes, detail
The borrower undertakes to use its best endeavours to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavours to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4(B)(vi) of the standard form OSLA.
Scheduled return date None (if any) Does the borrower have the right to return early?
Yes
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered. The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX. Date:
29-Sep-2026
Company’s name:
IPERIONX LTD
ISIN: Date of change of relevant interests:
AU0000208910
25-Sep-2026
Schedule Type of agreement Parties to agreement
Transfer date
Overseas Securities Lender’s Agreement (“OSLA”) JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) J.P. Morgan Securities plc (“borrower”) Settlement Date 19-Mar-2026 30-Mar-2026 09-Apr-2026 27-Aug-2026
Holder of voting rights
Borrower
Are there any restriction on voting rights
Yes
If yes, detail
The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4(B)(vi) of the standard form OSLA.
Scheduled return date (if any)
None
Does the borrower have the right to Yes return early?
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX.
Date: Company’s name:
29-Sep-2026
ISIN: Date of change of relevant interests: Schedule
AU0000208910
Type of agreement
IPERIONX LTD
25-Sep-2026
Global Master Securities Lending Agreement ("GMSLA")
Parties to agreement
J.P. Morgan Securities plc ("borrower") and State St Bank and Trust Company as agent ("lender")
Transfer date
Settlement Date 29-Jul-2026
Holder of voting rights
Borrower
Are there any restriction on voting Yes rights
If yes, detail
The borrower shall have no obligation to arrange for voting rights to be exercised in accordance with the instructions of the other party, unless otherwise agreed between the parties.
Scheduled return date (if any)
None
Does the borrower have the right to return early?
Yes
If yes, detail
Borrower has the right to terminate a loan and redeliver all and any equivalent securities due and outstanding to the lender in accordance with lender's instructions and lender shall accept such redelivery.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered. The borrower must return the
securities not later than the expiry of such notice in accordance with the lender’s instructions. Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix 3Y
Rule 3.19A.2
Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11
Name of entity
IperionX Limited
ABN
84 618 935 372
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director
Anastasios ARIMA
Date of last notice
July 14, 2026
Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
Direct or indirect interest
Direct and Indirect
Nature of indirect interest (including registered holder)
Moshos Family Investments Pty Ltd ATF Moshos Family Trust. Mr Arima is a director and shareholder of the trustee and a beneficiary of the trust.
Note: Provide details of the circumstances giving rise to the relevant interest.
Date of change
23 September 2026
No. of securities held prior to change
• • • • • • • • •
Class
Fully paid ordinary shares
Number acquired
Number disposed
Value/Consideration
12,455,502 Shares 12,800 ADSs (representing 128,000 Shares) 738,576 RSUs 564,759 A$18.00 Options 639,205 A$22.00 Options 435,806 A$6.00 Performance Rights 435,806 A$7.00 Performance Rights 435,806 A$8.00 Performance Rights 237,944 A$18.00 Performance Rights
Note: If consideration is non-cash, provide details and estimated valuation
No. of securities held after change
- See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Legal/86612406_2
•
12,455,502 Shares
Appendix 3Y Change of Director’s Interest Notice • • • • • • • •
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back
12,800 ADSs (representing 128,000 Shares) 738,576 RSUs 564,759 A$18.00 Options 639,205 A$22.00 Options 435,806 A$6.00 Performance Rights 435,806 A$7.00 Performance Rights 435,806 A$8.00 Performance Rights 237,944 A$18.00 Performance Rights
Off-market return of 1,000,000 fully paid ordinary shares released from collateral following a loan repayment. No change in beneficial ownership.
Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
Detail of contract
Existing loan facility and related security arrangements between Moshos Family Investments Pty Ltd ATF Moshos Family Trust and Equities First Holdings, LLC
Nature of interest
Following the loan repayment and return of shares, 3,850,000 ordinary shares remain held as collateral by HSBC Custody Nominees (Australia) Pty Ltd, as custodian for Equities First Holdings, LLC
Name of registered holder (if issued securities) Date of change
Not applicable
No. and class of securities to which interest related prior to change
Not applicable
23 September 2026
Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Not applicable
Interest disposed
Not applicable
Value/Consideration
Not applicable
Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change
Not applicable
Part 3 – +Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period?
No
If prior written clearance was provided, on what date was this provided?
Not applicable
Not applicable
- See chapter 19 for defined terms. Appendix 3Y Page 2
01/01/2011
Ti ta n i u m m eta l p roc: u cts a re L i g h twe i g h t S tr o n g C o r r o s i o n r e s i s ta n t B i o c o m p a ti b I e
Letter to Sh a reh ol ders 02 Con sol i dated Statem en t of P rofi t or Loss an d Oth er Com p reh en s i ve n com e 74 F i scal Year 2 02 6 H i gh l i gh ts 06 Overview 08 Con sol i dated Statem en t of F i n an cia l Position 75 Con sol i dated Statem en t of Ch an ges i n E qu i ty 76 Scal i n g A B reakth rou gh Ti tan i u m P rodu ction M odel 1 0 Stron g Partn ersh i ps With Th e U . S . Govern m en t 1 1 Con sol i dated Statem en t of Cash F l ows 77 Strategic Advan tages 1 2 N otes to th e Con sol i dated F i n an cia l Statem en ts 78 Con sol i dated E n ti ty D i scl osu re Statem en t 1 1 4 Ti tan i u m P rodu cts 1 4 Ti tan i u m M a rkets 1 6 D i rectors’ D ecl a ra ti on 1 1 5 5 perion X’s Ti tan i u m Tech n ol ogies 1 8 5 n depen den t Au d i tor ‘s Report 1 1 6 M i n era l Resou rces Statem en t 1 2 1 Su sta i n ab i l i ty 2 2 F i n an cia l Report 2 5 Corporate Govern an ce 1 2 5 D i rectors’ Report 2 6 ASX Addition a l n form a ti on 1 2 6 G l ossary of Term s an d D efin i ti on s 1 35 Au d i tor ‘s 5 n depen den ce D ecl a ra ti
2026 Annual Report Redefining titanium for the modern world
Titanium metal products are Lightweight Strong Corrosion resistant Biocompatible
Letter to Shareholders
02
Fiscal Year 2026 Highlights
06
Overview
08
Scaling A Breakthrough Titanium Production Model
10
Strong Partnerships With The U.S. Government
11
Strategic Advantages
12
Titanium Products
14
Titanium Markets
16
IperionX’s Titanium Technologies
18
Sustainability
22
Financial Report
25
Directors’ Report
26
Auditor’s Independence Declaration
73
Consolidated Statement of Profit or Loss and Other Comprehensive Income
74
Consolidated Statement of Financial Position
75
Consolidated Statement of Changes in Equity
76
Consolidated Statement of Cash Flows
77
Notes to the Consolidated Financial Statements
78
Consolidated Entity Disclosure Statement
114
Directors’ Declaration
115
Independent Auditor’s Report
116
Mineral Resources Statement
121
Corporate Governance
125
ASX Additional Information
126
Glossary of Terms and Definitions
135
Corporate Directory
137
Letter to Shareholders Dear Fellow Shareholders,
creating the opportunity to manufacture more competitive products while generating greater value from each ton of titanium.
IperionX is building an integrated American titanium business designed to make high-performance products more competitive, expand their use and create enduring shareholder value. Our strategy combines lower-cost titanium powder production with advanced manufacturing that preserves more of the metal and converts it into valuable, finished titanium components.
The Hydrogen Assisted Metallothermic Reduction™ (HAMR™) technology provides the lower-cost foundation for our titanium powder production. Powder metallurgy subsequently forms that powder into components that are close to their final shape. The Hydrogen Sintering and Phase Transformation™ (HSPT™) technology then develops the vital material properties required for high-end applications, while finishing processes prepare the final product for customer use. Integrating these stages gives us greater control over the cost, consistency and delivery of finished titanium parts.
During fiscal year 2026, we expanded our capacity to manufacture complex titanium components, demonstrated finished-product performance through independent testing, and advanced our proprietary continuous processing technologies with the potential to materially improve production economics. Further progress since year-end has strengthened the manufacturing system that connects these achievements, positioning us to convert these technological advantages into long-term growth.
The advantages can be particularly significant in products with high ‘buy-to-fly’ ratios, where conventional manufacturing removes much of the titanium originally purchased. Retaining more material in the finished component can reduce both metal consumption and machining, extending our cost advantage beyond titanium powder production.
Creating value from titanium, from powder to part A finished titanium component carries the cost of the entire manufacturing process: the feedstock purchased, the material lost, the processing required and the time taken to deliver it. Our proprietary technologies are designed to improve the economics throughout that supply chain,
“
We are pursuing titanium products where this scope for manufacturing efficiency meets attractive market pricing for performance, precision and reliability. That combination creates the potential to offer customers compelling economics while sharing in the value of a qualified, highperformance finished titanium part. Our manufacturing investments support this strategy. The 300-ton, six-axis press commissioned during fiscal year 2026 expanded compaction capacity and the complexity of components we can produce. Additional HSPT™ furnaces are designed to increase downstream throughput. Development of our GenX™ process provides the potential for a further step change in efficiency. Together, these investments establish a stronger route from product development to repeatable production at scale.
Our strategy combines lower-cost titanium powder production with advanced manufacturing that preserves more of the metal and converts it into valuable, finished titanium components.”
02
Anastasios (Taso) Arima Chief Executive Officer & Managing Director Todd Hannigan Executive Chairman
Independent validation, stronger commercial foundations Independent testing during fiscal year 2026 provided important evidence of what our manufacturing technologies can deliver.
for 700 components and the U.S. Army’s subsequent Joint Light Tactical Vehicle (JLTV) fastener prototype order provide specific applications through which to advance this work. Across these and other programs, we are developing the tooling, process control and manufacturing expertise required for sustained production. As these capabilities advance, we can pursue a broader customer base using an integrated manufacturing platform.
U.S. Army testing demonstrated approximately 20% higher torque-to-yield performance for our three-quarter-inch titanium fasteners than comparable Society of Automotive Engineers (SAE) Grade 8 steel fasteners, based on the midpoint of the reported results. Separate independent testing showed yield and ultimate tensile strengths above typical aerospace Grade 5 titanium fastener benchmarks.
Investing in a stronger manufacturing advantage
These results demonstrate that IperionX’s finished components meet the mechanical requirements for demanding applications, alongside titanium’s inherent weight and corrosion-resistance advantages. They strengthen the technical foundation for customer qualification and make our commercial proposition more tangible: high-performance products, an efficient manufacturing process and the security of American supply.
Continued process innovation can improve the productivity of our operations and strengthen the returns from future expansion. The GenX™ results announced in September provide tangible evidence of the progress made through our successful research and development investments. Across its first four campaigns, the continuous HAMR™ system processed more than 500 kilograms of titanium powder. The GenX™ furnace processed six times the volume of batch HAMR™, while unit consumption fell by more than 75% for power, 45% for magnesium and 60% for hydrogen.
Our priority is to combine that performance with competitive product economics and dependable delivery. American Rheinmetall’s prototype order
03
Letter to Shareholders // continued
Building with discipline for long-term returns
The next stage is integration into a complete powder production line, followed by engineering for industrial deployment. Realizing the full benefits of low-cost titanium powder requires downstream manufacturing capacity to keep pace. Higher powder throughput becomes more valuable when pressing, sintering and finishing capacity can convert it into products customers need.
We enter fiscal year 2027 with stronger product evidence, a more capable manufacturing platform and major advances in process technology. Our task is to turn those advantages into dependable products for customers and durable returns for shareholders. Our financial results carry the operating costs of this stage of development, including research, process and product development, and the capabilities needed to serve customers at greater scale. Much of this work precedes the recurring revenue it is intended to support.
August’s second U.S. Army task order, valued at up to US$25.4 million, supports that integration, with US$11.5 million of currently obligated funding toward expanded component manufacturing, continuous HSPT™ and dehydrogenation capacity, and in-house fastener finishing. These investments advance the downstream capabilities that complement our titanium powder production technologies.
The Titan and Atlas critical mineral projects add a further opportunity for long-term returns. Titan’s completed feasibility study and the Atlas acquisition have advanced the opportunity to develop a new American supply of titanium minerals, rare earths and zircon. Together, these are strategic critical mineral assets that can support an integrated American titanium mineral-to-product supply chain.
The titanium plate program announced in July extends the same strategy into larger products and demanding defense applications. It supports development, testing and scale-up for ballistic plate and other performance requirements, broadening the applications of our powder and metallurgical technologies.
To our employees, thank you for the expertise and determination behind our progress. To our customers, government partners, communities and shareholders, thank you for your continued support. We are building IperionX for the long term, to make American titanium more competitive for our customers and create shareholder value.
Together, these programs are building a more complete manufacturing system. Our investment priorities span that system, with a focus on connecting technical improvements to product quality, efficient conversion and customer demand.
With appreciation,
Anastasios (Taso) Arima Chief Executive Officer & Managing Director
04
Todd Hannigan Executive Chairman
05
Fiscal Year 2026 Highlights Fiscal year 2026 represented continued growth, a transition to a 24/7 production schedule, continued HAMR™ powder production and further momentum to reshore a 100% domestic, uninterruptible titanium supply chain.
2020-22 Company formation Acquisition of the Titan Critical Minerals Project ASX listing Initial rights to the titanium technologies Technical validation of the titanium technologies Pilot facility operations, Utah Commencement of customer engagement Nasdaq listing
2022-24
2024-25
Continued pilot facility operations and first commercial contracts
Ramp up of commercial operations in Virginia
Virginia site selected for commercial scale up
Complete acquisition of breakthrough titanium technologies
Patent portfolio growth
U.S. Government funding of US$47.1 million to secure titanium supply chain
U.S. Air Force titanium recycling challenge First UL validated 100% recycled titanium powder Production of titanium metal from Tennessee minerals Titan Project Scoping Study R&D 100 award Expansion of customer base Development and commissioning of commercial operations First US$12.7 million U.S. Department of War award Team and leadership growth
06
Receipt of US$99 million Small Business Innovation Research (SBIR) Phase III Indefinite Delivery, Indefinite Quantity Contract First Army task order under SBIR valued at US$1.3 million Accelerated expansion of U.S. titanium production Commencement of the Titan Project Definitive Feasibility Study
Low-cost, high-quality titanium 2025-26 Virginia commercial operations transitioned to a 24/7 production schedule
IperionX Ti-6Al-4V fasteners exceeded SAE Grade 8 steel torque-to-yield performance
Virginia operations transitioned to a 24/7 production schedule, with HAMR™ systems in ramp-up and supporting a scale-up of powder production capacity of approximately 1,400 tpa.
Independent testing by U.S. Army DEVCOM GVSC and Westmoreland Mechanical Testing & Research showed IperionX Ti-6Al-4V fasteners exceeded SAE Grade 8 steel torqueto-yield performance and achieved tensile properties above standard aerospace grade titanium fastener benchmarks.
Development of GenX™ Development of IperionX’s next generation continuous HAMR™ platform, GenX™, is designed to deliver a step change in capital efficiency, operating cost and throughput relative to the batch processing system. Accelerated titanium product manufacturing
U.S. Army GVSC purchase order for prototype titanium fasteners IperionX received a U.S. Army GVSC purchase order to manufacture prototype titanium fasteners for the JLTV and associated trailer.
Powder metallurgy scale-up continued with the optimization of the 100-ton uniaxial press, commissioning of the cold isostatic press and six-axis 300-ton SACMI powder metallurgy press, along with commissioning of additional HSPT™ sintering furnaces.
07
Completed the Titan Definitive Feasibility Study The U.S. Government-supported Titan Definitive Feasibility Study was completed in June 2026, delivering an after-tax NPV8 of US$813 million, after-tax IRR of 39.4%, after-tax payback of 3.6 years and forecast after-tax free cash flow of US$1.9 billion over an initial 14-year mine plan. Atlas acquisition completed Subsequent to year end, IperionX acquired the strategic Atlas critical mineral property and infrastructure assets, adding approximately 70 acres of at-surface critical-mineral stockpiles, approximately 180 acres of pre-stripped Lower McNairy mineralization and established power, water, natural gas and heavy-haul rail infrastructure.
Overview IperionX is an American-focused titanium metal and critical materials company building two mutually reinforcing growth platforms: a circular, low-cost titanium metal and advanced manufacturing business in Virginia, and a large-scale domestic critical-minerals platform in Tennessee. cost base. The Atlas-Titan platform adds a future domestic source of titanium minerals, heavy rare earths and zircon, creating both standalone critical-minerals value and longterm vertical-integration potential.
Together, they create a pathway from recycled titanium scrap and U.S. mineral feedstocks to high-performance titanium powder, mill products and finished components. The ambition is broader than re-shoring an existing supply chain. By breaking the cost and manufacturing constraints that have held titanium back for more than 80 years, IperionX aims to expand the market for one of the world’s best structural metals.
Fiscal year 2026 marked IperionX’s transition from technology development and commissioning into commercial operations and production ramp-up. The Virginia Titanium Manufacturing Campus is now operating on a 24/7 production schedule, downstream componentmanufacturing capacity is expanding and the focus has shifted to throughput, reliability, product qualification and revenue conversion.
At the core of the titanium platform are IperionX’s patented HAMR™ refining technology and HSPT™ and ThermoHydrogen Refinement of Microstructure™ (THRM™) product technologies. Together, they bypass major parts of the conventional Kroll, melt-remelt and hot-working route, enabling fewer process steps, higher material utilization, lower energy intensity and a structurally lower projected
A new American titanium platform is now operating Titanium combines an exceptional strength-to-weight ratio with corrosion resistance and high-temperature performance, making it essential to defense, aerospace and advanced manufacturing.
24/7 production schedule of the Virginia Titanium Manufacturing Campus
08
fiscal year 2026. IperionX is targeting an annualized titanium powder production run rate of approximately 200 tpa by the end of calendar year 2026, subject to completion of ramp-up and operating optimization. The operating priority is to translate demonstrated capability into reliable, repeatable and increasingly efficient production.
The U.S. no longer has commercial titanium sponge production and remains dependent on imports for a metal critical to national security and industrial resilience. China and Russia together control approximately 80% of global titanium sponge production capacity1, concentrating a strategically important supply chain outside the U.S. IperionX is building a domestic alternative that can transform U.S. titanium scrap - and, over time, U.S. mineral feedstocks - into high-quality powder and finished titanium products. This integration creates greater control across feedstock, metal production, product manufacturing and recycling, while reducing the number of vulnerable links in the conventional supply chain.
Capturing more value: from powder to finished products The commissioned SACMI powder metallurgy press triples existing powder metallurgy capacity and materially expands component complexity and repeatability. Additional HSPT™ furnace capacity is being installed to increase downstream throughput and support customer qualification, low-rate initial production and higher-volume manufacturing. This downstream capacity is central to IperionX’s strategy of converting low-cost powder into higher-value products and deeper customer relationships.
Technology demonstrated; industrial execution now drives progress HAMR™ powder production has consistently met or exceeded Grade 5 quality parameters, and Virginia operations transitioned to a 24/7 schedule during
1
2026 figures shown are estimates and projections, and Chinese data includes projections for incremental 2026 capacity from Argus Metals.
09
Scaling A Breakthrough Titanium Production Model
Next step: U.S. Government-backed expansion to approximately 1,400 tpa Planning, design and long-lead procurement are underway for a seven-fold expansion to approximately 1,400 tpa. The expansion has estimated capital expenditure of approximately US$75 million, including contingency, and targets titanium powder unit costs of approximately US$29/kg at full utilization. Supported by the fully obligated US$47.1 million IBAS award and IperionX’s balance sheet, the program is intended to bridge the Company from initial commercial production to industry-scale American titanium manufacturing.
Scale is not simply a volume objective for IperionX; it is the mechanism by which unit costs decline and the addressable market expands. The growth model is a staircase: approximately 200 tpa on the current platform, a U.S. Government-backed expansion to approximately 1,400 tpa of installed HAMR™ powder equipment capacity targeted during 2027, and a longer-term roadmap to more than 10,000 tpa of high-performance titanium components by 2030. Each step is designed to move titanium closer to value-in-use competitiveness with stainless steel and aluminum and open larger markets for Americanmade titanium.
Long-term ambition: global leadership in high-performance titanium products IperionX’s roadmap targets more than 10,000 tpa of highperformance titanium components by 2030. The objective is not only to become a larger titanium producer, but to reset the economics of titanium products by combining low-cost domestic powder with scalable near-netshape manufacturing. At sufficient scale, titanium can move beyond specialty applications and compete with stainless steel and aluminum across selected markets on value as well as performance. IperionX intends to lead that transition.
Current platform: approximately 200 tpa with a lower projected cost base Technology and operating improvements increased nameplate titanium powder capacity from 125 tpa to approximately 200 tpa - a 60% increase - without additional capital expenditure. At full utilization, projected steady-state titanium powder unit costs are approximately US$55/kg, compared with the prior estimate of US$75/kg. The capacity increase demonstrates the operating leverage available from process improvement and provides the foundation for the next expansion step.
10
Strong Partnerships With The U.S. Government
the award advances both pillars of IperionX’s domestic minerals-to-products strategy. During fiscal year 2026, the DoW obligated US$12.5 million in August 2025, a further US$25.0 million in September 2025 and the final US$4.6 million in January 2026. The US$47.1 million award is fully obligated, with funds available to be drawn by IperionX as milestone-based reimbursements.
U.S. Government support has progressed from early technology validation to industrial scale-up and now serves three important functions: providing non-dilutive growth capital, validating the strategic importance of IperionX’s platform and creating pathways to funded government demand. At June 30, 2026, the US$47.1 million IBAS award and US$12.7 million DPA Title III award were fully obligated, providing US$59.8 million of support for the Virginia titanium platform and the Titan Critical Minerals Project. IperionX also holds a U.S. Department of War (DoW) Small Business Innovation Research (SBIR) Phase III contract with a task-order ceiling of up to US$99 million.
Together with the US$12.7 million DPA Title III award for the initial production platform, this support provides growth capital, strategic validation and a clear government-backed pathway from domestic feedstock through titanium powder to advanced manufactured products.
US$99 million SBIR Phase III contracting pathway and further defense support In June 2025, IperionX executed an Indefinite Delivery, Indefinite Quantity SBIR Phase III contract supporting Low-Cost, Domestic Titanium for Defense Applications. Qualifying U.S. Government agencies can place projectspecific task orders under the contract, collectively capped at US$99 million, for IperionX titanium parts and components. The contract is a procurement pathway rather than committed revenue, but materially shortens the route through which successful programs can progress to funded orders.
During fiscal year 2026, the U.S. Government transferred approximately 290 metric tons of high-quality Ti-6Al-4V scrap to IperionX at no cost. Equivalent to approximately 1.5 years of feedstock at the current full operating capacity of 200 tpa, the transfer provides a secure domestic input for the Virginia ramp-up and demonstrates the strategic alignment between IperionX and the U.S. defense industrial base. The U.S. Army also issued an additional prototype purchase order for titanium fasteners for the JLTV and associated trailer, in addition to funding for scaling production of a range of titanium mill products and components. These programs extend government support from powder production capacity into specific products and manufacturing pathways.
The first task order, valued at US$1.3 million, was issued by the U.S. Army in June 2025 for titanium parts for ground-vehicle programs. It demonstrates how IperionX’s technology, manufacturing capability and government relationships can converge in specific revenue-generating programs.
Subsequent to year end, IperionX received Task Order 2 under its U.S. Army SBIR Phase III contract for Low-Cost, Domestic Titanium for Defense Applications that builds upon the previously announced US$1.3 million task order, lifting the aggregate potential value of task orders issued under the Company’s US$99 million SBIR Phase III contract to US$26.7 million.
The U.S. Army also issued an additional prototype purchase order for titanium fasteners for the JLTV and associated trailer, in addition to funding for scaling production of a range of titanium mill products and components. These programs extend government support from powder production capacity into specific products and manufacturing pathways.
US$47.1 million IBAS award fully obligated for Virginia scale-up and Titan The IBAS award is designed to strengthen the U.S. Defense Industrial Base by accelerating a resilient, low-cost and fully integrated American titanium supply chain. US$5.0 million was allocated to the Titan DFS, with the balance supporting long-lead equipment and capacity expansion at the Virginia Titanium Manufacturing Campus. In this way, 11
Strategic Advantages
Operations transitioned to a 24/7 schedule during fiscal year 2026, and powder production consistently met or exceeded Grade 5 quality parameters. IperionX continues to target an annualized run rate of approximately 200 tpa by the end of 2026, subject to ramp-up and operating optimization. The principal value drivers are now throughput, yield, reliability, product qualification and customer conversion.
IperionX’s advantage is not a single technology or asset; it is an integrated system. Patented process technologies, feedstock flexibility, closed-loop recycling, U.S. Government partnership, customer-qualified product pathways and vertical integration from mineral or scrap to finished product reinforce one another. The result is a platform that is difficult to replicate and whose economic and strategic advantages are designed to compound as it scales.
Scaling product capacity around low-cost titanium powder The 300-ton, six-axis SACMI powder metallurgy press was commissioned in May 2026, tripling IperionX’s existing powder metallurgy capacity and expanding the range, complexity and repeatability of near-net-shape components that can be manufactured in Virginia. Its high-cycle capability also creates a pathway toward materially higher-volume production for suitable component geometries.
An integrated flywheel; from domestic feedstock to finished product HAMR™ can use a broad range of titanium scrap and mineral-derived feedstocks to produce high-quality titanium powder while bypassing chlorination, vacuum distillation and multiple melting steps. This reduces process complexity and energy intensity, increases material utilization and enables more titanium scrap to remain within a high-value domestic supply chain.
The first of two additional HSPT™ sintering furnaces arrived during the quarter ended June 30, 2026 and entered installation and commissioning, with further furnace capacity expected to follow. These assets are designed to expand throughput, relieve downstream constraints and move customer programs from prototype production toward qualification, low-rate initial production and repeatable manufacturing.
HSPT™ and THRM™ are non-melt thermal and phasetransformation technologies that develop refined, wroughtlike microstructures and high mechanical performance without the full conventional forging and hot-working route. Combined with powder metallurgy and additive manufacturing, these technologies convert lower-cost domestic powder into near-net-shape components and mill products with less waste and shorter lead times. Each downstream step captures more value, while process scrap can be returned to HAMR™ and recycled into new titanium.
The current platform supports the expansion toward approximately 1,400 tpa and the longer-term target of more than 10,000 tpa of high-performance titanium components by 2030. GenX™, IperionX’s next-generation continuous HAMR™ development platform, provides additional longterm upside through the potential for higher throughput, lower cost and improved capital efficiency; it is not required for the current 200 tpa ramp.
IperionX’s Green Rutile™ and Alkaline Roasting and Hydrolysis™ (ARH™) mineral-upgrading technologies provide the connection to the Atlas-Titan platform. They offer a future pathway to convert U.S. titanium minerals into high-purity feedstock suitable for HAMR™, completing a fully integrated American mineral-to-product titanium supply chain.
Titan and Atlas: a second, high-value American platform The Titan Critical Minerals Project in Tennessee, with key mine-area permits already in place, is a district-scale domestic resource of titanium minerals, zircon and rare earth-bearing minerals. In June 2026, IperionX completed a U.S. Government-supported DFS based entirely on Proved and Probable Ore Reserves, establishing a technically defined development pathway and compelling project economics.
Commercial-scale capability; execution becomes the value driver Following more than a decade of research, pilot operations and industrialization, IperionX’s Virginia campus has demonstrated the commercial-scale capability of HAMR™.
12
Titan is designed to produce a heavy rare earth concentrate (HREC) containing strategically important dysprosium, terbium and yttrium, together with ilmenite, rutile and zircon concentrate. These products address upstream supply gaps for U.S. defense, permanent magnets, advanced manufacturing and titanium metal supply chains. Titan is therefore both a standalone criticalminerals opportunity and the upstream cornerstone of IperionX’s longer-term mineral-to-product strategy.
Atlas adds approximately 70 acres of at-surface, historically processed critical-mineral stockpiles; approximately 180 acres of pre-stripped Lower McNairy mineralization; mineral and property rights; mining and processing equipment; and established grid power, industrial water, natural gas and heavy-haul rail infrastructure. These features have the potential to reduce the time, capital and operating complexity required to establish initial production.
The DFS delivered an after-tax NPV₈ of US$813 million, an after-tax IRR of 39.4%, a 3.6-year payback and forecast after-tax free cash flow of US$1.9 billion over an initial 14-year mine plan. We believe these economics create material standalone value before considering the strategic benefits of integration with IperionX’s downstream titanium platform.
Atlas and Titan are located within the same McNairy mineral-sand system and are highly complementary. Titan provides a permitted, district-scale resource and defined project economics; Atlas adds high-grade stockpiles, prestripped mineralization and established infrastructure. IperionX is advancing sonic drilling, stockpile surveys, mineral assemblage and metallurgical test work, commercial qualification and an integrated economic assessment targeted for completion by the end of 2026. The combination has the potential to reduce upfront capital and operating costs, accelerate first production and improve overall economics relative to a standalone Titan development.
Atlas Acquisition can accelerate and enhance the upstream pathway On June 15, 2026, IperionX entered into an agreement to acquire mineral, property and infrastructure assets from Covia Solutions LLC adjacent to Titan for US$3.0 million. The acquisition, previously referred to as the Camden acquisition and now named Atlas, was completed subsequent to year-end on July 1, 2026. The modest acquisition cost provides IperionX with control of assets that have the potential to materially improve the sequencing and economics of the broader development pathway.
The integrated Atlas-Titan platform strengthens IperionX’s ability to connect Tennessee feedstocks containing titanium, zircon and heavy rare earth-bearing minerals with downstream U.S. processing, titanium metal production and advanced manufacturing. It also gives shareholders exposure to a critical-minerals platform with development value distinct from the pace of the Virginia titanium ramp.
13
Titanium Products IperionX’s commercial strategy is value-led: prioritize manufactured titanium products where vertical integration can materially reduce waste, shorten lead times and lower projected end-product cost. The largest opportunities are repeat-order products with high conventional ‘buy-to-fly’ ratios, long lead times or concentrated offshore supply chains. In each category, the objective is the same: replace a slower, more wasteful and often imported incumbent with an American-made titanium product that performs better, can be delivered faster and, at scale, is more affordable.
The combination of high-performance, lower component weight, corrosion resistance and scalable domestic manufacturing creates a pathway for titanium to substitute into selected applications currently served by high-strength steel.
Titanium powder remains a strategically important product for additive manufacturing and powder metallurgy. However, converting powder into near-net-shape components and mill products captures a greater share of the value chain, differentiates IperionX from commodity powder suppliers and gives customers a more complete domestic supply-chain solution.
Current programs include titanium impellers for Carver Pump and U.S. Navy applications, lightweight groundvehicle components with American Rheinmetall, and development work across track pins, brackets, gears, actuators and other defense and industrial components. These applications value resilience and performance, but also provide repeat-order potential if qualification and production milestones are achieved.
Fasteners and high-volume hardware
IperionX’s integrated powder-to-product route is designed to replace selected cast, forged and extensively machined components with near-net-shape alternatives that can reduce lead times and material loss while retaining high mechanical performance. The commercial advantage arises from the complete manufacturing route, not powder cost alone.
Defense and industrial components
Titanium fasteners are a large, repeat-order product category across defense, aerospace, marine and industrial markets. Independent testing by U.S. Army Combat Capabilities Development Command (DEVCOM) Ground Vehicle Systems Center (GVSC) and Westmoreland validated IperionX Ti-6Al-4V fasteners at performance levels above comparable SAE Grade 8 steel and standard aerospace titanium fastener benchmarks. The results demonstrate that IperionX’s manufacturing pathway can deliver performance as well as cost and supplychain advantages.
Automotive and consumer electronics Programs with Ford and consumer-electronics customers demonstrate the flexibility of the platform to supply both titanium powder and manufactured components. These markets also generate high-quality titanium scrap, creating the potential for closed-loop customer relationships in which scrap is returned to IperionX and converted into new products.
The commissioned SACMI press can operate at up to 24 pressing cycles per minute, equivalent to approximately 11 million single-cavity parts per year under stated operating assumptions before downstream sintering. This establishes a scalable manufacturing pathway for suitable high-volume component categories.
14
Titanium plate and mill products
A product platform designed to scale
IperionX is scaling production of titanium plate and large-format military components to extend the product platform beyond engineered parts into plate, sheet, bar and other mill-product pathways, materially broadening the addressable market.
The customer pipeline is increasingly moving beyond material sampling into finished-component validation, prototype purchase orders and funded scale-up programs. Commercialization remains a staged process: customer testing and qualification must be followed by stable manufacturing parameters, repeatable quality and dependable delivery. Near-term execution is therefore focused on delivering current orders, incorporating test feedback, commissioning sufficient HSPT™ capacity and moving priority products toward repeatable production.
Additive manufacturing and direct powder sales IperionX produces angular and spherical titanium powders for powder metallurgy and additive manufacturing. Direct powder sales remain part of the product mix, providing customer access and near-term revenue opportunities, while the Company prioritizes conversion into higher-value products where its manufacturing technologies can create the greatest commercial advantage.
IperionX products can either be sold into the powder markets or further processed into final titanium metal products.
IperionX products can either be sold into the powder markets or further processed into final titanium metal products
Titanium Scrap
HAMR
Powder Metallurgy
HSPT
Engineered Products
Sinter Based AM Mill Products
Melt Based AM Titanium Powders
15
Fasteners Enclosures Brackets Impellers Actuators & Gears
Plate Bar Sheet Wire
Spherical Angular
Titanium Markets Titanium and its alloys are used across defense, aerospace, automotive, energy, medical, consumer and advanced industrial markets. The metal’s exceptional strength-to-weight ratio, corrosion resistance and high-temperature performance make it technically superior to incumbent materials in many demanding applications. AUTOMOTIVE AND TRANSPORT Today’s titanium market reflects the economics of the legacy supply chain: titanium is generally used only where its performance justifies a significant cost premium. IperionX’s opportunity is therefore larger than capturing share of the existing market. By lowering end-to-end production cost and scaling near-net-shape manufacturing, IperionX seeks to open applications currently served by highstrength steel, stainless steel and aluminum. Each reduction in cost moves the boundary of where titanium can win on value as well as performance.
CONSUMER ELECTRONICS
AEROSPACE AND DEFENSE
ENERGY
MEDICAL
LUXURY GOODS
INDUSTRIAL
ROBOTICS
16
17
IperionX’s Titanium Technologies IperionX has assembled a portfolio of more than 40 global patents developed and enhanced through over a decade of research and development. The incumbent Kroll route requires multiple capital and energy-intensive stages, including chlorination, reduction, vacuum distillation, melting and remelting, followed by extensive hot working and machining. These steps create long lead times, high costs and significant material loss, restricting titanium largely to applications that can absorb a substantial price premium.
The technologies are not isolated inventions; they form an integrated platform spanning mineral and scrap feedstocks, titanium refining, powder production, alloy development, near-net-shape manufacturing and mill products. The platform provides two complementary feedstock pathways. In the near term, HAMR™ can recycle a broad range of titanium scrap, including high-oxygen material that conventional routes struggle to return to high-value use. Over time, Green Rutile™ and ARH™ can upgrade domestic titanium minerals from Atlas-Titan into high-purity feedstock for HAMR™. Both pathways converge in the same low-cost American powder and product platform.
IperionX’s technologies bypass or shorten major parts of that route. HAMR™ produces low-oxygen titanium powder from recycled or mineral-derived feedstocks; GSD™ creates high-quality spherical powder for additive manufacturing; and HSPT™ and THRM™ convert powder into highperformance products with fewer processing steps and higher material utilization.
This architecture addresses the principal constraint on titanium adoption: the cost, complexity and waste embedded across the conventional supply chain.
18
IperionX’s simple, low waste, vertically integrated solution IperionX offers a simple, low waste, vertically integrated solution Current Industry Feedstock
Titanium Minerals
Up to 10 forging / rolling steps
Chlorination
Reduction & Distillation
Vacuum Arc Remelting
Forging
Rolling
Machining
Products
Titanium Sponge
Titanium Ingot
Titanium Mill Products
Titanium Products
(<95% yield)
(<85% yield)
(~50-75% yield)
(~5-15% yield)
Feedstock
IPX HAMR Process
IPX HSPT Process
Machining
Products
Titanium Scrap and / or Minerals
Titanium Powder
Titanium Mill Products or Near-net-shapes
Titanium Products
(~85-95% yield)
(~85% yield)
(~50-80% yield)
Ipe rionX yield figures will vary depe nding on final products and consolidation routes shown. Titanium Powder yield varies de pen ding on scrap vs. mineral source.
- Based on implied yield los ses from TiCl4 to Sponge in N agesh et. Al. 2004 : “Me chanism of Titanium Sponge Formation in the Kroll Reduction Re actor”; 2. Oak Ridge National Laboratory (ORNL) 20 12 Re port: “Near Ne t Shape Manufacturing off New, Low Cos t Titanium Powders for Indus try”; 3. Boeing, ORNL, APCI 2012 Report for D oE: “Near-Ne t Shape Fabrication us ing Low-Cost Titanium Alloy P owders ”; 4. RAND Corporation 200 9 Rep ort: “Titanium Industrial Bas e, Price Trend, and Technology Initiatives”; 5. Dept. of Ene rgy 20 08 Re port “FY 200 8 Progres s Re port for Lightweighting Materials – 4. Automotive Metals – Titanium”
IperionX yield figures will vary depending on final products and consolidation routes shown. Titanium Powder yield varies depending on scrap vs. mineral source.
2
▪ Based on implied yield losses from TiCl4 to Sponge in Nagesh et. Al. 2004: “Mechanism of Titanium Sponge Formation in the Kroll Reduction Reactor” ▪ Oak Ridge National Laboratory (ORNL) 2012 Report: “Near Net Shape Manufacturing of New, Low Cost Titanium Powders for Industry” ▪ Boeing, ORNL, APCI 2012 Report for DoE: “Near-Net Shape Fabrication using Low-Cost Titanium Alloy Powders” ▪ RAND Corporation 2009 Report: “Titanium Industrial Base, Price Trend, and Technology Initiatives” ▪ Dept. of Energy 2008 Report “FY 2008 Progress Report for Lightweighting Materials – Automotive Metals – Titanium”
HAMRTM Titanium Technologies
The value of the portfolio lies in how the technologies connect. Lower-cost domestic feedstock flows into lower-cost powder; powder is converted into higher-value components and mill products; and process or customer scrap can be recycled back into new titanium. Each link reduces dependence on foreign-controlled supply chains and captures more value within IperionX.
HAMR™, or Hydrogen Assisted Metallothermic Reduction, is IperionX’s foundational titanium refining technology. Originally developed at the University of Utah with funding from the U.S. Department of Energy’s Advanced Research Projects Agency-Energy program, HAMR™ provides a direct pathway from titanium oxide or scrap to low-oxygen titanium powder.
The result is a near-term circular scrap-to-product platform and a longer-term mineral-to-product pathway. Together, they provide IperionX with a differentiated route to re-shore a complete titanium supply chain to the U.S.
The process uses hydrogen to destabilize titanium dioxide, allowing magnesium reduction to occur under thermodynamically favorable conditions. The resulting titanium hydride can then be deoxygenated, alloyed and processed into high-quality titanium powder with controlled chemistry and particle characteristics.
IperionX has already demonstrated the integration of these technologies by upgrading titanium minerals from the Titan Project to high-grade +99% TiO₂ feedstock and using that enriched material to manufacture high-quality spherical Ti-6Al-4V powder. Testing confirmed oxygen content that met or surpassed the requirements of industry-standard Grade 5 specifications.
HAMR™ can accept a broad range of feedstocks, including titanium minerals, manufacturing scrap and high-oxygen scrap that we believe is difficult to recycle through conventional routes. This feedstock flexibility is central to IperionX’s ability to build a secure, circular and lower-cost domestic supply chain. 19
IperionX’s Titanium Technologies // continued
By avoiding the need to chlorinate TiO₂ into TiCl₄ and removing vacuum distillation and multiple melting stages, HAMR™ can materially reduce process steps, energy use, capital intensity and emissions. It is the technology that connects recycled scrap and, over time, U.S. titanium minerals to IperionX’s downstream product platform.
HSPTTM Titanium Forging Technologies HSPT™, or Hydrogen Sintering and Phase Transformation, addresses a central challenge in titanium powder metallurgy: achieving wrought-like mechanical performance without the full cost and complexity of conventional forging and hot working.
Microstructure of IperionX HSPT (5µm) and Traditional Powder Metallurgy (40µm) titanium products.
Traditional titanium manufacturing typically converts sponge into ingot through repeated melting, then into bar, plate or sheet through energy-intensive forging and rolling. Finished components are subsequently machined from this stock, often generating high levels of scrap and long production lead times.
GSDTM Technologies GSD™, or Granulation-Sintering-Deoxygenation, is a patented thermochemical technology designed to produce spherical titanium powders for additive manufacturing. The process provides low oxygen content, controlled particle size and strong flowability while increasing usable powder yield.
Powder metallurgy and additive manufacturing can create near-net-shape products with much less waste, but conventional powder routes may not achieve the microstructure and fatigue performance required for demanding applications without further thermomechanical processing.
Conventional spherical powder methods, including gas atomization, plasma atomization and plasma rotating electrode processing, can produce high-quality powder but often generate relatively low yields within the fine particlesize ranges required by additive manufacturing. That yield loss is an important contributor to the high cost of spherical titanium powder.
IperionX’s patented HSPT™ technology uses hydrogenenabled sintering and phase transformation to develop an ultra-fine, wrought-like microstructure. This provides a pathway to high-performance titanium products with superior fatigue properties compared with traditional titanium powder metallurgy methods.
GSD™ addresses this constraint by increasing powder yield by up to 50% and providing a potentially more efficient route to additive-manufacturing feedstock. It expands IperionX’s addressable product mix and supports both direct powder sales and internally manufactured components.
When combined, HAMR™ and HSPT™ connect lower-cost titanium powder directly to high-performance nearnet-shape products. THRM™ extends the same phasetransformation principles to plate, sheet, bar and other mill-product pathways.
HAMR™ also offers flexibility in alloy design by introducing alloying elements from oxide feedstocks. This creates a pathway to advanced titanium and metal alloys containing elements such as iron, niobium, zirconium and molybdenum, including compositions that can be difficult to manufacture efficiently through conventional melt processing.
The commercial significance is fewer manufacturing steps, less machining waste and shorter lead times, while targeting material properties associated with conventionally forged or wrought titanium. This is the bridge between IperionX’s powder cost advantage and higher-value customer products.
20
Green RutileTM & ARHTM Technologies
The Scope 1 and 2 emissions associated with conventional synthetic rutile and titanium slag production are significant, estimated at approximately 3.3 tons and 2 tons of carbon dioxide equivalents (CO2e) per ton of product, respectively. Green Rutile™ does not use coal as a reductant and, when paired with renewable or low-carbon electricity, has the potential to produce high-quality titanium feedstock with materially lower emissions.
Green Rutile™ and ARH™ provide the technology link between IperionX’s Tennessee mineral assets and its titanium metal platform. Together, they are designed to upgrade lower-grade U.S. titanium minerals into high-purity feedstock suitable for HAMR™. The Green Rutile™ process upgrades ilmenite into a highergrade synthetic rutile titanium product and a purified iron oxide co-product. The iron oxide may have value in metal-alloying applications or as a precursor for lithium iron phosphate batteries.
IperionX is advancing plans to scale Green Rutile™ to upgrade ilmenite from the Atlas-Titan platform into a highquality synthetic rutile product and iron oxide co-product. This would create an additional value-adding step in Tennessee before titanium feedstock enters the metalproduction pathway.
Most global synthetic rutile production relies on the Becher process, which uses coal as a reductant and operates rotary kilns at temperatures above 1,100°C before removing metallic iron through an aerated salt-solution process.
ARH™, or Alkaline Roasting and Hydrolysis, can further upgrade rutile and Green Rutile™ into +99% TiO₂ feedstock suitable for HAMR™. This completes the technical pathway from domestic titanium minerals to American-made titanium metal and finished products.
21
Sustainability Sustainability as an operating advantage
People, safety and communities
IperionX was founded to build a lower-cost, lower-carbon and more resilient American titanium supply chain. Sustainability is embedded in that business model rather than treated as a separate objective: recycled feedstocks can lower input cost and reduce import dependence; nearnet-shape manufacturing can improve material utilization; renewable electricity can reduce operating emissions; and closed-loop recycling can deepen customer relationships. These attributes strengthen the commercial and strategic case for the platform.
IperionX values its employees and the communities in Virginia, Utah and Tennessee in which it operates. Protecting employees, contractors, visitors and local stakeholders is a core operating responsibility and fundamental to successful scale-up. The Company is committed to safe workplaces, compliance with applicable occupational and environmental laws and constructive, long-term relationships with host communities.
Circular titanium technologies IperionX’s patented technologies can use 100% titanium scrap, including high-oxygen material that many conventional processes cannot readily recycle into highquality metal. The resulting low-oxygen titanium powder can be manufactured into a broad range of products and, at the end of their useful lives, returned to the same platform as feedstock for future production.
Sustainability governance and disclosures Sustainability is overseen at Board and executivemanagement level, with the Sustainability Sub-Committee of the Nominating and Governance Committee coordinating related initiatives, annual reporting and performance goals. Day-to-day sustainability activities are led by the Vice President of Sustainability. IperionX reports its sustainability progress with reference to the Global Reporting Initiative and the Sustainability Accounting Standards Board.
“
This closed-loop capability can divert valuable titanium from downcycling or disposal and return it to high-value use. It provides customers with a pathway to reduce embedded carbon, improve product circularity and secure domestic feedstock while strengthening IperionX’s longterm cost and supply position.
Protecting employees, contractors, visitors and local stakeholders is a core operating responsibility and fundamental to successful scale-up.”
22
23
Sustainability // continued
Lower-carbon production
sustainability attributes of IperionX’s titanium products and reinforces our commitment to independent validation and transparency.
IperionX’s Virginia titanium production platform procures renewable electricity, resulting in zero market-based Scope 2 emissions from purchased electricity. The Company continues to assess and manage Scope 3 emissions, including opportunities to procure lowercarbon process inputs as production scales.
Responsible mineral development IperionX is committed to resource efficiency, responsible land management and biodiversity at the Atlas-Titan platform in Tennessee. The near-surface mineral-sands development pathway requires no blasting or hard-rock crushing. A phased approach with progressive reclamation is intended to limit the active disturbance footprint, while work with the University of Tennessee Institute of Agriculture is evaluating restoration methods designed to improve soil fertility and support a biodiverse ecosystem. The objective is to establish a model for responsible American critical-minerals development.
A comparative life-cycle assessment found that 100% recycled spherical titanium powder produced at IperionX’s Virginia facility has the potential for a life-cycle carbon footprint as low as 7.8 kilograms of CO₂e per kg of powder. This represents a reduction of more than 90% compared with conventionally produced titanium powder using plasma atomization, estimated at 88.8 kg CO₂e per kg of powder. The combination of lower emissions and domestic circularity can become an important point of differentiation for customers.
Environmental compliance UL Certified 100% recycled titanium powder
IperionX’s operations are subject to applicable environmental laws, regulations and permit conditions. Compliance is treated as the minimum operating standard, supported by internal systems and, where applicable, external audits and inspections.
IperionX’s low-carbon titanium metal powder became the first product globally to achieve an Underwriters Laboratories (UL) 2809 Recycled Content Certification Platinum rating for a 100% recycled mono-material, validating that it meets the highest tier of recycled content requirements under the new UL standard introduced during fiscal year 2026. As one of the world’s most trusted independent safety and standards organizations, UL provides rigorous third-party verification of product claims. This certification further demonstrates the unique
There were no known breaches of applicable environmental requirements by IperionX during the fiscal year ended June 30, 2026. More information on our fiscal year 2026 sustainability initiatives and progress will be shared in the forthcoming voluntary fiscal year 2026 Sustainability Report.
24
Financial Report Directors’ Report
26
Consolidated Entity Disclosure Statement
114
Auditor’s Independence Declaration
73
Directors’ Declaration
115
Consolidated Statement of Profit or Loss and Other Comprehensive Income
74
Independent Auditor’s Report
116
Mineral Resources Statement
121
Consolidated Statement of Financial Position
75
Corporate Governance
125
Consolidated Statement of Changes in Equity
76
ASX Additional Information
126
Consolidated Statement of Cash Flows
77
Glossary of Terms and Definitions
135
Notes to the Consolidated Financial Statements
78
Corporate Directory
137
25
Directors’ Report The Directors of IperionX Limited present their report on the consolidated entity consisting of IperionX Limited (“Company” or “IperionX”) and the entities it controlled at the end of, or during, the year ended June 30, 2026 (“Consolidated Entity” or “Group”).
Directors The names and details of the Company’s directors in office at any time during the financial year or since the end of the financial year are: Mr. Todd Hannigan
Executive Chairman
Mr. Anastasios Arima
Chief Executive Officer and Managing Director
Ms. Lorraine M. Martin
Lead Independent Director
Mr. Vaughn Taylor
Independent Non-Executive Director
Ms. Melissa G. Waller
Independent Non-Executive Director
Ms. Beverly M. Wyse
Independent Non-Executive Director
Mr. Tony Tripeny
Independent Non-Executive Director
Mr. Michael J. Loparco
Independent Non-Executive Director (appointed August 3, 2026)
Unless otherwise stated, Directors held their office from July 1, 2025 until the date of this report. Board Committee composition noted below was effective as of August 3, 2026.
Current Directors and Officers Mr. Todd Hannigan B.Eng (Hons), MBA Executive Chairman Mr. Hannigan was appointed as Non-Executive Chairman of IperionX on February 1, 2021, and as Executive Chairman on May 24, 2021. Todd Hannigan has over 29 years of global experience in natural resources as company founder, chief executive officer, private capital investor and non-executive director. Mr. Hannigan has worked internationally in the natural resources sector including for Piedmont Lithium Inc., Aston Resources, Hanson PLC and BHP Billiton. Mr. Hannigan holds a Bachelor of Engineering (Mining) from The University of Queensland and an MBA from INSEAD. Other Current Public Directorships ▪ Brazilian Rare Earths (January 2023 – present) ▪ Alurion Resources Limited (May 2026 - present) Former Public Directorships During the Past Three Years ▪ None
26
Mr. Anastasios (Taso) Arima BCom Chief Executive Officer & Managing Director Mr. Arima is a founder of IperionX and was appointed as Executive Director on December 1, 2020, and as Managing Director and CEO of the Company on March 1, 2021. Anastasios (Taso) Arima has over 16 years of experience in founding and developing critical material companies in North America. Mr. Arima was a founder and director of Piedmont Lithium and was instrumental in the development of the company. Mr. Arima attended the University of Western Australia and earned a Bachelor of Commerce whilst studying for a Bachelor of Engineering. Other Current Public Directorships ▪ InVert Graphite Limited (November 2021 – present) Former Public Directorships During the Past Three Years ▪ None
Ms. Lorraine M. Martin B.A. (Computational Mathematics), M.Sc (Computer Science) Lead Independent Director President and CEO of the National Safety Council IperionX Director since September 13, 2021 Lorraine M. Martin is a director, President and CEO of the National Safety Council, serving in this position since June 2019. She is also co-founder and President of Pegasus Springs Foundation, a non-profit organization focused on education and mentoring. Ms. Martin is the retired Executive Vice President and Deputy of Rotary and Mission Systems (“RMS”) for Lockheed Martin Corporation, a global aerospace, defense, security and advanced technologies company. Prior to RMS, Ms. Martin was Executive Vice President and General Manager for the F-35 Lightning II Program for Lockheed Martin Aeronautics Company. Her leadership of the F-35 program earned Pentagon recognition for reducing program costs while increasing production and fielding more aircraft worldwide. She joined Lockheed Martin in 1988 and during her tenure, held a variety of high visibility leadership positions across the corporation. Prior to joining Lockheed Martin, she served as an officer in the U.S. Air Force, holding various leadership positions for software intensive technology and development programs. She has a Master of Science degree in Computer Science from Boston University and a Bachelor of Arts degree in Computational Mathematics from DePauw University. Other Current Public Directorships ▪ Kennametal Inc. (July 2018 – present) Former Public Directorships During the Past Three Years ▪ None IperionX Board Committees ▪ Lead Independent Director ▪ Nominating and Governance Committee
27
Mr. Vaughn Taylor BBus (Accounting), SAFin Independent Non-Executive Director Former Executive Director and Chief Investment Officer of AMB Capital Partners IperionX Director since March 3, 2021 Vaughn Taylor previously served as Executive Director and Chief Investment Officer of AMB Capital Partners, (“AMB”) the global investment platform of the Bennett Family. Mr. Taylor was responsible for executing on the investment strategy, expanding the investment portfolio into international markets and sourcing new investment opportunities. Mr. Taylor is an active global investor and is a board member of a number of listed and private market organizations both in Australia and the U.S. across a range of sectors. Mr. Taylor holds a Bachelor of Business (Accounting) and a Master of Business (Real Estate) from RMIT University. Mr. Taylor also holds a Graduate Diploma in Applied Finance and Investment from Financial Services Professional Body, (FINSIA). Other Current Public Directorships ▪ Mixed Martial Arts Group Limited (formerly Alta Global Group Ltd) (August 2021 – present) Former Public Directorships During the Past Three Years ▪ None IperionX Board Committees ▪ Compensation Committee (Chair)
Ms. Melissa G. Waller B.A. (Journalism and Mass Communications) Independent Non-Executive Director Former Deputy Treasurer and Chief of Staff for the North Carolina Department of State Treasury IperionX Director since September 13, 2021 Melissa G. Waller has over 30 years’ experience as a senior finance executive and is President for the AIF Institute, providing essential education, research and resources to investors and investment firms globally with over US$50 trillion assets under management. Ms. Waller is the former Deputy Treasurer and Chief of Staff for the North Carolina Department of State Treasury, where she successfully oversaw Department strategic planning, operations, and public-policy implementation, along with a staff of more than 400 employees, including the North Carolina Retirement Systems, the pension fund for the state and the tenth largest public pension fund in the U.S., with assets in excess of US$90 billion. Ms. Waller has served as Chair of the Department’s Corporate Governance Committee, as well as on the Council of Institutional Investors Board of Directors and the Governor’s Board of Innovation for the North Carolina University System. She currently serves as Executive Program Director for the National Institute of Public Finance, as well as Director of Public and Private Partnerships for the Kenan Institute. Ms. Waller has a bachelor’s degree in journalism and mass communications from the University of North Carolina. Other Current Public Directorships ▪ None Former Public Directorships During the Past Three Years ▪ None IperionX Board Committee ▪ Nominating and Governance Committee (chair) ▪ Audit Committee
28
Ms. Beverly M. Wyse B.Sc. (Mechanical Engineering), MBA Independent Non-Executive Director Former President of Shared Services, Boeing IperionX Director since September 13, 2021 Beverly M. Wyse worked for over 30 years at Boeing, most recently as President of Shared Services, a multi-billion dollar operating group. In that role, she refocused and restructured the organization and also delivered improved efficiency and performance. Previously, she was Vice-President & General Manager of Boeing South Carolina, a major manufacturing, assembly and delivery site for Boeing where she led the team through successful production rate increases, major improvements in workforce relations and significant reductions in operating costs. Throughout her extensive career at Boeing, Ms. Wyse also successfully led the 737, 767 and 787 Charleston programs. Ms. Wyse holds an MBA and a B.Sc. in Mechanical Engineering from the University of Washington. Other Current Public Directorships ▪ None Former Public Directorships During the Past Three Years ▪ Héroux-Devtek Inc. (February 2019 – February 2025) IperionX Board Committees ▪ Audit Committee ▪ Compensation Committee
Mr. Tony Tripeny BS (Economics) Independent Non-Executive Director Former Executive Vice President and Chief Financial Officer of Corning Incorporated IperionX Director since March 17, 2025 Tony Tripeny brings over 40 years of financial and operational leadership in advanced manufacturing, technology and materials science. Mr. Tripeny’s successful 36-year career at Corning Incorporated, a global innovator and leader in advanced materials science, included senior roles of Executive Vice President and Chief Financial Officer, as well as Senior Vice President and Corporate Controller, until his retirement in 2022. Mr. Tripeny currently serves as a Director at Mesa Laboratories and Origin Materials. He holds an economics degree from the Wharton School of Business at the University of Pennsylvania. Other Current Public Directorships ▪ Mesa Laboratories, Inc. (NASDAQ: MLAB) (2022 – present) ▪ Origin Materials, Inc. (NASDAQ: ORGN) (May 2023 - present) Former Public Directorships During the Past Three Years ▪ None IperionX Board Committees ▪ Audit Committee (chair) ▪ Compensation Committee
29
Mr. Michael J. Loparco BA (International Business), JD Independent Non-Executive Director Chief Executive Officer and Co-Founder of OrcaWorcs.ai; former Chief Executive Officer of Symbotic Inc. IperionX Director since August 3, 2026 Michael J. Loparco is the Chief Executive Officer and Co-Founder of OrcaWorcs.ai and the former Chief Executive Officer of Symbotic Inc. (Nasdaq: SYM), where he led the company through its 2022 public listing. Mr. Loparco previously spent more than 20 years at Jabil Inc., including as Chief Executive Officer of Jabil EMS and Executive Vice President, overseeing global manufacturing and supply chain operations across 25 countries. Prior to this, he served as Chief Executive Officer of Jabil’s Engineered Solutions Group. He began his career as a corporate attorney at Holland & Knight LLP. Mr. Loparco holds a Bachelor of Arts in International Business from Eckerd College and a Juris Doctor, cum laude, from Stetson University College of Law. Other Current Public Directorships ▪ Sanmina Corporation (NASDAQ: SANM) (March 2025 to present) Former Public Directorships During the Past Three Years ▪ iRobot Corp (August 2024 - January 2026) IperionX Board Committee ▪ Nominating and Governance Committee ▪ Compensation Committee Ms. Louisa Martino, BComm, CA, CISI, FGIA Company Secretary Ms. Martino has over 15 years’ experience providing company secretarial and corporate advisory services to a number of listed entities. Her extensive experience includes assisting with corporate compliance and capital raisings, as well as previous employment at a major accounting firm in Perth, London and Sydney where she provided corporate advisory services and performed due diligence reviews. Louisa has a Bachelor of Commerce from the University of Western Australia, is a member of Chartered Accountants Australia and New Zealand, a member of the Chartered Institute for Securities & Investment (CISI) (formerly FINSIA) and a Fellow of the Governance Institute of Australia. Ms. Martino was appointed as Company Secretary of the Company on February 16, 2026.
30
Principal Activities The principal activities of the Group during the year consisted of the development of its titanium metal technologies and the exploration of its mineral properties in the U.S. The Group is operating a U.S. based, integrated titanium business to support a range of advanced industries, including consumer electronics, aerospace, defense, medical, bicycles, additive manufacturing, and automotive. We expect to offer a range of titanium products and alloys for customers across these key industries. Our portfolio of assets includes our operations at the Titanium Manufacturing Campus in Halifax County, Virginia; our AtlasTitan platform in Tennessee, and Industrial Pilot Facility (IPF) in Salt Lake City, Utah, that together are re-shoring a sustainable titanium supply chain in the U.S. IperionX owns patents to certain titanium and metal alloy production technologies and holds exclusive global licenses over the Technologies, including Hydrogen Assisted Metallothermic Reduction™, Granulation Sintering Deoxygenation™, low carbon titanium mineral enrichment, Hydrogen Sintering and Phase Transformation™, Alkaline Roasting and Hydrolysis™, and other titanium alloying technologies.
Operating and Financial Review Introduction During the fiscal year ended June 30, 2026, IperionX moved from commissioning into commercial operations and production ramp-up at its Virginia Titanium Manufacturing Campus. The Group’s operational focus is now on reliability, throughput, yield and quality; commissioning additional product-manufacturing capacity; and converting customer programs into repeatable production and revenue. IperionX operates across two connected platforms: titanium metal operations in Virginia and Utah, and critical mineral operations through the Atlas-Titan platform in Tennessee. Together, these assets support the Group’s strategy to establish a domestic U.S. supply chain from recycled scrap and mineral feedstocks through titanium powder, mill products and finished components. The Virginia platform uses proprietary HAMR™ technology to produce high-quality titanium powder and HSPT™ / THRM™ technologies, powder metallurgy and additive manufacturing to produce near-net-shape parts and other titanium products. The Titan and Atlas assets provide the potential for future domestic titanium mineral feedstocks together with heavy rare earth and zircon products. The incumbent titanium supply chain is based on the Kroll process and generally requires chlorination, batch reduction, vacuum distillation, multiple melting and remelting steps, extensive hot working and machining. This route is capital- and energy-intensive, has long lead times and can result in substantial material losses. IperionX’s technologies are designed to remove or shorten many of these steps and improve material utilization. The U.S. has no commercial titanium sponge production and depends on imported primary titanium for defense and advanced industries. IperionX is addressing this strategic vulnerability through two principal value drivers: ▪ Titanium metal operations: Virginia operations transitioned to a 24/7 production schedule during fiscal year 2026. HAMR™ powder consistently met or exceeded Grade 5 parameters, the commissioned SACMI press tripled powder metallurgy capacity, and additional HSPT™ furnace capacity entered installation. IperionX is targeting an annualized production run rate of approximately 200 tpa by the end of calendar year 2026, subject to ramp-up and operating optimization; and ▪ Critical mineral operations: The Titan DFS completed in June 2026 defined a staged development, with key minearea permits in place, producing HREC, titanium minerals and zircon from a domestic resource. Subsequent to yearend, IperionX completed the US$3.0 million Atlas acquisition, adding surface stockpiles, pre-stripped mineralization and established infrastructure adjacent to Titan. The Atlas assets are not included in the mineral resource and mineral reserve estimates reported in this report and no mineral resources or reserves have been determined for Atlas under JORC.
31
All critical systems at the Titanium Production Facility (TPF) were fully commissioned during the fiscal year. Technology and operating improvements increased nameplate titanium powder capacity from 125 tpa to approximately 200 tpa without additional capital expenditure, with projected steady-state unit costs of approximately US$55/kg at full utilization. Planning, design and long-lead procurement are underway for an expansion to approximately 1,400 tpa. Customer and government-supported programs advanced across fasteners, impellers, ground-vehicle components, titanium plate, consumer electronics, automotive and other defense and industrial products. The customer pipeline is increasingly progressing from material qualification into finished-component testing, prototype purchase orders and funded scale-up activities. The Group’s longer-term strategy is to integrate domestic feedstocks with titanium metal and product manufacturing, targeting more than 10,000 tpa of high-performance titanium components by 2030 and progressively improving titanium’s value-in-use competitiveness with stainless steel and aluminum in selected applications. The achievement of these objectives remains subject to successful production ramp-up, customer qualification and orders, financing, construction, commissioning and other operational and market conditions.
Why Titanium? Titanium combines high strength-to-weight performance, corrosion resistance and high-temperature capability. These characteristics make titanium important to defense, aerospace, marine, medical, industrial, automotive and consumerelectronics applications. However, high production and manufacturing costs have historically limited its use relative to stainless steel and aluminum. Primary titanium is generally produced through the Kroll process, a capital- and energy-intensive batch route that reduces titanium tetrachloride with magnesium. The resulting titanium sponge must then be melted, alloyed and remelted into ingots before further processing. Ingots are converted into mill products through repeated forging, rolling, extrusion and heat-treatment steps. Finished parts are commonly machined from these products, often removing a large proportion of the titanium as scrap. Spherical titanium powders may require additional conversion of mill products into wire followed by atomization. The U.S. relies on imported titanium to support defense and critical infrastructure. China and Russia’s share of global titanium sponge production capacity increased from approximately 61% in 2018 to approximately 80% in 2026, increasing the strategic importance of a secure domestic alternative. IperionX’s integrated route is designed to replace major elements of the incumbent chain by converting recycled scrap or mineral-derived feedstock into titanium powder and then into near-net-shape components and mill products. The objective is to reduce process steps, energy use, material loss, cost and lead time while maintaining high product performance.
Our Production Facilities Titanium Manufacturing Campus – Virginia The Titanium Manufacturing Campus in South Boston, Virginia comprises the TPF and the Advanced Manufacturing Center (AMC). During fiscal year 2026, titanium powder operations transitioned to a 24/7 schedule, producing angular and spherical powders for customer qualification, direct powder requirements and downstream product manufacturing. The TPF supplies the AMC, where IperionX uses powder metallurgy, HSPT™ / THRM™ and additive manufacturing to produce near-net-shape components, mill products and other high-value titanium products. The commissioned SACMI press and additional HSPT™ furnaces materially expand downstream capacity and product flexibility. Titanium Production Facility – from commissioning to 24/7 operations The first HAMR™ titanium deoxygenation run at the Virginia facility was completed in August 2024, followed by the first end-toend commercial production cycle in December 2024. All critical production systems were fully commissioned in September 2025, completing the transition from construction and commissioning into commercial operations and ramp-up.
32
The initial production run used 100% Ti-6Al-4V scrap and reduced oxygen content from 3.42% to below 0.07%, compared with the American Society for Testing and Materials maximum of 0.20% for Grade 5 titanium. During fiscal year 2026, HAMR™ production continued to meet or exceed Grade 5 quality parameters. IperionX remains focused on achieving an annualized production run rate of approximately 200 tpa, equivalent to 16.7 metric tons per month, by the end of 2026, subject to completion of ramp-up and operating optimization. GenX™ development continues as a longer-term continuous-production pathway and is not required for the current ramp. The Virginia scale-up program is designed to expand titanium powder capacity to approximately 1,400 tpa and, over time, support IperionX’s objective of more than 10,000 tpa of high-performance titanium components by 2030. Advanced Manufacturing Center – High-performance Titanium Product Manufacturing The AMC applies IperionX’s titanium powder, powder metallurgy, HSPT™ / THRM™ and additive manufacturing capabilities to produce near-net-shape components, mill products and other high-performance titanium products. During fiscal year 2026, IperionX commissioned the 300-ton, six-axis SACMI powder metallurgy press and commenced installation of additional HSPT™ sintering capacity. These investments are intended to support customer qualification, low-rate initial production and higher-volume manufacturing.
- The SACMI press triples existing powder metallurgy capacity, improves repeatability and geometry control, and can operate at up to 24 pressing cycles per minute, equivalent to approximately 11 million single-cavity parts per year under stated operating assumptions before downstream sintering.
- Additional HSPT™ furnaces are expected to relieve a downstream production constraint, increase throughput and provide greater scheduling flexibility across customer and product-development programs. Independent U.S. Army and third-party testing of IperionX Ti-6Al-4V fasteners provided product-level validation of the manufacturing platform, with yield torque up to approximately 20% above comparable SAE Grade 8 steel benchmarks and tensile strength approximately 15% above standard aerospace titanium fastener benchmarks. The AMC is being expanded in parallel with powder production so that a greater proportion of output can be converted into higher-value products where IperionX’s integrated process can provide the strongest commercial advantage. Industrial Pilot Facility – Utah The Salt Lake City facility has produced angular and spherical titanium powders and supported customer prototyping since
- It was the industrial pilot platform used to develop and validate the technologies before commercial-scale deployment in Virginia. Following the commissioning of Virginia operations, the Utah facility has been repurposed and expanded to approximately 15,000 square feet as a research and development center focused on HSPT™, THRM™, titanium plate, other mill products and additional titanium alloy and product pathways.
Re-shoring U.S. Critical Mineral Production with Atlas-Titan IperionX plans to use recycled titanium scrap as the principal near-term feedstock for Virginia. Over the longer term, the Group intends to evaluate integration of upgraded titanium mineral feedstocks from the Atlas-Titan platform in Tennessee. The Titan DFS completed in June 2026 defined an initial 14-year staged development producing HREC, ilmenite, rutile and zircon concentrate from a single domestic resource. The Study delivered an after-tax NPV₈ of US$813 million, an after-tax IRR of 39.4% and forecast after-tax free cash flow of US$1.9 billion. Subsequent to year-end, IperionX completed the Atlas acquisition adjacent to Titan for US$3.0 million. Atlas adds high-grade surface stockpiles, pre-stripped Lower McNairy mineralization and established utilities and rail infrastructure, creating the potential for an accelerated and lower-capital integrated development pathway.
33
The U.S. DoW allocated US$5.0 million of the IBAS award to the Titan DFS. IperionX is advancing drilling, mineralogy, metallurgy, commercial qualification and an integrated Atlas-Titan economic study targeted for completion by the end of 2026, together with engagement on potential U.S. Government funding pathways. The Titan Project’s Mineral Resources and Reserves, reported in accordance with the 2012 Edition of the JORC Code, are summarized below: Titan Project Mineral Resources at June 30, 2026
Mineral Resource Estimate Inclusive of Reserve Measured (M) Indicated (I) Total M+I Inferred (Inf) Total M+I+Inf Exclusive of Reserve Measured (M) Indicated (I) Total M+I Inferred (Inf) Total M+I+Inf Grand Total Measured (M) Indicated (I) Total M+I Inferred (Inf) Total M+I+Inf
THM Assemblage Rutile Ilmenite (%) (%)
In situ tons
THM (%)
THM (t)
Zircon (%)
REE (%)
120,434,000 28,388,000 148,823,000 148,823,000
2.5 2.9 2.6 2.6
3,060,000 828,000 3,887,000 3,887,000
11.1 11.8 11.2 11.2
9.5 9.2 9.4 9.4
40.9 52.0 43.2 43.2
1.5 1.5 1.5 1.5
96,851,000 102,190,000 199,041,000 97,832,000 296,872,000
1.5 2.0 1.8 1.8 1.8
1,489,000 2,013,000 3,502,000 1,774,000 5,276,000
10.4 9.8 10.0 9.3 9.8
9.2 10.2 9.8 9.6 9.7
40.1 38.9 39.4 38.0 39.0
1.2 1.5 1.4 1.2 1.3
217,285,000 130,578,000 347,863,000 97,832,000 445,695,000
2.1 2.2 2.1 1.8 2.1
4,548,000 2,841,000 7,389,000 1,774,000 9,163,000
10.8 10.4 10.6 9.3 10.4
9.4 9.9 9.6 9.6 9.6
40.6 42.7 41.4 38.0 40.8
1.4 1.5 1.4 1.2 1.4
Notes to accompany mineral resource table:
- Mineral Resources are reported using the definitions set out in the 2012 JORC Code and are current as at June 4, 2026. Mineral Resources are reported on an in situ basis, inclusive of Ore Reserves.
- The Competent Person responsible for the Mineral Resource estimate is John Eckman.
- Mineral Resources are reported within a conceptual pit shell that uses the key assumptions summarized in the Appendix of the DFS Report.
- Mineral Resources are reported above a cut-off grade of 0.4% THM.
- Estimates have been rounded. Titan Project Ore Reserve Estimates at June 30, 2026
THM Assemblages
Ore Reserve Estimate Unit
ROM tons Proved
THM
THM
Zircon
Rutile
Ilmenite
REE
(t)
(%)
(%)
(%)
(%)
Probable
Total
(%)
Upper McNairy
24,565,000
2,415,000
26,980,000
2.30
620,000
6.2
6.2
23.6
0.2
Lower McNairy
68,740,000
21,307,000
90,047,000
3.43
3,086,000
12.7
10.5
48.3
1.9
Total
93,306,000
23,722,000
117,027,000
3.17
3,706,000
11.6
9.8
44.2
1.6
Notes to accompany ore reserve table:
- Ore Reserves are reported using the definitions set out in the 2012 JORC code and are current as at June 4, 2026. Ore Reserves are reported at the point of delivery to the process plant.
- The Competent Person responsible for the Ore Reserve estimate is Justin Douthat.
- Ore Reserves are reported within a finalized mine design pit shell that uses the key assumptions summarized in the Appendix of the DFS Report.
- Ore Reserves are reported above a cut-off grade of 0.85% THM.
- Ilmenite includes leucoxene, pseudorutile, and ilmenite and REE includes monazite, xenotime, and unclassified REE.
- Estimates have been rounded.
34
Environmental Regulation and Performance IperionX’s operations are subject to various environmental laws and regulations under the relevant government’s legislation. Full compliance with these laws and regulations is regarded as a minimum standard for all operations to achieve. Instances of environmental non-compliance by an operation are identified either by external compliance audits or inspections by relevant government authorities. There have been no known breaches by the Group during the financial year ended June 30, 2026.
Highlights Key milestones during and subsequent to the end of the financial year were as follows: U.S. Government support for a domestic titanium supply chain US$47.1 million IBAS award fully obligated ▪ In February 2025, IperionX was awarded up to US$47.1 million through the U.S. DoW IBAS program to accelerate a resilient, low-cost and fully integrated U.S. mineral-to-metal titanium supply chain. US$5.0 million was allocated to advance the Titan Project to shovel-ready status through completion of the DFS, with the balance supporting Virginia production and manufacturing expansion. ▪ In August 2025, the DoW obligated US$12.5 million for long-lead equipment required for the expansion toward approximately 1,400 tpa, including titanium deoxygenation, sintering, powder metallurgy consolidation, near-net-shape component manufacturing and supporting infrastructure. ▪ A further US$25.0 million was obligated in September 2025 and the final US$4.6 million in January 2026, bringing the award to full obligation. The U.S. Government also transferred approximately 290 metric tons of Ti-6Al-4V scrap to IperionX at no cost, equivalent to approximately 1.5 years of feedstock at 200 tpa. US$99 million SBIR Phase III pathway and further defense support ▪ In June 2025, IperionX executed a U.S. DoW SBIR Phase III Indefinite Delivery, Indefinite Quantity contract with a task-order ceiling of up to US$99 million for low-cost domestic titanium products. The first U.S. Army task order, valued at US$1.3 million, supports titanium parts for ground-vehicle programs. ▪ In addition, subsequent to year end, IperionX received Task Order 2 under its U.S. Army SBIR Phase III contract for Low-Cost, Domestic Titanium for Defense Applications that has a base value of US$18.5 million, with options up to US $25.4 million, and builds upon the previously announced US$1.3 million task order, lifting the aggregate potential value of task orders issued under the Company’s US$99 million SBIR Phase III contract up to US$26.7 million. The DPA Title III and IBAS awards are reimbursable programs under which IperionX generally incurs eligible expenditure and subsequently seeks reimbursement following claim review and approval. This creates timing differences between program expenditure and associated cash receipts.
Program DPA Title III IBAS Total programs
Award $12.7m $47.1m $59.8m
Obligated $12.7m $47.1m $59.8m
Contract SBIR Phase III
Contract ceiling Up to $99.0m
Reimbursed to date $10.3m $12.4m $22.7m
Task orders received $19.8m
35
Remaining reimbursable funding $2.4m $34.7m $37.1m
Incurred, not yet reimbursed $2.4m $0.5m $2.9m
Contract balance Up to $79.2m
Customer and Product Programs Carver Pump – U.S. Navy impeller prototypes On December 15, 2025, IperionX announced an initial purchase order of approximately US$100,000 from Carver Pump for four prototype titanium impellers for pumps on U.S. Navy surface vessels. During the quarter ended June 30, 2026, IperionX advanced production of the prototypes. Each component can be produced in less than one week, compared with conventional casting lead times that often exceed 12 months, and successful validation could support larger production programs. American Rheinmetall – U.S. Army ground-vehicle components In January 2026, IperionX received a US$0.3 million prototype purchase order from American Rheinmetall for 700 lightweight titanium components for U.S. Army heavy ground combat systems. The components are produced from 100% recycled titanium using HAMR™ and HSPT™ technologies, targeting weight reductions of approximately 40–45% per component compared with incumbent steel parts. The program targets lower vehicle weight, improved mobility, corrosion resistance and supply-chain resilience. Successful delivery and validation of the initial scope may provide a pathway to larger-scale production opportunities. Fasteners, Ford and other customer programs Independent testing by U.S. Army DEVCOM GVSC and Westmoreland validated IperionX Ti-6Al-4V fasteners at performance levels above comparable SAE Grade 8 steel and standard aerospace titanium fastener benchmarks. In addition, the U.S. Army extended the fastener program through a prototype purchase order for the JLTV and associated trailer. Other active programs include automotive components for Ford, consumer-electronics powder qualification and additional defense, aerospace and industrial products. The customer pipeline is increasingly moving from material samples into finished-component testing, prototype purchase orders and funded scale-up programs, providing clearer milestones toward low-rate and potentially longer-duration supply arrangements. Near-term execution is focused on delivering current orders and prototypes, incorporating customer test feedback, commissioning sufficient HSPT™ capacity and establishing repeatable manufacturing parameters for priority products. The developing product portfolio includes fasteners, impellers, track pins, brackets, gears, actuators, enclosures, titanium plate and other mill products, together with angular and spherical titanium powders. Expansion of Titanium Operations U.S. Government-backed expansion to approximately 1,400 tpa In September 2025, IperionX announced plans to expand titanium powder production capacity to approximately 1,400 tpa. At full utilization, the expansion is intended to position IperionX as the largest-volume and lowest-cost American titanium powder producer. Total expansion capital is estimated at approximately US$75 million, including approximately US$17 million of contingency. The program is supported by the fully obligated US$47.1 million IBAS award and IperionX’s balance sheet, and targets titanium powder unit costs of approximately US$29/kg at full utilization. The expansion includes additional deoxygenation, powder processing, pressing, sintering, additive manufacturing and millproduct capability, allowing IperionX to address both powder demand and higher-value finished-product markets. Refer to the ASX announcement dated September 2, 2025 for further information and the material assumptions underpinning the capacity and cost targets.
36
2030 roadmap for high-performance titanium products IperionX aims to scale toward more than 10,000 tpa of high-performance titanium components by 2030. The roadmap is intended to combine lower-cost domestic powder with scalable near-net-shape and mill-product manufacturing, targeting value-in-use competitiveness with stainless steel and aluminum in selected applications. Achievement of the roadmap remains subject to successful scaling, customer qualification, financing and market demand. Titan and Atlas Critical Minerals Development Titan Definitive Feasibility Study On June 4, 2026, IperionX announced the results of the DFS for its 100%-owned Titan Critical Minerals Project near Camden, Tennessee. The Study confirms Titan as a large-scale, technically robust and high-return project designed to produce titanium minerals, zircon and a HREC from a single domestic resource. Key DFS highlights: ▪ After-tax NPV₈ of US$813 million and after-tax IRR of 39.4%; ▪ After-tax payback period of 3.6 years; ▪ Forecast life-of-mine EBITDA of US$2.8 billion and after-tax free cash flow of US$1.9 billion over the initial 14-year mine plan; ▪ Phase 1 development capital of US$228.1 million and Phase 2 incremental capital of US$153.2 million, for total staged development capital of US$381.3 million; ▪ Phase 2 forecast average annual EBITDA of US$226 million and average annual after-tax free cash flow of US$172 million; ▪ Maiden Ore Reserve of 117 Mt at 3.2% total heavy minerals (THM), with approximately 80% classified as Proved; and ▪ Forecast Phase 2 annual production of approximately 5,287 tpa HREC, 118,658 tpa ilmenite, 24,656 tpa rutile, and 65,668 tpa zircon concentrate. Titan is a near-surface, free-dig mineral sands project using conventional wet concentration, flotation and dry mineral separation, with no blasting or hard-rock crushing. Key mine-area permits and established regional infrastructure support a staged development pathway. The HREC contains strategically important dysprosium, terbium and yttrium. The initial 14-year production target is based entirely on Proved and Probable Ore Reserves, with no Inferred Mineral Resources included. Titan provides a potential domestic upstream source of titanium, heavy rare earth and zircon critical minerals that can complement IperionX’s downstream Virginia titanium platform. The DFS production targets and financial forecasts remain subject to the assumptions, qualifications and risks set out in the June 4, 2026 announcement. Development requires financing, procurement, construction, commissioning, operating performance and other approvals and conditions consistent with those assumptions, including final approval by management and our Board of Directors. Although the DFS includes a defined mine plan, we have not approved project development, secured the financing necessary to proceed with construction or commenced mine construction. The DFS was supported by US$5.0 million of funding under the U.S. DoW IBAS award, reflecting the strategic importance of Titan to domestic heavy rare earth, titanium and zircon supply chains. Atlas Project acquisition On June 15, 2026, IperionX entered into an agreement to acquire key mineral, property and infrastructure assets from Covia Solutions LLC adjacent to Titan for US$3.0 million. The transaction, previously referred to as the Camden acquisition and now named Atlas, was completed subsequent to year-end on July 1, 2026. The Atlas assets include: ▪ Approximately 70 acres of at-surface, historically processed critical-mineral stockpiles; ▪ Approximately 180 acres of pre-stripped Lower McNairy mineralization;
37
▪ Mineral and property rights, together with mining and processing equipment; ▪ Established grid power, industrial water, natural gas and heavy-haul rail infrastructure; ▪ Approximately 1,200 acres of owned property and approximately 1,300 acres of leased property; and ▪ Buildings, structures and associated site infrastructure. The cash purchase price was US$3.0 million. In connection with the acquisition, the Group assumed existing reclamation obligations for certain disturbed areas, principally involving re-grading, re-vegetation and stabilization. Management is evaluating the nature and extent of these obligations and the associated liability. Atlas is located within the same McNairy mineral-sand system as Titan and provides several potential development advantages: ▪ Additional feedstock optionality from high-grade, historically processed surface stockpiles; ▪ Potential access to pre-stripped Lower McNairy mineralization and integrated mine planning with Titan; ▪ Established industrial infrastructure that may reduce development complexity, capital requirements and time to first production; and ▪ Potential recovery of titanium minerals, zircon and heavy rare earth-bearing monazite and xenotime containing dysprosium, terbium and yttrium. IperionX is advancing sonic drilling, stockpile and pre-stripped-zone evaluation, detailed mineral assemblage and metallurgical test work, commercial qualification and an integrated Atlas-Titan economic assessment targeted for completion by the end of 2026. The combination has the potential to reduce upfront capital and operating costs and accelerate first production relative to a standalone Titan development. Strategic partners and offtake engagement ▪ During the period, IperionX continued engagement with downstream processors, strategic customers and potential financing and offtake partners for Titan’s titanium, heavy rare earth and zircon products. This engagement builds on bulk-sample test work previously completed by a major Japanese industrial group, with additional metallurgical and commercial qualification activities continuing during the year. Following completion of the DFS and the Atlas acquisition, engagement is increasingly focused on the integrated Atlas-Titan development pathway. Corporate ▪ In July 2025, IperionX launched a placement of 14.0 million new fully paid ordinary shares at A$5.00 per share to raise A$70.0 million (approximately US$46 million) before costs, with the first tranche of 13,566,770 shares settling in July 2025. The proceeds supported long-lead equipment orders and acceleration of the titanium production expansion. Directors subscribed for 433,230 shares, raising approximately A$2.2 million (approximately US$1.4 million), with these shares issued in October 2025 following shareholder approval at the General Meeting held on October 3, 2025. ▪ Subsequent to year-end, on July 7, 2026, IperionX completed an underwritten U.S. public offering of 2,275,000 ADSs at US$21.98 per ADS for gross proceeds of approximately US$50 million before costs. ▪ On August 3, 2026, the Company also announced its intention to pursue a redomiciliation to the U.S. through a Texasincorporated ultimate parent company, subject to shareholder, court, regulatory and other customary approvals, and appointed Michael J. Loparco as an independent non-executive director.
38
Results of Operations The Group’s net loss after tax for the financial year ended June 30, 2026 was US$66.8 million (2025: US$35.3 million). This loss is largely attributable to: a) research and development costs of US$25.2 million (2025: US$12.7 million) which is attributable to the Group’s accounting policy of expensing R&D costs in connection with the Group’s titanium processing technologies and processing operations at our IPF in Utah and Titanium Manufacturing Campus in Virginia, such as salaries and related personnel expenses, commercialization and scale-up activities, materials, development of the GenX™ next-generation continuous HAMR™ platform, expansion of manufacturing capabilities and advancement of customer qualification programs; b) exploration and evaluation expense of US$5.4 million (2025: US$2.9 million) which is attributable to the Group’s accounting policy of expensing exploration and evaluation expenditure, other than expenditures incurred in the acquisition of the rights to explore, including option payments to landowners. The definitive feasibility study (DFS) for the Titan project was completed in June 2026; c) corporate and administrative expenses of US$25.9 million (2025: US$10.7 million) which is attributable to increased personnel and employee-related costs, ERP system implementation and process enhancement initiatives, higher professional fees related to legal, audit, accounting and regulatory compliance matters, additional corporate infrastructure and overhead expenses required to support the continued growth, operational scale-up and strategic initiatives of the Company during fiscal 2026, and a non-recurring non-cash expenditure settled with share issuance; d) business development expenses of US$4.0 million (2025: US$3.4 million) which is attributable to costs of our customer engagement expenses, our investor relations expenses, including costs for press releases, maintenance of the Company’s website, our other investor marketing and information initiatives, and other fees for corporate advisory services; e) non-cash share-based payment expense of US$9.2 million (2025: US$9.6 million) which is attributable to expensing the value of unlisted options and performance rights granted to key employees, consultants and advisors, as required under AASB 2 - Share-based Payment. The value is measured at grant date and recognized over the vesting period of the incentive securities; f) finance income of US$1.9 million (2025: US$3.6 million) primarily attributable to interest income on cash balances; and g) other income of US$4.6 million (2025: US$0.9 million) is primarily related to income from the U.S. DoW for reimbursements for expenditures related to the Titan Project DFS in conjunction with the IBAS agreement. See Note 1(aa) to our audited consolidated financial statements for fiscal 2026, included in this annual report. The income was offset by a loss of US$0.1 million relating to certain property, plant and equipment.
Loss Per Share The basic and diluted loss per share for the year ended June 30, 2026, was US$0.20 per share (2025: US$0.12 per share).
Dividends No dividends were paid or declared since the start of the financial year (2025: nil). No recommendation for payment of dividends has been made.
Financial Position The financial statements have been prepared on the going concern basis, which contemplates the continuity of normal business activity and the realization of assets and the settlement of liabilities in the normal course of business. At June 30, 2026, the Group has cash and cash equivalents of US$35.2 million (2025: US$54.8 million) and net assets of US$88.3 million (2025: US$92.4 million). The Group had net outflows from operating and investing activities of US$63.5 million for fiscal 2026 (2025: US$46.1 million) (2024: US$25.1 million). On July 7, 2026, the Company completed the placement of 2,275,000 new fully paid ADSs, each representing 10 ordinary shares, to raise gross proceeds of US$50.0 million before costs.
39
IperionX's principal committed source of non-dilutive funding is the U.S. DoW industrial-base programs under which its Virginia titanium production facility is being built: the DPA Title III award (US$12.7 million) and the IBAS award (US$47.1 million) are fully obligated by the Government, US$22.7 million had been reimbursed at June 30, 2026 and US$37.1 million of obligated, reimbursable funding remained available to be drawn against qualifying expenditure over the expansion to 1,400 tons per annum. In addition, IperionX holds a U.S. Army SBIR Phase III indefinite-delivery contract with a ceiling of US$99.0 million, under which two firm-fixed-price task orders totaling approximately US$19.8 million have been awarded (Task Order 2, awarded in August 2026, has a base value of US$18.5 million of which US$11.5 million was funded at award, with options to US$25.4 million), plus other U.S. Government awards of up to US$6.6 million. The U.S. Government has also transferred approximately 290 metric tons of titanium alloy scrap to IperionX at no cost, reducing feedstock purchases for approximately eighteen months of production at the current 200 tons per annum capacity. Beyond these contracted sources, IperionX has a number of potential sources of liquidity: Customer receipts are expected to grow as the Virginia facility moves from prototype and qualification work into low-rate production; IperionX has purchase orders and supply arrangements with the U.S. Army (DEVCOM Ground Vehicle Systems Center), American Rheinmetall, Ford Motor Company and Carver Pump, among others. The remaining US$79.2 million of ceiling under the SBIR Phase III task order awarded and other awards referred to above may be accessed through further task orders at the Government's discretion. IperionX has demonstrated continuing access to equity capital markets, having raised more than US$250 million through the date of filing, from institutional and retail investors since listing, and its Nasdaq and ASX listings provide the ability to raise further capital. Finally, a substantial portion of IperionX’s forecast expenditure, including GenX™ development, Titan and Atlas development work and the pace of the 1,400 tons per annum expansion, is discretionary and can be deferred or reduced if necessary. Further, the U.S. Government has materially expanded the capital available to domestic critical-minerals and metals producers, including through the DoW’s Office of Strategic Capital, which since July 2025 has committed loans of approximately US$2.5 billion to domestic rare earth, magnet and scandium metal projects under loan authority of up to approximately US$100 billion, and through two 2026 Defense Industrial Base Consortium solicitations for domestic criticalminerals processing capacity, the most recent of which specifically names titanium, including sponge and sponge substitutes, for which IperionX has submitted proposals. Based on the assessment of the Company’s financial position, cash flows, and future projections, management has concluded that there are no conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern for the foreseeable future, which is defined as at least twelve months from the date of issuance of the financial statements.
Business Strategies and Prospects for Future Financial Years The objective of the Group is to create long-term shareholder value by combining its patented titanium technologies to continue to scale a low-cost titanium supply chain business in the U.S. and, in time, globally. IperionX has transitioned from a pilot scale to be a commercial producer of 100% recycled titanium metal products in the U.S., based on the Virginia Titanium Manufacturing Campus. IperionX produces low-cost and high-quality angular and spherical titanium powder, which is used to produce near-net-shape and final titanium parts through powder metallurgy or additive manufacturing. These technologies provide IperionX with a sustainable competitive advantage and significant value uplift from upgrading raw titanium materials through to finished high-performance titanium products when compared to traditional titanium industry supply chains. To achieve its objective, the Group currently has the following business strategies and prospects over the medium to longterm: ▪ commercialize the Technologies to produce titanium metal and metal powders for key markets, including consumer electronics, aerospace, defense, medical, bicycles, additive manufacturing and automotive; ▪ continue to investigate alternative applications of the Technologies to additional value-added metal closed-loop production capabilities, including zircon and synthetic rutile, and the potential production of rare earth elements; ▪ continue discussions with current and potential customers and strategic partners for future production and sale of titanium metal products, titanium minerals and other critical minerals, including, but not limited to, rare earth elements;
40
▪ continue to expand IperionX’s critical mineral land position in the U.S., explore for additional critical minerals and secure final permit and zoning approvals; ▪ continue the development of the Atlas-Titan project, with an integrated economic assessment targeted for completion by the end of 2026. The combination has the potential to reduce upfront capital and operating costs and accelerate first production relative to a standalone Titan development; and ▪ vertically integrate the Technologies with titanium material feedstocks from the Titan Project to develop an end-to-end U.S.-based titanium and critical mineral supply chain. These activities are inherently risky and the Board is unable to provide certainty of the expected results of these activities, or that any or all of these likely developments will be achieved. The material business risks faced by the Group that could have an effect on the Group’s future prospects, and how the Group manages these risks, include: Mineral development risk – The exploration for, and development of, mineral deposits involves a high degree of risk. Few properties that are explored are ultimately developed into producing mines. To mitigate this risk, the Company will undertake systematic and staged exploration and testing programs on its mineral properties and, subject to the results of these exploration programs, the Company will then progressively undertake a number of technical and economic studies with respect to its projects prior to making a decision to mine. However there can be no guarantee that the studies will confirm the technical and economic viability of the Company’s mineral properties or that the properties will be successfully brought into production; Capital and funding risk – Future expansion of the Company’s titanium facilities and any future development of the Company’s mineral properties will require substantial additional financing. Failure to obtain sufficient additional financing may result in delay or postponement of further development of the Company’s titanium facilities and/or mineral properties or even a loss of property interest. There can be no assurance that additional capital or other types of financing will be available if needed or that, if available, the terms of such financing will be favorable to the Company; Commodity price risk – The price of titanium metal and other critical minerals, including titanium feedstocks, rare earth elements, silica sand and zircon fluctuate widely and are affected by numerous factors beyond the control of the Group. Future production from the Group’s titanium metal facilities or mineral properties will be affected by commodity prices being adequate to make these facilities or properties economic. The Group currently does not engage in any hedging or derivative transactions to manage commodity price risk. As the Group’s operations change, this policy will be reviewed periodically going forward; and Competition risk – The Group competes with other domestic and international companies in the titanium technology and critical minerals industries, some of whom have larger financial and operating resources. Increased competition could lead to higher supply or lower overall pricing. There can be no assurance that the Company will not be materially affected by increased competition. In addition, while the Group is continuing to secure additional surface and mineral rights, there can be no guarantee that the Group will succeed in these efforts, which could affect the results of the Group’s operations.
Significant Changes in the State of Affairs a) On August 26, 2025, the Company announced that the U.S. DoW had obligated US$12.5 million under IperionX’s previously announced US$47.1 million award to strengthen the U.S. Defense Industrial Base by accelerating the scale-up of a resilient, low-cost, and fully-integrated U.S. mineral-to-metal titanium supply chain. The US$12.5 million was applied to purchase orders for long-lead, major capital equipment required for the next stage of capacity scale-up to approximately 1,400 metric tons per year at the Virginia Titanium Manufacturing Campus. b) On October 10, 2025, the Company completed a placement of 14.0 million new fully paid ordinary shares at A$5.00 per share, to raise gross proceeds of A$70.0 million (approximately US$45.7 million) before costs. The placement positioned the company to capitalize on the American demand for a reliable domestic source of titanium metal – particularly for defense, aerospace and advanced manufacturing applications. Ordering long-lead capital items at that time was expected to shorten the construction schedule for planned scale-up in titanium production capacity and underpinned ongoing engagement with the U.S. DoW.
41
c) On January 16, 2026, the Company announced that the U.S. DoW through its IBAS program, has obligated the final US$4.6 million under IperionX’s previously awarded US$47.1 million award. Additionally, the U.S. Government has transferred ~290 metric tons (320 short tons) of high-quality titanium alloy (Ti64) scrap metal, which is material that is surplus to its needs, to IperionX for no cost, the equivalent to approximately 1.5 years’ worth of IperionX’s titanium feedstocks at the existing full operating capacity. d) On January 22, 2026, the Company announced it had received a US$0.3 million prototype purchase order from American Rheinmetall for the production of 700 lightweight titanium components for U.S. Army heavy ground combat systems. This initial purchase order has the potential to lead to a significantly larger production agreement upon successful delivery of this initial scope of work. e) On May 21, 2026, the Company announced the successful completion of site acceptance and commissioning of its advanced 300-ton six-axis SACMI powder metallurgy press at IperionX's Titanium Manufacturing Campus in South Boston, Virginia, increasing IperionX’s compaction capacity and the ability to manufacture a broader range of complex titanium components using its powder metallurgy technologies. f) On June 4, 2026 the Company announced the results of the DFS for our 100%-owned Titan Critical Minerals Project in Camden, Tennessee which confirms Titan as a large-scale critical minerals project and underpins our initial 14-year mine plan based entirely on Proved and Probable Ore Reserves. g) On June 30, 2026, the U.S. Army issued an additional prototype purchase order for titanium fasteners for the JLTV and associated trailer. These programs extend government support from powder production capacity into specific products and manufacturing pathways. Other than the above, there were no significant changes in the state of affairs of the Group during the year ended June 30, 2026, not otherwise disclosed.
Significant Events After the Balance Date a) On July 1, 2026, the Company completed the acquisition of key assets from Covia Solutions LLC’s Camden, Tennessee silica sand operation for US$3 million. The assets include mineral rights, at-surface pre-processed mineral stockpiles, mining and processing equipment, an existing rail spur, approximately 1,200 acres of owned property, approximately 1,300 acres of leased property, buildings and structures, and associated electrical, water, and gas infrastructure. b) On July 7, 2026, the Company completed the placement of 2,275,000 new fully paid ADS shares, each representing 10 ordinary shares, to raise gross proceeds of US$50 million before costs. Proceeds from the offering will be used to continue the commercialization and scale-up of certain of our titanium and metal alloy production technologies, including continued scale-up and expansion of the Company’s Titanium Manufacturing Campus in Virginia and associated titanium metal research and development activities, continued development of the Atlas-Titan Project in Tennessee, and for general corporate purposes. c) On August 3, 2026, the Company announced a proposed redomiciliation of its ultimate parent company to Texas, U.S., subject to shareholder, court, regulatory and other customary approvals. Subject to completion of the transaction and applicable exchange approvals, the Company expects the common stock of the new U.S. parent company to be listed directly on Nasdaq, replacing the existing ADS structure. The proposed redomiciliation is not expected to impact the Company's underlying assets, operations or strategic priorities. On that same announcement, the Company announced the appointment of Michael J. Loparco as an independent nonexecutive director effective August 3, 2026. d) On August 26, 2026, IperionX received Task Order 2 under its U.S. Army SBIR Phase III contract for Low-Cost, Domestic Titanium for Defense Applications that builds upon the previously announced US$1.3 million task order, lifting the aggregate potential value of task orders issued under the Company’s US$99 million SBIR Phase III contract up to US$26.7 million. This additional task order will fund the physical equipment and manufacturing systems required to increase throughput, bring critical production steps in-house, reduce acquisition and production costs, and accelerate delivery of titanium components for U.S. defense applications.
42
Other than the above, as at the date of this report there are no matters or circumstances that have arisen since June 30, 2026 that have significantly affected or may significantly affect: ▪ the operations, in financial years subsequent to June 30, 2026, of the Group; ▪ the results of those operations, in financial years subsequent to June 30, 2026, of the Group; or ▪ the state of affairs, in financial years subsequent to June 30, 2026, of the Group.
Indemnification and Insurance of Officers and Auditors The Constitution of the Company requires the Company, to the extent permitted by law, to indemnify any person who is or has been a director or officer of the Company or Group for any liability caused by such a director or officer and any legal costs incurred by a director or officer in defending an action for any liability caused by such a director or officer. During or since the end of the financial year, no amounts have been paid by the Company or Group in relation to the above indemnities. During the financial year, an insurance premium of US$405,650 was paid by the Group to insure against a liability incurred by a person who is or has been a director or officer of the Company or Group. The Company has agreed to indemnify its auditors, PricewaterhouseCoopers, to the extent permitted by law, against any claim by a third party arising from the Company’s breach of their agreement. The indemnity stipulates that the Company will meet the full amount of any such liabilities including a reasonable amount of legal costs.
Directors’ Interests As at the date of this report, the Directors’ interests in the securities of the Company are as follows: Ordinary Shares(1)
Unlisted Options(2)
Performance Rights(3)
Restricted Stock Units(4)
Todd Hannigan
27,133,334
992,170
1,114,992
454,464
Anastasios Arima
12,583,502
1,203,964
1,545,362
738,576
Lorraine Martin
1,265,688
90,216
Vaughn Taylor
973,457
84,771
Tony Tripeny
119,107
51,010
Melissa Waller
486,318
84,771
Beverly Wyse
745,868
84,771
Michael Loparco
58,584
Notes: (1) ‘Ordinary Shares’ means fully paid ordinary shares in the capital of the Company. (2) ‘Unlisted Options’ means an unlisted option to subscribe for one Ordinary Share in the capital of the Company. (3) ‘Performance Rights’ means an unlisted performance right that converts to one Ordinary Share in the capital of the Company upon the
satisfaction of the relevant performance condition. (4) ‘Restricted Stock Units’ means an unlisted restricted stock unit that converts to one Ordinary Share in the capital of the Company upon the
satisfaction of the relevant service vesting condition.
43
Convertible Securities At the date of this report the following convertible securities have been issued over unissued Ordinary Shares of the Company: ▪ 235,000 employee options exercisable at A$10.00 each on or before April 1, 2027; ▪ 1,305,000 employee options exercisable at A$8.00 each on or before June 30, 2027; ▪ 1,374,746 employee options exercisable at A$5.00 each on or before April 10, 2029; ▪ 511,972 employee options exercisable at A$11.00 each on or before April 2, 2030; ▪ 947,062 employee options exercisable at A$11.00 each on or before August 6, 2030; ▪ 1,566,690 director and employee options exercisable at A$18.00 each on or before April 2, 2031; ▪ 1,773,209 director and employee options exercisable at A$22.00 each on or before April 2, 2031; ▪ 4,169,254 director and employee RSUs that vest upon achieving various service-based conditions (118,875 expiring December 23, 2026, 1,095,330 expiring December 31, 2026, 135,044 expiring December 5, 2027, 16,755 expiring December 31, 2027, 20,820 expiring March 2, 2028, 15,500 expiring April 2, 2028, 58,584 expiring August 3, 2028, 141,620 expiring December 16, 2028, 242,985 expiring December 31, 2028, 1,637,975 expiring April 10, 2029, 476,734 expiring December 31, 2029, and 209,032 expiring April 2, 2030); ▪ 2,885,000 employee performance rights that vest upon achieving a 30-day VWAP of A$4.00 per share and other various (non-market based) performance conditions (445,000 expiring December 31, 2027 and 2,440,000 expiring December 21, 2028); ▪ 1,157,803 employee performance rights that vest upon achieving a 30-day VWAP of A$6.00 per share, expiring April 10, 2031; ▪ 1,157,803 employee performance rights that vest upon achieving a 30-day VWAP of A$7.00 per share, expiring April 10, 2031; ▪ 1,157,803 employee performance rights that vest upon achieving a 30-day VWAP of A$8.00 per share, expiring April 10, 2031; ▪ 660,077 director and employee performance rights that vest upon achieving a 30-day VWAP of A$18.00 per share, expiring April 2, 2031; and ▪ 30,000 employee performance rights that vest upon achieving various (non-market based) performance conditions expiring December 31, 2026. During the year ended June 30, 2026 and up to the date of this report, 4,289,126 ordinary shares have been issued as a result of the exercise of Unlisted Options, RSUs, and Performance Rights.
44
Directors’ Meetings The number of meetings of directors held during the fiscal year and the number of meetings attended by each director for their respective committee memberships were as follows:
Audit Committee Meetings
Board Meetings
Director Anastasios Arima Todd Hannigan Lorraine Martin Vaughn Taylor Tony Tripeny Melissa Waller Beverly Wyse
Number eligible to attend 4 4 4 4 4 4 4
Number attended 4 4 4 3 4 4 4
Number eligible to attend 5 5 5
Number attended 4 5 5
Compensation Committee Meetings
Nominating and Governance Committee Meetings
Number eligible to attend 4 4 4
Number eligible to attend 4 4 4 4
Number attended 4 4 4
Number attended 4 4 4 4
Note: Board committee composition was updated effective August 3, 2026
Audit and Non-audit Services Details of the amounts paid or payable to the auditor for audit and non-audit services during the year are disclosed in note 23 Auditor’s Remuneration. The company may decide to employ the auditor on assignments additional to their statutory audit duties where the auditor’s expertise and experience with the company and/or the group are important. The board of directors, in accordance with advice provided by the audit committee, is satisfied that the provision of the nonaudit services is compatible with the general standard of independence for auditors imposed by the Corporations Act 2001. The directors are satisfied that the provision of non-audit services by the auditor did not compromise the auditor independence requirements of the Corporations Act 2001 for the following reasons: all non-audit services have been reviewed by the audit committee to ensure they do not impact the impartiality and objectivity of the auditor, and none of the services undermine the general principles relating to auditor independence as set out in APES 110 Code of Ethics for Professional Accountants.
Auditor’s Independence Declaration The lead auditor’s independence declaration for the year ended June 30, 2026, has been received and can be found on page 73 of the Annual Report.
Signed in accordance with a resolution of the directors.
Anastasios Arima CEO and Managing Director September 29, 2026
45
Letter from Chair of the Compensation Committee Dear Shareholders, On behalf of the Board of Directors of the Company, I am pleased to present IperionX’s Remuneration Report for the financial year ended June 30, 2026. Our remuneration framework is designed to attract and retain the leadership required to build IperionX, reward delivery against clear objectives and align executive outcomes with long-term shareholder value. The Committee’s responsibility is to ensure that the structure of remuneration, the performance expectations and the resulting rewards support those objectives. Performance and remuneration in fiscal year 2026 During fiscal year 2026, IperionX expanded its manufacturing capabilities, completed the Titan Critical Minerals Project Definitive Feasibility Study, raised US$46 million in equity and strengthened internal control systems required for SarbanesOxley compliance. The Company also recorded zero recordable injuries in calendar 2025. These achievements advanced the business, while total shareholder return for fiscal year 2026 was negative 14%. We recognize the importance of that deficit to shareholders. Our framework links remuneration to both the annual objectives required to develop the business and the longer-term returns that development is expected to deliver. Short-term incentives are assessed against a weighted scorecard of four strategic goals established by the Board before the financial year began. Assessment against that scorecard resulted in an outcome of 114% of target for eligible executive key management personnel. The Executive Chairman received no short-term incentive for the year. The annual incentive outcome reflects performance against those predetermined objectives. The longer-term component of remuneration provides a separate link to the value executives help create for shareholders over time. Linking long-term rewards to shareholder value Over the three and five years to June 30, 2026, IperionX delivered cumulative total shareholder returns of 266% and 332%, respectively. In each period, those returns exceeded those of fourteen of the fifteen companies in our remuneration benchmark group. That record provides context for the Company’s development and our emphasis on long-term alignment with shareholders. Future equity rewards are governed by the conditions attached to each award, linking executive outcomes to further performance and continued service. The fiscal year 2026 long-term awards to the Chief Executive Officer and Executive Chairman set demanding conditions for reward. The A$18.00 and A$22.00 option exercise prices represent increases of approximately 166% and 225%, respectively, over the A$6.76 valuation-date share price on February 2, 2026. Performance rights require a 30-day volume-weighted average share price of at least A$18.00 within the four-year measurement period, together with the other vesting conditions. The performance rights depend on satisfying these demanding price hurdles and other vesting conditions; the options generate a gain on exercise only above their respective exercise prices. The awards also incorporate a four-year continuous-service condition. The performance rights and resulting shares carry an additional one-year holding restriction, extending the executives’ exposure to share price performance beyond vesting. This structure supports continuity and links the potential rewards from these awards to material share price appreciation. It is designed to encourage decisions that strengthen the business over the long term. Competitive remuneration for an American business Our remuneration benchmarks reflect the market in which IperionX operates and competes for talent. All of IperionX’s operating assets are in the U.S., more than 95% of our employees are American, and over 90% of our customers and suppliers are U.S. based. We compete in that market for the specialist engineering, manufacturing and leadership expertise needed to execute our strategy. U.S. peers therefore provide the most relevant basis for assessing remuneration. This approach grounds our decisions in the market where we must attract and retain talent, while maintaining discipline over pay and alignment with shareholder interests.
46
Within that market, our framework places deliberate emphasis on equity over cash compensation. Target total cash compensation for executive key management personnel is positioned near the 25th percentile of our benchmark group, while target total compensation is near the median. This approach balances competitive remuneration with cash discipline. It preserves cash for the development and operation of the business while making equity an important part of executives’ potential rewards. Benchmarking informs the level of target remuneration; performance and the applicable award conditions determine incentive outcomes. Shareholder engagement and accountability We continued to engage with shareholders during the year and value the perspectives they bring to remuneration, performance expectations and executive alignment. That dialogue informs our continuing review of the framework and the clarity of our disclosures. Shareholders should be able to understand what executives are rewarded for, how performance is assessed and how remuneration outcomes relate to their interests. We remain focused on making those connections clear. As IperionX develops, our remuneration framework must continue to support the capabilities and results required for our next stage of growth. The Committee’s focus is on retaining strong leadership, setting high expectations and maintaining a clear relationship between executive rewards and the creation of long-term shareholder value. Thank you for your continued engagement and support. I commend the Remuneration Report to you.
Vaughn Taylor Chair, Compensation Committee
47
Remuneration Report This Remuneration Report, which forms part of the Directors’ Report, sets out information about the remuneration of the KMP of the Group. The Remuneration Report has been audited as required by section 308 (3C) of the Corporations Act 2001.
Details of Key Management Personnel The KMP of the Group during or since the end of the financial year were as follows: Directors Mr. Todd W. Hannigan
Executive Chairman
Mr. Anastasios Arima
Chief Executive Officer and Managing Director
Ms. Lorraine M. Martin
Lead Independent Director
Mr. Vaughn Taylor
Independent Non-Executive Director
Ms. Melissa G. Waller
Independent Non-Executive Director
Ms. Beverly M. Wyse
Independent Non-Executive Director
Mr. Tony Tripeny
Independent Non-Executive Director
Mr. Michael J. Loparco
Independent Non-Executive Director (appointed August 3, 2026)
Other KMP Mr. Toby E. Symonds
President and Chief Strategy Officer
Mr. W. Scott Sparks
Chief Operating Officer
Mr. Dominic P. Allen
Chief Commercial Officer
Ms. Marcela Castro
Chief Financial Officer
Unless otherwise disclosed, the KMP held their position from July 1, 2025, until the date of this report.
Executive Remuneration Snapshot Overview of Fiscal 2026 Executive Remuneration Framework Executive remuneration arrangements for fiscal 2026 have been designed to: ▪ Benchmark to where we operate: Reflect the Company’s U.S. business, workforce, customer base, and asset footprint. ▪ Align interests with shareholders: Emphasize pay-for-performance with clear links to long-term value creation. ▪ Support commitment and stability: Promote sustained leadership focus and continuity through multi-year incentive design. ▪ Prioritize execution and resilience: Tie outcomes to commercialization milestones, scale-up delivery, balance-sheet strength and long-term value creation.
48
Fiscal 2026 Company Performance Overview Fiscal 2026 Operational Performance Highlights The following Remuneration Report for fiscal 2026 sets out the remuneration framework for the Company’s executive KMP and Non-Executive Directors (NEDs). For fiscal 2026, the remuneration framework was heavily weighted towards rewarding executive KMP for progressing the commercialization of our assets and balance sheet strength, and focusing on delivery of key scale-up targets. The Compensation Committee is pleased to report that throughout fiscal 2026 the Company achieved the following key milestones: ▪ Funding, Corporate, Financial and Investor Relations – Raised US$46 million in equity from existing shareholders. Completed the deployment of an ERP system and related upgrades to support compliance with the Sarbanes-Oxley Act; ▪ Operations – Completed commissioning and increased nameplate powder capacity 60% to 200 metric tons per annum through operational process improvements. Issued the annual Sustainability Report, highlighting additional accomplishments for FY 2025. No recordable injuries in calendar 2025. Completed the Titan Project Definitive Feasibility Study. ▪ Commercial and Government Engagements - Significant progress above expectation on publicly announced and confidential commercial engagements and government contracts, including funding programs and other confidential engagements; ▪ Product Innovation / R&D / IP - Confidential ongoing innovation and protection of existing IP. During fiscal 2026, short-term and long-term incentives were awarded to executive KMP and restricted stock units were awarded to NEDs. Fiscal 2026 Market Performance Highlights The table below outlines the Company’s market performance since December 1, 2020.
Dividends paid (US$) Share price at end of period (ASX:IPX) 1-year total shareholder return (ASX:IPX) 3-year total shareholder return (%) (ASX:IPX) 5-year total shareholder return (%) (ASX:IPX) Market capitalization at end of period (ASX:IPX)
Fiscal 2026
Fiscal 2025
– A$4.08 -14% 266% 332% A$1.4 billion
– A$4.75 133% 479% N/A A$1.5 billion
Fiscal 2024
Fiscal 2023
December 1, 2020 to June 30, 2022
– – – A$2.04 A$1.12 A$0.82 83% 36% 215%(1) 113% 329% N/A N/A N/A N/A A$525 million A$216 million A$115 million
Notes: (1) Calculated using a starting share price of A$0.26, being the closing share price of the Company on ASX on December 1, 2020, which was
the date of completion of the reverse acquisition of the Company by HMAPL.
49
Fiscal 2026 Market Performance Highlights (continued)
Remuneration Framework Overview IperionX is a U.S.–based titanium technology and manufacturing company listed on both the ASX and Nasdaq. Our executives, employees, customers, and operating assets are overwhelmingly in the U.S., and our strategy is anchored in building a low-cost and resilient U.S. titanium supply chain. The Remuneration Framework for KMP is developed by the Board and its Compensation Committee, with independent advice from Pearl Meyer (U.S.). It is designed to: ▪ Compete for U.S. leadership talent in advanced manufacturing and hard-tech; ▪ Align rewards to long-term shareholder value, strategic execution, and long-term success; ▪ Reinforce multi-year commitment to scaling operations safely, reliably and profitably; and ▪ Drive performance while managing risk, particularly during rapid commercial scale-up. Our structure combines fixed remuneration with a meaningful “at-risk” component across short- and long-term incentives. Deliberately lower fixed pay and a higher proportion of performance-based long-term equity ensure executive outcomes closely mirror shareholder outcomes. A significant share of total compensation is contingent on achieving clearly defined milestones tied to value creation. The table below provides an overview of the remuneration elements for fiscal year 2026.
50
Why our remuneration is benchmarked to the United States IperionX is a founder-led, U.S.-based titanium metal technology and manufacturing company with a valuable, award-winning patented technology portfolio. When we listed via a reverse takeover in 2020, we started with an early-stage mineral exploration asset in Tennessee, no proprietary technology, a market capitalization of less than A$10 million (share price ~A$0.10), and less than A$2 million in cash. From these modest beginnings - and with the crucial support of our long-term shareholders - we have built an emerging leader in the U.S. titanium industry. Today, by every operational and strategic measure, IperionX is a U.S. enterprise: ▪ People and Leadership: Over 95% of our employees and the majority of our Board of Directors are U.S. citizens ▪ Operations: All operating assets - from our Virginia Titanium Campus, R&D centers in Utah and Virginia, to our Titan Critical Minerals Project in Tennessee - are located in the U.S. ▪ Customers and Suppliers: More than 90% of our customers and suppliers are U.S.-based, reflecting our strategic domestic supply chain focus ▪ Capital Markets: Dual-listed on Nasdaq and ASX, with over 40% of our non-employee shareholders U.S. domiciled ▪ National Strategic Role: The U.S. Government has committed up to US$159 million in non-dilutive funding to accelerate the re-shoring of a domestic titanium supply chain. Beyond being our largest non-equity financier, the U.S. government is poised to become a major customer Given this footprint, the U.S. market is the appropriate reference point for recruiting, rewarding, and retaining the specialized leadership required to execute our growth strategy. Benchmarking to the U.S. ensures competitiveness for scarce talent, reinforces pay-for-performance, and aligns incentives with the markets, customers, and regulators most critical to IperionX’s long-term success. Remuneration Mix Executive remuneration includes fixed remuneration and performance-based remuneration (STIs and LTIs). The remuneration framework for fiscal 2026 comprised the following elements: Fixed Remuneration Recognizes the requirements and responsibilities of the role
Drives the achievement of annual operational objectives
Long-Term Incentive (LTI) Encourages sustained long-term business growth and shareholder value
Not applicable
Varies for each KMP
Varies for each KMP
25th percentile
25th percentile
Median
Cash
Cash
Performance criteria
None
Given the growth stage of the business, the Company uses milestone based KPIs aligned to the strategic plan approved by the Board
Timeframe before reward is realized
Immediate
1 year
Purpose Target Opportunity (% of fixed remuneration) Target Opportunity compared to Peer Group Delivery mechanism
Short-Term Incentive (STI)
51
Equity in the form of Performance Rights, Unlisted Options, and RSUs Hurdles - “out-of-the-money” share price hurdles for Performance Rights and Options tied to significant shareholder value creation, Service Period - 3-5 year service period requirements for Performance Rights and RSUs Subject to the achievement of performance and service conditions, over a period up to five years
To attract and retain executive talent with the skills and experience to deliver the Company’s strategy additional forms of remuneration including sign-on incentives, and other one-off incentives may be provided to executive KMP at the Board’s discretion. Clawback Policy In order to prevent a covered executive from retaining an inappropriate benefit arising from an accounting restatement due to the Company’s material non-compliance with any financial reporting requirement under the federal securities laws, the Compensation Committee may determine that excess incentive-based compensation received by a covered executive is subject to recovery (clawback). The Company will recover such excess amounts on a reasonably prompt basis. Recovery may be effected by requiring repayment to the Company, set-off, reduction of future compensation, or such other means as the Compensation Committee determines to be appropriate. The clawback policy applies to incentive-based compensation (compensation granted, earned or vested based in whole or in part on the attainment of a financial reporting measure) that was received by a covered executive on or after October 2, 2023, after the person began service as a covered executive, and who served as a covered executive at any time during the relevant performance period. The recovery period is the three completed fiscal years immediately preceding the date the Company is required to prepare the accounting restatement (plus any applicable transition period of less than nine months).
52
Shareholder and Proxy Feedback Throughout the years, the Company has engaged with shareholders on a wide range of topics, including executive compensation, corporate governance, and environmental and social issues. This ongoing engagement gives us valuable insight into shareholders’ perspectives and guides enhancements to our governance and disclosures. By actively addressing shareholder questions and concerns, we ensure that the matters most important to our investors remain at the forefront of our decision-making and strategic priorities. It was pleasing to hear directly from many of our largest U.S. and Australian active long-term shareholders who are very supportive of our remuneration framework and that they recognize the need for a U.S. remuneration framework. We were also pleased to receive positive feedback from both shareholders and proxy advisors on our uplifted disclosures. In the interest of full transparency, we have provided key feedback received and our responses below. Proxy Advisor Feedback Given the Company is listed on the ASX as its primary listing, compensation structures and the remuneration framework should be based on Australian standard, not U.S. standard.
Fixed remuneration pay reviews of more than 15% are substantial and should be limited
You have a 30 June fiscal year end, however your remuneration measurement period is based on 31 December calendar year. You should align these.
We are used to STI targets that are tied to quantitative financial targets (revenue, earnings, margins etc) and quantitative operational targets (production rates etc). Provide more information on the peer group comparisons that influence KMP compensation reviews Preference for KMP performance-based incentives to be a number of measures, not just share price, with a preference of > 50% of Long Term Incentive Plan (LTIP) being performance based.
Response We value ASX standards; however, our remuneration framework is intentionally aligned with U.S. practices in light of our strategic focus on increased manufacturing investments, strong market fundamentals in the U.S. titanium sector, and our technology-driven business model. As we continue to expand our American operations and innovate in advanced titanium production, attracting and retaining top U.S. talent is critical to the long-term success of our business. By tailoring our compensation structure to the U.S. market, we are better positioned to drive longterm shareholder value and ensure the operational and commercial success of our titanium technologies. Fixed remuneration continues to grow at above average levels from a low base. The market capitalization of the company has grown significantly over the last few years, which has resulted in a new peer group being selected by Pearl Meyer, which has also resulted in an increase in fixed remuneration levels. As the Company continues to grow in complexity moving into commercialization phase and also continued growth in market capitalization, we expect to see growth in fixed remuneration above market averages. While our primary listing is on the ASX, we operate to calendar year with regards to our business plan, budgeting and targets, which is standard for a U.S. operating company. Rather than incurring the unnecessary financial expense of varying our financial year for audited financial statements, especially now that we have to comply with the Sarbanes Oxley Act in the U.S., we will ultimately make a decision to align the two around a potential redomicile event in the future. The board believes that the current approach to STI measurements is the best approach given the growth and scale up stage of the business. We are not yet at the stage of implementing such STI financial and operational targets. However, we envisage our STI targets will shift to these financial and operational metrics over time as the business moves into steady state production. Following this feedback, we have included the Peer Group in this year’s remuneration report. Historically, more than 50% of LTIPs on issue have been performance-based. Following the remuneration and benchmarking review by Pearl Meyer in fiscal year 2025, the current company LTIP plan has been aligned to long term value creation with a higher weighting on performance linked equity versus time-based equity. For KMP, performance-based incentives now comprise more than 50% and, in some cases, more than 80% for the CEO, President and Executive Chairman. Further, these LTIP awards are issued with share price targets or exercise price targets that are significantly “out of the money” at the time of issuance. LTIP issuances also have a minimum 3-year service period, in some cases 5-years, before the equity vests and/ or is accessible by the KMP.
LTIP granted to KMP should have a minimum threeyear cliff vesting profile, not annual vesting. To remove potential risk of conflict, any equity grants for NED should have a vesting profile of no longer than one (1) year, and if the NED resigns, there should be a pro-rata allocation up to the date of resignation.
This has been incorporated into the new LTIP plan designed by Pearl Meyer. Performance Rights have a five-year service period requirement and RSUs have a three-year service period requirement. No annual vesting. This has been incorporated into the LTIP plan designed by Pearl Meyer.
53
Remuneration Benchmarking Overview As noted in our FY 2025 Annual Report, from late 2024 to April 2025, the Compensation Committee engaged Pearl Meyer, a U.S.-based independent remuneration consultant, to review IperionX’s remuneration structure, policy, and strategy for executives and employees. This review was prompted by the Company’s significant growth since the last benchmarking exercise and by stakeholder feedback on previous Remuneration Reports. Pearl Meyer benchmarked IperionX against comparable U.S. businesses, reflecting IperionX’s position as a U.S.-based technology and metals manufacturing company rather than an ASX resource company. The resulting framework emphasizes: ▪ Retaining key employees and attracting skilled talent to advance disruptive titanium technologies within the realities of competing in a highly competitive U.S. market. ▪ Aligning executive compensation with complex development and commercial initiatives over multi-year horizons to create long-term shareholder returns. Key characteristics of the 15 selected U.S. peers included: ▪ Industry – Vertically integrated metals, specialty chemicals, 3D printing, and manufacturing technology companies, mirroring IperionX’s business model. ▪ Stage – A mix of both operating and developing companies, encompassing pre-revenue/profit and post-revenue/profit organizations. When analyzing benchmarking data, Pearl Meyer considered: ▪ Size and Complexity – The peer group includes companies of varying maturity levels and revenue and cash flow profiles, which can create compensation differences. To address this, data was segmented at a US$2 billion enterprise value threshold as a proxy for the stage of the business cycle. ▪ Role Comparison – Individual roles at IperionX were assessed to ensure like-for-like benchmarking with comparable positions in the peer group.
54
Peer Group The table below is the selected group of peers from the remuneration review with Pearl Meyer that has informed the Fixed Remuneration, STI Targets and LTI allocations for KMP.
Company Tronox Holdings plc Kaiser Aluminum Corporation Minerals Technologies Inc. Century Aluminum Company Materion Corporation Metallus Inc.
GICS Industry Commodity Chemicals Aluminum Specialty Chemicals Aluminum
Headquarters Stamford, CT Franklin, TN New York, NY Chicago, IL
Market Cap (US$ millions) @6/30/26 $1,005 $3,197 $2,294 $4,554
Diversified Metals and Mining
Mayfield Heights, OH
$6,186
+276%
+38%
+32%
Annualized TSR as of 6/30/26 1-Yr 3-Yr 5-Yr +30% -17% -19% +152% +45% +14% +35% +9% -1% +155% +74% +29%
Steel
Canton, OH
$778
+21%
-5%
+6%
Compass Minerals International, Inc.
Diversified Metals and Mining
Overland Park, KS
$1,306
+55%
-2%
-11%
Proto Labs, Inc.
Industrial Machinery and Supplies and Components
Maple Plain, MN
$1,940
+104%
+33%
-2%
3D Systems Corporation
Industrial Machinery and Supplies and Components
Rock Hill, SC
$444
+96%
-33%
-40%
Luxfer Holdings PLC
Industrial Machinery and Supplies and Components
Milwaukee, WI
$483
+54%
+13%
0%
Elevra Lithium Limited1 Energy Fuels Inc.
Diversified Metals and Mining Coal and Consumable Fuels
Brisbane, QLD Lakewood, CO
$1,289 $3,623
+311% +152%
-25% +33%
-21% +19%
Origin Materials, Inc.4
Commodity Chemicals
West Sacramento, CA
$5
-93%
-80%
-67%
Automotive Parts and Equipment
Louisville, CO
$583
+18%
+1%
-24%
Diversified Metals and Mining
Vancouver, BC
$1,919
-33%
+40%
-15%
$2,745 $1,306 $680
+152% +55% +25%
+35% +9% -11%
+10% -2% -20%
$953 35%
-10% 10%
+56% 96%
+32% 99%
A$1,385 million
-14%
+54%
+34%
Solid Power, Inc.3 TMC the metals company Inc.3 75th Percentile Median 25th Percentile Converted to USD5 IperionX Limited Percentile Rank In AUD5 IperionX Limited
South Boston, VA
Source and basis of preparation. Total shareholder return is the annualized (compound) return to June 30, 2026 on dividend-reinvested (adjusted) closing prices measured from the corresponding date one, three and five years earlier (June 30, 2025, 2023 and 2021). Prices and point-in-time market capitalizations are per Yahoo Finance and stockanalysis.com, independently reconciled against one another. Market capitalizations are stated in USD millions. This basis reproduces the prior (February 1, 2025) peer table to a mean absolute difference of 0.5 percentage points across 41 peer/period observations, and reproduces the Company's own market performance table at June 30, 2026 exactly.
- Elevra Lithium Limited replaces Piedmont Lithium Inc., which ceased to exist as a separate listing on August 29, 2025 on completion of its merger with Sayona Mining. TSR is chain-linked through the transaction on the shareholder-experience basis: each Piedmont share converted into 527 Elevra ordinary shares, being 0.3513 Elevra ADSs (ADS ratio 1,500 ordinary shares : 1 ADS).
- All fifteen peers now carry a five-year TSR. In the February 2025 table, four peers were shown as n/a because their price histories began after the five-year base date. Measured from June 30, 2021 every peer has a full five-year record.
- TMC, Solid Power and Origin Materials were listed at June 30, 2021 only through their predecessor special purpose acquisition companies, then trading at or near trust value. Their five-year returns are measured from that base and should be read with that in mind. Excluding all three, the five-year peer percentiles would be 75th +15%, median -0.5%, 25th -13%.
- Origin Materials remained Nasdaq-listed at the measurement date and has since resolved to delist voluntarily and deregister; its last trade was July 1, 2026. Figures are retro-adjusted for its 1-for-30 reverse share split.
55
Peer Group (continued) 5. IperionX market capitalization and TSR are taken from the ASX primary listing (A$1,385 million at June 30, 2026) and translated at the AUD/USD spot rate on each measurement date (0.6882 at June 30, 2026; 0.6533, 0.6620 and 0.7514 at the one, three and five-year base dates). The USD block reports IperionX's return to a USD-based holder, on the same currency footing as the US-listed peers; the AUD line reports the return to an Australian shareholder. Percentile ranks are calculated on the USD basis. 6. Relative position. Over three years, IperionX's return in both USD and AUD, was higher than fourteen of the fifteen peers — second to Century Aluminum. Over five years, IperionX’s return in AUD ranked first and IperionX’s return in USD tied Materion for first. Over one year, IperionX ranked in the bottom decile of the group, which recorded a median one-year return of +55%. 7. Percentiles and percentile ranks use linear interpolation.
Beyond the selected peer group, survey data was also evaluated. Where both peer group and survey data were available, a weighted average was used to determine competitive market rates, assigning greater weight to proxy compensation data for KMP. At this stage, the large U.S. titanium and advanced metal manufacturers - including Howmet Aerospace, Carpenter Technology, and ATI - were not included in the peer group. While these companies produce a range of titanium products for similar end markets and represent potential competitors for executive and managerial talent, their larger size, valuation, and complexity currently set them apart for benchmarking. However, they remain prospective peers for future benchmarking reviews as IperionX grows. Benchmarking Outcomes The benchmarking review revealed that total remuneration - encompassing fixed remuneration and both STI and LTI awards for KMP was between the 25th percentile and the median of the sub-$2 billion enterprise value peer group. This gap was even more pronounced when the entire peer group was considered. As outlined in the 2025 Annual Report, to ensure that IperionX can effectively attract, retain, and motivate high-caliber Executive KMP, the Board and the Compensation Committee approved an executive remuneration framework, which includes:
- Target Total Cash Compensation: Positioned near the 25th percentile of the peer group.
- Target Total Compensation: Positioned near the median of the peer group.
- Remuneration Mix Weightings: Weighted more heavily toward “at-risk” components that reflect both immediate priorities and longer-term strategic objectives. In determining the remuneration mix, the Company places greater emphasis on longterm incentives, aligned with the extended timelines required to achieve its strategic goals, retaining talent and delivering sustained shareholder value. The executive remuneration framework has not changed for fiscal year 2026. ▪ Pearl Meyer was consulted on appropriate market based salary increases for KMP, which ranged from 3% to 12%, with an overall average of 5%. Pearl Meyer also assisted the Compensation Committee with the valuation and structure of issued LTIP to KMP during the year. Further, issuances to Taso Arima and Todd Hannigan were approved by shareholders at the General Meeting held on 19 March 2026. ▪ The proposed LTIP issuances fall within the remuneration framework and peer group analysis as outlined above. The proposed Option strike prices and Performance Rights performance hurdles are significantly “out of the money” and set between 63-225% above the share price of A$6.76 as at the date of Board approval of the LTIP, resulting in very strong alignment between targeted executive remuneration outcomes and long-term shareholder returns.
56
Under this framework, the Compensation Committee and Board approved the following compensation packages for KMP during fiscal year 2026, effective January 1, 2026. Amounts shown in the table below are for calendar year 2025 and calendar year 2026.
Base Target STI (US$) (US$) Todd Hannigan (Executive Chairman)
Total Target Cash Compensation STI Target % (US$)
Target LTIP (US$)
Target Total % Compensation Performance (US$) Related
2026
402,000
282,000
70%
684,000
2,132,323
2,816,323
86%
2025
385,000
270,000
70%
655,000
1,732,500
2,387,500
84%
Taso Arima (Chief Executive Officer and Managing Director) 2026
575,000
403,000
70%
978,000
2,587,500
3,565,500
84%
2025
550,000
385,000
70%
935,000
2,465,000
3,400,000
84%
Toby Symonds (President and Chief Strategy Officer) 2026
546,000
382,000
70%
928,000
2,458,125
3,386,125
84%
2025
523,000
366,000
70%
889,000
2,351,250
3,240,250
84%
Dominic Allen (Chief Commercial Officer) 2026
325,000
163,000
50%
488,000
487,500
975,500
67%
2025
315,000
158,000
50%
473,000
630,000
1,103,000
71%
Scott Sparks (Chief Operating Officer) 2026
325,000
163,000
50%
488,000
487,500
975,500
67%
2025
315,000
158,000
50%
473,000
630,000
1,103,000
71%
Marcela Castro (Chief Financial Officer) 2026
325,000
163,000
50%
488,000
487,500
975,500
67%
2025
290,000
145,000
50%
435,000
290,000
725,000
60%
Over time and subject to progression of the Company towards revenue generation and profitability, to ensure the Company continues to attract and retain top-tier global talent, it is the intention to adjust Executive KMP to the 60th to 75th percentile on a Total Compensation basis compared to peer comparator groups.
57
Executive Remuneration The Group’s executive remuneration policy is to provide a fixed remuneration component and a performance-based component (STIs and LTIs). The Board believes that this remuneration policy is appropriate given the considerations discussed in the section above and is appropriate in aligning executives’ objectives with shareholder and business objectives. In a significant year for IperionX, executive KMP demonstrated strong performance, and their remuneration outcomes reflect their performance and significant contributions in fiscal 2026. Fixed Remuneration Fixed remuneration consists of base salaries, as well as employer 401(k) contributions or contributions to superannuation funds and other non-cash benefits. Non-cash benefits may include provision of motor vehicles, rental allowance, health care benefits, health insurance, and life insurance. Fixed remuneration is reviewed annually by the Board. The process consists of a review of company and individual performance, relevant comparative remuneration externally and internally and, where appropriate, external advice on policies and practices. As outlined above, the fixed remuneration of Executive KMP was benchmarked to peer comparator groups, with an average increase of 5% across KMP as per the below table: The table below provides the base salary component of the fixed remuneration:
Executive KMP Todd Hannigan (Executive Chairman) Anastasios Arima (CEO) Toby Symonds (President and CSO) W. Scott Sparks (COO) Dominic Allen (CCO) Marcela Castro (CFO)
Previous (US$) 385,000 550,000 523,000 315,000 315,000 290,000
Current (US$) 402,000 575,000 546,000 325,000 325,000 325,000
Increase (US$) 17,000 25,000 23,000 10,000 10,000 35,000
Increase (%) 4% 5% 4% 3% 3% 12%
Note: Base salary is approved for the calendar year.
Performance Based Remuneration – Short-Term Incentive Some executive KMP are entitled to an annual cash bonus upon achieving various KPIs, as set by the Board. Having regard to the current size, nature and opportunities of the Group, the Board has determined that these KPIs will include measures related to successful completion of activities as outlined in the below table. Prior to the end of each financial year, the Board assesses performance against these criteria.
58
The following table sets out the key criteria which were set by the Board and used to determine executive short-term incentive (STI) outcomes paid during the fiscal year 2026. Feature Eligibility Opportunity
Payout Methodology
Description Limited to select employees, as determined by the Board. The target opportunity as a percentage of the base salary component of fixed remuneration (FR) is set out below: Executive KMP Target STI (% of FR) Todd Hannigan (Executive Chairman) 70% Anastasios Arima (CEO) 70% Toby Symonds (President and CSO) 70% W. Scott Sparks (COO) 50% Dominic Allen (CCO) 50% Marcela Castro (CFO) 50% The total payout is calculated based on incremental objectives completed. To receive a payout, the total completion percentage must exceed 50% and is capped at 200% of target. The relationship between weighted score card achievement and payout is reflected in the chart below: Weighted Scorecard Payout % of Achievement Target STI Threshold
Performance Assessment
0% - 50%
—%
Target
75%
100%
Maximum
100%
200%
IperionX utilizes a weighted scorecard methodology to award annual cash bonuses to executive KMP, which enhances transparency on the determination of annual cash bonuses. This approach links shortterm incentives for executive KMP to clearly defined Company objectives to create a performancebased compensation opportunity that furthers stockholders’ interests while motivating and challenging our executive talent to achieve strategic priorities. The cash bonus scorecard for the STI paid in fiscal year 2026 consists of four primary strategic goals, each weighted between 20-30%. Each of these goals contained a number of defined objectives measured at December 31, 2025. As part of the methodology, scorecard completion determines the total payout. Measure Measure Weighting Ongoing innovation and Product Innovation / R&D / IP 20% protection of existing IP Focus on progressing various Commercial and Government commercial and government 30% Engagements contracts Operations
Funding, Corporate, Financial and Investor Relations Payment
Focus on delivery of key scale-up targets, recruitment and retention of key talent, execute on safety plans and promote sustainable development Focus on securing funding to support the Company's strategic plans and drive key corporate initiatives
25%
25%
The STI awards were paid in cash after the completion of reviews at December 31, 2025.
59
The following table outlines performance against the above short-term incentive criteria for calendar year 2025: Measure
Description
Weighting ▪
Product Innovation / R&D / IP
Ongoing innovation and protection of existing IP
Commercial and Government Engagements
Focus on progressing various commercial and government contracts
20%
▪
▪ 30%
▪ ▪
Operations
Focus on delivery of key scale-up targets, recruitment and retention of key talent, execute on safety plans and promote sustainable development
▪ 25%
▪ ▪ ▪ ▪
Funding, Corporate, Financial and Investor Relations
Focus on securing funding to support the Company's strategic plans and drive key corporate initiatives
Total
▪ 25% ▪
Achievement Significant advancement in GenXTM technology Ongoing reviews and careful maintenance of existing patent portfolio
- securing IP critical for commercialization and long-term success Significant progress above expectation on publicly announced and confidential commercial engagements Secured SBIR Phase III IDIQ contract enabling task orders up to US$99M Completed commissioning and increased nameplate powder capacity 60% to 200 metric tons per annum through operational process improvements. Hired full-time Environmental, Health and Safety manager Issued our annual Sustainability Report highlighting additional accomplishments for FY 2025 Achieved zero recordable injuries in 2025 Progressed the Titan Project DFS (completed on schedule in June 2026) Raised US$46 million in capital from existing investors Awarded US$47.1 million by the U.S. DoW’s IBAS program to develop a secure, low-cost, mineral-to-metal titanium supply chain Completed the deployment of an ERP system and related upgrades to support compliance with the Sarbanes-Oxley Act
Score
Achievement
100%
20.0%
60%
18.0%
62%
15.5%
100%
25.0%
100%
78.5%
NOTE: The Committee does not disclose the individual objectives beneath each scorecard measure. They relate to customer qualification programs and commercial agreements carrying confidentiality obligations, to contracting and funding arrangements with agencies of the U.S. Government, and to the timing and scope of patent filings. Where an objective ceases to be commercially sensitive, the Committee will disclose it retrospectively.
The total weighted average score of 78.5% corresponds to a STI payment equal to 114% of target. Based on these performance outcomes, the table below outlines the STI awarded to executive KMP with respect to performance in calendar year 2025. During fiscal 2026, cash bonuses of US$1,383,000 (2025: US$1,486,000) were paid to executive KMP. Target STI (% of FR)
Target STI (US$)
STI Awarded for 2026 (US$)
% of Target STI Awarded
Todd Hannigan (Executive Chairman)
70%
270,000
-%
Anastasios Arima (CEO)
70%
385,000
440,000
114%
Toby Symonds (President and CSO)
70%
366,000
418,000
114%
W. Scott Sparks (COO)
50%
158,000
180,000
114%
Dominic Allen (CCO)
50%
158,000
180,000
114%
Marcela Castro (CFO)
50%
145,000
165,000
114%
Executive KMP
Note: Mr. Hannigan declined his entitlement to a cash STI.
60
Performance Based Remuneration – Long-Term Incentive The Group has a LTIP to reward executive KMP and other key employees and contractors for long-term performance. This plan is based on best practice for companies operating in the U.S. This LTIP was designed in consultation with Pearl Meyer, our U.S.-based remuneration consultant. The Plan provides for the issuance of Performance Rights, RSUs and Unlisted Options to eligible employees and contractors as part of their remuneration and incentive arrangements in order to attract and retain their services and to provide an incentive linked to the performance of the Group. The allocation to Performance Rights, RSUs and/or Options is determined by the Board based on the assessment of the contribution by the executive KMP to all aspects of the company’s growth. To achieve its corporate objectives, the Group needs to attract, incentivize, and retain its executive KMP and other key employees and contractors. The Board believes that grants made to eligible participants under the Plan will provide a useful tool to underpin the Group’s employment and engagement strategy, and enables the Group to: ▪ recruit, incentivize and retain KMP and other key employees and contractors needed to achieve the Group’s business objectives; ▪ link the reward of key staff with the achievement of strategic goals and the long-term performance of the Group; ▪ align the financial interest of participants of the Plan with those of Shareholders; and ▪ provide incentives to participants of the Plan to focus on superior performance that creates shareholder value. The issuance of Performance Rights, RSUs and Options for fiscal 2026 is considered in line with U.S.-based peer group comparators and aligned with linking sustained Company performance, retention and long-term shareholder value. The table below summarizes RSUs, Performance Rights and Options that were granted, vested or lapsed relating to executive KMP remuneration during fiscal 2026.
Granted during 2026 156,774 660,077 3,723,878
RSUs Performance Rights Options
Vested/Exercised during 2026 (1,019,668) (625,000)
Lapsed or expired during 2026 (2,560,000)
As at June 30, 2026, the Company had a total of 18,031,866 outstanding Performance Rights, RSUs and Unlisted Options on issue that had been granted to employees and contractors of the Company as part of their remuneration arrangements, representing 5.05% of the Company’s total shares on issue (on a fully diluted basis). The Board considers this reasonable and in-line with peer group comparators. (i) Performance Rights The LTIP provides for the issuance of Performance Rights to eligible participants which, upon satisfaction of the relevant performance conditions attached to the Performance Rights, will result in the issue of an Ordinary Share for each Performance Right. Performance Rights are issued for no consideration and no amount is payable upon conversion thereof. Performance Rights granted under the Plan to eligible participants will be linked to the achievement by the Group of certain performance conditions as determined by the Board from time to time. These performance conditions must be satisfied in order for the Performance Rights to vest. Upon Performance Rights vesting, Ordinary Shares are automatically issued for no consideration. If a performance condition of a Performance Right is not achieved by the expiry date, then the Performance Right will lapse. During fiscal 2026, 660,077 Performance Rights were granted to executive KMP as outlined in the table below. These Performance Rights were granted to selected executive KMP as one-off grants as retention awards. These awards are linked to the creation of shareholder value growth through the utilization of “out of the money” share price hurdles and continuous service periods acting as a retention tool for our executives.
61
The Compensation Committee has received commentary from certain investors that their preference is to have operating metrics alongside share price hurdles and that share price hurdles create an opportunity for management awards to vest in situations where the stock price increases (beyond management control). The Compensation Committee has taken this into consideration and in addition to performance criteria, these Performance Rights also had a 4-year continuous service period requirement, as well as an additional 1-year lock-up period, meaning even if the vesting condition was achieved, the KMP is required to be in continuous service until April 2, 2031. Given the stage of business, operating metrics are not yet included in LTIP targets, however will likely be in the future. Further, the Compensation Committee is of the view that if the share price does remain above the A$18.00 hurdle for more than 30 days, given trading volume in the stock is relatively liquid, shareholders will have the opportunity to exit and crystallize any gains. To achieve the current A$18.00 hurdle, the share price would have to increase 3.4x from the closed date as of June 30, 2026 and 1.7x from the February 2, 2026 effective date of board approval, creating strong shareholder alignment to value creation and share price growth. In determining the size of grant, the Board engaged a third-party consultant via Pearl Meyer to value the performance rights utilizing a Monte Carlo simulation model, with a start date of February 2, 2026 (effective date of Board approval). This resulted in a fair value (as of February 2, 2026) of A$3.94 for the A$18.00 performance rights. The fair value of these performance rights was updated when shareholder approval was received and / or when the performance rights were actually issued. For accounting purposes, the share price at the grant date was utilized in the financial statements.
KMP Todd Hannigan (Executive Chairman)
No. Performance Rights Awarded 2026 196,086
Anastasios Arima (CEO)
237,944
Toby Symonds (President and CSO)
226,047
Rationale Vesting Conditions Tied to performance and shareholder value Vest upon four years of continuous creation. The A$18.00 share price hurdle for a service and the Company period of 30 days represents a premium of achieving a 30-day VWAP of at over 166% to the closing share price of least A$18.00 per share, expiring A$6.76 at the time of Board approval April 2, 2031 (February 2, 2026). Represents 25% of LTIP award for 2026 Tied to performance and shareholder value Vest upon four years of continuous creation. The A$18.00 share price hurdle for a service and the Company period of 30 days represents a premium of achieving a 30-day VWAP of at over 166% to the closing share price of least A$18.00 per share, expiring A$6.76 at the time of Board approval April 2, 2031 (February 2, 2026). Represents 25% of LTIP award for 2026 Tied to performance and shareholder value Vest upon four years of continuous creation. The A$18.00 share price hurdle for a service and the Company period of 30 days represents a premium of achieving a 30-day VWAP of at over 166% to the closing share price of least A$18.00 per share, expiring A$6.76 at the time of Board approval April 2, 2031 (February 2, 2026). Represents 25% of LTIP award for 2026
(ii) Restricted Stock Units In fiscal 2026, the Board chose to grant RSUs to attract and retain executives. The use of RSUs aligns with the long-term incentive vehicles used by peer group comparators. The RSUs vest and convert into an equivalent number of Ordinary Shares over a three-year period with a three-year vesting cliff. If the relevant service-based vesting condition is not met by the applicable expiry date, the RSUs will automatically lapse.
62
During fiscal 2026, 156,774 RSUs were granted to executive KMP as outlined in the table below. In determining the size of grant, the Board utilized an issue price of A$6.76, being the closing price of the Company’s Shares on the ASX on February 2, 2026. For accounting purposes, the share price at the date of grant was utilized in the financial statements.
Executive KMP
Notes
No. RSUs Awarded 2026
W. Scott Sparks (COO)
50% of LTIP award
52,258
Dominic Allen (CCO)
50% of LTIP award
52,258
Marcela Castro (CFO)
50% of LTIP award
52,258
(iii) Unlisted Options The LTIP provides for the issuance of Unlisted Options to eligible participants. The Board’s policy is to grant Unlisted Options to KMP with exercise prices at or above market share price (at the time of agreement). As such, the Unlisted Options granted to KMP are generally only of benefit if the KMP performs to the level whereby the value of the Group increases sufficiently to warrant exercising the Unlisted Options granted. Other than service-based vesting conditions (if any) and the exercise price required to exercise the Unlisted Options, there are no additional performance criteria on the Unlisted Options granted to KMP. The Group prohibits executive KMP from entering into arrangements to limit their exposure to Unlisted Options granted as part of their remuneration package. In determining the size of grant, the Board engaged a third-party consultant to value the Unlisted Options utilizing a Black Scholes model, with a start date of February 2, 2026 (effective date of board approval). This resulted in a fair value (as of February 2, 2026) of the A$11.00 strike, A$18.00 strike and A$22.00 strike options of A$2.76, A$2.49 and A$2.22 respectively. The fair value of these unlisted options was updated when the unlisted options were actually issued. For accounting purposes, the share price as of the grant date was utilized in the financial statements.
63
During fiscal 2026, Unlisted Options were granted to executive KMP as outlined in the table below.
KMP Todd Hannigan (Executive Chairman)
Anastasios Arima (CEO)
No. Unlisted Options awarded 2026 Rationale 992,170 Tied to performance and shareholder value creation. The A$18.00 and A$22.00 option exercise price exceeded the A$6.76 spot price at the time of board approval by ~166% and 225%, respectively.
Vesting Conditions Vest upon four years of continuous service. 526,760 exercisable at A$22.00 each, and 465,410 exercisable at A$18.00 each, expiring April 2, 2031
Represents 75% of LTIP award for 2026 Tied to performance and shareholder value creation. The A$18.00 and A$22.00 option exercise price exceeded the A$6.76 spot price at the time of board approval by ~166% and 225%, respectively.
Vest upon four years of continuous service. 639,205 exercisable at A$22.00 each, and 564,759 exercisable at A$18.00 each, expiring April 2, 2031
Represents 75% of LTIP award for 2026 Tied to performance and shareholder value creation. The A$18.00 and A$22.00 option exercise price exceeded the A$6.76 spot price at the time of board approval by ~166% and 225%, respectively.
Vest upon four years of continuous service. 607,244 exercisable at A$22.00 each, and 536,521 exercisable at A$18.00 each, expiring April 2, 2031
Represents 75% of LTIP award for 2026 Tied to performance and shareholder value creation. The A$11.00 option exercise price exceeded the A$6.76 spot price at the time of board approval by ~63%
Vest upon three years of continuous service and are exercisable at A$11.00 each, expiring April 2, 2030
Represents 50% of LTIP award for 2026 Tied to performance and shareholder value creation. The A$11.00 option exercise price exceeded the A$6.76 spot price at the time of board approval by ~63%
Vest upon three years of continuous service and are exercisable at A$11.00 each, expiring April 2, 2030
Represents 50% of LTIP award for 2026 Tied to performance and shareholder value creation. The A$11.00 option exercise price exceeded the A$6.76 spot price at the time of board approval by ~63%
Vest upon three years of continuous service and are exercisable at A$11.00 each, expiring April 2, 2030
1,203,964
Toby Symonds (President and CSO)
1,143,765
W. Scott Sparks (COO)
127,993
Dominic Allen (CCO)
127,993
Marcela Castro (CFO)
127,993
Represents 50% of LTIP award for 2026
64
Non-Executive Director Remuneration The Board’s policy is to remunerate NEDs at market rates for comparable companies for time, commitment and responsibilities. Given the current size, nature and risks of the Group, RSUs, Unlisted Options, and Performance Rights have been used to attract and retain NEDs, where deemed appropriate. The Board determines payments to the NEDs and reviews their remuneration annually, based on market practice, duties and accountability. Independent external advice is sought when required. The maximum aggregate amount of fees that can be paid to NEDs is subject to approval by shareholders at a General Meeting. Directors’ fees paid to NEDs accrue on a daily basis. Fees for NEDs are not linked to the performance of the economic entity. However, to align Directors’ interests with shareholder interests, the Directors are encouraged to hold shares in the Company and, subject to shareholder approval, on an annual basis, the Company grants each NED such number of RSUs calculated by dividing US$125,000 by the VWAP of a share on the ASX over the five trading days immediately prior to the date of the notice of AGM of shareholders. The Lead Independent Director receives such number of RSUs calculated by dividing US$155,000 by the five-day VWAP. The Company prohibits NEDs from entering into arrangements to limit their exposure to options granted as part of their remuneration package. The issuance of RSUs is in-line with U.S.-based peer group comparators and aligned with linking sustained Company performance, retention and long-term shareholder value. Fees for NEDs have been set at US$50,000 (2025: US$50,000) per annum. The Lead Director fee has been set at an additional US$30,000 per annum. These fees cover main board activities only. NEDs may receive additional remuneration for other services provided to the Company, including but not limited to, membership of committees. Committee fees have been set at US$15,000 for the Chair of each committee (US$30,000 for the Audit Committee Chair) and US$10,000 for committee members. The Company reimburses NEDs for reasonable expenses incurred in performing their duties (including in relation to any authorized independent professional advice sought by the NEDs to assist them in carrying out their duties as Directors). These fees are in line with the median of the benchmarked peer comparator groups. During fiscal 2026, 118,875 RSUs were granted to NEDs as set out below: Director Fees 2026 (US$) 100,000 75,000 80,000 75,000 80,000
Non-Executive Director Lorraine Martin Vaughn Taylor Tony Tripeny Melissa Waller Beverly Wyse
No. RSUs Awarded 2026 28,131 22,686 22,686 22,686 22,686
During fiscal 2026, 347,306 RSUs held by NEDs vested and converted into Ordinary Shares. 918,279 unlisted Options were exercised by NEDs during fiscal 2026. No RSUs, Unlisted Options or Performance Rights held by NEDs lapsed during fiscal 2026.
65
Relationship between Remuneration of KMP and Shareholder Wealth IperionX is a U.S.-based titanium technology and manufacturing company in the scale-up phase of its business. The Board anticipates that the Group will retain its cash resources to expand titanium production capacity at the Virginia Titanium Campus, to advance the Titan Project following completion of its DFS in June 2026, and to fund continued product development and qualification. The Group does not have a policy with respect to the payment of dividends or returns of capital, and no dividends were paid and no capital was returned during the current or previous four financial years. There is accordingly no relationship between the Board’s remuneration policy and dividends or returns of capital over that period. At this stage of the Company’s development, shareholder wealth is created through share price growth, and the remuneration framework is built around it. Between 84% and 86% of target total compensation for the Executive Chairman, Chief Executive Officer and President is performance-related. The long-term incentives granted during fiscal 2026 deliver value only at share prices of A$18.00 and A$22.00 — premiums of approximately 166% and 225% to the closing share price of A$6.76 at the date of Board approval — and also require four years of continuous service, with the Performance Rights subject to a further oneyear holding lock. Total shareholder return over the one, three and five years to June 30, 2026 was -14%, 266% and 332% respectively, as set out under “Fiscal 2026 Market Performance Highlights”. Short-term incentives are assessed against a weighted scorecard of four measures — Product Innovation / R&D / IP; Commercial and Government Engagements; Operations; and Funding, Corporate, Financial and Investor Relations — which are operational and strategic rather than share price based, as described under “Performance Based Remuneration – ShortTerm Incentive”.
Relationship between Remuneration of KMP and Earnings The Group is in the scale-up phase of its business. Titanium production at the Virginia Titanium Campus is currently directed to prototype production, product development, qualification testing and low-rate initial production, and the Group did not recognize revenue in the current or any of the previous four financial years. The Group recorded a net loss after tax of US$66.8 million for fiscal 2026 (2025: US$35.3 million), and a basic and diluted loss per share of US$0.20 (2025: US$0.12). Earnings are therefore not yet a meaningful measure of management performance, and the Board did not have regard to earnings in determining the nature and amount of remuneration of KMP over that period. The Board expects this to change. As the business moves toward steady-state production, the Committee intends to introduce financial and operational measures into the short-term incentive scorecard, consistent with the response to shareholder and proxy adviser feedback set out earlier in this report. Remuneration Governance The Board has overall accountability for the oversight of the Company’s remuneration approach for Executive KMP and NEDs, having regard to the recommendations made by the Compensation Committee. The Compensation Committee reviews and makes recommendations to the Board on remuneration and at-risk remuneration policies, taking into account the Company’s strategic objectives, corporate governance principles, market practice and stakeholder interests. The diagram below shows the Company’s remuneration governance framework, the key responsibilities of the Board, Compensation Committee and management.
66
Remuneration Advisors As detailed in the 2025 Annual Report, the Compensation Committee engaged Pearl Meyer to provide remuneration recommendations regarding the remuneration quantum for KMP and advise on LTIP and STI structures. The executive remuneration framework has not changed for fiscal year 2026, but Pearl Meyer was consulted regarding appropriate marketbased salary increases for KMP and for LTIP performance award calculations. The Compensation Committee considered the recommendations, along with other factors, in making its remuneration decisions. The Compensation Committee is satisfied the advice received from Pearl Meyer is free from undue influence from the KMP to whom the remuneration recommendations apply. US$12,100 was paid to remuneration advisors during the 2026 fiscal year. Pearl Meyer was engaged by, and reported directly to, the Compensation Committee, provided no other services to the Company during the year, and management had no role in the engagement or in the preparation of the recommendations.
67
Emoluments of KMP Details of the nature and amount of each element of the emoluments of each KMP of the Group for the year ended June 30, 2026, are as follows: Short-term benefits
2026
Directors Todd Hannigan Anastasios Arima Lorraine Martin Vaughn Taylor Tony Tripeny Melissa Waller(1) Beverly Wyse Other KMP Toby Symonds W. Scott Sparks Dominic Allen(2) Marcela Castro Total
Salary & fees US$
Cash bonus US$
393,500 562,500 100,000 75,000 80,000 75,000 80,000
440,000
534,500 320,000 320,000 307,500 2,848,000
418,000 180,000 180,000 165,000 1,383,000
Postemployment benefits US$
Share-based payment expense US$
Total US$
Performance related(3) %
9,012
20,375 9,007
1,220,955 1,813,143 127,352 117,312 91,318 117,312 117,315
1,634,830 2,824,655 227,352 201,319 171,318 192,312 197,315
75% 80% 56% 58% 53% 61% 59%
22,170 12,299 22,170 65,651
9,357 6,841 8,432 54,012
1,544,196 688,004 536,289 287,898 6,661,094
2,528,223 1,207,144 1,036,289 791,000 11,011,757
78% 72% 69% 57%
Other US$
Notes: (1) Melissa Waller is paid through Arete Innovative Resources LLC, a company in which she has a controlling interest. (2) Dominic Allen is paid through Westoz Services Trust, of which he is a trustee. (3) Performance related percentage for 2026 considers both short-term cash bonus and long-term share-based payment expense as a
percentage of the total compensation. No termination benefits were paid or payable to KMPs during the year. Short-term benefits
2025 Directors
Todd Hannigan(1) Anastasios Arima Lorraine Martin Vaughn Taylor Tony Tripeny Melissa Waller Beverly Wyse Other KMP Toby Symonds W. Scott Sparks Dominic Allen Marcela Castro Total
Postemployment benefits US$
Share-based payment expense US$
Total US$
Performance related %
7,857
19,411 9,296
834,131 1,047,347 111,052 93,217 19,887 111,052 111,052
1,171,042 2,010,204 186,052 183,346 39,054 186,052 191,052
71% 52% 60% 51% 51% 60% 58%
456,000 250,000 150,000 150,000
23,010 14,674 49,425 23,010
9,075 8,800 16,050
2,040,207 465,379 278,638 384,108
2,979,792 1,021,353 760,563 843,168
68% 46% 37% 46%
1,486,000
117,976
62,632
5,496,070
9,571,678
Salary & fees US$
Cash bonus US$
317,500 475,000 75,000 80,833 19,167 75,000 80,000
480,000
451,500 282,500 282,500 270,000 2,409,000
Other US$
Notes: (1) Mr. Hannigan’s share-based payments includes 141,844 shares issued in lieu of his cash bonus of US$250,000, as approved by
shareholders on June 27, 2025. No termination benefits were paid or payable to KMPs during the year.
68
Loans with Key Management Personnel No loans were provided to or received from KMP during the year ended June 30, 2026 (2025: Nil).
Other Transactions with Key Management Personnel Performance Industries, Inc., a company associated with Mr. Scott Sparks, COO of the Company, was paid US$70,660 during the fiscal year 2026 (2025: nil) for the provision of engineering and construction services to the Group. The Company considers that the services provided by Performance Industries, Inc. were provided on an arm’s length or better basis. Balances and transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated on consolidation and are not disclosed in this note.
Options, Rights and RSUs Granted to Key Management Personnel Details of Unlisted Options, Performance Rights and RSUs granted, exercised or lapsed for each KMP of the Group for the year ended June 30, 2026 financial year are as follows:
2026 Directors Todd Hannigan Anastasios Arima Lorraine Martin Vaughn Taylor Tony Tripeny Melissa Waller Beverly Wyse Other KMP Toby Symonds W. Scott Sparks Dominic Allen Marcela Castro Total
Value of Value of Value of options, No. of options, options, rights and options, No. of rights and rights and RSUs No. of options, rights and options, RSUs RSUs included in rights and RSUs rights and granted exercised remuneration RSUs granted exercised RSUs lapsed during year(1) during year(2) for year during year # during year # during year # US$ US$ US$ 1,188,256 1,441,908 28,131 22,686 22,686 22,686 22,686
(159,333) (318,667) (389,379) (189,379) (14,162) (389,379) (283,286)
(560,000) (1,000,000)
923,007 1,120,038 97,591 78,701 78,701 78,701 78,701
758,117 1,516,238 1,606,172 757,104 67,384 1,746,210 1,239,478
1,220,955 1,813,143 127,352 117,312 91,318 117,312 117,315
1,369,812 180,251 180,251 180,251
(302,667) (279,667) (504,667) (79,667)
(320,000) (680,000)
2,557,914 486,981 486,981 486,981
1,440,109 1,330,674 2,112,264 379,061
1,544,196 688,004 536,289 287,898
4,659,604
(2,910,253)
(2,560,000)
6,474,297
12,952,811
6,661,094
Notes: (1) Determined at the time of grant per AASB 2, using an exchange rate of US$0.6789=A$1.00, being the average exchange rate for 2026. (2) Determined at the time of exercise or conversion at the intrinsic value using the exchange rate on the date of exercise.
69
Details of Unlisted Options, Performance Rights and RSUs granted by the Company to each KMP of the Group during the financial year are as follows:
2026 Todd Hannigan
Anastasios Arima
Lorraine Martin Vaughn Taylor Tony Tripeny Melissa Waller Beverly Wyse Toby Symonds
W. Scott Sparks Dominic Allen Marcela Castro
Grant Date 19-Mar-26 19-Mar-26 19-Mar-26
Expiry Date 2-Apr-31 2-Apr-31 2-Apr-31
Service Vesting Date 19-Mar-30 19-Mar-30 19-Mar-30
Exercise Price A$ A$22.00 A$18.00
Rights
19-Mar-26
2-Apr-31
19-Mar-30
A$18.00
A$1.72
237,944
Options Options RSUs RSUs RSUs RSUs RSUs Rights Options Options Options RSUs Options RSUs Options RSUs
19-Mar-26 19-Mar-26 28-Nov-25 28-Nov-25 28-Nov-25 28-Nov-25 28-Nov-25 8-Mar-26 8-Mar-26 8-Mar-26 8-Mar-26 8-Mar-26 8-Mar-26 8-Mar-26 8-Mar-26 8-Mar-26
2-Apr-31 2-Apr-31 23-Dec-26 23-Dec-26 23-Dec-26 23-Dec-26 23-Dec-26 2-Apr-31 2-Apr-31 2-Apr-31 2-Apr-30 2-Apr-30 2-Apr-30 2-Apr-30 2-Apr-30 2-Apr-30
19-Mar-30 19-Mar-30 23-Dec-26 23-Dec-26 23-Dec-26 23-Dec-26 23-Dec-26 8-Mar-30 8-Mar-30 8-Mar-30 8-Mar-29 2-Apr-29 8-Mar-29 2-Apr-29 8-Mar-29 2-Apr-29
A$18.00 A$22.00 A$18.00 A$22.00 A$11.00 A$11.00 A$11.00
A$18.00
A$1.11 A$0.96 A$5.11 A$5.11 A$5.11 A$5.11 A$5.11 A$4.47 A$2.57 A$2.27 A$2.93 A$6.55 A$2.93 A$6.55 A$2.93 A$6.55
564,759 639,205 28,131 22,686 22,686 22,686 22,686 226,047 536,521 607,244 127,993 52,258 127,993 52,258 127,993 52,258
Security Class Rights Options Options
Vesting Grant Date Hurdle (30Fair day VWAP) Value(1) A$ A$18.00 A$1.72 A$0.96 A$1.11
Number Granted 196,086 526,760 465,410
Options, Rights, and RSU holdings of Key Management Personnel
2026 Directors Todd Hannigan Anastasios Arima Lorraine Martin Vaughn Taylor Tony Tripeny Melissa Waller Beverly Wyse Other KMP Toby Symonds W. Scott Sparks Dominic Allen Marcela Castro Total
Exercise of Held at Granted as options, rights July 1, 2025 remuneration and RSUs
Net change other
Held at June 30, 2026
Vested and exercisable at June 30, 2026
2,092,703 3,364,661 451,464 251,464 42,486 451,464 451,464
1,188,256 1,441,908 28,131 22,686 22,686 22,686 22,686
(159,333) (318,667) (389,379) (189,379) (14,162) (389,379) (283,286)
(560,000) (1,000,000)
2,561,626 3,487,902 90,216 84,771 51,010 84,771 190,864
106,093
3,362,951 2,218,900 1,913,900 458,340 15,059,797
1,369,812 180,251 180,251 180,251 4,659,604
(302,667) (279,667) (504,667) (79,667) (2,910,253)
(320,000) (680,000) (2,560,000)
4,430,096 1,799,484 909,484 558,924 14,249,148
106,093
70
Shareholdings of Key Management Personnel
2026 Directors Todd Hannigan Anastasios Arima Lorraine Martin Vaughn Taylor Tony Tripeny Melissa Waller Beverly Wyse Other KMP Toby Symonds W. Scott Sparks Dominic Allen Marcela Castro Total
Held at July 1, 2025
Exercise of Options and Rights
Net Change Other
Ord(1)
Ord(1)(3)
Ord(1)(4)
Perf(2)
25,443,775 1,260,000 11,405,113 2,250,000 763,144 931,318 304,489 304,489
Perf(2)
Perf(2)
Held at June 30, 2026 Ord(1)
Perf(2)
159,333 318,667 389,379 176,139 14,162 331,829 283,286
1,005,226 (1,260,000) 721,002 (2,250,000) 72,165 (134,000) 66,485 (150,000) 52,000
26,608,334 12,444,782 1,224,688 973,457 80,647 486,318 639,775
3,188,146 302,667 1,393,971 720,000 279,667 4,507,168 1,530,000 504,667 340,795 79,667 48,582,408 5,760,000 2,839,463
7,276 (39,039) (720,000) 1 (1,530,000) (38,621) 1,562,495 (5,760,000)
3,498,089 1,634,599 5,011,836 381,841 52,984,366
Notes: (1) ‘Ord’ means Ordinary Shares. (2) ‘Perf’ means Performance Shares issued to the original vendors of HMAPL as consideration for the Company’s acquisition of HMAPL in
fiscal 2021. For the avoidance of doubt, these Performance Shares do not form part of remuneration. (3) Exercise of Options and Rights are shown net of shares surrendered to settle the exercise price under net settlement arrangements. (4) Includes shares sold to cover withholding tax obligations.
71
Employment Contracts with Key Management Personnel Mr. Arima, CEO and Managing Director, has an employment agreement with the Group which may be terminated upon six months’ advance written notice, unless mutually agreed upon with the Company. Mr. Arima receives a fixed remuneration component of US$575,000 starting in January 2026, (2025: US$550,000) per annum and a discretionary target annual bonus of US$403,000 (2025: US$385,000) to be paid upon the successful completion of KPIs as determined by the Board and is entitled to participate in the LTIP on terms to be determined by the Board. Mr. Symonds, President and CSO, has an employment agreement with the Group which may be terminated upon six months’ advance written notice, unless mutually agreed upon with the Company. Mr. Symonds receives a fixed remuneration component of US$546,000 starting in January 2026, (2025: US$523,000) per annum and a discretionary target annual bonus of US$382,000 (2025: US$366,000) to be paid upon the successful completion of KPIs as determined by the Board and is entitled to participate in the LTIP on terms to be determined by the Board. Mr. Hannigan, Executive Chairman, has a director appointment letter with the Group. Mr. Hannigan receives a fixed remuneration component of US$402,000 starting in January 2026, (2025: US$385,000) per annum and a discretionary target annual bonus of US$282,000 (2025: US$270,000) to be paid upon the successful completion of KPIs as determined by the Board and is entitled to participate in the LTIP on terms to be determined by the Board. Mr. Allen, CCO, has a service agreement, as a Trustee for Westoz Services Trust, with the Group which may be terminated upon three months’ advance written notice, unless mutually agreed upon with the Company. Mr. Allen receives a fixed remuneration component of US$325,000 starting in January 2026, (2025: US$315,000) per annum and a discretionary target annual bonus of US$163,000 (2025: US$158,000) to be paid upon the successful completion of KPIs as determined by the Board and is entitled to participate in the LTIP on terms to be determined by the Board. Mr. Sparks, COO, has an employment agreement with the Group which may be terminated upon six months’ advance written notice, unless mutually agreed upon with the Company. Mr. Sparks receives a fixed remuneration component of US$325,000 starting in January 2026, (2025: US$315,000) per annum and a discretionary target annual bonus of US$163,000 (2025: US$158,000) to be paid upon the successful completion of KPIs as determined by the Board and is entitled to participate in the LTIP on terms to be determined by the Board. Ms. Castro, CFO, has an employment agreement with the Group which may be terminated upon four weeks’ advance written notice, unless mutually agreed upon with the Company. Ms. Castro receives a fixed remuneration component of US$325,000 starting in January 2026, (2025: US$290,000) per annum, a discretionary target annual bonus of US$163,000 (2025: US$145,000) to be paid upon the successful completion of KPIs as determined by the Board and is entitled to participate in the LTIP on terms to be determined by the Board. The annual discretionary target bonus is subject to the Plan rules, including the scorecards and weightings related to the Short-Term Incentive Plan as described in “Performance Based Remuneration – Short-Term Incentive”. All NEDs have a letter of appointment confirming the terms and conditions of their appointment as Director of the Company.
End of Remuneration Report.
72
Auditor’s Independence Declaration
pwc Auditor's Independence Declaration As lead auditor of IperionX Limited's financial report for the year ended 30 June 2026, I declare that, to
the best of my knowledge and belief, there have been: a) no contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the audit of the financial report; and b) no contraventions of any applicable code of professional conduct in relation to the audit of the financial report.
Melbourne
Anthony Hodge Partner PricewaterhouseCoopers
29 September 2026
P1icewaterhouseCoopers, ABN 52 780 433 757 2 Riverside Quay, SOUTHBANK VIC 3006, GPO Box 1331 MELBOURNE VIC 3001 T: +6138603 1000, F: +61386031999, www.pwc.com.au
pwc.com.au
Liabilitylimitedby a scheme approvedunder ProfessionalStandardsLegislation.
73
Consolidated Statement of Profit or Loss and Other Comprehensive Income Year ended June 30, 2026 Notes Continuing operations Research and development costs Exploration and evaluation expenses Corporate and administrative expenses Business development expenses Share–based payment expenses Finance income Finance costs Other income and expenses Loss before income tax Income tax expense Loss for the year Loss attributable to shareholders of IperionX Limited
2 2 22(a) 2 2 2 3
Other comprehensive income Items that may be reclassified subsequently to profit or loss: Exchange differences arising on translation into presentation currency Other comprehensive income (loss) for the year, net of tax Total comprehensive loss for the year Total comprehensive loss attributable to shareholders of IperionX Limited Basic loss per share (US$ per share) Diluted loss per share (US$ per share)
17(f)
19 19
2026 US$
2025 US$
(25,193,985) (5,380,636) (25,917,366) (4,049,905) (9,166,334) 1,871,307 (3,465,223) 4,534,380 (66,767,762) (66,767,762) (66,767,762)
(12,748,973) (2,894,369) (10,686,376) (3,373,992) (9,568,191) 3,550,633 (306,250) 678,843 (35,348,675) (35,348,675) (35,348,675)
3,709,446 3,709,446 (63,058,316)
(1,602,139) (1,602,139) (36,950,814)
(63,058,316)
(36,950,814)
(0.20) (0.20)
(0.12) (0.12)
The above Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the accompanying notes.
74
Consolidated Statement of Financial Position As of June 30, 2026 US$
2025 US$
5 6 7 8
35,244,220 3,282,481 1,533,721 3,907,597 43,968,019
54,814,125 823,268 3,238,894 58,876,287
9 10 11 7
41,185,930 12,268,824 7,768,418 559,834 61,783,006 105,751,025
25,197,638 13,550,993 6,512,326 897,735 46,158,692 105,034,979
12 13 14 12
10,449,787 1,771,531 628,933 738,039 13,588,290
7,489,397 472,018 467,001 8,428,416
12 14
333,000 3,530,046 3,863,046 17,451,336 88,299,689
700,000 3,462,564 4,162,564 12,590,980 92,443,999
16 17 18
250,976,753 13,321,423 (175,998,487) 88,299,689
197,985,920 3,688,804 (109,230,725) 92,443,999
Notes Assets Current Assets Cash and cash equivalents Trade and other receivables Prepayments Inventories Total Current Assets Non-current Assets Property, plant and equipment Intangible assets Exploration and evaluation assets Prepayments Total Non-current Assets Total Assets Liabilities Current Liabilities Trade and other payables Deferred income Loans and borrowings Provisions Total Current Liabilities Non-current Liabilities Other long-term liabilities Loans and borrowings Total Non-current Liabilities Total Liabilities Net Assets Equity Contributed equity Reserves Accumulated losses Total Equity
The above Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes.
75
Consolidated Statement of Changes in Equity Year ended June 30, 2026
Balance at June 30, 2024 Net loss for the year Exchange differences arising on translation into presentation currency Total comprehensive loss for the year Issue of shares – share placement Issue of shares – exercise of options Issue of shares – conversion of RSUs Issue of shares – conversion of rights Issue of shares to consultants Issue of shares to director in lieu of bonus Share issue costs Share-based payment expense Balance at June 30, 2025 Net loss for the year Exchange differences arising on translation into presentation currency Total comprehensive loss for the year Issue of shares - share placement Issue of shares - exercise of options Issue of shares - conversion of RSUs Issue of shares - conversion of rights Issue of shares - payment of expenses Share issue costs Share-based payment expense Balance at June 30, 2026
Contributed Equity US$ 112,959,638
Share-Based Payments Reserve US$ 13,440,265
Currency Translation Reserve US$ (1,178,258)
Accumulated Losses US$ (73,882,050) (35,348,675)
Total US$ 51,339,595 (35,348,675)
(1,602,139)
(1,602,139)
70,919,564 205,525 2,094,041 13,724,952 470,262
(2,094,041) (13,724,952) (470,262)
(1,602,139)
(35,348,675)
(36,950,814) 70,919,564 205,525
250,000
(250,000)
(2,638,062) 197,985,920
9,568,191 6,469,201
(2,780,397)
(109,230,725) (66,767,762)
(2,638,062) 9,568,191 92,443,999 (66,767,762)
3,709,446
3,709,446
45,717,352 971,471 2,234,348 603,498 5,230,000 (1,765,836) 250,976,753
(405,315) (2,234,348) (603,498) 9,166,334 12,392,374
3,709,446 929,049
(66,767,762) (175,998,487)
(63,058,316) 45,717,352 566,156 5,230,000 (1,765,836) 9,166,334 88,299,689
The above Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying notes.
76
Consolidated Statement of Cash Flows Year ended June 30, 2026
Operating activities Payments to suppliers and employees Government reimbursements for Titan Project DFS Receipts from third-parties Interest paid Interest received Taxes paid Net cash flows used in operating activities Investing activities Purchase of property, plant and equipment Proceeds from sale of property, plant and equipment Purchases of intangible assets Purchase of exploration and evaluation assets Other investing Net cash flows used in investing activities Financing activities Proceeds from issue of shares Share issue costs Repayment of borrowings Payment of principal portion of lease liabilities Net cash flows from financing activities Net (decrease) increase in cash and cash equivalents Net foreign exchange differences Cash and cash equivalents at beginning of the year Cash and cash equivalents at the end of the year Supplemental cash flow information: Property, plant, equipment additions in accounts payable and other accrued liabilities Intangible additions in accounts payable, other accrued liabilities and other long-term liabilities
Notes
2026 US$
2025 US$
5
(51,173,711) 4,623,906 63,480 (327,019) 1,871,307 (12,625) (44,954,662)
(24,336,800) 96,151 569,484 (329,740) 2,203,220 (21,797,685)
(17,781,134) 1,903,700 (1,353,836) (1,256,092) (73,694) (18,561,056)
(16,963,016) 9,417 (6,678,750) (644,661) (24,277,010)
46,283,506 (1,787,964) (792,031) (521,942) 43,181,569 (20,334,149) 764,244 54,814,125 35,244,220
71,125,089 (2,615,882) (5,826) (511,749) 67,991,632 21,916,937 (260,168) 33,157,356 54,814,125
4,568,067
2,508,971
804,912
2,140,371
9 9 10 11
5
The above Consolidated Statement of Cash Flows should be read in conjunction with the accompanying notes.
77
Notes to the Consolidated Financial Statements Year ended June 30, 2026
- Statement of Material Accounting Policies The material accounting policies adopted in preparing the consolidated financial statements of IperionX Limited (“IperionX” or “Company”) and its consolidated entities (“Consolidated Entity” or “Group”) for the years ended June 30, 2026 and 2025 are stated to assist in a general understanding of the consolidated financial statements. IperionX is a for-profit company limited by shares, incorporated and domiciled in Australia. Our ordinary shares are listed on the Australian Securities Exchange, or ASX, under the symbol “IPX”, and our American Depositary Shares, or ADSs, each representing ten (10) of our ordinary shares, are listed on the Nasdaq Capital Market, or Nasdaq, under the symbol “IPX”. The principal activities of the Group during the year consisted of the development of its titanium metal technologies and the exploration of its mineral properties in the U.S. The Group is operating a U.S. based, integrated titanium business to support a range of advanced industries, including consumer electronics, aerospace, defense, medical, bicycles, additive manufacturing, and automotive. We expect to offer a range of titanium products and alloys for customers across these key industries. Our portfolio of assets includes our operations at the Titanium Manufacturing Campus in Halifax County, Virginia; our AtlasTitan platform in Tennessee, and Industrial Pilot Facility (IPF) in Salt Lake City, Utah, that together are re-shoring a sustainable titanium supply chain in the U.S. IperionX owns patents to certain titanium and metal alloy production technologies and holds exclusive global licenses over the Technologies, including Hydrogen Assisted Metallothermic Reduction™, Granulation Sintering Deoxygenation™, low carbon titanium mineral enrichment, Hydrogen Sintering and Phase Transformation™, Alkaline Roasting and Hydrolysis™, and other titanium alloying technologies. The consolidated financial statements of the Group for the year ended June 30, 2026 were authorized for issue in accordance with a resolution of the Directors on September 29, 2026.
(a) Basis of Preparation The financial report is a general purpose financial report, which has been prepared in accordance with Australian Accounting Standards as issued by the AASB and the Corporations Act 2001. The financial report also complies with International Financial Reporting Standards as issued by the International Accounting Standards Board. The consolidated financial report has also been prepared on a historical cost basis, except for other financial assets and inventory received through government program (See Note 1(h)), which have been measured at fair value. The consolidated financial statements are presented in U.S. dollars (US$ or $). Certain prior year expense balances have been reclassified and presented on a more disaggregated basis to conform to the current year presentation. These reclassifications were immaterial and had no effect on previously reported net income, total assets, or stockholders’ equity.
78
- Statement of Material Accounting Policies (continued) Going Concern The financial statements have been prepared on the going concern basis, which contemplates the continuity of normal business activity and the realization of assets and the settlement of liabilities in the normal course of business. At June 30, 2026, the Group has cash and cash equivalents of US$35.2 million (2025: US$54.8 million) and net assets of US$88.3 million (2025: US$92.4 million). The Group had net outflows from operating and investing activities of US$63.5 million for fiscal 2026 (2025: US$46.1 million). On July 7, 2026, the Company completed the placement of 2,275,000 new fully paid ADSs, each representing 10 ordinary shares, to raise gross proceeds of US$50.0 million before costs. IperionX's principal committed source of non-dilutive funding is the U.S. DoW industrial-base programs under which its Virginia titanium production facility is being built: the DPA Title III award (US$12.7 million) and the IBAS award (US$47.1 million) are fully obligated by the Government, US$22.7 million had been reimbursed at June 30, 2026 and US$37.1 million of obligated, reimbursable funding remained available to be drawn against qualifying expenditure over the expansion to approximately 1,400 tons per annum. In addition, IperionX holds a U.S. Army SBIR Phase III indefinite-delivery contract with a ceiling of US$99.0 million, under which two firm-fixed-price task orders totaling approximately US$19.8 million have been awarded (Task Order 2, awarded in August 2026, has a base value of US$18.5 million of which US$11.5 million was funded at award, with options to US$25.4 million), plus other U.S. Government awards of up to US$6.6 million. The U.S. Government has also transferred approximately 290 metric tons of titanium alloy scrap to IperionX at no cost, reducing feedstock purchases for approximately eighteen months of production at the current 200 tons per annum capacity. Beyond these contracted sources, IperionX has a number of potential sources of liquidity: Customer receipts are expected to grow as the Virginia facility moves from prototype and qualification work into low-rate production; IperionX has purchase orders and supply arrangements with the U.S. Army (DEVCOM Ground Vehicle Systems Center), American Rheinmetall, Ford Motor Company and Carver Pump, among others. The remaining US$79.2 million of ceiling under the SBIR Phase III task order awarded and other awards referred to above may be accessed through further task orders at the Government's discretion. IperionX has demonstrated continuing access to equity capital markets, having raised more than US$250 million through the date of filing, from institutional and retail investors since listing, and its Nasdaq and ASX listings provide the ability to raise further capital. Finally, a substantial portion of IperionX’s forecast expenditure, including GenX™ development, Titan and Atlas development work and the pace of the 1,400 tons per annum expansion, is discretionary and can be deferred or reduced if necessary. Further, the U.S. Government has materially expanded the capital available to domestic critical-minerals and metals producers, including through the DoW’s Office of Strategic Capital, which since July 2025 has committed loans of approximately US$2.5 billion to domestic rare earth, magnet and scandium metal projects under loan authority of up to approximately US$100 billion, and through two 2026 Defense Industrial Base Consortium solicitations for domestic criticalminerals processing capacity, the most recent of which specifically names titanium, including sponge and sponge substitutes, for which IperionX has submitted proposals. Based on the assessment of the Company’s financial position, cash flows, and future projections, management has concluded that there are no conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern for the foreseeable future, which is defined as at least twelve months from the date of issuance of the financial statements. No adjustments are required to the carrying amounts or classification of assets and liabilities in the financial statements.
(b) New Standards, Interpretations and Amendments In the current year, the Group has adopted all of the new and revised Accounting Standards and Interpretations effective from July 1, 2025 that are mandatory. The adoption of the aforementioned standards has had no impact on the financial statements of the Company as at June 30, 2026. The Group has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective.
79
- Statement of Material Accounting Policies (continued) Issued standards and interpretations not early adopted Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet effective have not been adopted by the Group for the year ended June 30, 2026. Those which may be relevant to the Group are set out in the table below, but these are not expected to have any significant impact on the Group’s financial statements: Standard/Interpretation
Application Date of Standard
Application Date for the Group
AASB 18 Presentation and Disclosure in Financial Statements
January 1, 2027
July 1, 2027
AASB S2025-1 Amendments to Greenhouse Gas Emissions Disclosures
January 1, 2027
July 1, 2027
AASB 2014-10 Amendments to Australian Accounting Standards – Sale or Contribution of Assets between an Investor and its Associate or Joint Venture
January 1, 2028
July 1, 2028
A discussion on the impact of the adoption of AASB 18 Presentation and Disclosure in Financial Statements is included below. The adoption of the other aforementioned standards is not expected to have any significant impact on the Group’s financial statements. AASB 18 Presentation and Disclosure in Financial Statements AASB 18 Presentation and Disclosure in Financial Statements replaces AASB 101 Presentation of Financial Statements and introduces new requirements for the presentation of financial statements. AASB 18 will not change the recognition and measurement of items in the financial statements but will affect presentation and disclosure in the financial statements, including introducing new categories and subtotals in the statement of profit or loss and other comprehensive income, requiring the disclosure of management defined performance measures, and changing the grouping of information in the financial statements.
(c) Principles of Consolidation The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of the Company. Control is achieved when the Company has power over the investee, is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to use its power to affect its returns. The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above. When the Company has less than a majority of the voting rights of an investee, it has power over the investee when the voting rights are sufficient to give it the practical ability to direct the relevant activities of the investee unilaterally. The Company considers all relevant facts and circumstances in assessing whether or not the Company’s voting rights in an investee are sufficient to give it power. Subsidiaries are all those entities (including special purpose entities) over which the Company has the power to govern the financial and operating policies, so as to obtain benefits from its activities, generally accompanying a shareholding of more than one-half of the voting rights. The existence and effect of potential voting rights that are currently exercisable or convertible are considered when assessing whether the Company controls another entity. The financial statements of the subsidiaries are prepared for the same reporting period as the Company, using consistent accounting policies. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Company. Subsidiaries are fully consolidated from the date on which control is transferred to the Company. They are de-consolidated from the date that control ceases. Intercompany transactions and balances, income and expenses and profits and losses between Group companies, are eliminated.
80
- Statement of Material Accounting Policies (continued) (d) Foreign Currencies (i) Functional and Presentation Currency The functional currency of each of the Group’s entities is measured using the currency of the primary economic environment in which that entity operates. The parent Company’s functional currency is Australian dollars. The Group’s financial statements are presented in U.S. dollars which is the Group’s presentation currency. U.S. dollars have been chosen as the Group’s presentation currency to better reflect the Groupʼs business activities in the U.S. and to enhance comparability with its industry peer group, the majority of which report in U.S. dollars. (ii) Transactions and Balances Foreign currency transactions are translated into functional currency using the exchange rates prevailing at the date of the transaction. Foreign currency monetary items are translated at the year-end exchange rate. Non-monetary items measured at historical cost continue to be carried at the exchange rate at the date of the transaction. Non-monetary items measured at fair value are reported at the exchange rate at the date when fair values were determined. Exchange differences arising on the translation of monetary items are recognized in the income statement, except where deferred in equity as a qualifying cash flow or net investment hedge. Exchange differences arising on the translation of non-monetary items are recognized directly in equity to the extent that the gain or loss is directly recognized in equity, otherwise the exchange difference is recognized in the income statement. (iii) Group Companies The financial results and position of operations whose functional currency is different from the Group’s presentation currency are translated as follows: ▪ assets and liabilities are translated at year-end exchange rates prevailing at that reporting date; ▪ income and expenses are translated at average exchange rates for the year; and ▪ retained earnings are translated at the exchange rates prevailing at the date of the transaction. Exchange differences arising on translation into the presentation currency are transferred directly to the Group’s foreign currency translation reserve in equity. These differences are recognized in profit or loss in the year in which the operation is disposed.
(e) Cash and Cash Equivalents Cash and cash equivalents include cash on hand, deposits held at call with banks and other short-term highly liquid investments with original maturities of three months or less.
(f) Trade and Other Receivables Trade receivables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest method, less allowance for any expected credit loss applying the simplified approach. If collection of the amounts is expected in one year or less, they are classified as current assets. If not, they are presented as non-current assets. Trade receivables are generally due for settlement within 30 days and therefore are all classified as current. As the majority of receivables are short term in nature, their carrying amount is assumed to be the same as their fair value. An estimate for the expected credit loss is made based on the historical risk of default and expected loss rates at the inception of the transaction. Inputs are selected for the expected credit loss impairment calculation based on the Group’s past history, existing market conditions as well as forward looking estimates.
81
- Statement of Material Accounting Policies (continued) (g) Prepayments Prepayments represent payments in advance of receipt of goods or services. The Group recognizes a prepayment as an asset within other current and non-current assets when payment for goods or services has been made in advance of the Group obtaining a right to access those goods or services. These prepayments are assessed for indicators of impairment each year. If future economic benefits are no longer expected to occur, and economic benefits cannot be derived from the prepayment in any other way, the prepayment will be derecognized.
(h) Inventory Inventories are stated at the lower of cost and net realizable value. Cost is determined on a first-in, first-out basis. Raw materials are valued at cost of purchase. For work-in-process and finished goods, cost includes the cost of purchase and costs of conversion, with labor and manufacturing overhead applied using standard costing techniques that approximate actual cost. Unallocated overhead associated with abnormally low production levels, including costs incurred during the commissioning and ramp-up of manufacturing operations, is expensed as incurred and excluded from the cost of inventory. Costs incurred with respect to raw materials, work-in-process, and finished goods are expensed as research and development expense as incurred when such materials or products are used in research and development activities. Costs are capitalized as inventory when they are incurred in bringing inventories to their present location and condition and are expected to be recovered through sale. Titanium powder held for consumption in the production of engineered products is classified as raw materials. The Company reviews inventory each reporting period and writes down excess, slow-moving, or obsolete items to net realizable value where required, with such write-downs recognized in operating expenses. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and costs necessary to make the sale. Titanium scrap and feedstock received from U.S. Government programs at no cost, and without the transfer of a distinct good or service to the Government, are accounted for as non-monetary government grants. Such grants are recognized at fair value upon receipt and presented as deferred income in the statement of financial position. Refer to Note 1(n).
(i) Property, Plant and Equipment Property, plant and equipment are stated at cost less accumulated depreciation and impairment charges. Depreciation is provided on a straight-line basis over the estimated useful lives of the assets, except for land which is not depreciated. Depreciation commences when an asset is available for use. Where assets are under construction or yet to be commissioned, judgment is applied in determining the point at which the asset is in the location and condition necessary for it to be capable of operating in the manner intended by management. Currently the Group only has plant and equipment, buildings and leasehold improvements. Plant and equipment is depreciated over a period between 2 and 20 years. Buildings and leasehold improvements are depreciated over a period between 8 and 10 years. The carrying amounts of property, plant and equipment are reviewed for impairment in accordance with the policy described in Note 1(u).
(j) Intangible Assets Intangible assets are stated at cost, net of accumulated amortization and accumulated impairment losses, if any. Cost in relation to patents includes registration, documentation and other legal fees associated with obtaining the patent. The costs of internally generated intangible assets are not capitalized and the expense is reflected as research and development costs in the statement of profit or loss as it is incurred. The cost of intangible assets is amortized on a straight-line basis over their estimated useful lives, which are reviewed at least annually. The expected changes in the useful life or in the pattern of consumption of the future economic benefits of the asset
82
- Statement of Material Accounting Policies (continued) are accounted for when changing the period or amortization method, as appropriate, and they are treated as changes in the accounting estimates. Amortization expense is recognized in the statement of profit or loss as research and development costs. The Group’s primary patents each have a useful life between 8 and 20 years, with a remaining weighted-average useful life of 10.7 years. Additional patents granted in various jurisdictions will be used to extend the territorial coverage of the primary patent. Intangible assets are tested for impairment when there is an indicator of impairment, as well as possible reversal of previous impairment losses.
(k) Exploration and Evaluation Expenditures Exploration and evaluation expenditures are accounted for in accordance with the ‘area of interest’ method and with AASB 6 Exploration for and Evaluation of Mineral Resources. Exploration and evaluation expenditures comprise costs incurred in connection with the exploration for and evaluation of mineral resources before the technical feasibility and commercial viability of extracting a mineral resource have been demonstrated. For each area of interest, costs incurred to acquire rights to explore are capitalized and recognized as exploration and evaluation assets. Such costs include option payments made to landowners under the Group's option agreements, to the extent they are directly attributable to the acquisition of exploration rights. Exploration and evaluation assets are initially measured at cost and are carried forward where the Group's rights of tenure are current and one of the following conditions is met: ▪ the expenditures are expected to be recovered through the successful development and commercial exploitation of the area of interest, or alternatively through its sale; or ▪ exploration and evaluation activities in the area of interest have not yet reached a stage that permits technical feasibility and commercial viability to be demonstrated, and active and significant operations are continuing. The Group has identified proved and probable reserves within certain areas of interest and has completed a DFS for these properties. However, as of the reporting date, management has not yet committed to proceed with development. Advancement of these projects remains dependent upon securing adequate financing and/or a strategic development partner, as well as management's final approval to proceed. Accordingly, the related expenditures continue to be classified as exploration and evaluation. Once management has committed to proceed with development, the related exploration and evaluation assets are assessed for impairment and reclassified to mine development properties. Following commencement of commercial production, mine development properties are amortized over the expected life of the economically recoverable reserves associated with the relevant area of interest. The recoverability of exploration and evaluation assets is dependent upon the successful development and commercial exploitation of the relevant properties, or alternatively their sale. Impairment Capitalized exploration costs are reviewed each reporting date to establish whether an indication of impairment exists. If any such indication exists, the recoverable amount of the capitalized exploration costs is estimated to determine the extent of the impairment loss (if any). Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but only to the extent that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset.
83
- Statement of Material Accounting Policies (continued) (l) Research and Development Expenditure All costs associated with research and development are expensed as incurred. Research and development activities are directed toward the development of new products as well as improvements in existing titanium processing technologies. These costs primarily include salaries and related personnel expenses, subcontractor expenses, patent registration expenses, materials, depreciation and amortization, allocated overhead, and other development expenses associated with processing operations at our IPF in Utah and TPF in Virginia.
(m) Trade and Other Payables These amounts represent liabilities for goods and services provided to the Group prior to the end of the financial year which are unpaid. The amounts are unsecured and are usually paid within 60 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months from the reporting date. They are recognized initially at their fair value and subsequently measured at amortized cost using the effective interest method. The carrying amounts of trade and other payables are considered to be the same as their fair values, due to their short-term nature.
(n) Deferred Income Deferred income represents amounts received or receivable from customers for which the related performance obligations have not yet been satisfied, or where the conditions for revenue recognition have not been met as of the reporting date. These amounts are recognized as contract liabilities in the statement of financial position. Deferred income arising from contracts with customers is recognized as revenue when, or as, the related performance obligations are satisfied. Revenue is recognized either at a point in time or over time, depending on the nature of the underlying performance obligation. The amount recognized reflects the consideration to which the Company expects to be entitled in exchange for transferring the promised goods or services to the customer. Deferred income may also arise from government grants, including grants received in the form of non-monetary assets such as inventory. In accordance with AASB 120 - Accounting for Government Grants and Disclosure of Government Assistance, non-monetary government grants are measured at fair value on initial recognition, with the corresponding grant recognized as deferred income in the statement of financial position. Deferred income is subsequently recognized in profit or loss on a systematic basis over the periods in which the related costs are incurred or the applicable grant conditions are satisfied. Refer to Note 1(aa) for further discussion.
(o) Provisions Provisions are recognized when the Group has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured. Provisions include the Group’s liability for employee benefits arising from services rendered by employees to balance date. Employee benefits that are expected to be settled wholly within 12 months have been measured at the amounts expected to be paid when the liability is settled, plus related on-costs.
(p) Interest Income Interest income is recognized on a time proportionate basis that takes into account the effective yield on the financial asset.
(q) Income Tax The income tax expense for the year is the tax payable on the current year’s taxable income based on the national income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences between the tax bases of assets and liabilities and their carrying amounts in the financial statements, and to unused tax losses.
84
- Statement of Material Accounting Policies (continued) Deferred tax assets and liabilities are recognized for temporary differences at the tax rates expected to apply when the assets are recovered or liabilities are settled, based on those tax rates which are enacted or substantively enacted for each jurisdiction. The relevant tax rates are applied to the cumulative amounts of deductible and taxable temporary differences to measure the deferred tax asset or liability. An exception is made for certain temporary differences arising from the initial recognition of an asset or a liability. No deferred tax asset or liability is recognized in relation to these temporary differences if they arose on goodwill or in a transaction, other than a business combination, that at the time of the transaction did not affect either accounting profit or taxable profit or loss. Deferred tax liabilities and assets are not recognized for temporary differences between the carrying amount and tax bases of investments in controlled entities where the Company is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future. Deferred tax assets are recognized for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses. The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized. Unrecognized deferred income tax assets are reassessed at each balance date and are recognized to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered. Current and deferred tax balances attributable to amounts recognized directly in equity are also recognized directly in equity. Deferred tax assets and deferred tax liabilities are offset only if a legally enforceable right exists to set off current tax assets against tax liabilities and the deferred tax liabilities relate to the same taxable entity and the same taxation authority.
(r) Earnings per Share Basic EPS is calculated by dividing the net profit attributable to members of the Company for the reporting period, after excluding any costs of servicing equity, by the weighted average number of ordinary shares of the Company, adjusted for any bonus issue. Diluted EPS is calculated by dividing the basic EPS earnings, adjusted by the after tax effect of financing costs associated with dilutive potential Ordinary Shares and the effect on revenues and expenses of conversion to Ordinary Shares associated with dilutive potential Ordinary Shares, by the weighted average number of Ordinary Shares and dilutive Ordinary Shares adjusted for any bonus issue. Diluted earnings per share excludes all dilutive potential shares if their effect is anti-dilutive.
(s) Use and Revision of Accounting Estimates, Judgments and Assumptions The preparation of the financial report requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the year in which the estimate is revised if the revision affects only that year, or in the year of the revision and future years if the revision affects both current and future years. In particular, information about significant areas of estimation uncertainty and critical judgements in applying accounting policies that have the most significant effect on the amount recognized in the financial statements are described in Note 22: Share-based payments.
(t) Operating Segments An operating segment is a component of an entity that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity), whose operating results are regularly reviewed by the entity’s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance and for which discrete financial information is available. This includes
85
- Statement of Material Accounting Policies (continued) start up operations which are yet to earn revenues. Management will also consider other factors in determining operating segments such as the existence of a line manager and the level of segment information presented to and reviewed by the chief operating decision maker. Operating segments have been identified based on the information provided to the chief operating decision makers. The Group aggregates two or more operating segments when they have similar economic characteristics, and the segments are similar in each of the following respects: ▪ Nature of the products and services; ▪ Nature of the production processes; ▪ Type or class of customer for the products and services; ▪ Methods used to distribute the products or provide the services; and if applicable ▪ Nature of the regulatory environment. Operating segments that meet the quantitative criteria as prescribed by AASB 8 are reported separately. However, an operating segment that does not meet the quantitative criteria is still reported separately where information about the segment would be useful to users of the financial statements. Information about other business activities and operating segments that are below the quantitative criteria are combined and disclosed in a separate category for “all other segments”. Currently, the Group has only one operating segment, being exploration and development of minerals and metals in the U.S.
(u) Impairment of Non-Financial Assets The Group assesses at each reporting date whether there is an indication that an asset may be impaired. If any such indication exists, or when annual impairment testing for an asset is required, the Group makes an estimate of the asset’s recoverable amount. An asset’s recoverable amount is the higher of its fair value less costs of disposal and its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets and the asset’s value in use cannot be estimated to be close to its fair value. In such cases the asset is tested for impairment as part of the cash-generating unit to which it belongs. When the carrying amount of an asset or cash-generating unit exceeds its recoverable amount, the asset or cash-generating unit is considered impaired and is written down to its recoverable amount. In assessing the value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. An assessment is also made at each reporting date as to whether there is any indication that previously recognized impairment losses may no longer exist or may have decreased. If such indication exists, the recoverable amount is estimated. A previously recognized impairment loss is reversed only if there has been a change in the estimates used to determine the asset’s recoverable amount since the last impairment loss was recognized. If that is the case the carrying amount of the asset is increased to its recoverable amount. That increased amount cannot exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognized for the asset in prior years. After such a reversal the depreciation charge is adjusted in future years to allocate the asset’s revised carrying amount, less any residual value, on a systematic basis over its remaining useful life.
(v) Fair Value Estimation The fair value of financial assets and financial liabilities must be estimated for recognition and measurement or for disclosure purposes. The fair value of financial instruments traded in active markets (such as publicly traded derivatives, and equity securities classified as fair value through other comprehensive income) is based on quoted market prices at the reporting date. The
86
- Statement of Material Accounting Policies (continued) quoted market price used for financial assets held by the Group is the current bid price; the appropriate quoted market price for financial liabilities is the current ask price. The nominal value less estimated credit adjustments of trade receivables and payables are assumed to approximate their fair values. The fair value of financial liabilities for disclosure purposes is estimated by discounting the future contractual cash flows at the current market interest rate that is available to the Group for similar financial instruments.
(w) Issued and Unissued Capital Ordinary Shares and Performance Shares are classified as equity. Issued and paid up capital is recognized at the fair value of the consideration received by the Company. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.
(x) Dividends Provision is made for the amount of any dividend declared on or before the end of the year but not distributed at balance date.
(y) Share-Based Payments Equity-settled share-based payments are provided to officers, employees, consultants and other advisors. These share-based payments are measured at the fair value of the equity instrument at the grant date. The fair value of options is estimated using the Black Scholes option valuation model. The fair value of performance rights that have market-based vesting conditions is estimated using a trinomial valuation model. The fair value of restricted stock units and performance rights that do not have market-based vesting conditions is estimated based on the underlying share price. The fair value determined at the grant date is expensed on a straight-line basis over the vesting period, based on the Company’s estimate of equity instruments that will eventually vest. At each reporting date, the Company revises its estimate of the number of equity instruments expected to vest. The impact of the revision of the original estimates, if any, is recognized in profit or loss over the remaining vesting period, with a corresponding adjustment to the share-based payments reserve. Equity-settled share-based payments may also be provided as consideration for the acquisition of assets. Where ordinary shares are issued, the transaction is recorded at fair value based on the quoted price of the ordinary shares at the date of issue. The acquisition is then recorded as an asset or expensed in accordance with accounting standards.
(z) Leases The Group assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Group recognizes lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets. Right-of-Use Assets The Group recognizes right-of-use assets at the commencement date of the lease (i.e. the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are depreciated on a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets. If ownership of the leased asset transfers to the Group at the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset. The rightof-use assets are also subject to impairment.
87
- Statement of Material Accounting Policies (continued) Lease liabilities At the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties for terminating the lease, if the lease term reflects the Group exercising the option to terminate. In calculating the present value of lease payments, the Group uses its incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the lease payments (e.g. changes to future payments resulting from a change in an index or rate used to determine such lease payments) or a change in the assessment of an option to purchase the underlying asset. Short-term Leases and Leases of Low-Value Assets The Group applies the short-term lease recognition exemption to its short-term leases of machinery and equipment (i.e. those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets recognition exemption to leases of office equipment that are considered to be low value. Lease payments on short-term leases and leases of low-value assets are recognized as expense on a straight-line basis over the lease term.
(aa) Accounting for Government Funding Arrangements The U.S. government has invested significant resources to re-shore to the U.S. a secure domestic titanium supply chain. As of June 30, 2026, IperionX’s U.S. Government support includes the US$12.7 million DPA Title III award, the fully obligated US$47.1 million IBAS award, and the SBIR Phase III contracting pathway of up to US$99 million. Depending on the substance of contractual terms, some of these arrangements are accounted for under AASB 120 Accounting for Government Grants and Disclosure of Government Assistance, while others may be accounted for under AASB 15 - Revenue from Contracts with Customers. For other arrangements, the Company may act as an agent in procuring equipment on behalf of the government. As the Company does not obtain control of the equipment, a receivable is recognized for the reimbursement due from the government, and no corresponding asset, expense, or grant income is recognized. Title to all assets purchased by the Group with funds from the U.S. government vests with the U.S. government during the term of the technology investment agreement. The U.S. government can elect to, but is not obliged to, transfer such title to all (or some) of the assets to the Company at the end of the agreement, which is scheduled to terminate on January 30, 2027, if the Group's performance is satisfactory. Accordingly, the Company does not have an enforceable right to the assets acquired with federal funds, even where the conditions of the agreement are complied with, and so there is no current grant to be recognized. Instead, for accounting purposes, the Company’s role with respect to the equipment is to acquire it on behalf of the U.S. government in an agency capacity. Upon procurement of the asset for the U.S. government, only a receivable is recognized reflecting the reimbursement due from the U.S. government. If, per the agreement, the government subsequently decides to transfer title of the assets to the Company at the end of the program, this is the point at which a grant would crystallize and the Company would record a non-monetary government grant. Funding under DPA Title III US$12.7 million In October 2023, IperionX executed a US$12.7 million contract in funding under the U.S. DoW DPA Title III authorities to address the U.S. titanium supply chain vulnerabilities. The government share will be matched with US$13.4 million in funding from IperionX, for a total funding amount of US$26.1 million. This funding is being applied towards the Group’s TPF in Virginia. The agreement has an initial term of 39 months, scheduled to terminate on January 30, 2027, and provides that it may be
88
- Statement of Material Accounting Policies (continued) extended by mutual agreement. Under the agreement, the Company and the U.S. government have agreed to use best efforts to achieve the goals of the agreement, which include the Company conducting a research and development program with respect to titanium technology. As of June 30, 2026, the Company procured assets on behalf of the government that cost approximately US$12.7 million, of which US$10.3 million was reimbursed by the government. The remaining US$2.4 million receivable was reimbursed subsequent to year end. Funding under IBAS US$47.1 million In February 2025, the Company was awarded up to US$47.1 million by the U.S. DoW to strengthen the U.S. Defense Industrial Base by accelerating the scale-up of a resilient, low-cost, and fully-integrated U.S. mineral-to-metal titanium supply chain. The program will be matched with US$49.2 million in funding by IperionX, for a total funding amount of US$96.3 million. This funding aims to bolster the U.S. defense industrial base by developing a fully integrated, low-cost titanium supply chain sourced domestically. The project scope under the IBAS program had been revised to prioritize accelerated expansion of IperionX’s titanium metal and manufacturing production capacity at IperionX’s Virginia Titanium Manufacturing Campus. As part of the initial phase, the DoW obligated US$5.0 million, and IperionX contributed US$1.0 million, to expedite the Titan Project in Tennessee to ‘shovel-ready’ status, an important milestone in securing a new domestic source of titanium, rare earths and zircon critical minerals. Government reimbursements provided as grants are subject to conditional funding provisions. Grants for the initial phase are recognized as “Other income and expenses” in the consolidated statements of profit or loss and other comprehensive income, once all conditions for reimbursement are met. The DoW obligated an additional US$12.5 million in August of 2025, US$25.0 million in September of 2025 and US$4.6 million in January of 2026, through the IBAS program to purchase orders for long-lead, major capital equipment required for the next stage of capacity scale-up to approximately 1,400 metric tons per year at the Virginia Titanium Manufacturing Campus. As of June 30, 2026, the entire US$47.1 million has been obligated by the DoW. Of that, the Company has incurred costs of US$5.0 million toward the Titan Project DFS and has requested reimbursements from U.S. DoW in the amount of US$4.1 million (2025: US$0.9 million) which is recognized as “Other income and expenses” in the consolidated statements of profit or loss and other comprehensive income. We have received cash reimbursements from the U.S. DoW of US$4.6 million during the twelve months ended June 30, 2026. (2025: US$0.1 million). Cash receipts from government reimbursements for the Titan Project DFS and the related qualifying expenditures are presented on a gross basis in the consolidated statements of cash flows, with government reimbursements reflected as operating cash inflows and the associated expenditures reflected within operating cash outflows. Funding under SBIR Phase III US$99.0 million In June 2025, IperionX received the first task order for US$1.3 million, from the U.S. Army under a SBIR Phase III Indefinite Delivery Indefinite Quantity contract with the U.S. DoW. The task order facilitates the purchase of equipment to aid in the production and delivery of titanium parts for U.S. Army ground programs. As of June 30, 2026, the Company has procured assets on behalf of the government that cost approximately US$0.3 million (2025: nil). We expect to utilize the remaining US$1.0 million of available funding by the end of fiscal year 2027.
89
- Income and Expenses Note Research & development costs Wages and benefits Payroll taxes on stock compensation benefits Depreciation of property, plant and equipment Amortization of patents Amortization of right-of-use assets Other operating expenses(1)
9 10 9
Corporate and administrative expenses Wages and benefits Non-cash expenses settled with share issuance Professional fees and system implementation costs Legal expenses Payroll taxes on stock compensation benefits Other operating expenses(2) Employee benefits expense Salaries, wages and benefits Post-employment benefits Share-based payment expenses
22
Finance income Interest income Net foreign exchange gain Finance costs Interest expense Net foreign exchange loss Other finance costs Other income and expenses Other income(3) Loss on disposal of property, plant and equipment
2026 US$
2025 US$
(9,235,933) (1,764,132) (1,300,546) (621,874) (12,271,500) (25,193,985)
(5,519,763) (183,373) (683,678) (768,128) (710,678) (4,883,353) (12,748,973)
(8,874,230) (5,230,000) (5,115,183) (1,432,661) (218,105) (5,047,187) (25,917,366)
(4,956,272) (2,456,898) (246,546) (994,640) (2,032,020) (10,686,376)
(21,501,910) (411,210) (9,166,334) (31,079,454)
(14,578,178) (252,005) (9,568,191) (24,398,374)
1,871,307 1,871,307
2,203,220 1,347,413 3,550,633
(311,744) (3,153,479) (3,465,223)
(279,541) (26,709) (306,250)
4,584,952 (50,572) 4,534,380
939,412 (260,569) 678,843
Notes: (1) R&D other operating expenses primarily includes expenses for the R&D facilities, materials, consumables, and consulting fees for
continuous technology research, including commercialization and scale-up activities, materials, development of the GenX™ next-generation continuous HAMR™ platform, expansion of manufacturing capabilities and advancement of customer qualification programs. (2) Corporate and administrative other operating expenses primarily includes insurance, software licenses, rents and other corporate fees related to operating a public company. (3) Other income includes US$4,130,072 (2025: US$869,928) for government grant income billed to the U.S. DoW under the IBAS program.
See Note 1(aa) for additional details.
90
- Income Tax 2026 US$ Recognized in profit or loss Current income tax: Current income tax benefit in respect of the current year Deferred income tax: Origination and reversal of temporary differences Income tax expense reported in profit or loss Reconciliation between tax expense and accounting loss before income tax Accounting loss before income tax At the Australian income tax rate of 30% Effect of lower income tax rate in the United States Expenditure not allowable for income tax purposes Income not assessable for income tax purposes Exchange differences Adjustments in respect of deferred tax of previous years Effect of deferred tax assets not brought to account Income tax expense reported in profit or loss Deferred tax assets and liabilities Deferred tax liabilities: Right-of-use assets Deferred tax assets used to offset deferred tax liabilities Deferred tax assets: Accrued expenditures Provisions Lease liabilities Capital allowances Tax losses available to offset against future taxable income Deferred tax assets used to offset deferred tax liabilities Other deferred tax assets not brought to account(1)
2025 US$
(66,767,762) (20,030,329) 177,763 5,387,521 (1,335,225) 15,800,270
(35,348,675) (10,604,603) 1,032,615 2,885,033 (404,224) (639) (738,316) 7,830,134
1,297,345 (1,297,345)
980,747 (980,747)
51,793 192,887 1,036,572 31,742,587 5,486,228 (1,297,345) (37,212,722)
117,578 122,051 1,023,320 10,394,779 9,668,204 (980,747) (20,345,185)
Notes: (1) The benefit of deferred tax assets not brought to account will only be subsequently recognized if: (a) future assessable income is derived of
a nature and of an amount sufficient to enable the benefit to be realized; (b) the conditions for deductibility imposed by tax legislation continue to be complied with; and (c) no changes in tax legislation adversely affect the Group in realizing the benefit.
- Dividends Paid or Provided for on Ordinary Shares No dividends have been paid or proposed for the year ended June 30, 2026 (2025: nil).
91
- Cash and Cash Equivalents
Cash at bank and on hand Reconciliation of loss before income tax to net cash flows from operations Loss for the year Adjustment for non-cash income and expense items Share-based payments expense Non-cash expenses settled with share issuance Amortization of right-of-use assets Amortization of intangibles Depreciation of property, plant and equipment Net foreign exchange (gain)/loss Loss on disposal of property, plant and equipment Changes in assets and liabilities Inventory Receivables and prepayments Payables and provisions Net cash outflow from operating activities
2026 US$ 35,244,220
2025 US$ 54,814,125
(66,767,762)
(35,348,675)
9,166,334 5,230,000 771,147 1,300,546 2,278,003 3,153,479 50,572
9,568,191 793,981 768,128 716,147 (1,347,413) 260,569
(1,149,702) (282,576) 1,295,297 (44,954,662)
1,121,984 1,669,403 (21,797,685)
2026 US$
2025 US$
3,175,925 106,556 3,282,481
774,248 49,020 823,268
- Trade and Other Receivables
Current Receivables from U.S. Government(1) Receivables from other third-parties Total trade and other receivables Notes:
(1) As disclosed in Note 1(aa), receivables from the U.S. Government comprise amounts due for reimbursement of equipment purchases made
under government programs, and qualifying expenditures incurred in connection with the Titan DFS.
- Prepayments
Current Construction prepayments Other prepayments Total current prepayments Non-current Security deposits Other non-current prepayments Total non-current prepayments
92
2026 US$
2025 US$
731,202 802,519 1,533,721
2,741,220 497,674 3,238,894
559,834 559,834
438,704 459,031 897,735
-
Inventory Inventories are stated at the lower of cost and net realizable value as described in Note 1(h). During the half year ended December 31, 2025, the Company began capitalizing raw material costs as inventory following commercial milestones achieved during the period. Prior to that point, all such costs were expensed as research and development expense. No write-down charges were recorded, during the periods ended June 30, 2026 and 2025. As of June 30, 2026, the Company had US$3,907,597 in inventory, primarily related to raw material, including the scrap and feedstock received from the government as described in Note 1(h). (2025: nil). No inventory was pledged as security for liabilities.
-
Property, Plant and Equipment
2026 Carrying amount at June 30, 2025 Additions Disposals(1) Depreciation Carrying amount at June 30, 2026(2)
- at cost
- accumulated depreciation and impairment 2025 Carrying amount at June 30, 2024 Additions Disposals Depreciation Carrying amount at June 30, 2025
- at cost
- accumulated depreciation and impairment
Plant and Equipment US$
Right-of-Use Assets US$
Total US$
21,445,038 20,813,687 (3,758,805) (2,278,003) 36,221,917 40,072,636 (3,850,719)
3,752,600 1,982,560 (771,147) 4,964,013 6,361,118 (1,397,105)
25,197,638 22,796,247 (3,758,805) (3,049,150) 41,185,930 46,433,754 (5,247,824)
6,188,697 15,996,078 (23,590) (716,147) 21,445,038 22,350,584 (905,546)
1,585,115 2,961,466 (793,981) 3,752,600 5,444,538 (1,691,938)
7,773,812 18,957,544 (23,590) (1,510,128) 25,197,638 27,795,122 (2,597,484)
Notes: (1) During the twelve months ended June 30, 2026, proceeds of US$1,903,700 were received, with the outstanding balance recorded as a
current receivable. (2) During the twelve months ended June 30, 2026, a non-cash reclassification of approximately US$667,000 related to an equipment lease
that was finalized during the year. The fully amortized leased asset was transferred to property, plant and equipment, resulting in an increase to gross cost and accumulated depreciation with no corresponding impact on net property, plant and equipment.
93
- Intangibles Intellectual Property Rights US$ 2026 Carrying amount at June 30, 2025 Additions Amortization Carrying amount at June 30, 2026
- at cost
- accumulated amortization 2025 Carrying amount at June 30, 2024 Transfers from prepayments Additions Amortization Carrying amount at June 30, 2025
- at cost
- accumulated amortization
13,550,993 18,377 (1,300,546) 12,268,824 14,337,498 (2,068,674) 5,500,000 8,819,121 (768,128) 13,550,993 14,319,121 (768,128)
During the fiscal year 2025, the Group exercised its exclusive option to purchase intellectual property rights of Blacksand Technology, LLC. The group now holds the exclusive commercial rights for more than 40 global patents through a license agreement with the University of Utah including the global patents for patented technologies that can produce low-cost and low-carbon titanium metal.
- Exploration and Evaluation Assets Titan Project(1) US$ 2026 Carrying amount at June 30, 2025 Additions Carrying amount at June 30, 2026(1) (2) 2025 Carrying amount at June 30, 2024 Additions Write-offs Carrying amount at June 30, 2025
6,512,326 1,256,092 7,768,418 6,114,061 644,661 (246,396) 6,512,326
Notes: (1) At June 30, 2026, the Titan Project comprised over 10,000 acres of surface and associated mineral rights in Tennessee prospective for
heavy mineral sands, including titanium, rare earth minerals, high grade silica sand, and zircon, of which approximately 1,500 acres are owned by IperionX, approximately 1,200 acres are subject to long-term lease by IperionX, and approximately 7,500 acres are subject to exclusive option agreements with IperionX. These exclusive option agreements, upon exercise, allow the Group to lease, or in some cases purchase, the surface property and associated mineral rights. (2) The ultimate recoupment of costs carried forward for exploration and evaluation is dependent on the successful development and
commercial exploitation or sale of the respective areas of interest.
94
- Trade and Other Payables, Provisions and Other Long-term Liabilities Trade and other payables
Current Trade payables Accruals Other payables Total trade and other payables
2026 US$
2025 US$
8,746,938 1,687,214 15,635 10,449,787
6,004,071 1,307,087 178,239 7,489,397
Provisions The current provisions balance of US$738,039 (2025: US$467,001) represents the Group's best estimate of employee entitlement obligations, including annual leave and other short-term benefit accruals that are expected to be settled within twelve months of the reporting date.
Other long-term liabilities The other long-term liability of US$333,000 (2025: US$700,000) relates to the remaining deferred consideration payable in connection with the Group's acquisition of exclusive intellectual property rights from Blacksand Technology, LLC. See Note 10 for further discussion.
- Deferred Income During the period, the Government transferred approximately 290 metric tons of high-quality titanium scrap metal to the Company at no cost. The material was surplus to government needs and was transferred in connection with the IBAS grant program, which is intended to strengthen U.S. defense supply chains by fostering a resilient, low-cost, titanium platform that reduces reliance on imports and establishes a secure, domestic source of critical materials. The Company recognizes government grants related to non-monetary assets by recording the fair value of the inventory received and establishing a corresponding deferred income liability. Deferred income is recognized in profit or loss on a systematic basis over the periods in which the related costs are incurred or the inventory is consumed. The deferred income related to the inventory received was measured at its fair value of US$2,757,895 on the date of receipt, based on prevailing market prices for titanium scrap. 2026 US$ Deferred Income Carrying amount at June 30, 2025 Grant recognized during the period Amounts released to profit or loss Carrying amount at June 30, 2026
2,757,895 (986,364) 1,771,531
2025 US$
As of the reporting date, the Company has complied with all conditions attached to the Grant, and no repayment obligation has been recognized.
95
- Loans and Borrowings Other Loans and Borrowings US$ 2026 Carrying amount at June 30, 2025 Additions(1) Repayments Carrying amount at June 30, 2026 Current Non-Current 2025 Carrying amount at June 30, 2024 Additions Repayments Carrying amount at June 30, 2025 Current Non-Current
Lease Liabilities US$
Total Loans and Borrowings US$
19,067 965,723 (792,031) 192,759 187,040 5,719
3,915,515 572,647 (521,942) 3,966,220 441,893 3,524,327
3,934,582 1,538,370 (1,313,973) 4,158,979 628,933 3,530,046
24,893 (5,826) 19,067 6,764 12,303
1,465,780 2,961,565 (511,830) 3,915,515 465,254 3,450,261
1,490,673 2,961,565 (517,656) 3,934,582 472,018 3,462,564
Other Loans and Borrowings US$ 188,836 5,769 194,605 (1,846) 192,759
Lease Liabilities US$ 738,331 700,937 698,734 688,568 637,881 1,760,943 5,225,394 (1,259,174) 3,966,220
Notes: (1)
Relates to non cash additions for insurance premiums financed.
The following table sets forth the maturity schedule of the Company’s loans and borrowings:
2027 2028 2029 2030 2031 Thereafter Total payments Less: imputed interest Present value of loans and borrowings
96
- Leases The Group leases office facilities, storage facilities, vehicles, and plant and equipment in the U.S. The lease arrangements do not contain any material restrictive covenants or other significant restrictions. The carrying amounts of right-of-use assets (included under property, plant and equipment) and the movements during the year are in Note 9. The carrying amounts of lease liabilities (included under financial liabilities) and the movements during the year are set out in Note 14. The following are the amounts recognized in profit or loss in respect of leases:
Amortization of right-of-use assets Interest expense on lease liabilities Expense relating to short-term leases and leases of low-value assets Net amount recognized in profit or loss
2026 US$ (771,147) (282,870) (326,442) (1,380,459)
2025 US$ (793,981) (278,186) (143,789) (1,215,956)
Note
2026 US$
2025 US$
16(a)
250,976,753
197,985,920
Note 9
- Contributed Equity
Issued capital 339,384,066 (2025: 319,927,854) fully paid ordinary shares
We do not have a limit on our authorized share capital and the concept of par value is not recognized under Australian law.
97
- Contributed Equity (continued) (a) Movements in Issued Capital Number of Ordinary Shares 2026 Opening balance at June 30, 2025 Issue of shares – share placements Issue of shares – exercise of options Issue of shares – conversion of RSUs Issue of shares – conversion of rights Issue of shares – payment of expenses Conversion of performance shares Share issue costs Closing balance at June 30, 2026 2025 Opening balance at June 30, 2024 Issue of shares – share placements Issue of shares – exercise of options Issue of shares – conversion of RSUs Issue of shares – conversion of rights Issue of shares to consultants Issue of shares to Director in lieu of cash bonus Conversion of performance shares Share issue costs Closing balance at June 30, 2025
Number of Class A Performance Shares
Number of Class B Performance Shares
US$
319,927,854 14,000,000 2,047,487 1,540,516 595,000 1,273,179 30 339,384,066
19,800,000 (19,800,000)
197,985,920 45,717,352 971,471 2,234,348 603,498 5,230,000 (1,765,836) 250,976,753
257,244,759 34,951,630 1,525,000 1,639,496 24,273,335 151,760 141,844 30 319,927,854
19,800,000 (19,800,000)
19,800,000 19,800,000
112,959,638 70,919,564 205,525 2,094,041 13,724,952 470,262 250,000 (2,638,062) 197,985,920
Notes: Shares issued upon exercise of options are shown net of shares surrendered to settle the exercise price under net settlement arrangements.
(b) Rights Attaching to Ordinary Shares The rights attaching to fully paid Ordinary Shares arise from a combination of the Company’s Constitution, statute and general law: ▪ Shares - The issue of shares in the capital of the Company and options over unissued shares by the Company is under the control of the directors, subject to the Corporations Act 2001, ASX Listing Rules and any rights attached to any special class of shares. ▪ Meetings of Members - Directors may call a meeting of members whenever they think fit. Members may call a meeting as provided by the Corporations Act 2001. The Constitution contains provisions prescribing the content requirements of notices of meetings of members and all members are entitled to a notice of meeting. A meeting may be held in two or more places linked together by audio-visual communication devices. A quorum for a meeting of members is two shareholders. The Company holds annual general meetings in accordance with the Corporations Act 2001 and the Listing Rules.
98
- Contributed Equity (continued) ▪ Voting - Subject to any rights or restrictions attached at the time to any shares or class of shares of the Company, each member of the Company is entitled to receive notice of, attend and vote at a general meeting. Under the Company’s constitution, resolutions of members will be decided by a show of hands unless a poll is demanded. However, in accordance with the Corporations Act 2001 (Commonwealth - Cth), the Company decides all resolutions proposed at its shareholder meetings by poll. On a show of hands each eligible voter present has one vote. Where a person present at a general meeting represents personally or by proxy, attorney or representative more than one member, on a show of hands the person is entitled to one vote only despite the number of members the person represents. On a poll each eligible member has one vote for each fully paid share held and a fraction of a vote for each partly paid share determined by the amount paid up on that share. ▪ Changes to the Constitution - The Company’s Constitution can only be amended by a special resolution passed by at least 75% of the votes cast by members entitled to vote. At least 28 days’ written notice specifying the intention to propose the resolution as a special resolution must be given. ▪ Listing Rules - Provided the Company remains admitted to the Official List, then despite anything in its Constitution, no act may be done that is prohibited by the Listing Rules, and authority is given for acts required to be done by the Listing Rules. The Company’s Constitution will be deemed to comply with the Listing Rules as amended from time to time.
(c) Rights Attaching to Performance Shares As of June 30, 2024, Performance Shares comprised of 19,800,000 Class A and 19,800,000 Class B Performance Shares issued in relation to the acquisition of HMAPL and could have been issued based upon the following terms and conditions: The Performance Shares could convert into Ordinary Shares as follows: ▪ Each Class A Performance Share could convert into one (1) Ordinary Share upon completion of a positive pre-feasibility study (prepared in accordance with the JORC Code and independently verified by a Competent Person) for heavy mineral sands mining and processing on any of the Titan Project area which demonstrates a net present value of at least A$200,000,000 before September 17, 2024 (the “Pre-Feasibility Study Milestone”). The Pre-Feasibility Study Milestone was not met by September 17, 2024. ▪ Each Class B Performance Share could convert into one (1) Ordinary Share upon the commencement of commercial production from the Titan Project area before September 17, 2025 (the “First Production Milestone”). The First Production Milestone was not met by September 17, 2025; ▪ As the Performance Shares did not convert into Ordinary Shares by the applicable expiry date, (being December 1, 2024 for the Class A Performance Shares and December 1, 2025 for the Class B Performance Shares), all such Performance Shares for each holder automatically lapsed and were combined into one (1) single Performance Share that was then converted into one (1) single Ordinary Share; ▪ The 19,800,000 Class A Performance Shares did not convert into Ordinary Shares by the applicable expiry date of December 1, 2024, so the 19,800,000 Class A Performance Shares lapsed and converted into 30 Ordinary Shares during fiscal 2025; and ▪ The 19,800,000 Class B Performance Shares did not convert into Ordinary Shares by the applicable expiry date of December 1, 2025, so the 19,800,000 Class B Performance Shares lapsed and converted into 30 Ordinary Shares during fiscal 2026.
99
- Reserves Note 17(b) 17(f)
Share-based payments reserve Foreign currency translation reserve
2026 US$ 12,392,374 929,049 13,321,423
2025 US$ 6,469,201 (2,780,397) 3,688,804
(a) Nature and Purpose of Reserves (i) Share-Based Payments Reserve The share-based payments reserve is used to record the fair value of Unlisted Options, RSUs and Performance Rights issued by the Group. (ii) Foreign Currency Translation Reserve Exchange differences arising on translation of entities whose functional currency is different to the Group’s presentation currency are taken to the foreign currency translation reserve, as described in Note 1(d).
(b) Movements in Share-Based Payments Reserve During the Year
2026 June 30, 2025 Grant of employee options, rights and RSUs Exercise of options, rights and RSUs Lapse/forfeiture of employee options, rights and RSUs Share-based payment expense June 30, 2026 2025 June 30, 2024 Grant of employee options, rights and RSUs Exercise of options, rights and RSUs Issue of shares to consultants Issue of shares to Director in lieu of bonus Lapse/forfeiture of employee rights and RSUs Share-based payment expense June 30, 2025
Number of Unlisted Options (Note 17(c))
Number of Performance Rights (Note 17(d))
No. of Restricted Stock Units (Note 17(e))
12,904,118 4,086,871 (2,118,279)
7,504,409 769,077 (595,000)
4,798,225 853,979 (1,540,516)
6,469,201 (3,243,161)
(8,000,000)
(630,000)
(1,018)
6,872,710
7,048,486
4,110,670
9,166,334 12,392,374
11,749,372 2,679,746 (1,525,000) 12,904,118
27,469,335 5,288,409 (24,273,335) (980,000) 7,504,409
4,377,034 2,220,020 (1,639,496) (159,333) 4,798,225
13,440,265 (15,818,993) (470,262) (250,000) 9,568,191 6,469,201
US$
Note: For details on the valuation of Unlisted Options, Performance Rights and RSUs, including models and assumptions used, refer to Note 22 of the financial statements.
100
- Reserves (continued) (c) Terms and Conditions of Unlisted Options Unlisted Options granted as share-based payments have the following terms and conditions: ▪ Each Unlisted Option entitles the holder to the right to subscribe for one share upon the exercise of each Unlisted Option; ▪ The Unlisted Options outstanding at the end of the financial year have the following exercise prices and expiry dates: ◦ 106,093 director options exercisable at A$0.87 each on or before December 5, 2026; ◦ 235,000 unlisted options exercisable at A$10.00 each on or before April 1, 2027; ◦ 1,305,000 unlisted options exercisable at A$8.00 each on or before June 30, 2027; ◦ 1,374,746 employee options exercisable at A$5.00 each on or before April 10, 2029; ◦ 511,972 employee options exercisable at A$11.00 each on or before April 2, 2030; ◦ 1,566,690 director and employee options exercisable at A$18.00 each on or before April 2, 2031; and ◦ 1,773,209 director and employee options exercisable at A$22.00 each on or before April 2, 2031. ▪ The Unlisted Options are exercisable at any time prior to the Expiry Date, subject to vesting conditions being satisfied (if applicable); ▪ Shares issued on exercise of the Unlisted Options rank equally with the then Shares of the Company; ▪ Application will be made by the Company to ASX for official quotation of the Shares issued upon the exercise of the Unlisted Options; ▪ If there is any reconstruction of the issued share capital of the Company, the rights of the Unlisted Option holders may be varied to comply with the ASX Listing Rules which apply to the reconstruction at the time of the reconstruction; and ▪ No application for quotation of the Unlisted Options will be made by the Company.
(d) Terms and Conditions of Performance Rights Performance Rights granted as share-based payments have the following terms and conditions: ▪ Each Performance Right automatically converts into one Share upon vesting of the Performance Right; ▪ Each Performance Right is subject to performance conditions (as determined by the Board from time to time) which must be satisfied in order for the Performance Right to vest; ▪ The Performance Rights outstanding at the end of the financial year have the following performance conditions and expiry dates: ◦ 2,885,000 employee performance rights that vest upon achieving a 30-day VWAP of A$4.00 per share (2,440,000 expiring December 21, 2028 and 445,000 expiring December 31, 2027); ◦ 660,077 director and employee performance rights that vest upon achieving a 30-day VWAP of A$18.00 expiring April 2, 2031; ◦ 1,157,803 employee performance rights that vest upon achieving a 30-day VWAP of A$6.00 expiring April 10, 2031; ◦ 1,157,803 employee performance rights that vest upon achieving a 30-day VWAP of A$7.00 per share expiring April 10, 2031; ◦ 1,157,803 employee performance rights that vest upon achieving a 30-day VWAP of A$8.00 per share expiring April 10, 2031; and
101
- Reserves (continued) ◦ 30,000 employee performance rights that vest upon achieving various (non-market based) performance conditions expiring December 31, 2026. ▪ Application will be made by the Company to ASX for official quotation of the Shares issued upon conversion of the Performance Rights; ▪ If there is any reconstruction of the issued share capital of the Company, the rights of the Performance Right holders may be varied to comply with the ASX Listing Rules which apply to the reconstruction at the time of the reconstruction; ▪ No application for quotation of the Performance Rights will be made by the Company; and ▪ Without approval of the Board, Performance Rights may not be transferred, assigned or novated, except, upon death, a participant’s legal personal representative may elect to be registered as the new holder of such Performance Rights and exercise any rights in respect of them.
(e) Terms and Conditions of Restricted Stock Units RSUs granted as share-based payments have the following terms and conditions: ▪ Each RSU automatically converts into one Share upon vesting of the RSU; ▪ Each RSU is subject to service-based performance conditions (as determined by the Board from time to time) which must be satisfied in order for the RSU to vest; ▪ The RSUs outstanding at the end of the financial year have the following conditions and expiry dates: ◦ 118,875 director RSUs that vest upon achieving various service-based conditions, expiring December 23, 2026; ◦ 1,095,330 director and employee RSUs that vest upon achieving various service-based conditions, expiring December 31, 2026; ◦ 135,044 director RSUs that vest upon achieving various service-based conditions, expiring December 5, 2027; ◦ 16,755 employee RSUs that vest upon achieving various service-based conditions, expiring December 31, 2027; ◦ 20,820 employee RSUs that vest upon achieving various service-based conditions, expiring March 2, 2028; ◦ 15,500 employee RSUs that vest upon achieving various service-based conditions, expiring April 2, 2028; ◦ 141,620 director RSUs that vest upon achieving various service-based conditions, expiring December 16, 2028; ◦ 242,985 employee RSUs that vest upon achieving various service-based conditions, expiring December 31, 2028; ◦ 1,637,975 director and employee RSUs that vest upon achieving various service-based conditions, expiring April 10, 2029; ◦ 476,734 employee RSUs that vest upon achieving various service-based conditions, expiring December 31, 2029; and ◦ 209,032 employee RSUs that vest upon achieving various service-based conditions, expiring April 2, 2030. ▪ Application will be made by the Company to ASX for official quotation of the Shares issued upon conversion of the RSUs; ▪ If there is any reconstruction of the issued share capital of the Company, the rights of the RSU holders may be varied to comply with the ASX Listing Rules which apply to the reconstruction at the time of the reconstruction; ▪ No application for quotation of the RSUs will be made by the Company; and ▪ Without approval of the Board, RSUs may not be transferred, assigned or novated, except, upon death, a participant’s legal personal representative may elect to be registered as the new holder of such RSUs and exercise any rights in respect of them.
102
- Reserves (continued) (f) Movements in Foreign Currency Translation Reserve During the Year
Balance at beginning of the year Exchange differences arising on translation into presentation currency Balance at June 30
2026 US$ (2,780,397) 3,709,446 929,049
2025 US$ (1,178,258) (1,602,139) (2,780,397)
2026 US$ (109,230,725) (66,767,762) (175,998,487)
2025 US$ (73,882,050) (35,348,675) (109,230,725)
2026 US$ (0.20) (0.20)
2025 US$ (0.12) (0.12)
- Accumulated Losses
Balance at beginning of the year Net loss for the year Balance at June 30
- Loss Per Share
Basic loss per share Diluted loss per share
The following reflects the income and share data used in the calculations of basic earnings per share:
Net loss used in calculating basic and dilutive earnings per share
Weighted average number of Ordinary Shares used in calculating basic and dilutive earnings per share
2026 US$ (66,767,762)
2025 US$ (35,348,675)
Number of Ordinary Shares 2026
Number of Ordinary Shares 2025
335,741,001
296,887,872
(a) Anti-Dilutive Securities As at June 30, 2026, 6,872,710 Unlisted Options, 7,048,486 Performance Rights, and 4,110,670 RSUs, which together represent 18,031,866 potential Ordinary Shares (2025: 45,006,752), were not included in the calculation of diluted loss per share because they are considered anti-dilutive as they would decrease the loss per share for the years presented.
(b) Conversions, Calls, Subscriptions or Issues after June 30, 2026 Subsequent to June 30, 2026, the Company has: ▪ issued 22,750,000 ordinary shares pursuant to a placement of ordinary shares; ▪ issued 106,093 ordinary shares pursuant to the exercise of unlisted options; ▪ issued 58,584 unlisted RSUs to a director; and ▪ issued 947,062 unlisted options to a contractor. Other than as above, there have been no other conversions to, calls of, or subscriptions for Ordinary Shares or issues of potential Ordinary Shares since the reporting date and before the completion of this financial report.
103
- Related Parties (a) Subsidiaries
Hyperion Metals (Australia) Pty Ltd IperionX Critical Minerals LLC IperionX Technology LLC IperionX Inc.
Country of Incorporation Australia United States United States United States
Equity Interest 2026 2025 100% 100% 100% 100% 100% 100% 100% 100%
(b) Ultimate Parent IperionX Limited is the ultimate parent of the Group.
(c) Key Management Personnel The aggregate compensation made to KMP of the Group is set out below: 2026 US$ 4,296,651 54,012 6,661,094 11,011,757
Short-term employee benefits Post-employment benefits Share-based payments Total compensation
2025 US$ 4,012,976 62,632 5,496,070 9,571,678
No loans were provided to or received from KMP during the year ended June 30, 2026 (2025: nil).
(d) Other Transactions with Related Parties Performance Industries, Inc., a company associated with Mr. Scott Sparks, COO of the Company, was paid US$70,660 during the fiscal year 2026, (2025: nil) for the provision of engineering and construction services to the Group. The Company considers that the services provided by Performance Industries, Inc. were provided on an arm’s length or better basis. Balances and transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated on consolidation and are not disclosed in this note.
104
- Parent Entity Disclosures (a) Financial Position
Assets Current Assets Non-Current Assets Total Assets Liabilities Current Liabilities Total Liabilities Equity Contributed equity Reserves Accumulated losses Total Equity
2026 US$
2025 US$
32,842,245 56,368,561 89,210,806
52,877,593 40,096,372 92,973,965
911,117 911,117
529,966 529,966
250,976,753 18,691,089 (181,368,153) 88,299,689
197,985,920 1,900,687 (107,442,608) 92,443,999
2026 US$ (73,925,545) 10,867,221 (63,058,324)
2025 US$ (33,021,422) (1,964,695) (34,986,117)
(b) Financial Performance
Loss for the year Other comprehensive gain (loss) Total comprehensive loss
(c) Other No guarantees have been entered into by the parent entity in relation to its subsidiaries. Refer to Note 26 for details of contingent assets and liabilities.
- Share-Based Payments (a) Recognized Share-Based Payment Expense From time to time, the Group grants ordinary shares, unlisted options, performance rights, and RSUs to officers, employees, consultants and other key advisors as part of remuneration and incentive arrangements. The number of Shares, Options, Rights, and RSUs granted, and the terms of the Shares, Options, Rights, and RSUs granted are determined by the Board. Shareholder approval is sought where required. During fiscal 2026 and 2025, the following equity-settled share-based payments have been recognized in profit or loss:
Expense arising from staff remuneration arrangements Total expense arising from equity-settled share-based payment transactions
105
2026 US$ (9,166,334) (9,166,334)
2025 US$ (9,568,191) (9,568,191)
- Share-Based Payments (continued) (b) Summary of Securities Granted as Share-Based Payments The following table illustrates the number and weighted-average exercise price of Options, and weighted-average grant date fair value for Rights and RSUs granted as share-based payments during fiscal 2026, and fiscal 2025:
Restricted Stock Units
WA Grant Date Fair Value A$
Performance Rights Awards (market-based conditions)
WA Grant Date Fair Value A$
Performance Rights Awards (performance conditions)
WA Grant Date Fair Value A$
0.28
4,377,034
2.04
25,613,335
0.74
1,856,000
1.08
2,679,746
6.46
2,220,020
3.99
4,938,409
3.49
350,000
3.81
(1,525,000)
(0.20)
(1,639,496)
(1.93)
(23,273,335)
(0.79)
(1,000,000)
(1.24)
(159,333)
(2.27)
(920,000)
(0.98)
(60,000)
(0.91)
June 30, 2025
12,904,118
1.57
4,798,225
2.97
6,358,409
2.66
1,146,000
1.78
Granted
4,086,871
18.40
853,979
6.53
660,077
2.66
109,000
5.43
Exercised/Converted
(2,118,279)
(0.62)
(1,540,516)
(2.23)
(595,000)
(1.53)
Forfeited
(8,000,000)
(0.20)
(1,018)
(6.91)
(630,000)
(2.45)
June 30, 2026
6,872,710
13.47
4,110,670
3.99
7,018,486
2.66
30,000
5.99
Stock Option Awards
WA Exercise Price A$
June 30, 2024
11,749,372
Granted Exercised/Converted Forfeited
The following Options, Rights and RSUs were granted as share-based payments during fiscal 2026 and 2025: 2026 Series 1
Security Type Rights
Number 45,000
Grant Date 6-Aug-25
Expiry Date 31-Dec-26
Exercise Price A$
Vesting Hurdle (30-day VWAP) A$
Fair Value A$ 5.99
Series 2
RSUs
118,875
28-Nov-25
23-Dec-26
5.11
Series 3
RSUs
12,000
5-Dec-25
31-Dec-26
5.02
Series 4
Options
235,000
5-Dec-25
1-Apr-27
10.00
0.40
Series 5
Rights
64,000
20-Dec-25
31-Dec-25
5.03
Series 6
RSUs
477,752
5-Mar-26
31-Dec-29
6.91
Series 7
Options
511,972
8-Mar-26
2-Apr-30
11.00
2.93
Series 8
Options
607,244
8-Mar-26
2-Apr-31
22.00
2.27
Series 9
Options
536,521
8-Mar-26
2-Apr-31
18.00
2.57
Series 10
Rights
226,047
8-Mar-26
2-Apr-31
18.00
4.47
Series 11
RSUs
209,032
8-Mar-26
2-Apr-30
6.55
Series 12
RSUs
20,820
9-Mar-26
2-Mar-28
6.55
Series 13
RSUs
15,500
9-Mar-26
2-Apr-28
6.55
Series 14
Options
1,165,965
19-Mar-26
2-Apr-31
22.00
0.96
Series 15
Options
1,030,169
19-Mar-26
2-Apr-31
18.00
1.11
Series 16
Rights
434,030
19-Mar-26
2-Apr-31
18.00
1.72
106
- Share-Based Payments (continued)
Expiry Date 31-Dec-27
Exercise Price A$
Vesting Hurdle (30-day VWAP) A$ 4.00
Fair Value A$ 2.98
23-Apr-26
3.00
3.12
1-Nov-24
23-Apr-26
4.00
2.53
1-Nov-24
31-Dec-25
3.40
1-Nov-24
23-Apr-26
3.40
1-Nov-24
31-Dec-27
3.40
169,944
22-Nov-24
16-Dec-28
4.40
120,000
20-Dec-24
31-Dec-25
4.60
42,486
9-Mar-25
16-Dec-28
3.37
RSUs
40,000
6-May-25
31-Dec-28
3.49
RSUs
113,475
8-May-25
31-Dec-28
3.40
Series 12
RSUs
56,738
9-May-25
31-Dec-28
3.55
Series 13
RSUs
82,335
10-May-25
10-Apr-29
3.55
Series 14
Options
216,672
10-May-25
10-Apr-29
5.00
1.87
Series 15
RSUs
13,617
12-May-25
31-Dec-28
3.41
Series 16
RSUs
8,511
13-May-25
31-Dec-28
3.17
Series 17
RSUs
400,533
15-May-25
10-Apr-29
3.11
Series 18
Rights
415,695
15-May-25
10-Apr-31
6.00
2.76
Series 19
Rights
415,695
15-May-25
10-Apr-31
7.00
2.68
Series 20
Rights
415,695
15-May-25
10-Apr-31
8.00
2.60
Series 21
RSUs
48,227
16-May-25
31-Dec-28
3.20
Series 22
RSUs
82,335
23-May-25
10-Apr-29
3.55
Series 23
Options
216,672
23-May-25
10-Apr-29
5.00
1.86
Series 24
RSUs
24,823
29-May-25
31-Dec-28
3.58
Series 25
RSUs
9,362
30-May-25
31-Dec-28
3.69
Series 26
RSUs
26,326
31-May-25
31-Dec-28
3.69
Series 27
RSUs
357,732
12-Jun-25
10-Apr-29
4.10
Series 28
Options
941,402
12-Jun-25
10-Apr-29
5.00
2.26
Series 29
RSUs
3,404
12-Jun-25
31-Dec-28
4.10
Series 30
Options
1,305,000
26-Jun-25
30-Jun-27
8.00
1.09
Series 31
RSUs
715,040
27-Jun-25
10-Apr-29
4.75
Series 32
Rights
742,108
27-Jun-25
10-Apr-31
6.00
4.48
Series 33
Rights
742,108
27-Jun-25
10-Apr-31
7.00
4.38
Series 34
Rights
742,108
27-Jun-25
10-Apr-31
8.00
4.29
2025 Series 1
Security Type Rights
Number 445,000
Grant Date 1-Nov-24
Series 2
Rights
435,000
1-Nov-24
Series 3
Rights
585,000
Series 4
Rights
30,000
Series 5
Rights
200,000
Series 6
RSUs
25,132
Series 7
RSUs
Series 8
Rights
Series 9
RSUs
Series 10 Series 11
(c) Weighted Average Remaining Contractual Life At June 30, 2026, the weighted average remaining contractual life of Unlisted Options was 3.37 years (2025: 0.96 years).
(d) Option, Right and RSU Pricing Models The fair value of granted RSUs and Rights that do not have market-based vesting conditions is estimated as at the date of grant based on the underlying share price.
107
- Share-Based Payments (continued) The fair value of granted Options is estimated as at the date of grant using the Black Scholes option valuation model taking into account the terms and conditions upon which the Unlisted Options were granted. The table below lists the inputs to the valuation models used for Options granted by the Group during fiscal 2026, and 2025: 2026 4.16 years 3.70% 73% -%
Expected life (weighted average) Risk-free interest rate (weighted average) Expected volatility (weighted average) Expected dividend yield
2025 2.96 years 3.28% 80% -%
The fair value of granted Rights that have market-based vesting conditions is estimated as at the date of grant using a trinomial valuation model taking into account the market-based vesting criteria upon which the Rights were granted. The table below lists the inputs to the valuation models used for the Rights that have market-based vesting conditions granted by the Group during fiscal 2026, and fiscal 2025: 2026 4.98 years 4.62% 75% A$2.66 A$4.58 A$18.00
Expected life (weighted average) Risk-free interest rate (weighted average) Expected volatility (weighted average) Fair value at grant date (weighted average) Share price at grant date (weighted average) Vesting hurdle (30-day VWAP) (weighted average)
2025 4.69 years 3.73% 77% A$3.49 A$3.94 A$6.02
Expected volatility was determined by reference to historical share price volatility over a period consistent with the expected life of the Options or Rights.
- Auditors’ Remuneration 2026 US$ PwC and related network firms: Audit or review of financial reports – Group Other assurance services
595,000 212,339 807,339
2025 US$ 400,000 400,000
- Segment Information AASB 8 requires operating segments to be identified on the basis of internal reports about components of the Consolidated Entity that are regularly presented to and reviewed by the chief operating decision maker in order to allocate resources to the segment and to assess its performance. The Consolidated Entity operates in one segment, being exploration and development of minerals and metals in the U.S.
(a) Reconciliation of non-current assets by geographical location 2026 US$ 61,223,170 61,223,170
United States
108
2025 US$ 45,719,988 45,719,988
- Financial Risk Management Objectives and Policies (a) Overview The Group’s principal financial instruments comprise cash, receivables, other financial assets, payables, loans and borrowings and lease liabilities. The main risks arising from the Group’s financial instruments are interest rate risk, foreign currency risk, credit risk and liquidity risk. The Group manages its exposure to key financial risks in accordance with the Group’s financial risk management policy. Key risks are monitored and reviewed as circumstances change and policies are revised as required. The overall objective of the Group’s financial risk management policy is to support the delivery of the Group’s financial targets whilst protecting future financial security. Given the nature and size of the business and uncertainty as to the timing and amount of cash inflows and outflows, the Group does not enter into derivative transactions to mitigate the financial risks. In addition, the Group’s policy is that no trading in financial instruments shall be undertaken for the purposes of making speculative gains. As the Group’s operations change, the Directors will review this policy periodically going forward. The Board of Directors has overall responsibility for the establishment and oversight of the risk management framework. The Board reviews and agrees policies for managing the Group’s financial risks as summarised below.
(b) Credit Risk Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet its contractual obligations. This arises principally from cash and cash equivalents, receivables, and other financial assets. There are no significant concentrations of credit risk within the Group. The carrying amount of the Group’s financial assets represents the maximum credit risk exposure, as represented below: Note 5 6
Cash and cash equivalents Trade and other receivables
2026 US$ 35,244,220 3,282,481 38,526,701
2025 US$ 54,814,125 823,268 55,637,393
With respect to credit risk arising from cash and cash equivalents, the Group’s exposure arises from default of the counter party, with a maximum exposure equal to the carrying amount of these instruments. The credit risk for cash and cash equivalents is considered negligible, since the counterparties are reputable banks with high quality external credit ratings. Trade and other receivables comprise primarily receivables from government funding programs, deposits, accrued interest and GST refunds due. Where possible the Group trades only with recognized, creditworthy third parties. It is the Group’s policy that all customers who wish to trade on credit terms are subject to credit verification procedures. In addition, receivable balances are monitored on an ongoing basis with the result that the Group’s exposure to bad debts is not significant. There were no past due receivables at the date of this report.
109
- Financial Risk Management Objectives and Policies (continued) (c) Liquidity Risk Liquidity risk is the risk that the Group will not be able to meet its financial obligations as they fall due. The Board’s approach to managing liquidity is to ensure, as far as possible, that the Group will always have sufficient liquidity to meet its liabilities when due. At June 30, 2026, the Group had sufficient liquid assets to meet its financial obligations. The Group had no financial covenants during the 2026 and 2025 financial periods, as the Group’s lease liabilities and other loans and borrowings do not impose any financial covenants other than the security interests in the leased assets that are held by the lessor. Leased assets may not be used as security for borrowing purposes. The contractual maturities of financial liabilities are provided in Note 14 - Loans and Borrowings. There are no netting arrangements in respect of financial liabilities.
(d) Interest Rate Risk The Group’s exposure to the risk of changes in market interest rates relates primarily to the cash and short-term deposits with a floating interest rate. These financial assets with variable rates expose the Group to cash flow interest rate risk. All other financial assets and liabilities are either non-interest bearing (for example, receivables and payables) or have fixed interest rates (for example, lease liabilities, sub-lease receivables, and loans and borrowings). At the reporting date, the interest rate profile of the Group’s financial instruments was: Note Interest-bearing financial instruments Cash at bank and on hand
5
2026 US$
2025 US$
35,244,220 35,244,220
54,814,125 54,814,125
The Group’s cash at bank and on hand and short-term deposits had a weighted average floating interest rate at year-end of 2.89% (2025: 3.48%). The Group currently does not engage in any hedging or derivative transactions to manage interest rate risk. Interest Rate Sensitivity A sensitivity of 0.5% (50 basis points) has been selected as this is considered reasonable given the current level of both short term and long-term interest rates. A 0.5% (50 basis points) movement in interest rates at the reporting date would have increased (decreased) equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular foreign currency rates, remain constant. Profit or Loss +0.5% US$ –0.5% US$ 2026 Cash and cash equivalents 2025 Cash and cash equivalents
Equity +0.5% US$
–0.5% US$
176,221
(176,221)
176,221
(176,221)
274,071
(274,071)
274,071
(274,071)
(e) Foreign Currency Risk Foreign currency risk is the risk that the fair value of future cash outflows will fluctuate because of changes in foreign currency exchange rates. The Group’s exposure to the risk of changes in foreign exchange rate relates primarily to assets and liabilities that are denominated in currencies other than the functional currency of the group entity.
110
- Financial Risk Management Objectives and Policies (continued) The Parent Company’s functional currency is Australian dollars. The financial statements are presented in U.S. dollars which is the Group’s presentation currency. The Group also has transactional currency exposures relating to transactions denominated in currencies other than the functional currency of the entity. It is the Group’s policy not to enter into any hedging or derivative transactions to manage foreign currency risk. At the reporting date, the Group’s exposure to financial instruments denominated in currencies other than the functional currency of the group entity: Assets and liabilities denominated in currencies other than the functional currency of the group entity Financial assets Cash and cash equivalents Financial liabilities Trade and other payables Net exposure
2026 US$ Equivalent
2025 US$ Equivalent
26,592,658
29,417,896
(2,985) 26,589,673
(1,130,814) 28,287,082
Foreign Exchange Rate Sensitivity At the reporting date, had the US$ appreciated or depreciated against the A$, as illustrated in the table below, profit or loss and equity would have been affected by the amounts shown below. This analysis assumes that all other variables remain constant.
2026 Group 2025 Group
Profit or Loss +10% US$ –10% US$
Equity +10% US$
–10% US$
2,658,967
(2,658,967)
2,658,967
(2,658,967)
2,828,707
(2,828,707)
2,828,707
(2,828,707)
(f) Commodity Price Risk The Group’s major commodity price exposure is to the price of titanium and titanium products. The price of titanium is affected by numerous factors beyond the control of the Group. The Group is currently researching, developing and commercializing its titanium metal technologies and exploring its mineral properties in the U.S. To date, the Group has not had significant sales of titanium and titanium products, but anticipates product sales now that the Group's Titanium Manufacturing Campus in Virginia has started operations. We currently do not enter into hedging or derivative transactions to manage commodity price risk.
(g) Capital Management The Board’s policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. Given the stage of development of the Group, the Board’s objective is to minimize debt and to raise funds as required through the issue of new shares. The Group is not subject to externally imposed capital requirements. There were no changes in the Group’s approach to capital management during the year.
(h) Fair Value The fair value of financial assets and financial liabilities approximates their carrying value. The methods for estimating fair value are outlined in the relevant notes to the consolidated financial statements.
111
-
Contingent Assets and Liabilities Titan Project The Titan Project is prospective for critical mineral sands including titanium minerals, rare earth minerals, high grade silica sand and zircon minerals. At June 30, 2026, the Group had entered into exclusive option agreements with local landowners in Tennessee, in relation to its Titan Project, which upon exercise, allows the Group to lease or, in some cases purchase, the acres of surface property and the associated mineral rights from the local landowners. As of June 30, 2026, the Titan Project comprised over 10,000 acres of surface and associated mineral rights in Tennessee, of which approximately 1,500 acres are owned by IperionX, approximately 1,200 acres are subject to long-term lease by IperionX, and approximately 7,500 acres are subject to exclusive option agreements with IperionX. During the option period, our option agreements provide us with exclusive right to access, enter, occupy and use the surface property for all purposes related to exploring for and evaluating all minerals in return for making annual option payments and bonus payments during periods when we conduct drilling. Upon exercise, in the case of an option to lease, the Company will pay a production royalty to the landowners, subject to a minimum royalty. Upon exercise, in the case of a purchase, the Company will pay cash consideration approximating the fair market value of the property, excluding the value of any minerals, plus a premium. On June 15, 2026, the Company entered into an agreement to acquire certain mining and infrastructure assets associated with Covia Solutions LLC’s Camden silica sand operation in Camden, Tennessee, adjacent to the Company’s Titan Project. The assets include mineral rights, at-surface pre-processed mineral stockpiles, mining and processing equipment, an existing rail spur, approximately 1,200 acres of owned property, approximately 1,300 acres of leased property, buildings and structures, and associated electrical, water, and gas infrastructure. The purchase price for the assets is US$3 million in cash. The acquisition was completed on July 1, 2026. In connection with the acquisition, the Company has agreed to assume Covia’s existing reclamation obligations related to certain disturbed property, which primarily consist of re-grading, re-vegetation, and stabilization of affected land. The Company is in the process of assessing the timing and estimated cost of these obligations, which will be recognized as a liability upon closing of the acquisition in accordance with applicable accounting standards. The acquisition is expected to provide strategic synergies with the Titan Project through consolidated mineral rights within the McNairy Formation, additional feedstock optionality from existing stockpiles and pre-stripped horizons, and utilization of established infrastructure. There are no material contingencies related to the purchase price; however, the assumed reclamation obligations represent a commitment that may result in future cash outflows. No other material commitments or contingencies related to this transaction have been identified as of the date of this report.
-
Events Subsequent to Balance Date (a) On July 1, 2026, the Company completed the acquisition of key assets from Covia Solutions LLC’s Camden, Tennessee silica sand operation for US$3 million. The assets include mineral rights, at-surface pre-processed mineral stockpiles, mining and processing equipment, an existing rail spur, approximately 1,200 acres of owned property, approximately 1,300 acres of leased property, buildings and structures, and associated electrical, water, and gas infrastructure. As of the date of issuance of these financial statements, management has not yet completed its determination of the fair values of the individual assets acquired. (b) On July 7, 2026, the Company completed the placement of 2,275,000 new fully paid ADSs, each representing 10 ordinary shares, to raise gross proceeds of US$50 million before costs. Proceeds from the offering will be used to continue the commercialization and scale-up of certain of our titanium and metal alloy production technologies, including continued scale-up and expansion of the Company’s Titanium Manufacturing Campus in Virginia and associated titanium metal research and development activities, continued development of the Atlas-Titan Project in Tennessee, and for general corporate purposes.
112
- Events Subsequent to Balance Date (continued) (c) On August 3, 2026, the Company announced a proposed redomiciliation of its ultimate parent company to Texas, U.S., subject to shareholder, court, regulatory and other customary approvals. Subject to completion of the transaction and applicable exchange approvals, the Company expects the common stock of the new U.S. parent company to be listed directly on Nasdaq, replacing the existing ADS structure. The proposed redomiciliation is not expected to impact the Company's underlying assets, operations or strategic priorities. On that same announcement, the Company announced the appointment of Michael J. Loparco as an independent nonexecutive director effective August 3, 2026. (d) On August 26, 2026, IperionX received Task Order 2 under its U.S. Army SBIR Phase III contract for Low-Cost, Domestic Titanium for Defense Applications that builds upon the previously announced US$1.3 million task order, lifting the aggregate potential value of task orders issued under the Company’s US$99 million SBIR Phase III contract up to US$26.7 million. This additional task order will fund the physical equipment and manufacturing systems required to increase throughput, bring critical production steps in-house, reduce acquisition and production costs, and accelerate delivery of titanium components for U.S. defense applications. Other than the above, as at the date of this report there are no other matters or circumstances which have arisen since June 30, 2026 that have significantly affected or may significantly affect: ▪ the operations, in financial years subsequent to June 30, 2026, of the Group; ▪ the results of those operations, in financial years subsequent to June 30, 2026, of the Group; or ▪ the state of affairs, in financial years subsequent to June 30, 2026, of the Group.
113
Consolidated Entity Disclosure Statement As At June 30, 2026 Trustee, partner or participant in Place of Joint Venture Incorporation
% of Share Capital
Australian resident or foreign resident
Foreign jurisdiction(s) of foreign residents
Entity Name
Entity Type
IperionX Limited
Body corporate
N/A
Australia
N/A
Australia
N/A
Hyperion Metals (Australia) Pty Ltd
Body corporate
N/A
Australia
100%
Australia
N/A
IperionX Critical Minerals Body corporate LLC
N/A
United States
100%
Foreign
United States
IperionX Technology LLC Body corporate
N/A
United States
100%
Foreign
United States
IperionX Inc.
N/A
United States
100%
Foreign
United States
Body corporate
Basis of Preparation This consolidated entity disclosure statement has been prepared in accordance with the Corporations Act 2001 and includes information for each entity that was part of the consolidated entity as at the end of the financial year in accordance with AASB 10 Consolidated Financial Statements.
Determination of Tax Residency Section 295 (3A)(vi) of the Corporations Act 2001 defines tax residency as having the meaning in the Income Tax Assessment Act 1997. The determination of tax residency involves judgment as there are different interpretations that could be adopted, and that could give rise to a different conclusion on residency. In determining tax residency, the consolidated entity has applied the following interpretations: ▪ Australian tax residency: the consolidated entity has applied current legislation and judicial precedent, including having regard to the Tax Commissioner’s public guidance in Tax Ruling 2018/5; and ▪ Foreign tax residency: where necessary, the consolidated entity has used independent tax advisers in foreign jurisdictions to assist in its determination of tax residency to ensure applicable foreign tax legislation has been complied with (see section 295(3A)(vii) of the Corporations Act 2001).
114
Directors’ Declaration In accordance with a resolution of the directors of IperionX Limited:
- In the opinion of the directors: (a) the attached financial statements, notes and the additional disclosures included in the directors’ report designated as audited, are in accordance with the Corporations Act 2001, including: (i) compliance with accounting standards and Corporations Regulations 2001 and other mandatory professional reporting requirements; and (ii) giving a true and fair view of the consolidated entity’s financial position as at June 30, 2026 and of its performance for the financial year ended on that date; and (b) there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable; and (c) the consolidated entity disclosure statement required by section 295(3A) of the Corporations Act 2001 is true and correct.
- The attached financial statements are in compliance with International Financial Reporting Standards as issued by the International Accounting Standards Board, as stated in note 1 to the financial statements.
- The Directors have been given the declarations required by section 295A of the Corporations Act 2001 for the financial year ended June 30, 2026. On behalf of the Board
Anastasios Arima CEO and Managing Director September 29, 2026
115
Independent Auditor’s Report To the Members of IperionX Limited
pwc Independent auditor's report To the members ofiperionX Limited
Report on the audit of the financial report Our opinion In our opinion, the accompanying financial report of IperionX Limited (the Company) and its controlled entities (together the Group) is in accordance with the Corporations Act 2001, including: a) giving a true and fair view of the Group's financial position as at 30 June 2026 and of its financial performance for the year then ended; and b) complying with Australian Accounting Standards and the Corporations Regulations 2001. What we have audited
The financial report comprises: • the consolidated statement of financial position as at 30 June 2026; • the consolidated statement of profit or loss and other comprehensive income for the year then ended; • the consolidated statement of changes in equity for the year then ended; • the consolidated statement of cash flows for the year then ended; • the notes to the consolidated financial statements, including material accounting policy information and other explanatory information; • the consolidated entity disclosure statement as at 30 June 2026; and • the directors' declaration.
PricewaterhouseCoopers, ABN 52 780 433 757 2 Riverside Quay, SOUTHBANK VIC 3006, GPO Box 1331 MELBOURNE VIC 3001 T: +61 3 8603 1000, F: +61386031999, www.pwc.com.au
pwc.com.au
Liabilitylimitedby a scheme approved under ProfessionalStandardsLegislation.
116
Independent Auditor’s Report (Continued)
pwc Basis for opinion We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial report section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Independence
We are independent of the Group in accordance with the auditor independence requirements of the Corporations Act 2001 and the ethical requirements of the Accounting Professional & Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (including Independence Standards) (the Code) that are relevant to audits of the financial report of public interest entities in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.
Our audit approach An audit is designed to provide reasonable assurance about whether the financial report is free from material misstatement. Misstatements may arise due to fraud or error. They are considered material if individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial report. We tailored the scope of our audit to ensure that we performed enough work to be able to give an opinion on the financial report as a whole, taking into account the geographic and management structure of the Group, its accounting processes and controls and the industry in which it operates. Audit Scope
Our audit focused on where the Group made subjective judgements; for example, significant accounting estimates involving assumptions and inherently uncertain future events. In establishing the overall approach to the group audit, we determined the type of work that needed to be performed by us, as the group auditor.
117
Independent Auditor’s Report (Continued)
pwc Key audit matters
Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report for the current period. The key audit matters were addressed in the context ofour audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. Further, any commentary on the outcomes of a particular audit procedure is made in that context. We communicated the key audit matter to the Audit Committee.
Key audit matter
How our audit addressed the key audit matter
Valuation of share-based payments
We performed the following procedures, amongst others
As described in Notes 1(y) and 22 to the financial report, the Group recognised share-based payment expenses of $9.2 million for the year ended 30 June 2026. The share-based payments are measured by the Group at fair value using valuation models that involved the use of significant assumptions including risk-free interest rate and share price volatility. The principal considerations for our determination that performing procedures relating to the valuation of share-based payments is a key audit matter are:
• testing the Group's process for determining the fair value of the sharebased payments; • testing the completeness and accuracy of the underlying data used in the estimate
• the significant judgement applied by the Group, including the use of the Group's expert, in determining the fair value of the share-based payments; • a high degree of auditor judgement, subjectivity and effort in performing procedures and evaluating audit evidence related to the Group's (a) valuation models and (b) significant assumptions related to risk-free interest rate and share price volatility • the audit effort involved the use of professionals with specialised skill and
knowledge
• evaluating the work of the Group's expert involved in the determination of significant judgements and assumptions; • involving professionals with specialised skill and knowledge to assist in evaluating the appropriateness of the Group's valuation models and certain significant assumptions • evaluating the disclosures made regarding the share-based payment expenses recognised in the financial report against the requirements of Australian Accounting Standards
Other information The directors are responsible for the other information. The other information comprises the information included in the annual report for the year ended 30 June 2026, but does not include the financial report and our auditor's report thereon.
118
Independent Auditor’s Report (Continued)
pwc Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon through our opinion on the financial report. We have issued a separate opinion on the remuneration report. In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed on the other information that we obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.
Responsibilities of the directors for the financial report The directors of the Company are responsible for the preparation of the financial report in accordance with Australian Accounting Standards and the Corporations Act 2001, including giving a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error. In preparing the financial report, the directors are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.
Auditor's responsibilities for the audit of the financial report Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial report. A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website at: https: //auasb.gov.au/media/bwvjcgre/an 2024.pdf. This description forms part of our auditor's report.
119
Independent Auditor’s Report (Continued)
pwc Report on the remuneration report Our opinion on the remuneration report We have audited the remuneration rep01t included in the directors' report for the year ended 30 June 2026. In our opinion, the remuneration report oflperionX Limited for the year ended 30 June 2026 complies with section 300A of the Col'pomtions Act 2001.
Responsibilities The directors of the Company are responsible for the preparation and presentation of the remuneration report in accordance with section 300A of the Cot'porations Act 2001. Our responsibility is to express an opinion on the remuneration report, based on our audit conducted in accordance with Australian Auditing Standards.
PricewaterhouseCoopers
Anthony Hodge Partner
Melbourne 29 September 2026
120
Mineral Resources Statement Mineral Resource Estimate The Titan Project, located in Tennessee USA, hosts a Mineral Resource of approximately 445.7 million tons at 2.1% total heavy mineral (“THM”), containing approximately 9.16 million tons of THM with an assemblage of zircon, rutile, ilmenite and rare earth elements. Mineral Resources are reported using the Mineral Resource definitions set out in the 2012 JORC Code on a 100% basis. The reference point for the estimate is in situ, and the Mineral Resource is inclusive of Ore Reserves. Titan Project Mineral Resources at June 30, 2026
Titan Project Mineral Resource Estimate Inclusive of Reserve Measured (M) Indicated (I) Total M+I Inferred (Inf) Total M+I+Inf Exclusive of Reserve Measured (M) Indicated (I) Total M+I Inferred (Inf) Total M+I+Inf Grand Total Measured (M) Indicated (I) Total M+I Inferred (Inf) Total M+I+Inf
THM Assemblage Rutile Ilmenite (%) (%)
In situ tons
THM (%)
THM (t)
Zircon (%)
120,434,000 28,388,000 148,823,000 148,823,000
2.5 2.9 2.6 2.6
3,060,000 828,000 3,887,000 3,887,000
11.1 11.8 11.2 11.2
9.5 9.2 9.4 9.4
40.9 52.0 43.2 43.2
1.5 1.5 1.5 1.5
96,851,000 102,190,000 199,041,000 97,832,000 296,872,000
1.5 2.0 1.8 1.8 1.8
1,489,000 2,013,000 3,502,000 1,774,000 5,276,000
10.4 9.8 10.0 9.3 9.8
9.2 10.2 9.8 9.6 9.7
40.1 38.9 39.4 38.0 39.0
1.2 1.5 1.4 1.2 1.3
217,285,000 130,578,000 347,863,000 97,832,000 445,695,000
2.1 2.2 2.1 1.8 2.1
4,548,000 2,841,000 7,389,000 1,774,000 9,163,000
10.8 10.4 10.6 9.3 10.4
9.4 9.9 9.6 9.6 9.6
40.6 42.7 41.4 38.0 40.8
1.4 1.5 1.4 1.2 1.4
Notes to accompany mineral resource table:
- Mineral Resources are reported using the definitions set out in the 2012 JORC Code and are current as at June 4, 2026. Mineral Resources are reported on an in situ basis, inclusive of Ore Reserves.
- The Competent Person responsible for the estimate is John Eckman.
- Mineral Resources are reported within a conceptual pit shell.
- Mineral Resources are reported above a cut-off grade of 0.4% THM.
- Estimates have been rounded.
121
REE (%)
Ore Reserves Estimates The DFS released on June 4, 2026 delivered an Ore Reserve for the Titan Project of approximately 117.0 million tons at 3.17% THM, comprising approximately 93.3 million tons of Proved and 23.7 million tons of Probable Ore Reserves, which underpins the 14-year mine plan and the DFS economic analysis. Ore Reserves were converted from Measured and Indicated Mineral Resources. Inferred Mineral Resources were set to waste. Ore Reserves are reported using the Ore Reserve definitions set out in the 2012 JORC Code on a 100% basis. Titan Project Ore Reserve Estimates at June 30, 2026
THM Assemblages
Titan Project Ore Reserve Estimate Unit
ROM tons
THM
THM
Zircon
Rutile
Ilmenite
REE
Proved
Probable
Total
(%)
(t)
(%)
(%)
(%)
(%)
Upper McNairy
24,565,000
2,415,000
26,980,000
2.30
620,000
6.2
6.2
23.6
0.2
Lower McNairy
68,740,000
21,307,000
90,047,000
3.43
3,086,000
12.7
10.5
48.3
1.9
Total
93,306,000
23,722,000
117,027,000
3.17
3,706,000
11.6
9.8
44.2
1.6
Notes to accompany ore reserve table:
- Ore Reserves are reported using the definitions set out in the 2012 JORC Code and are current as at June 4, 2026. Ore Reserves are reported at the point of delivery to the process plant.
- The Competent Person responsible for the estimate is Justin Douthat.
- Ore Reserves are reported within a finalized mine design pit shell.
- Ore Reserves are reported above a cut-off grade of 0.85% THM.
- Ilmenite includes leucoxene, pseudorutile, and ilmenite and REE includes monazite, xenotime, and unclassified REE.
- Estimates have been rounded.
122
Comparison of Current and Prior Year Mineral Resource and Ore Reserve Estimates In accordance with the Company’s annual reporting practices under the JORC Code (2012 Edition) and ASX Listing Rules, the Company compares current Mineral Resource and Ore Reserve estimates for material mining projects with corresponding prior estimates and explains material changes where applicable. This comparison assists investors in understanding whether changes in reported tons, grades, contained minerals or classifications resulted from exploration, updated modelling, changes in cut-off grade, updated modifying factors, changes in economic assumptions, depletion or other technical or commercial factors. The 4 June 2026 DFS updated the Mineral Resource estimate for the Titan Project and established the maiden Ore Reserve estimate for the Project. The changes from the prior year primarily reflect completion of the DFS, updated geological modelling, updated mineral assemblage data, application of modifying factors, mine planning, metallurgical assumptions, capital and operating cost assumptions, product pricing assumptions and conversion of a portion of Inferred and Indicated Mineral Resources to Measured, and of Measured and Indicated Mineral Resources to Proved and Probable Ore Reserves. Inferred Mineral Resources were treated as waste and were not used to support Ore Reserves or the Production Target. Mineral Resource Estimate Compared with Prior Year Measured (M) Indicated (I) Total M+I Inferred (Inf) Total M+I+Inf
In situ tons (Mt) 2026 217 131 348 98 446
2025 241 241 190 431
THM Assemblage THM (%) 2026 2.1 2.2 2.1 1.8 2.1
2025 2.2 2.2 2.2 2.2
THM (Mt) 2026 4.5 2.8 7.4 1.8 9.2
2025 5.3 5.3 4.2 9.5
Zircon (%)
Rutile (%)
Ilmenite (%)
2026 10.8 10.4 10.6 9.3 10.4
2026 9.4 9.9 9.6 9.6 9.6
2026 40.6 42.7 41.4 38.0 40.8
2025 11.3 11.3 11.7 11.5
2025 9.3 9.3 9.7 9.5
2025 39.7 39.7 41.2 40.3
REE (%) 2026 1.4 1.5 1.4 1.2 1.4
2025 2.1 2.1 2.2 2.1
Notes to accompany mineral resource table:
- Mineral Resources are reported using the definitions set out in the 2012 JORC Code. Mineral Resources are reported on an in-situ basis, and for 2026 are inclusive of Ore Reserves.
- Mineral Resources are reported above a cut-off grade of 0.4% THM.
- Estimates have been rounded.
123
Governance of Mineral Resources The Company’s governance arrangements and internal controls for reporting its Mineral Resource and Mineral Reserve Estimates include reporting on an annual basis and in compliance with the 2012 Edition of JORC and the ASX Listing Rules. Geological and assay data used in resource and reserve estimation are collected in accordance with industry-standard protocols and quality control procedures. Mineral Resource and Reserve estimates are prepared by a competent person who is suitably qualified and experienced as defined in the 2012 Edition of JORC. The Company engages external consultants and competent persons (as determined pursuant to the JORC Code) to prepare and calculate estimates of its Mineral Resources and Reserves. Management and the Board review these estimates and underlying assumptions for reasonableness and accuracy. The results of the Mineral Resource estimates and Reserve estimates are then reported in accordance with the requirements of the JORC Code and other applicable rules (including ASX Listing Rules). Where material changes occur during the year to a project, including the project’s size, title, exploration results or other technical information then previous resource and reserve estimates and market disclosures are reviewed for completeness. The Company reviews its Mineral Resources and Reserves as at June 30 each year. Where a material change has occurred in the assumptions or data used in previously reported Mineral Resources and Reserves, then where possible a revised Mineral Resource estimate and Mineral Reserve estimate will be prepared as part of the annual review process. However, there are circumstances where this may not be possible (e.g. an ongoing drilling program), in which case a revised Mineral Resource and Reserve Estimate will be prepared and reported as soon as practicable.
Competent Persons Statement The information in this report that relates to the Mineral Resource Estimate is based on, and fairly represents, information compiled and/or reviewed by Mr. John Eckman, a Competent Person who is a Certified Professional Geologist, American Institute of Professional Geologists (#CPG-11383) and a registered member of the Society for Mining, Metallurgy & Exploration (SME #4197942), both of which are Recognized Professional Organizations (RPO). Mr. Eckman is an employee of Marshall Miller & Associates. Mr. Eckman has sufficient experience which is relevant to the style and type of mineralization present at the Titan Project area and to the activity that he is undertaking to qualify as a Competent Person as defined in the 2012 edition of the “Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves” (the 2012 JORC Code). Mr. Eckman consents to the inclusion in this report of the matters based on this information in the form and context in which it appears. The information in this report that relates to the Ore Reserve Estimate is based on, and fairly represents, information compiled and/or reviewed by Mr. Justin Douthat, a Competent Person who is a Registered Member of the Society for Mining, Metallurgy & Exploration (SME #4028345), which is a Recognized Professional Organization (RPO). Mr. Douthat is an employee of Marshall Miller & Associates. Mr. Douthat has sufficient experience which is relevant to the style and type of mineralization present at the Titan Project area and to the activity that he is undertaking to qualify as a Competent Person as defined in the 2012 edition of the “Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves” (the 2012 JORC Code). Mr. Douthat consents to the inclusion in this report of the matters based on this information in the form and context in which it appears.
124
Corporate Governance IperionX Limited (IperionX or Company) and the entities it controls believe corporate governance is important for the Company in conducting its business activities. The Board has adopted a suite of charters and key corporate governance documents which articulate the policies and procedures followed by IperionX. These documents are available in the Governance section of the Company’s website, www.iperionx.com. These documents are reviewed at least annually to address any changes in governance practices and the law. This Corporate Governance Statement (Statement), which is current at June 30, 2026 and has been approved by the Company’s Board, explains how IperionX complies with the ASX Corporate Governance Council’s ‘Corporate Governance Principles and Recommendations – 4th Edition’ (ASX Principles and Recommendations), which were published in February 2019 in relation to the year ended June 30, 2026. Since the Company listed on Nasdaq in June 2022, it must also comply with the rules and laws applicable to a Foreign Private Issuer in the U.S. The sources of these rules and laws are principally the U.S. Securities and Exchange Commission and Nasdaq. In addition to the ASX Corporate Governance Council’s ‘Corporate Governance Principles and Recommendations – 4th Edition’ and applicable U.S. rules, the Board has taken into account a number of important factors in determining its corporate governance policies and procedures, including the: ▪ cost versus benefit of additional corporate governance requirements or processes; ▪ Board’s experience in the manufacturing and mineral resources sectors; ▪ organizational reporting structure and number of reporting functions, operational divisions and employees; and ▪ direct shareholder feedback.
The Company's 2026 Corporate Governance Statement is available at the Company's website. Please refer to https://iperionx.com/company-overview/governance-corporate-directory/
125
ASX Additional Information The shareholder information set out below was applicable as at August 31, 2026.
- Twenty Largest Holders of Listed Securities The names of the twenty largest holders of listed securities are listed below: No. of Ordinary Shares Held 147,954,735 42,877,379 21,932,246 14,033,171 10,191,060 6,613,448 6,440,000 5,222,144 4,198,713 4,000,002 3,639,881 2,909,772 2,677,501 2,534,675 2,500,000 2,396,534 1,900,000 1,784,501 1,773,791 1,500,000 1,500,000 288,579,553 73,660,610 362,240,163
Name HSBC Custody Nominees (Australia) Limited Citicorp Nominees Pty Limited J P Morgan Nominees Australia Pty Limited BNP Paribas Nominees Pty Ltd <Clearstream> BNP Paribas Noms Pty Ltd Moshos Family Investments Pty Ltd <Moshos Family A/c> UBS Nominees Pty Ltd Mr James Fisher McDonald BNP Paribas Nominees Pty Ltd <IB AU NOMS Retail Client> Arredo Pty Ltd M D H Pty Ltd BNP Paribas Nominees Pty Ltd <HUB24 Custodial Serv Ltd> Mr Dominic Paul Allen <Westoz Services A/c> Verve Investments Pty Ltd Halibery Hotels Pty Ltd HSBC Custody Nominees (Australia) Limited <GSCO Customers A/C> Petrus Holdings Pty Ltd Mr Lamont Edwin Leatherman Netwealth Investments Limited <Wrap Services A/C> Mrs Elizabeth Kate Whiting(1) Mr Neil Francis Michael Day(1) Total top 20 holders Other holders Total issued capital
Percentage of Issued Shares 40.8% 11.8% 6.1% 3.9% 2.8% 1.8% 1.8% 1.4% 1.2% 1.1% 1.0% 0.8% 0.7% 0.7% 0.7% 0.7% 0.5% 0.5% 0.5% 0.4% 0.4% 79.7% 20.3% 100.0%
(1) Tied position with the same number of ordinary shares held.
- Distribution of Equity Securities Analysis of numbers of holders by size of holding: Number of Shareholders 2,163 1,613 576 797 156 5,305
Distribution 1 – 1,000 1,001 – 5,000 5,001 – 10,000 10,001 – 100,000 More than 100,000 Totals
There were 566 holders of less than a marketable parcel of ordinary shares.
126
Number of Shares 926,931 4,267,691 4,358,134 24,170,930 328,516,477 362,240,163
% of Shares 0.3% 1.2% 1.2% 6.7% 90.7% 100%
- Distribution of Equity Securities (continued) Number of holders of unlisted Total Units Distribution options (1)* Held 1 – 1,000 — — 1,001 – 5,000 — — 5,001 – 10,000 — — 10,001 – 100,000 — — More than 100,000 4 1,374,746 Totals 4 1,374,746
Number of holders of % unlisted Total Units Held options (2)* Held —% — — —% — — —% — — —% — — 100% 2 1,305,000 100% 2 1,305,000
Number of holders of % unlisted Total Units Held options (3)* Held —% — — —% — — —% — — —% — — 100% 1 235,000 100% 1 235,000
% Held —% —% —% —% 100% 100%
Number of holders of % unlisted Total Units Held options (2) Held —% — — —% — — —% — — —% — — 100% 3 1,566,690 100% 3 1,566,690
Number of holders of % unlisted Total Units Held options (3) Held —% — — —% — — —% — — —% — — 100% 3 1,773,209 100% 3 1,773,209
% Held —% —% —% —% 100% 100%
(1) Exercise price A$5, expiring 10 April 2029 (2) Exercise price A$8, expiring 30 June 2027 (3) Exercise price A$10, expiring 1 April 2027
*Issued under the Company’s employee incentive scheme
Number of holders of unlisted Total Units Distribution options (1)* Held 1 – 1,000 — — 1,001 – 5,000 — — 5,001 – 10,000 — — 10,001 – 100,000 — — More than 100,000 4 511,972 Totals 4 511,972 (1) Exercise price A$11, expiring 2 April 2030 (2) Exercise price A$18, expiring 2 April 2031 (3) Exercise price A$22, expiring 2 April 2031
*Issued under the Company’s employee incentive scheme
Distribution 1 – 1,000 1,001 – 5,000 5,001 – 10,000
Number of holders of unlisted options (1)* — — —
Total Units Held — — —
% Held —% —% —%
Number of holders of performance rights(2)* — — —
Total Units Held — — —
10,001 – 100,000
—
—
More than 100,000 Totals
% Held —% —% —%
Number of holders of performance rights (3)* — — —
Total Units Held — — —
% Held —% —% —%
—%
1
30,000
100%
—
—
—%
1
947,062 100%
—
—
—%
3
2,440,000 100%
1
947,062 100%
1
30,000
100%
3
2,440,000 100%
(1) Exercise price A$11, expiring 6 August 2030 (2) Expiring 31 December 2026 and vest upon achieving various (non-market based) performance conditions (3) Expiring 21 December 2028 and vest upon achieving a 30-day VWAP of A$4.00 per share and other various (non-market based) performance conditions
*Issued under the Company’s employee incentive scheme
127
- Distribution of Equity Securities (continued)
Distribution 1 – 1,000 1,001 – 5,000 5,001 – 10,000 10,001 – 100,000 More than 100,000 Totals
Number of holders of performance rights(1)* — — — 2
Total Units % Held Held — —% — —% — —% 145,000 33%
Number of holders of performance rights(2) — — — —
2
300,000 67%
3
1,157,803 100%
3
1,157,803 100%
4
445,000 100%
3
1,157,803 100%
3
1,157,803 100%
Total Units Held — — — —
% Held —% —% —% —%
Number of holders of performance rights(3) — — — —
Total Units Held — — — —
% Held —% —% —% —%
(1) Expiring 31 December 2027 and vest upon achieving a 30-day VWAP of A$4.00 per share and other various (non-market based) performance conditions (2) Expiring 10 April 2031 and vest upon achieving a 30-day VWAP of A$6.00 per share (3) Expiring 10 April 2031 and vest upon achieving a 30-day VWAP of A$7.00 per share
*Issued under the Company’s employee incentive scheme
Distribution 1 – 1,000 1,001 – 5,000 5,001 – 10,000 10,001 – 100,000 More than 100,000 Totals
Number of holders of performance rights(1) — — — —
Total Units Held — — — —
% Held —% —% —% —%
Number of holders of performance rights(2) — — — —
Total Units Held — — — —
% Held —% —% —% —%
Number of Total holders of Units RSUs(3) Held — — — — — — 1 16,755
% Held —% —% —% 100%
3
1,157,803 100%
3
660,077 100%
—
—
—%
3
1,157,803 100%
3
660,077 100%
1
16,755
100%
(1) Expiring 10 April 2031 and vest upon achieving a 30-day VWAP of A$8.00 per share (2) Expiring 2 April 2031 and vest upon achieving a 30-day VWAP of A$18.00 per share (3) Expiring 31 December 2027
Number of holders of Total Units Distribution RSUs(1) Held 1 – 1,000 — — 1,001 – 5,000 — — 5,001 – 10,000 — — 10,001 – 100,000 5 141,620 More than 100,000 — — Totals 5 141,620
Number of % holders of Total Units Held RSUs(2) Held —% — — —% — — —% — — 100% 2 164,670 —% 5 1,473,305 100% 7 1,637,975
(1) Expiring 16 December 2028 (2) Expiring 10 April 2029 (3) Expiring 31 December 2028
128
Number of % holders of Total Units Held RSUs(3) Held —% — — —% 3 9,833 —% 3 20,993 10% 8 212,159 90% — — 100% 14 242,985
% Held —% 4% 9% 87% —% 100%
- Distribution of Equity Securities (continued) Number of holders of Total Units Distribution RSUs(1) Held 1 – 1,000 — — 1,001 – 5,000 — — 5,001 – 10,000 — — 10,001 – 100,000 5 118,875 More than 100,000 — — Totals 5 118,875
Number of % holders of Total Units Held RSUs(2) Held —% — — —% 11 37,814 —% 13 94,052 100% 14 344,868 —% — — 100% 38 476,734
Number of % holders of Total Units Held RSUs(3) Held —% — — 8% 1 1,820 20% — — 72% 1 19,000 —% — — 100% 2 20,820
% Held —% 9% —% 91% —% 100%
Number of % holders of Total Units Held RSUs(2) Held —% — — —% — — —% — — 100% 1 58,584 —% — — 100% 1 58,584
Number of % holders of Total Units Held RSUs(3) Held —% — — —% — — —% — — 100% 4 135,044 —% — — 100% 4 135,044
% Held —% —% —% 100% —% 100%
Number of % holders of Total Units Held RSUs(2) Held —% — — —% — — —% — — 29% 1 15,500 71% — — 100% 1 15,500
% Held —% —% —% 100% —% 100%
(1) Expiring 23 December 2026 (2) Expiring 31 December 2029 (3) Expiring 2 March 2028
Number of holders of Total Units Distribution RSUs(1) Held 1 – 1,000 — — 1,001 – 5,000 — — 5,001 – 10,000 — — 10,001 – 100,000 4 209,032 More than 100,000 — — Totals 4 209,032 (1) Expiring 2 April 2030 (2) Expiring 3 August 2028 (3) Expiring 5 December 2027
Number of holders of Total Units Distribution RSUs(1) Held 1 – 1,000 — — 1,001 – 5,000 — — 5,001 – 10,000 — — 10,001 – 100,000 5 314,664 More than 100,000 3 780,666 Totals 8 1,095,330 (1) Expiring 31 December 2026 (2) Expiring 2 April 2028
129
- Voting Rights The voting rights attached to securities are set out below:
Ordinary shares – On a show of hands each eligible voter present has one vote. Where a person present at a general meeting represents personally or by proxy, attorney or representative more than one member, on a show of hands the person is entitled to one vote only despite the number of members the person represents. On a poll each eligible member has one vote for each fully paid share held and a fraction of a vote for each partly paid share determined by the amount paid up on that share. Under the Company’s constitution resolutions of members will be decided by a show of hands unless a poll is demanded. However, in accordance with the Corporations Act 2001 (Commonwealth - Cth), the Company decides all resolutions proposed at its shareholder meetings by poll.
Unlisted options – The unlisted options on issue do not carry any voting rights. Performance rights – The performance rights on issue do not carry any voting rights. Restricted Stock Units – The Restricted Stock Units on issue do not carry any voting rights.
-
Substantial Shareholders Substantial shareholder notices have been received from the following: Substantial Shareholder The Bank of New York Mellon Corporation and its associates (ADR program) FMR LLC and its associates DITM Holdings Pty Ltd and its associates State Street Corporation JP Morgan Chase & Co
-
On-market Buy Back There is currently no on-market buyback program for any of IperionX Limited’s listed securities.
130
Number of Shares 96,768,001 26,097,578 27,133,334 27,793,172 24,126,965
- Unquoted Securities The names of the security holders holding 20% or more of an unlisted class of security at 31 August 2026, not issued or acquired under an employee incentive scheme, are listed below:
Holder
Nalaroo Holdings Pty Ltd Lorraine Martin Tony Tripeny Melissa Waller Beverly Wyse Michael Loparco Anastasios Arima Todd Hannigan Toby Symonds Others (less than 20%) Total Total holders
Director Director Director Director Employee Employee Restricted Restricted Restricted Restricted Restricted Restricted Stock Units, Stock Units, Stock Units, Stock Units, Stock Units, Stock Units, expiring expiring expiring expiring expiring expiring December December December August 3, December April 10, 5, 2027 16, 2028 23, 2026 2028 31, 2026 2029
33,761 33,761 33,761 33,761 135,044 4
28,324 28,324 28,324 28,324 28,324 141,620 5
22,686 28,131 22,686 22,686 22,686 118,875 5
58,584 58,584 1
Employee Options A$18, expiring April 2, 2031
Employee Options A$22, expiring April 2, 2031
318,666 419,910 564,759 639,205 465,410 526,760 302,666 400,533 536,521 607,244 473,998 817,532 1,095,330 1,637,975 1,566,690 1,773,209 8 7 3 3
Holder
Employee Restricted Stock Units, expiring April 2, 2030
Employee Restricted Stock Units, expiring March 2, 2028
Employee Restricted Stock Units, expiring April 2, 2028
Employee Restricted Stock Units, expiring December 31, 2027
Employee Restricted Stock Units, expiring December 31, 2028
Employee Restricted Stock Units, expiring December 31, 2029
Employee Performance Rights, expiring April 10, 2031
Employee Performance Rights, expiring April 2 2031
Anastasios Arima Todd Hannigan Toby Symonds David Landrith Dominic Allen Marcela Castro Scott Sparks Michael Spath Eric Colby Cameron Dowle Shiva Venkataraman Others (less than 20%) Total Total holders
52,258 52,258 52,258 52,258 209,032 4
19,000 1,820 20,820 2
15,500 15,500 1
16,755 16,755 1
56,737 186,248 242,985 14
476,734 476,734 38
1,307,418 918,906 1,247,085 3,473,409 3
237,944 196,086 226,047 660,077 3
- Restricted Securities There are no securities restricted or the subject of voluntary escrow.
131
- Exploration Interests Titan Project The Titan Project property consists of over 10,000 acres of surface and associated mineral rights in Tennessee, of which approximately 1,500 acres are owned by IperionX Critical Minerals LLC, approximately 1,200 acres are subject to long-term lease by IperionX Critical Minerals LLC, and approximately 7,500 acres are subject to exclusive option agreements with IperionX Critical Minerals LLC. These exclusive option agreements, upon exercise, allow IperionX to lease or, in some cases, purchase the surface property and associated mineral rights.
Project Atlas Project Atlas property consists of approximately 2,500 acres of surface and associated mineral rights in Tennessee, of which approximately 1,200 acres are owned by IperionX Critical Minerals LLC, and approximately 1,300 acres are subject to longterm mineral and surface rights leases held by IperionX Critical Minerals LLC. Land Parcel Number
State
Interest in Surface and Mineral rights
Project Titan 168.014.03, 167.006.00, 171.009.00, 171.009.01, 171 005.03, 171.009.03, 171.009.04, 005 002.00, 044 016.01, 171 002.00, 171 003.00, 171 009.02, 171 013.00, 171 008.00, 171 011.00, 175 013.01, 023 002.0, 171 010.01, 005 003.00, 171 010.00, 006.030.00, 026.009.00, 025.017.00, 171.001.00, 022.020.00, 168.005.02, 168.011.00, 134.014.01, 150.008.05, 151.008.03, 152.009.00, 152.011.00, 152.013.03, 152.020.01, 168.018.01, 168.019.04, 168.013.00, 005.002.01, 168.005.00, 168.005.01, 064.022.00, 063.005.01, 063.005.00, 063.006.00, 061.010.00, 064.020.00, 064.021.00, 171.005.00, 168.017.00, 171.005.01, 048.017.00, 171.005.02, 171.005.04, 169.017.01, 060.001.00, 129.027.00, 129.027.01, 135.005.01, 129.028.00, 162.009.001, 162.018.00, 163.009.00, 162.009.00, 165.019.00, 010.001.00, 050.020.00, 050.036.01, 166.011.00, 010.014.00, 010.013.00, 011.037.03, 010.014.01, 151.008.00, 151.009.00, 151.009.04, 151.009.03, 064.010.00, 064.007.00
Tennessee
100%
Tennessee
100%
Project Atlas 086.058.00, 086.085.01, 089.002.01, 091.007.01, 089.009.00, 090.001.02, 088.014.00, 091.008.00, 085.002.00, 085.009.00, 085.002.02, 085.001.00, 085.003.00, 085.009.02, 085.009.01, 090.002.00, 086.058.01, 097.010.00, 097.016.00, 097.010.02, 096.014.00, 089.004.00, 090.001.01, 085.008.05, 086.006.00, 091.007.02, 091.007.12, 089.003.00, 097.010.01, 085.011.00, 088.001.01, 085.008.00
- Phase 2 Material Assumptions and Cautionary Statements 1,400 tpa – “Phase 2” - (Refer ASX announcement dated September 2, 2025) Engineering and design work relating to the production capacities referred to in this report has been undertaken to determine the potential viability of the Company’s proposed Phase 2 facility to produce titanium metal products. The results should not be considered a profit forecast or a production forecast. While the Company considers all of the material assumptions contained in the ASX announcement dated September 2, 2025 to be based on reasonable grounds, there is no certainty that they will prove to be correct or that the range of outcomes indicated by the Phase 2 projections will be achieved. Estimates for capital and operating costs are subject to a variety of potential variances including, but not limited to, price of labor, price of consumables, foreign exchange impacts, and raw material prices. To achieve the Phase 2 capacity estimates, funding in the order of US$75 million, including contingency, will likely be required, which may be sourced from existing cash balance and government grants, including the DoW IBAS and SBIR Phase III programs.
132
- ASX Compliance Statements This report contains information relating to a Mineral Resource Estimate and an Ore Reserve Estimate for the Titan deposit (where the Mineral Resource Estimate was prepared by Mr. John Eckman, a Competent Person, and the Ore Reserve Estimate was prepared by Mr. Justin Douthat, also a Competent Person) extracted from an ASX market announcement titled “IperionX Titan DFS Confirms High-Return U.S. Rare Earths and Critical Minerals Project” and published on the ASX platform (www.asx.com.au) on June 4, 2026. The Company confirms that it is not aware of any new information or data that materially affects the information included in the original market announcement and that all material assumptions and technical parameters underpinning the estimates in the release of June 4, 2026 continue to apply and have not materially changed. The Company confirms that the form and context in which the Competent Persons' findings are presented have not been materially modified from the original market announcement. This report contains exploration results relating to the Atlas deposit extracted from an ASX market announcement titled “Acquisition Delivers High Value Critical Minerals” and published on the ASX platform (www.asx.com.au) on July 2, 2026. The Company confirms that it is not aware of any new information or data that materially affects the information included in the original market announcement. The Company confirms that the form and context in which the Competent Persons' findings are presented have not been materially modified from the original market announcement. The Competent Person was Mr Adam Karst. This report contains production target and forecast financial information extracted from an ASX announcement titled “IperionX Titan DFS Confirms High-Return U.S. Rare Earths and Critical Minerals Project” and published on the ASX platform (www.asx.com.au) on June 4, 2026. The Company confirms that all material assumptions underpinning the production target and forecast financial information disclosed in the ASX announcement dated June 4, 2026 continue to apply and have not materially changed.
133
- Forward Looking Statements This report may include forward-looking statements. Often, but not always, forward looking statements can generally be identified by the use of forward-looking words such as “may”, “will”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “continue”, and “guidance”, or other similar words and may include, without limitation, statements regarding plans, strategies and objectives of management, anticipated production or construction commencement dates and expected costs or production outputs. Forward looking statements inherently involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance, and achievements to differ materially from any forecast future results, performance, or achievements. Relevant factors may include, but are not limited to, changes in commodity prices, foreign exchange fluctuations and general economic conditions, increased costs and demand for production inputs, the speculative nature of exploration and project development, including the risks of obtaining necessary licenses and permits and diminishing quantities or grades of mineralization, the Company’s ability to comply with the relevant contractual terms to access the technologies, commercially scale its closed-loop titanium production processes, or protect its intellectual property rights, political and social risks, changes to the regulatory framework within which the Company operates or may in the future operate, environmental conditions including extreme weather conditions, recruitment and retention of personnel, industrial relations issues and litigation. Forward looking statements are based on the Company and its management’s good faith assumptions relating to the financial, market, regulatory and other relevant environments that will exist and affect the Company’s business and operations in the future. The Company does not give any assurance that the assumptions on which forward looking statements are based will prove to be correct, or that the Company’s business or operations will not be affected in any material manner by these or other factors not foreseen or foreseeable by the Company or management or beyond the Company’s control. Although the Company attempts and has attempted to identify factors that would cause actual actions, events or results to differ materially from those disclosed in forward looking statements, there may be other factors that could cause actual results, performance, achievements, or events not to be as anticipated, estimated or intended, and many events are beyond the reasonable control of the Company. Accordingly, readers are cautioned not to place undue reliance on forward looking statements. Forward looking statements in these materials speak only at the date of issue. Subject to any continuing obligations under applicable law or any relevant stock exchange listing rules, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based.
134
GLOSSARY OF TERMS AND DEFINITIONS When the following terms and abbreviations appear in the text of this report, they have the meanings indicated below: AASB ADSs AMC ARHTM ASTM ASX Atlas or Atlas Project Blacksand CCO CEO CFO CO2e COO CSO DEVCOM DFS DoW DRS DTC DPA Title III EBITDA EPS Exchange Act FR GenXTM Green RutileTM GSDTM GVSC HAMRTM HMAPL HREC HSPTTM HfO₂ IAS IASB IBAS IDIQ IFRS IperionX Limited IP IPF IRR JLTV JORC Code kg
Australian Accounting Standards Board American Depositary Shares Advanced Manufacturing Center IperionX proprietary technology for alkaline roasting and hydrolysis American Society for Testing and Materials Australian Securities Exchange Mineral, property and infrastructure assets acquired from Covia Solutions LLC on July 1, 2026 Blacksand Technology LLC Chief Commercial Officer Chief Executive Officer Chief Financial Officer Carbon dioxide equivalents Chief Operating Officer Chief Strategy Officer U.S. Army Combat Capabilities Development Command Definitive Feasibility Study Department of War, also referred to as "Department of Defense", renamed by Executive order 14347, “Restoring the United States Department of War” Direct Registration System Depository Trust Company A provision of the Defense Production Act of 1950 that allows the President to expand the production and supply of critical materials necessary for national defense. Earnings before interest, taxes, depreciation and amortization Earnings per share U.S. Securities Exchange Act of 1934, as amended Fixed remuneration IperionX's next-generation continuous HAMRTM platform IperionX proprietary technology for low carbon titanium mineral enrichment IperionX proprietary technology for the Granulation Sintering DeoxygenationTM process DEVCOM Ground Vehicle Systems Center IperionX patented technology for Hydrogen Assisted Metallothermic ReductionTM Hyperion Metals (Australia) Pty Ltd Heavy rare earth concentrate IperionX patented technology for hydrogen sintering and phase transformation process Hafnium Dioxide International Accounting Standards International Accounting Standards Board U.S. DoW Industrial Base Analysis and Sustainment grant program Indefinite delivery, indefinite quantity International Financial Reporting Standards “Company” or “IperionX”, “Consolidated Entity” or “Group” Intellectual property Industrial Pilot Facility in West Valley City, Utah internal rate of return Joint Light Tactical Vehicle Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves kilogram
135
KMP KPI LTI LTIP m m3 Mt N/A Nasdaq NEDs NPV Ordinary Shares Performance Rights Performance Shares PwC QP R&D REE REO ROM RSUs SAE SBIR STI Technologies THM THRMTM TiCl4 TiO2 TiH2 Ti-6Al-4V Titan Project tpa TPF Treaty
Key Management Personnel Key performance indicators Long-term incentives Long-term incentive plan meter cubic meter Million metric tons Not applicable Nasdaq Capital Market Non-Executive Directors Net Present Value Common shares, equity instruments that give shareholders voting rights and potential dividends Equity awards requiring achievement of relevant performance conditions Contingent stock awards that are vesting based on performance metrics PricewaterhouseCoopers Qualified Person Research and development Rare earth elements Rare earth oxide Run of mine Restricted stock units Society of Automotive Engineers Small Business Innovation Research Short term incentives IperionX's collection of patents to certain titanium and metal alloy production technologies Total heavy mineral(s) IperionX patented technology for Thermo-Hydrogen Refinement of MicrostructureTM Titanium tetrachloride Titanium dioxide Titanium hydride Grade 5 titanium alloy Titan Critical Minerals Project in Tennessee Metric tons per annum Titanium Production Facility
UL U.S. U.S. GAAP Unlisted Options VWAP WA ZrO2
Underwriters Laboratories United States of America U.S. generally accepted accounting principles Unquoted incentive options Volume-weighted average price Weighted average Zirconium Dioxide
the Convention between the Government of the United States of America and the Government of Australia for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income, as amended
136
Corporate Directory Directors
Website
Mr. Todd Hannigan – Executive Chairman
Mr. Anastasios Arima – CEO & Managing Director Ms. Lorraine Martin – Lead Independent Director
Stock Exchange Listings
Mr. Michael J. Loparco – Independent Non-Executive Director
Nasdaq Capital Market (NASDAQ: IPX)
Mr. Vaughn Taylor – Independent Non-Executive Director
Australian Securities Exchange (ASX: IPX)
Mr. Tony Tripeny – Independent Non-Executive Director Ms. Melissa G. Waller – Independent Non-Executive Director Ms. Beverly M. Wyse – Independent Non-Executive Director
Share Registry Company Secretary
Automic Pty Ltd
Ms. Louisa Martino
Tel: 1300 288 664 Int: +61 2 9698 5414
Offices Lawyers Principal Executive Office 1092 Confroy Drive
United States
South Boston, VA 24592
Gibson, Dunn & Crutcher
UNITED STATES
Australia Tennessee Office
Thomsons
279 West Main Street
Bankers
Camden, TN 38320 UNITED STATES
United States Utah Office
The Bank of New York Mellon Corp
1782 W 2300 S
PNC Bank
West Valley City, UT 84119
Australia
UNITED STATES
National Australia Bank
Registered Office Level 5, 56 Pitt Street
Auditor
Sydney NSW 2000
PricewaterhouseCoopers
AUSTRALIA
Melbourne, Australia
Int: +61 2 8823 3179
137
iperionx.com
Rules 4.7.3 and 4.10.3
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity
IperionX Limited
ABN/ARBN
Financial year ended:
84 618 935 372
June 30, 2026
Our corporate governance statement1 for the period above can be found at:2
☐
These pages of our annual report:
☒
This URL on our website:
https://iperionx.com/company-overview/governance-corporate-directory/
The Corporate Governance Statement is accurate and up to date as at 30 June 2026 and has been approved by the board. The annexure includes a key to where our corporate governance disclosures can be located. 3 Date:
September 29, 2026
Name of authorised officer authorising lodgement:
Louisa Martino – Company Secretary
1 “Corporate governance statement” is defined in Listing Rule 19.12 to mean the statement referred to in Listing Rule 4.10.3 which
discloses the extent to which an entity has followed the recommendations set by the ASX Corporate Governance Council during a particular reporting period. Listing Rule 4.10.3 requires an entity that is included in the official list as an ASX Listing to include in its annual report either a corporate governance statement that meets the requirements of that rule or the URL of the page on its website where such a statement is located. The corporate governance statement must disclose the extent to which the entity has followed the recommendations set by the ASX Corporate Governance Council during the reporting period. If the entity has not followed a recommendation for any part of the reporting period, its corporate governance statement must separately identify that recommendation and the period during which it was not followed and state its reasons for not following the recommendation and what (if any) alternative governance practices it adopted in lieu of the recommendation during that period. Under Listing Rule 4.7.4, if an entity chooses to include its corporate governance statement on its website rather than in its annual report, it must lodge a copy of the corporate governance statement with ASX at the same time as it lodges its annual report with ASX. The corporate governance statement must be current as at the effective date specified in that statement for the purposes of Listing Rule 4.10.3. Under Listing Rule 4.7.3, an entity must also lodge with ASX a completed Appendix 4G at the same time as it lodges its annual report with ASX. The Appendix 4G serves a dual purpose. It acts as a key designed to assist readers to locate the governance disclosures made by a listed entity under Listing Rule 4.10.3 and under the ASX Corporate Governance Council’s recommendations. It also acts as a verification tool for listed entities to confirm that they have met the disclosure requirements of Listing Rule 4.10.3. The Appendix 4G is not a substitute for, and is not to be confused with, the entity's corporate governance statement. They serve different purposes and an entity must produce each of them separately. 2 Tick whichever option is correct and then complete the page number(s) of the annual report, or the URL of the web page, where
your corporate governance statement can be found. You can, if you wish, delete the option which is not applicable. 3 Throughout this form, where you are given two or more options to select, you can, if you wish, delete any option which is not
applicable and just retain the option that is applicable. If you select an option that includes “OR” at the end of the selection and you delete the other options, you can also, if you wish, delete the “OR” at the end of the selection. See notes 4 and 5 below for further instructions on how to complete this form. ASX Listing Rules Appendix 4G (current at 17/7/2020)
Page 1
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations
ANNEXURE – KEY TO CORPORATE GOVERNANCE DISCLOSURES Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
PRINCIPLE 1 – LAY SOLID FOUNDATIONS FOR MANAGEMENT AND OVERSIGHT 1.1
1.2
1.3
1.4
A listed entity should have and disclose a board charter setting out: (a) the respective roles and responsibilities of its board and management; and (b) those matters expressly reserved to the board and those delegated to management.
☒
☐
set out in our Corporate Governance Statement OR
and we have disclosed a copy of our board charter at: https://iperionx.com/company-overview/governance-corporatedirectory/
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity should: (a) undertake appropriate checks before appointing a director or senior executive or putting someone forward for election as a director; and (b) provide security holders with all material information in its possession relevant to a decision on whether or not to elect or re-elect a director.
☒
☐
set out in our Corporate Governance Statement OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity should have a written agreement with each director and senior executive setting out the terms of their appointment.
☒
☐
set out in our Corporate Governance Statement OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
The company secretary of a listed entity should be accountable directly to the board, through the chair, on all matters to do with the proper functioning of the board.
☒
☐
set out in our Corporate Governance Statement OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
4
Tick the box in this column only if you have followed the relevant recommendation in full for the whole of the period above. Where the recommendation has a disclosure obligation attached, you must insert the location where that disclosure has been made, where indicated by the line with “insert location” underneath. If the disclosure in question has been made in your corporate governance statement, you need only insert “our corporate governance statement”. If the disclosure has been made in your annual report, you should insert the page number(s) of your annual report (eg “pages 10-12 of our annual report”). If the disclosure has been made on your website, you should insert the URL of the web page where the disclosure has been made or can be accessed (eg “www.entityname.com.au/corporate governance/charters/”). 5
If you have followed all of the Council’s recommendations in full for the whole of the period above, you can, if you wish, delete this column from the form and re-format it.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
Page 2
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
1.5
A listed entity should: (a) have and disclose a diversity policy; (b) through its board or a committee of the board set measurable objectives for achieving gender diversity in the composition of its board, senior executives and workforce generally; and (c) disclose in relation to each reporting period: (1) the measurable objectives set for that period to achieve gender diversity; (2) the entity’s progress towards achieving those objectives; and (3) either: (A) the respective proportions of men and women on the board, in senior executive positions and across the whole workforce (including how the entity has defined “senior executive” for these purposes); or (B) if the entity is a “relevant employer” under the Workplace Gender Equality Act, the entity’s most recent “Gender Equality Indicators”, as defined in and published under that Act. If the entity was in the S&P / ASX 300 Index at the commencement of the reporting period, the measurable objective for achieving gender diversity in the composition of its board should be to have not less than 30% of its directors of each gender within a specified period.
☐
☒
set out in our Corporate Governance Statement OR
and we have disclosed a copy of our diversity policy at: …………………………………………………………………………….. [insert location] and we have disclosed the information referred to in paragraph (c) at: …………………………………………………………………………….. [insert location] and if we were included in the S&P / ASX 300 Index at the commencement of the reporting period our measurable objective for achieving gender diversity in the composition of its board of not less than 30% of its directors of each gender within a specified period.
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity should: (a) have and disclose a process for periodically evaluating the performance of the board, its committees and individual directors; and (b) disclose for each reporting period whether a performance evaluation has been undertaken in accordance with that process during or in respect of that period.
☒
☐ ☐
set out in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable
1.6
ASX Listing Rules Appendix 4G (current at 17/7/2020)
and we have disclosed the evaluation process referred to in paragraph (a) in our Corporate Governance Statement and whether a performance evaluation was undertaken for the reporting period in accordance with that process in our Corporate Governance Statement
Page 3
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
1.7
☒
☐
set out in our Corporate Governance Statement OR
and we have disclosed the evaluation process referred to in paragraph (a) in our 2026 Annual Report (Remuneration Report) and whether a performance evaluation was undertaken for the reporting period in accordance with that process.
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity should: (a) have and disclose a process for evaluating the performance of its senior executives at least once every reporting period; and (b) disclose for each reporting period whether a performance evaluation has been undertaken in accordance with that process during or in respect of that period.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
Page 4
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
PRINCIPLE 2 - STRUCTURE THE BOARD TO BE EFFECTIVE AND ADD VALUE 2.1
2.2
2.3
The board of a listed entity should: (a) have a nomination committee which: (1) has at least three members, a majority of whom are independent directors; and (2) is chaired by an independent director, and disclose: (3) the charter of the committee; (4) the members of the committee; and (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have a nomination committee, disclose that fact and the processes it employs to address board succession issues and to ensure that the board has the appropriate balance of skills, knowledge, experience, independence and diversity to enable it to discharge its duties and responsibilities effectively.
☒
☐
set out in our Corporate Governance Statement OR
and we have disclosed a copy of the charter of the committee at: https://iperionx.com/company-overview/governance-corporatedirectory/ and the information referred to in paragraphs (4) and (5) in our 2026 annual report and at: https://iperionx.com/company-overview/governance-corporatedirectory/
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity should have and disclose a board skills matrix setting out the mix of skills that the board currently has or is looking to achieve in its membership.
☒
☐
set out in our Corporate Governance Statement OR
and we have disclosed our board skills matrix in our Corporate Governance Statement
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity should disclose: (a) the names of the directors considered by the board to be independent directors; (b) if a director has an interest, position, affiliation or relationship of the type described in Box 2.3 but the board is of the opinion that it does not compromise the independence of the director, the nature of the interest, position or relationship in question and an explanation of why the board is of that opinion; and (c) the length of service of each director.
☒
☐
set out in our Corporate Governance Statement
ASX Listing Rules Appendix 4G (current at 17/7/2020)
and we have disclosed the names of the directors considered by the board to be independent directors in our Corporate Governance Statement and, where applicable, the information referred to in paragraph (b) in our Corporate Governance Statement and the length of service of each director in our Corporate Governance Statement
Page 5
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
2.4
A majority of the board of a listed entity should be independent directors.
☒
☐
set out in our Corporate Governance Statement OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
The chair of the board of a listed entity should be an independent director and, in particular, should not be the same person as the CEO of the entity.
☐
☒
set out in our Corporate Governance Statement OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity should have a program for inducting new directors and for periodically reviewing whether there is a need for existing directors to undertake professional development to maintain the skills and knowledge needed to perform their role as directors effectively.
☒
☐
set out in our Corporate Governance Statement OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
☐
set out in our Corporate Governance Statement
☐
set out in our Corporate Governance Statement
☐
set out in our Corporate Governance Statement
☐
set out in our Corporate Governance Statement
2.5
2.6
PRINCIPLE 3 – INSTIL A CULTURE OF ACTING LAWFULLY, ETHICALLY AND RESPONSIBLY 3.1
A listed entity should articulate and disclose its values.
☒ and we have disclosed our values at: https://iperionx.com/companyoverview/governance-corporate-directory/
3.2
3.3
3.4
A listed entity should: (a) have and disclose a code of conduct for its directors, senior executives and employees; and (b) ensure that the board or a committee of the board is informed of any material breaches of that code.
☒
A listed entity should: (a) have and disclose a whistleblower policy; and (b) ensure that the board or a committee of the board is informed of any material incidents reported under that policy.
☒
A listed entity should: (a) have and disclose an anti-bribery and corruption policy; and (b) ensure that the board or committee of the board is informed of any material breaches of that policy.
☒
ASX Listing Rules Appendix 4G (current at 17/7/2020)
and we have disclosed our code of conduct at: https://iperionx.com/company-overview/governance-corporatedirectory/
and we have disclosed our whistleblower policy at: https://iperionx.com/company-overview/governance-corporatedirectory/
and we have disclosed our anti-bribery and corruption policy at: https://iperionx.com/company-overview/governance-corporatedirectory/
Page 6
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
PRINCIPLE 4 – SAFEGUARD THE INTEGRITY OF CORPORATE REPORTS 4.1
The board of a listed entity should: (a) have an audit committee which: (1) has at least three members, all of whom are nonexecutive directors and a majority of whom are independent directors; and (2) is chaired by an independent director, who is not the chair of the board, and disclose: (3) the charter of the committee; (4) the relevant qualifications and experience of the members of the committee; and (5) in relation to each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have an audit committee, disclose that fact and the processes it employs that independently verify and safeguard the integrity of its corporate reporting, including the processes for the appointment and removal of the external auditor and the rotation of the audit engagement partner.
☒
4.2
The board of a listed entity should, before it approves the entity’s financial statements for a financial period, receive from its CEO and CFO a declaration that, in their opinion, the financial records of the entity have been properly maintained and that the financial statements comply with the appropriate accounting standards and give a true and fair view of the financial position and performance of the entity and that the opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.
4.3
A listed entity should disclose its process to verify the integrity of any periodic corporate report it releases to the market that is not audited or reviewed by an external auditor.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
☐
set out in our Corporate Governance Statement
☐
☒
set out in our Corporate Governance Statement
☒
☐
set out in our Corporate Governance Statement
and we have disclosed a copy of the charter of the committee at: https://iperionx.com/company-overview/governance-corporatedirectory/ and the information referred to in paragraphs (4) and (5) in our 2026 annual report and at: https://iperionx.com/company-overview/governance-corporatedirectory/
Page 7
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
A listed entity should have and disclose a written policy for complying with its continuous disclosure obligations under listing rule 3.1.
☒
☐
set out in our Corporate Governance Statement
5.2
A listed entity should ensure that its board receives copies of all material market announcements promptly after they have been made.
☒
☐
set out in our Corporate Governance Statement
5.3
A listed entity that gives a new and substantive investor or analyst presentation should release a copy of the presentation materials on the ASX Market Announcements Platform ahead of the presentation.
☒
☐
set out in our Corporate Governance Statement
A listed entity should provide information about itself and its governance to investors via its website.
☒
☐
set out in our Corporate Governance Statement
6.2
A listed entity should have an investor relations program that facilitates effective two-way communication with investors.
☒
☐
set out in our Corporate Governance Statement
6.3
A listed entity should disclose how it facilitates and encourages participation at meetings of security holders.
☒
☐
set out in our Corporate Governance Statement
6.4
A listed entity should ensure that all substantive resolutions at a meeting of security holders are decided by a poll rather than by a show of hands.
☒
☐
set out in our Corporate Governance Statement
6.5
A listed entity should give security holders the option to receive communications from, and send communications to, the entity and its security registry electronically.
☒
☐
set out in our Corporate Governance Statement
PRINCIPLE 5 – MAKE TIMELY AND BALANCED DISCLOSURE 5.1
and we have disclosed our continuous disclosure compliance policy at: https://iperionx.com/company-overview/governance-corporatedirectory/
PRINCIPLE 6 – RESPECT THE RIGHTS OF SECURITY HOLDERS 6.1
ASX Listing Rules Appendix 4G (current at 17/7/2020)
and we have disclosed information about us and our governance on our website at: https://iperionx.com/company-overview/governance-corporatedirectory/
and we have disclosed how we facilitate and encourage participation at meetings of security holders in our Corporate Governance Statement
Page 8
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
The board of a listed entity should: (a) have a committee or committees to oversee risk, each of which: (1) has at least three members, a majority of whom are independent directors; and (2) is chaired by an independent director, and disclose: (3) the charter of the committee; (4) the members of the committee; and (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have a risk committee or committees that satisfy (a) above, disclose that fact and the processes it employs for overseeing the entity’s risk management framework.
☒
☐
set out in our Corporate Governance Statement
The board or a committee of the board should: (a) review the entity’s risk management framework at least annually to satisfy itself that it continues to be sound and that the entity is operating with due regard to the risk appetite set by the board; and (b) disclose, in relation to each reporting period, whether such a review has taken place.
☒
☐
set out in our Corporate Governance Statement
A listed entity should disclose: (a) if it has an internal audit function, how the function is structured and what role it performs; or (b) if it does not have an internal audit function, that fact and the processes it employs for evaluating and continually improving the effectiveness of its governance, risk management and internal control processes.
☒
☐
set out in our Corporate Governance Statement
PRINCIPLE 7 – RECOGNISE AND MANAGE RISK 7.1
7.2
7.3
ASX Listing Rules Appendix 4G (current at 17/7/2020)
and we have disclosed the fact that we do not have a risk committee or committees that satisfy (a) and the processes we employ for overseeing our risk management framework at: https://iperionx.com/company-overview/governance-corporatedirectory/
and we have disclosed whether a review of the entity’s risk management framework was undertaken during the reporting period in our Corporate Governance Statement
and we have disclosed the fact that we do not have an internal audit function and the processes we employ for evaluating and continually improving the effectiveness of our risk management and internal control processes, in our Corporate Governance Statement
Page 9
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
7.4
☒
☐
A listed entity should disclose whether it has any material exposure to environmental or social risks and, if it does, how it manages or intends to manage those risks.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
set out in our Corporate Governance Statement
and we have disclosed whether we have any material exposure to environmental and social risks and, if we do, how we manage or intend to manage those risks, in our Corporate Governance Statement
Page 10
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
The board of a listed entity should: (a) have a remuneration committee which: (1) has at least three members, a majority of whom are independent directors; and (2) is chaired by an independent director, and disclose: (3) the charter of the committee; (4) the members of the committee; and (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have a remuneration committee, disclose that fact and the processes it employs for setting the level and composition of remuneration for directors and senior executives and ensuring that such remuneration is appropriate and not excessive.
☒
☐
set out in our Corporate Governance Statement OR
and we have disclosed a copy of the charter of the committee at: https://iperionx.com/company-overview/governance-corporatedirectory/ and the information referred to in paragraphs (4) and (5) in our 2026 annual report and at: https://iperionx.com/company-overview/governance-corporatedirectory/
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity should separately disclose its policies and practices regarding the remuneration of non-executive directors and the remuneration of executive directors and other senior executives.
☒
☐
set out in our Corporate Governance Statement OR
and we have disclosed separately our remuneration policies and practices regarding the remuneration of non-executive directors and the remuneration of executive directors and other senior executives at: https://iperionx.com/company-overview/governance-corporatedirectory/
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity which has an equity-based remuneration scheme should: (a) have a policy on whether participants are permitted to enter into transactions (whether through the use of derivatives or otherwise) which limit the economic risk of participating in the scheme; and (b) disclose that policy or a summary of it.
☒
☐
set out in our Corporate Governance Statement OR
and we have disclosed our policy on this issue or a summary of it at: https://iperionx.com/company-overview/governance-corporatedirectory/
☐
we do not have an equity-based remuneration scheme and this recommendation is therefore not applicable OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
PRINCIPLE 8 – REMUNERATE FAIRLY AND RESPONSIBLY 8.1
8.2
8.3
ASX Listing Rules Appendix 4G (current at 17/7/2020)
Page 11
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
ADDITIONAL RECOMMENDATIONS THAT APPLY ONLY IN CERTAIN CASES 9.1
9.2
9.3
A listed entity with a director who does not speak the language in which board or security holder meetings are held or key corporate documents are written should disclose the processes it has in place to ensure the director understands and can contribute to the discussions at those meetings and understands and can discharge their obligations in relation to those documents.
☐
☐
set out in our Corporate Governance Statement OR
and we have disclosed information about the processes in place at: ……………………………………………………………………… [insert location]
☒
we do not have a director in this position and this recommendation is therefore not applicable OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
A listed entity established outside Australia should ensure that meetings of security holders are held at a reasonable place and time.
☐
☐
set out in our Corporate Governance Statement OR
☒
we are established in Australia and this recommendation is therefore not applicable OR
☐
we are an externally managed entity and this recommendation is therefore not applicable
☐
set out in our Corporate Governance Statement OR
☒
we are established in Australia and not an externally managed listed entity and this recommendation is therefore not applicable
☐
we are an externally managed entity that does not hold an AGM and this recommendation is therefore not applicable
☐
set out in our Corporate Governance Statement
A listed entity established outside Australia, and an externally managed listed entity that has an AGM, should ensure that its external auditor attends its AGM and is available to answer questions from security holders relevant to the audit.
☐
ADDITIONAL DISCLOSURES APPLICABLE TO EXTERNALLY MANAGED LISTED ENTITIES
Alternative to Recommendation 1.1 for externally managed listed entities: The responsible entity of an externally managed listed entity should disclose: (a) the arrangements between the responsible entity and the listed entity for managing the affairs of the listed entity; and (b) the role and responsibility of the board of the responsible entity for overseeing those arrangements.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
☐ and we have disclosed the information referred to in paragraphs (a) and (b) at: …………………………………………………………………………….. [insert location]
Page 12
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Corporate Governance Council recommendation
Where a box below is ticked,4 we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:
Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
☐
☐
Alternative to Recommendations 8.1, 8.2 and 8.3 for externally managed listed entities: An externally managed listed entity should clearly disclose the terms governing the remuneration of the manager.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
set out in our Corporate Governance Statement
and we have disclosed the terms governing our remuneration as manager of the entity at: …………………………………………………………………………….. [insert location]
Page 13
Page 1 of 10
CORPORATE GOVERNANCE STATEMENT | 2026
CORPORATE GOVERNANCE STATEMENT 2026 June 2026
IperionX Limited (“IperionX” or “Company”) and the en66es it controls believe corporate governance is important for the Company in conduc6ng its business ac6vi6es. The Board has adopted a suite of charters and key corporate governance documents which ar6culate the policies and procedures followed by IperionX. These documents are available in the Governance sec6on of the Company’s website, www.iperionx.com. These documents are reviewed at least annually to address any changes in governance prac6ces and the law. This Corporate Governance Statement (“Statement”), which is current at June 30, 2026 and has been approved by the Company’s Board, explains how IperionX complies with the ASX Corporate Governance Council’s ‘Corporate Governance Principles and Recommenda5ons – 4th Edi5on’ (ASX Principles and Recommenda6ons), which were published in February 2019 in rela6on to the year ended June 30, 2026. Since the Company listed on Nasdaq in June 2022, it must also comply with the rules and laws applicable to a Foreign Private Issuer in the United States. The sources of these rules and laws are principally the US Securi6es and Exchange Commission and Nasdaq. In addi6on to the ASX Corporate Governance Council’s ‘Corporate Governance Principles and Recommenda5ons – 4th Edi5on’ and applicable US rules, the Board has taken into account a number of important factors in determining its corporate governance policies and procedures, including the: • • • •
cost versus benefit of addi6onal corporate governance requirements or processes; Board’s experience in the manufacturing and mineral resources sectors; organiza6onal repor6ng structure and number of repor6ng func6ons, opera6onal divisions and employees; and direct shareholder feedback.
Virginia 1092 Confroy Drive South Boston, VA 24592
Tennessee 279 West Main Street Camden, TN 38320
Utah 1782 W 2300 S West Valley City, UT 84119
Page 2 of 10
Principle 1: Lay solid founda4ons for management and oversight RECOMMENDATION
IPERIONX’S COMPLIANCE WITH RECOMMENDATIONS
1.1. Roles and ResponsibiliRes of Board and management
The Board has established a clear disRncRon between the funcRons and responsibiliRes reserved for the Board and those delegated to management, which are set out in the Company’s Board Charter.
RECOMMENDATION FOLLOWED IN FULL FOR WHOLE OF 2026 YEAR? Yes
A copy of the Board Charter is available in the Governance secRon of the Company’s website, hVps://iperionx.com/company-overview/governance-corporatedirectory/. 1.2. InformaRon regarding elecRon and re-elecRon of director candidates
IperionX carefully considers the character, experience, educaRon and skillset of potenRal candidates for appointment to the Board and conducts appropriate background checks to verify the suitability of the candidate, prior to their elecRon. These checks include examinaRons of the candidates’ character, experience, educaRon, criminal record and bankruptcy history.
Yes
The Company has appropriate procedures in place to ensure that material informaRon relevant to a decision to elect or re-elect a director, is disclosed in the relevant noRce of meeRng provided to shareholders. Director profiles are also included in the Director’s Report of the Company’s Annual Report and on the Company’s website. 1.3. WriVen contracts of appointment
In addiRon to being set out in the Board Charter, the roles and responsibiliRes of Directors are also formalized in the leVer of appointment which each Director receives and commits to on their appointment.
Yes
The leVers of appointment specify the term of appointment, Rme commitment envisaged, expectaRons in relaRons to commiVee work or any other special duRes aVaching to the posiRon, reporRng lines, remuneraRon arrangements, disclosure obligaRons in relaRon to personal interests, confidenRality obligaRons, insurance and indemnity enRtlements and details of the Company’s key governance policies. Each senior execuRve enters into a service contract which sets out the material terms of employment, including a descripRon of posiRon and duRes, reporRng lines, remuneraRon arrangement and terminaRon rights and enRtlements. 1.4. Company Secretary
The Company Secretary reports directly to the Board through the Chairman on Board maVers and all Directors have access to the Company Secretary. The appointment or removal of the Company Secretary is a maVer for the Board. Details of the Company Secretary’s experience and qualificaRons are set out in Company’s Annual Report.
CORPORATE GOVERNANCE STATEMENT | 2026
Yes
Page 3 of 10
Principle 1: Lay solid founda4ons for management and oversight RECOMMENDATION
IPERIONX’S COMPLIANCE WITH RECOMMENDATIONS
1.5. Diversity
The Company has not adopted a Diversity Policy, nor has it established measurable objecRves for achieving gender diversity for the 2026 year. However, given the relaRvely early stage of the Company, the Board considers that the Company is not currently of a size to warrant adopRng a Diversity Policy. The Board will review its posiRon and may adopt a Diversity Policy and develop measurable objecRves when the Company's operaRons increase.
RECOMMENDATION FOLLOWED IN FULL FOR WHOLE OF 2026 YEAR? No
The Company recognizes that a diverse and talented workforce is a compeRRve advantage and encourages a culture that embraces diversity. At June 30, 2026, the Company had 4 male Directors, 3 female Directors, 5 male other KMP, and 1 female other KMP. 1.6. Board Reviews
The 2025-2026 Board Assessment was conducted based upon best pracRces noted by key sources: NaRonal AssociaRon of Corporate Directors (NACD), Australian InsRtute of Company Directors, Nasdaq-Board Vantage, and Council for InsRtuRonal Investors (CII).
Yes
The Chair of the NominaRng-Governance CommiVee conducted the Board Assessment, which included:
• •
Self and Board skills matrix review and updates
•
CommiVee Chair and CommiVee assessments
Individual Board member interviews, including weighted/rated quesRons, free-form quesRons, and 360 feedback for all Board members
The results of the assessment were uRlized in the Board’s strategic planning process, commiVee assignments, skills matrix update, and developing the framework for new Director recruitment.
1.7. Management reviews
Each year the Board evaluates the performance of its senior execuRves against key performance indicators as set by the Board. Details of the process followed are set out in the RemuneraRon Report of the Company’s Annual Report. For the 2026 year, the Board undertook a performance evaluaRon of its KMP and senior execuRves in accordance with that process.
CORPORATE GOVERNANCE STATEMENT | 2026
Yes
Page 4 of 10
Principle 2: Structure the Board to be effec4ve and add value RECOMMENDATION FOLLOWED IN FULL FOR WHOLE OF 2026 YEAR?
RECOMMENDATION
IPERIONX’S COMPLIANCE WITH RECOMMENDATIONS
2.1 NominaRng-Governance CommiVee
The Board has established a separate NominaRng-Governance CommiVee (formerly the RemuneraRon and NominaRon CommiVee). At 30 June 2026, the NominaRng-Governance CommiVee comprised Ms. Melissa Waller (chair), Ms. Lorraine MarRn, Mr. Tony Tripeny, and Ms. Beverly Wyse, all of whom are considered independent directors.
Yes
The NominaRng-Governance CommiVee operates under a charter approved by the Board which is available in the Corporate Governance secRon of the Company’s website at hVps://iperionx.com/company-overview/governance-corporatedirectory/. The NominaRng-Governance CommiVee, on behalf of the Board, oversees and assists the Board in fulfilling its responsibiliRes relaRng to Board member recruitment, succession planning and overseeing and improving the Company’s governance policies and pracRces. The NominaRng-Governance CommiVee includes a Sustainability Sub-CommiVee consisRng of the same members, which oversees the company’s sustainability policies and efforts. 2.2 Board skills matrix
The Board seeks a mix of skills suitable for the Company’s mission and objecRves. A summary of the key board skills matrix is set out below. Further details regarding the skills and experience of each Director are included in the Directors’ Report of the Company’s Annual Report. Todd Hannigan
Anastasios Arima
Lorraine Mar2n
Vaughn Taylor
Melissa Waller
Beverly Wyse
Yes
Tony Tripeny
Board of Directors / Public Sector Execu2ve Experience Finance / Accoun2ng / Capital Alloca2on Mining Industry Experience Manufacturing Industry Experience Human Capital Management / Labor / Compensa2on Interna2onal Government / Regulatory Sustainability
2.3 Disclose independence and length of service
The Board has assessed the independence status of its Directors and has determined the following as of June 30, 2026: Name
Posi*on
Independent?
Length of Service
Todd Hannigan
Execu/ve Chairman
No
5.4 years
Anastasios Arima
CEO & Managing Director
No
5.6 years
Vaughn Taylor
Non-Execu/ve Director
Yes
5.3 years
Lorraine Mar/n
Non-Execu/ve Director
Yes
4.8 years
Melissa Waller
Non-Execu/ve Director
Yes
4.8 years
Beverly Wyse
Non-Execu/ve Director
Yes
4.8 years
Tony Tripeny
Non-Execu/ve Director
Yes
1.3 years
Further details regarding the Directors are set out in the Directors’ Report of the Company’s Annual Report.
CORPORATE GOVERNANCE STATEMENT | 2026
Yes
Page 5 of 10
Principle 2: Structure the Board to be effec4ve and add value RECOMMENDATION FOLLOWED IN FULL FOR WHOLE OF 2026 YEAR?
RECOMMENDATION
IPERIONX’S COMPLIANCE WITH RECOMMENDATIONS
2.4 Majority of directors are independent
At June 30, 2026, a majority of the Directors of the Company were independent. As disclosed against RecommendaRon 2.3, five out of the seven Directors as of June 30, 2026 are considered independent.
Yes
2.5 Chair independent
The Chairperson, Mr. Todd Hannigan, is an ExecuRve Director and is therefore not considered independent. However, the Board believes that Mr. Hannigan can, and does, make quality and independent judgments in the best interests of the Company on all relevant issues.
No
As set out in the ASX Principles or RecommendaRons, because the Chairperson is not an independent director, during fiscal 2025, the Company appointed Ms. Lorraine MarRn as Lead Independent Director to fulfil the role whenever the Chairperson is conflicted, and to assist the Board in reviewing the performance of the Chairperson and in providing a separate channel of communicaRon for security holders. 2.6 InducRon and professional development
The Board has implemented a new Director onboarding framework that includes a variety of resources including training videos, a digital binder, and a mentorship program. Each new Director receives and commits to a leVer of appointment which includes details of the Company’s key policies and processes and conRnuing professional development is expected of all Directors.
Yes
AddiRonally, the Board has been structured such that its composiRon and size will enable it to effecRvely discharge its responsibiliRes and duRes. Each Director has been appointed because they already possess the relevant industry experience and specific experRse relevant to the Company’s business and level of operaRons. Directors are also enRtled to seek independent professional advice at the expense of the Company (subject to approval) as may be reasonably required to assist them in carrying out their duRes as a Director.
Principle 3: Instil a culture of acting lawfully, ethically and responsibly RECOMMENDATION
IPERIONX’S COMPLIANCE WITH RECOMMENDATIONS
3.1 Values
The Board has established a Code of Conduct for its Directors, execuRves and employees, a copy of which is available in the Governance secRon of the Company’s website, hVps://iperionx.com/company-overview/governance-corporatedirectory/.
RECOMMENDATION FOLLOWED IN FULL FOR WHOLE OF 2026 YEAR? Yes
The Code of Conduct arRculates its values and is provided to all employees as part of the recruitment process. The Code of Conduct forms the foundaRon for the behavior expectaRons that the Company has for its Directors, senior execuRves, employees and contract personnel. 3.2 Code of conduct
The Board has established a Code of Conduct for its Directors, execuRves and employees, a copy of which is available in the Governance secRon of the Company’s
CORPORATE GOVERNANCE STATEMENT | 2026
Yes
Page 6 of 10
Principle 3: Instil a culture of acting lawfully, ethically and responsibly RECOMMENDATION
IPERIONX’S COMPLIANCE WITH RECOMMENDATIONS
website, directory/. 3.3 Whistleblower Policy
RECOMMENDATION FOLLOWED IN FULL FOR WHOLE OF 2026 YEAR?
hVps://iperionx.com/company-overview/governance-corporate-
The Company has adopted a Compliance ReporRng Policy (formerly the Whistleblower Policy) intended to support and protect persons who speak up about any unlawful, unethical or irresponsible behavior within the organizaRon, a copy of which is available in the Corporate Governance secRon of the Company’s website, hVps://iperionx.com/company-overview/governance-corporatedirectory/.
Yes
The Board are informed of material incidents reported under the Company’s Compliance Reporting Policy. 3.4 AnR-Bribery & CorrupRon Policy
The Company has adopted an AnR-Bribery and CorrupRon (“ABC”) Policy which links to the Code of Conduct by which the Company expects its operaRons and business dealings to be managed, a copy of which is available in the Corporate Governance secRon of the Company’s website, hVps://iperionx.com/companyoverview/governance-corporate-directory/
Yes
The ABC Policy prohibits the giving of bribes or other improper payments and specifies the controls around the giving of donaRons and the acceptance of gips or hospitality by officers of the Company. The Board is informed of any material breaches of the ABC Policy.
Principle 4: Safeguard the integrity of corporate reports RECOMMENDATION
IPERIONX’S COMPLIANCE WITH RECOMMENDATIONS
4.1 Audit commiVee
The Board has established a separate Audit CommiVee. At 30 June 2026, the Audit CommiVee comprised Mr. Tony Tripeny (chair), Mr. Vaughn Taylor, and Ms. Beverly Wyse, all of whom are considered independent directors.
RECOMMENDATION FOLLOWED IN FULL FOR WHOLE OF 2026 YEAR? Yes
The Audit CommiVee operates under a charter approved by the Board which is available in the Corporate Governance secRon of the Company’s website at hVps://iperionx.com/company-overview/governance-corporate-directory/ The Audit CommiVee, on behalf of the Board, exercises the Board’s authority with respect to determining when to seek the appointment or removal of the external auditor, and subject to any statutory requirements, will also seek rotaRon of the audit partner on an as required basis. 4.2 CEO and CFO cerRficaRon of financial statements
In respect to full year and half year financial reports, the Board has obtained a wriVen declaraRon from the CEO (or equivalent) and CFO (or equivalent) that, in their opinion, the financial records of the Company have been properly maintained and the financial statements comply with the appropriate accounRng standards and give a true and fair view of the financial posiRon and performance of the enRty and that the opinion is formed on the basis of a sound system of risk management
CORPORATE GOVERNANCE STATEMENT | 2026
No
Page 7 of 10
Principle 4: Safeguard the integrity of corporate reports RECOMMENDATION
IPERIONX’S COMPLIANCE WITH RECOMMENDATIONS
RECOMMENDATION FOLLOWED IN FULL FOR WHOLE OF 2026 YEAR?
and internal control and that the system is operaRng effecRvely in all material respects in relaRon to financial reporRng and material business risks. However, the Board does not receive declaraRons from the CEO (or equivalent) and CFO (or equivalent) in respect to the quarterly cash flow reports prepared and lodged in compliance with Appendix 5B of the LisRng Rules, as these quarterly cash flow reports are considered by the Board:
4.3 Verifying the Integrity of Periodic Corporate Reports
•
not to be a financial report or interim financial report as defined under Australian accounRng standards; and/or
•
not to be capable, as a standalone report, of giving a true and fair view of the financial posiRon and performance of the Company, only its cash flows for the relevant reporRng period.
The Company has an effecRve system of internal control and mulRple review and approval stages which it applies to public documents that are not reviewed or audited by its external auditor.
Yes
Principle 5: Make 4mely and balanced disclosure RECOMMENDATION
IPERIONX’S COMPLIANCE WITH RECOMMENDATIONS
5.1 Disclosure and CommunicaRons Policy
The Company has adopted a ConRnuous Disclosure Policy which sets out the processes and pracRces that ensure its compliance with the conRnuous disclosure requirements under applicable LisRng Rules and applicable corporaRon law (including the CorporaRons Act).
RECOMMENDATION FOLLOWED IN FULL FOR WHOLE OF 2026 YEAR? Yes
A copy of the ConRnuous Disclosure Policy is available in the Corporate Governance secRon of the Company’s website, hVps://iperionx.com/companyoverview/governance-corporate-directory/. 5.2 Material Market Announcements
The Company ensures that Directors are provided with a copy of all material market releases either before, or promptly aper lodgement.
Yes
5.3 Investor or Analyst PresentaRons
The Company ensures that any new substanRve investor or analyst presentaRon is released on the Company’s announcements plasorms ahead of the presentaRon.
Yes
CORPORATE GOVERNANCE STATEMENT | 2026
Page 8 of 10
Principle 6: Respect the rights of security holders RECOMMENDATION
IPERIONX’S COMPLIANCE WITH RECOMMENDATIONS
6.1 InformaRon on website
The Company keeps investors informed of its corporate governance, financial performance and prospects via its website.
RECOMMENDATION FOLLOWED IN FULL FOR WHOLE OF 2026 YEAR? Yes
Investors can access copies of all announcements to the ASX, noRces of meeRngs, annual reports and financial statements, investor presentaRons via the ‘Investors’ page and can access general informaRon regarding the Company and the structure of its business under the ‘OperaRons’ page on the Company’s website, www.iperionx.com. Investors can access informaRon about the Company’s corporate governance pracRces via the ‘Company Overview’ page at hVps://iperionx.com/companyoverview/governance-corporate-directory/, where all relevant corporate governance informaRon can be accessed. 6.2 Investor relaRons programs
The Company has an investor relaRons program that is commensurate with the size of the Company and its level of operaRons. This program involves acRvely engaging with interested investors. The Company responds as appropriate to inquiries received from investors from Rme to Rme.
Yes
In addiRon, Shareholders are provided with access to Directors and key management personnel at the Company’s Annual General MeeRng of Shareholders, and Shareholders are given an opportunity to ask quesRons of Directors and management, either during or aper meeRngs. Any presentaRons prepared by the Company are posted on the Company’s website (www.iperionx.com), which also offers the opportunity for interested parRes to join the mailing list to receive regular updates from the Company. 6.3 Facilitate parRcipaRon at meeRngs of security holders
The Board encourages parRcipaRon of Shareholders at its meeRngs of shareholders and Shareholders are provided with all noRces of meeRng prior to meeRngs, which are set at Rmes and places to promote maximum aVendance by Shareholders.
Yes
Shareholders are given the opportunity to ask quesRons of Directors and management, either during or aper meeRngs. In addiRon, the Company’s auditor is also made available for quesRons at the Company’s Annual General MeeRng of Shareholders (“AGM”). 6.4 VoRng by Poll
The Company has adopted the process required by ASX Guidance Note 35 which sRpulates that all LisRng Rule resoluRons be decided by poll. The Company has extended the conduct of a poll to all resoluRons proposed at shareholder meeRngs.
Yes
6.5 Facilitate electronic communicaRons
The Company welcomes electronic communicaRons from its Shareholders via its publicized email address ([email protected]) and the Company’s website (www.iperionx.com) provides the opportunity for interested parRes to join the mailing list to receive regular electronic updates from the Company.
Yes
The Company’s share registry also engages with Shareholders electronically and makes available a range of relevant forms on its website. Shareholders can register with the share registry to access their personal informaRon and shareholdings via the internet.
CORPORATE GOVERNANCE STATEMENT | 2026
Page 9 of 10
Principle 7: Recognize and manage risk RECOMMENDATION
IPERIONX’S COMPLIANCE WITH RECOMMENDATIONS
7.1 Risk commiVee
The Board has decided not to form a separate Risk CommiVee. Due to the size and stage of the Company, the Board believes that few efficiencies or other benefits would be gained by establishing a separate Risk CommiVee.
RECOMMENDATION FOLLOWED IN FULL FOR WHOLE OF 2026 YEAR? Yes
The Board as a whole is ulRmately responsible for idenRfying the principal risks of the Company’s business and ensuring the implementaRon of appropriate systems to manage those risks. For further details of the responsibiliRes of the Board, the Chief ExecuRve Officer, the President, and other management in the evaluaRon and conRnual improvement of the Company’s risk management and internal control processes, refer to the Company’s Risk Management Policy, which is available in the Governance secRon of the Company’s website, hVps://iperionx.com/companyoverview/governance-corporate-directory/. 7.2 Annual risk review
On at least an annual basis, the Board reviews its material business risks and how its material business risks are being managed.
Yes
For the 2026 year, management provided to the Board the Company’s Risk Register summarizing the significance of each risk as well as acRons taken by management to miRgate the risks. Management also provided to the Board a report on the effecRveness of the Company’s management of its material business risks throughout the 2026 year. 7.3 Internal audit
The Board has not established an internal audit funcRon at this Rme. The Board as a whole oversees the effecRveness of risk management and internal control processes.
Yes
Refer to the Company’s Risk Management Policy for responsibiliRes of the Board, the Chief ExecuRve Officer, the Chief Risk Officer, and other management in the evaluaRon and conRnual improvement of the Company’s risk management and internal control processes. A copy of the Risk Management Policy is available in the Corporate Governance secRon of the Company’s website, hVps://iperionx.com/companyoverview/governance-corporate-directory/. 7.4 Sustainability risks
The Company idenRfies and manages material exposures to environmental and social risks, broadly referred to as “sustainability risks”, in a manner consistent with its Risk Management Policy, which is available in the Corporate Governance secRon of the Company’s website, hVps://iperionx.com/company-overview/governancecorporate-directory/. The material risks faced by the Company that could affect the Company’s future prospects, include: (a) intellectual property risks; (b) exploraRon and development risks; (c) availability of further funding; (d) fluctuaRons in commodity prices; (e) compeRRon; and (f) global financial condiRons. Further details of these risks and how the Company manages or intends to manage these risks are set out in the Directors’ Report of the Company’s Annual Report.
CORPORATE GOVERNANCE STATEMENT | 2026
Yes
Page 10 of 10
Principle 8: Remunerate fairly and responsibly RECOMMENDATION
IPERIONX’S COMPLIANCE WITH RECOMMENDATIONS
8.1 RemuneraRon commiVee
The Board has established a separate CompensaRon CommiVee (formerly the RemuneraRon and NominaRon CommiVee). At 30 June 2026, the CompensaRon CommiVee comprised Mr. Vaughn Taylor (chair), Ms. Melissa Waller, and Ms. Beverly Wyse, all of whom are considered independent directors.
RECOMMENDATION FOLLOWED IN FULL FOR WHOLE OF 2026 YEAR? Yes
The CompensaRon CommiVee operates under a charter approved by the Board which is available in the Corporate Governance secRon of the Company’s website at hVps://iperionx.com/company-overview/governance-corporate-directory/. The CompensaRon CommiVee charter sets out the processes the Board employs for sevng the level and composiRon of compensaRon for directors and senior execuRves and ensuring that such compensaRon is appropriate and not excessive. 8.2 Disclosure of ExecuRve and Non-ExecuRve Director remuneraRon policy
The Company seeks to aVract and retain high-performance Directors and ExecuRves with appropriate skills, qualificaRons and experience to add value to the Company and fulfil the roles and responsibiliRes required. It reviews requirements of addiRonal capabiliRes at least annually.
Yes
ExecuRve remuneraRon is structured to reflect performance and, accordingly, remuneraRon comprises a fixed component and a performance-based remuneraRon component. Non-ExecuRve Directors are paid fixed fees for their services in accordance with the Company’s ConsRtuRon. Fees paid are a composite fee (covering all Board and CommiVee responsibiliRes) and any contribuRons by the Company to a fund for the purpose of superannuaRon benefits for a Director. No other reRrement benefits schemes are in place in respect to Non-ExecuRve Directors. Further details regarding the remuneraRon of the ExecuRve and Non-ExecuRve Directors are set in the in the ExecuRve CompensaRon secRon of the Company’s Annual Report. 8.3 Policy on hedging equity incenRve schemes
The Company’s Directors and ExecuRves must not enter into any hedging arrangement in relaRon to any performance rights they may be granted or otherwise enRtled to under an incenRve scheme or plan, prior to exercising those rights or, once exercised, while the securiRes are subject to a transfer restricRon. Further details regarding the Company’s hedging policy are set out in the Company’s SecuriRes Trading Policy which is available in the Corporate Governance secRon of the Company’s website, hVps://iperionx.com/companyoverview/governance-corporate-directory/.
CORPORATE GOVERNANCE STATEMENT | 2026
Yes
PRESS RELEASE | NASDAQ: IPX | ASX: IPX
September 28, 2026
DATE OF AGM AND CLOSING DATE FOR DIRECTOR NOMINATIONS IperionX Limited (NASDAQ: IPX, ASX: IPX) (IperionX or Company) advises, in accordance with ASX Listing Rule 3.13.1, that the Company’s Annual General Meeting (AGM) will be held on Wednesday, November 25, 2026. An item of business at the AGM will be the election of Directors. In accordance with clause 7.2 of the Company’s Constitution, the closing date for receipt of nominations from persons wishing to be considered for election as a Director is Wednesday, October 7, 2026. Any nominations must be received at the Company’s registered office, Level 5, 56 Pitt Street, Sydney NSW 2000, no later than 5.00pm (Sydney time) on Wednesday, October 7, 2026. This announcement has been authorized for release by the Company Secretary.
603
15 July 2001
page 1/2
Form 603
Corporations Act 2001 Section 671B
Notice of initial substantial holder To Company Name/Scheme
IperionX Ltd
ACN/ARSN
618 935 372
- Details of substantial holder (1) Name ACN/ARSN (if applicable)
Vanguard Group (The Vanguard Group, Inc. and its controlled entities including those listed in Annexure A) N/A
The holder became a substantial holder on
18 September 2026
- Details of voting power The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in on the date the substantial holder became a substantial holder are as follows: Class of securities (4) Ordinary
Number of securities 18,307,532
Person’s votes (5) 18,409,250
Voting power (6) 5.082%
- Details of relevant interests The nature of the relevant interest the substantial holder or an associate had in the following voting securities on the date the substantial holder became a substantial holder are as follows: Holder of relevant interest Vanguard Group
Nature of relevant interest (7) Vanguard Group is the manager of various Mutual funds and accounts and in that capacity has the power to dispose of the shares. The other members of Vanguard Group have a relevant interest under section 608(3) of the Corporations Act.
Class and number of securities Ordinary – 18,307,532
- Details of present registered holders The persons registered as holders of the securities referred to in paragraph 3 above are as follows: Holder of relevant interest
Registered holder of securities
Person entitled to be registered as holder (8)
Class and number of securities
Vanguard Group
Brown Brothers Harriman
Various funds and other accounts of Vanguard Group
Ordinary – 247,972
Vanguard Group
BNY Mellon
Various funds and other accounts of Vanguard Group
Ordinary – 1,285,579
Vanguard Group
JP Morgan Chase Bank, N.A.
Various funds and other accounts of Vanguard Group
Ordinary – 13,539,008
Vanguard Group
State Street Bank and Trust Company
Various funds and other accounts of Vanguard Group
Ordinary – 3,223,671
Vanguard Personalized Indexing Management LLC
Various Others
Various funds and other accounts of Vanguard Group
ADR – 11,302
External Use Authorized
603
page 2/2
15 July 2001
- Consideration The consideration paid for each relevant interest referred to in paragraph 3 above, and acquired in the four months prior to the day that the substantial holder became a substantial holder is as follows: Holder of relevant interest
Date of acquisition
See Annexure A
Consideration (9)
Class and number of securities
- Associates The reasons the persons named in paragraph 3 above are associates of the substantial holder are as follows:
Name and ACN/ARSN (if applicable)
Nature of association
N/A
N/A
- Addresses The addresses of persons named in this form are as follows: Name Vanguard Group
Address P.O. Box 2600, V26 Valley Forge, PA 19482 USA
print name
Shawn Acker
sign here
capacity
date
External Use Authorized
Compliance Manager
23 September 2026
DIRECTIONS (1)
If there are a number of substantial holders with similar or related interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 7 of the form.
(2)
See the definition of “associate” in section 9 of the Corporations Act 2001.
(3)
See the definition of “relevant interest” in sections 608 and 671B(7) of the Corporations Act 2001.
(4)
The voting shares of a company constitute one class unless divided into separate classes.
(5)
The total number of votes attached to all the voting shares in the company or voting interests in the scheme (if any) that the person or an Associate has a relevant interest in.
(6)
The person’s votes divided by the total votes in the body corporate or scheme multiplied by 100.
(7)
Include details of: (a) any relevant agreement or other circumstances by which the relevant interest was acquired. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers (b) or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies). See the definition of “relevant agreement” in section 9 of the Corporations Act 2001.
(8)
If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write “unknown”.
(9)
Details of the consideration must include any and all benefits, moneys and other, that any person from whom a relevant interest has acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder of its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
External Use Authorized
Annexure A
To Company ACN/ARSN
IperionX Ltd 618 935 372
Substantial Holder Name ACN/ARSN
Vanguard Group N/A
Date of change 02-Jun-2026 15-Jun-2026 19-Jun-2026 19-Jun-2026 01-Jul-2026 17-Jul-2026 20-Jul-2026 05-Aug-2026 10-Aug-2026 11-Aug-2026 18-Aug-2026 21-Aug-2026 21-Aug-2026 26-Aug-2026 27-Aug-2026 27-Aug-2026 27-Aug-2026 11-Sep-2026 15-Sep-2026 18-Sep-2026 18-Sep-2026 18-Sep-2026 18-Sep-2026 18-Sep-2026 18-Sep-2026 21-May-2026 21-May-2026 25-May-2026 25-May-2026 26-May-2026 27-May-2026 28-May-2026 29-May-2026 01-Jun-2026 02-Jun-2026 03-Jun-2026 05-Jun-2026 09-Jun-2026 09-Jun-2026 10-Jun-2026 11-Jun-2026 12-Jun-2026 15-Jun-2026 15-Jun-2026 15-Jun-2026 17-Jun-2026 18-Jun-2026 19-Jun-2026 19-Jun-2026 19-Jun-2026 19-Jun-2026 22-Jun-2026 22-Jun-2026 22-Jun-2026 23-Jun-2026 23-Jun-2026 24-Jun-2026 25-Jun-2026 26-Jun-2026 26-Jun-2026 26-Jun-2026
Nature of Change(6) BUY BUY SELL SELL BUY BUY BUY BUY SELL BUY BUY BUY SELL SELL BUY BUY SELL SELL BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY SELL BUY BUY SELL SELL BUY SELL BUY BUY SELL BUY SELL BUY BUY BUY SELL SELL BUY BUY SELL BUY BUY BUY SELL BUY BUY BUY BUY SELL
Person whose relevant interest changed The Vanguard Group, Inc. The Vanguard Group, Inc. The Vanguard Group, Inc. The Vanguard Group, Inc. The Vanguard Group, Inc. The Vanguard Group, Inc. The Vanguard Group, Inc. The Vanguard Group, Inc. The Vanguard Group, Inc. The Vanguard Group, Inc. The Vanguard Group, Inc. The Vanguard Group, Inc. The Vanguard Group, Inc. The Vanguard Group, Inc. The Vanguard Group, Inc. The Vanguard Group, Inc. The Vanguard Group, Inc. The Vanguard Group, Inc. The Vanguard Group, Inc. The Vanguard Group, Inc. The Vanguard Group, Inc. The Vanguard Group, Inc. The Vanguard Group, Inc. The Vanguard Group, Inc. The Vanguard Group, Inc. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd.
Consideration given in relation to change(7) 6.06 AUD 5.44 AUD 4.36 AUD 4.36 AUD 4.46 AUD 3.33 AUD 3.27 AUD 3.41 AUD 3.47 AUD 3.67 AUD 3.28 AUD 2.94 AUD 2.94 AUD 3.04 AUD 2.93 AUD 2.96 AUD 2.96 AUD 2.65 AUD 2.50 AUD 2.98 AUD 2.98 AUD 2.98 AUD 2.98 AUD 2.98 AUD 2.98 AUD 4.90 AUD 4.90 AUD 5.56 AUD 5.56 AUD 5.27 AUD 5.44 AUD 5.32 AUD 5.83 AUD 5.87 AUD 6.01 AUD 5.92 AUD 5.43 AUD 5.24 AUD 5.24 AUD 5.06 AUD 5.03 AUD 5.12 AUD 5.44 AUD 5.44 AUD 5.44 AUD 4.57 AUD 4.50 AUD 4.36 AUD 4.36 AUD 4.36 AUD 4.36 AUD 4.35 AUD 4.35 AUD 4.35 AUD 4.19 AUD 4.19 AUD 4.23 AUD 3.83 AUD 3.65 AUD 3.65 AUD 3.65 AUD
External Use Authorized
Class Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary
Number of securities Person's votes affected affected 6,923 6,923 536 536 (7,922) (7,922) (20,233) (20,233) 75,500 75,500 3,590 3,590 5,505 5,505 536 536 (294,694) (294,694) 3,642 3,642 857 857 9,301 9,301 (9,301) (9,301) (5,310) (5,310) 1,374 1,374 68,732 68,732 (68,732) (68,732) (9,708) (9,708) 761 761 291,240 291,240 190,716 190,716 195,671 195,671 33,139 33,139 6,699 6,699 93,335 93,335 846 846 3,280 3,280 14,564 14,564 8,275 8,275 3,320 3,320 2,487 2,487 1,992 1,992 (59,430) (59,430) 4,620 4,620 2,268 2,268 (70,520) (70,520) (660) (660) 4,980 4,980 (1,405) (1,405) 2,338 2,338 2,672 2,672 (5,695) (5,695) 3,360 3,360 (843) (843) 2,352 2,352 2,028 2,028 3,460 3,460 (12,654) (12,654) (933) (933) 333 333 20,233 20,233 (3,330) (3,330) 7,659 7,659 1,998 1,998 3,360 3,360 (1,866) (1,866) 1,494 1,494 3,370 3,370 2,688 2,688 2,688 2,688 (2,241) (2,241)
Annexure A
Date of change 29-Jun-2026 30-Jun-2026 30-Jun-2026 01-Jul-2026 01-Jul-2026 02-Jul-2026 07-Jul-2026 07-Jul-2026 08-Jul-2026 09-Jul-2026 09-Jul-2026 09-Jul-2026 10-Jul-2026 13-Jul-2026 14-Jul-2026 14-Jul-2026 15-Jul-2026 16-Jul-2026 17-Jul-2026 17-Jul-2026 17-Jul-2026 21-Jul-2026 21-Jul-2026 21-Jul-2026 22-Jul-2026 22-Jul-2026 23-Jul-2026 24-Jul-2026 27-Jul-2026 28-Jul-2026 29-Jul-2026 29-Jul-2026 30-Jul-2026 30-Jul-2026 30-Jul-2026 30-Jul-2026 31-Jul-2026 03-Aug-2026 04-Aug-2026 05-Aug-2026 05-Aug-2026 05-Aug-2026 06-Aug-2026 07-Aug-2026 11-Aug-2026 12-Aug-2026 13-Aug-2026 13-Aug-2026 14-Aug-2026 14-Aug-2026 17-Aug-2026 19-Aug-2026 19-Aug-2026 21-Aug-2026 25-Aug-2026 25-Aug-2026 26-Aug-2026 27-Aug-2026 27-Aug-2026 27-Aug-2026 28-Aug-2026 28-Aug-2026 01-Sep-2026 01-Sep-2026 02-Sep-2026 02-Sep-2026 04-Sep-2026 07-Sep-2026
Nature of Change(6) BUY SELL BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY SELL SELL SELL BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY SELL SELL BUY SELL BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY SELL BUY SELL SELL BUY BUY BUY BUY BUY BUY BUY
Person whose relevant interest changed Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd.
Consideration given in relation to change(7) 3.85 AUD 4.08 AUD 4.08 AUD 4.32 AUD 4.32 AUD 4.19 AUD 4.03 AUD 4.03 AUD 3.46 AUD 3.44 AUD 3.44 AUD 3.44 AUD 3.59 AUD 3.55 AUD 3.71 AUD 3.71 AUD 3.66 AUD 3.54 AUD 3.27 AUD 3.27 AUD 3.27 AUD 3.23 AUD 3.23 AUD 3.23 AUD 3.51 AUD 3.51 AUD 3.33 AUD 3.07 AUD 3.21 AUD 3.25 AUD 3.09 AUD 3.09 AUD 2.83 AUD 2.83 AUD 2.83 AUD 2.83 AUD 3.05 AUD 3.01 AUD 3.13 AUD 3.41 AUD 3.42 AUD 3.41 AUD 3.41 AUD 3.44 AUD 3.72 AUD 3.58 AUD 3.46 AUD 3.46 AUD 3.29 AUD 3.29 AUD 3.54 AUD 3.02 AUD 3.02 AUD 2.89 AUD 3.05 AUD 3.05 AUD 3.06 AUD 2.94 AUD 2.93 AUD 2.93 AUD 3.03 AUD 3.05 AUD 3.10 AUD 3.10 AUD 2.89 AUD 2.89 AUD 2.96 AUD 3.12 AUD
External Use Authorized
Class Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary
Number of securities Person's votes affected affected 1,496 1,496 (14,597) (14,597) 2,776 2,776 3,420 3,420 5,130 5,130 3,033 3,033 1,685 1,685 2,359 2,359 10,742 10,742 2,952 2,952 2,214 2,214 620 620 2,380 2,380 2,223 2,223 5,070 5,070 2,704 2,704 2,964 2,964 2,964 2,964 2,223 2,223 2,004 2,004 2,004 2,004 2,366 2,366 2,704 2,704 1,482 1,482 (2,720) (2,720) (4,446) (4,446) (2,964) (2,964) 2,688 2,688 933 933 2,076 2,076 3,440 3,440 2,752 2,752 2,223 2,223 2,964 2,964 2,223 2,223 2,387 2,387 2,768 2,768 3,159 3,159 933 933 (3,705) (3,705) (127,740) (127,740) 2,784 2,784 (5,144) (5,144) 2,401 2,401 5,145 5,145 1,715 1,715 2,052 2,052 5,130 5,130 933 933 3,105 3,105 3,123 3,123 1,482 1,482 2,064 2,064 3,177 3,177 2,106 2,106 3,710 3,710 3,450 3,450 (70,363) (70,363) 936 936 (936) (936) (276,704) (276,704) 2,154 2,154 2,148 2,148 4,296 4,296 6,278 6,278 1,436 1,436 2,202 2,202 5,430 5,430
Annexure A
Date of change 07-Sep-2026 07-Sep-2026 09-Sep-2026 10-Sep-2026 11-Sep-2026 11-Sep-2026 14-Sep-2026 15-Sep-2026 15-Sep-2026 15-Sep-2026 16-Sep-2026 16-Sep-2026 17-Sep-2026 17-Sep-2026 17-Sep-2026 17-Sep-2026 18-Sep-2026 18-Sep-2026 21-May-2026 26-May-2026 26-May-2026 26-May-2026 26-May-2026 28-May-2026 28-May-2026 28-May-2026 29-May-2026 03-Jun-2026 03-Jun-2026 04-Jun-2026 08-Jun-2026 08-Jun-2026 08-Jun-2026 09-Jun-2026 10-Jun-2026 10-Jun-2026 12-Jun-2026 17-Jun-2026 17-Jun-2026 17-Jun-2026 18-Jun-2026 18-Jun-2026 18-Jun-2026 18-Jun-2026 22-Jun-2026 22-Jun-2026 22-Jun-2026 22-Jun-2026 23-Jun-2026 23-Jun-2026 23-Jun-2026 25-Jun-2026 25-Jun-2026 25-Jun-2026 25-Jun-2026 25-Jun-2026 25-Jun-2026 25-Jun-2026 25-Jun-2026 25-Jun-2026 26-Jun-2026 26-Jun-2026 26-Jun-2026 26-Jun-2026 26-Jun-2026 29-Jun-2026 29-Jun-2026
Nature of Change(6) BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY SELL BUY BUY BUY BUY BUY BUY BUY SELL SELL SELL BUY BUY SELL SELL BUY BUY SELL SELL BUY BUY SELL SELL BUY SELL SELL SELL SELL SELL SELL BUY SELL BUY BUY BUY
Person whose relevant interest changed Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Investments Australia Ltd. Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management
Consideration given in relation to change(7) 3.12 AUD 3.12 AUD 3.10 AUD 2.85 AUD 2.64 AUD 2.64 AUD 2.55 AUD 2.50 AUD 2.50 AUD 2.50 AUD 2.56 AUD 2.56 AUD 2.72 AUD 2.72 AUD 2.72 AUD 2.72 AUD 2.98 AUD 2.98 AUD 36.76 USD 39.06 USD 39.03 USD 39.04 USD 39.08 USD 39.55 USD 38.99 USD 39.69 USD 40.72 USD 40.02 USD 40.13 USD 40.00 USD 36.26 USD 36.25 USD 36.18 USD 35.99 USD 34.67 USD 34.60 USD 36.51 USD 32.44 USD 32.06 USD 32.44 USD 30.74 USD 30.71 USD 30.59 USD 30.66 USD 30.81 USD 30.83 USD 30.92 USD 30.92 USD 29.22 USD 29.05 USD 28.99 USD 26.13 USD 26.19 USD 26.05 USD 26.23 USD 26.23 USD 26.23 USD 26.02 USD 26.13 USD 26.04 USD 26.27 USD 26.57 USD 26.14 USD 26.33 USD 26.38 USD 26.54 USD 26.70 USD
External Use Authorized
Class Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR
Number of securities Person's votes affected affected 1,810 1,810 1,488 1,488 6,601 6,601 2,190 2,190 5,400 5,400 2,160 2,160 5,535 5,535 1,256 1,256 1,500 1,500 1,256 1,256 1,880 1,880 1,880 1,880 2,274 2,274 2,241 2,241 7,580 7,580 3,790 3,790 13,028 13,028 285,433 285,433 530 53 66 660 13 130 130 13 13 130 13 130 13 130 11 110 130 13 29 290 29 290 1,210 121 14 140 14 140 (150) (15) 19 190 14 140 35 350 134 1,340 16 160 16 160 16 160 (14) (140) (14) (140) (130) (13) 16 160 21 210 (140) (14) (12) (120) 16 160 160 16 (14) (140) (53) (530) 18 180 18 180 (18) (180) (15) (150) 18 180 (18) (180) (13) (130) (15) (150) (16) (160) (21) (210) (15) (150) 19 190 (13) (130) 19 190 19 190 19 190
Annexure A
Date of change 29-Jun-2026 29-Jun-2026 29-Jun-2026 29-Jun-2026 29-Jun-2026 29-Jun-2026 29-Jun-2026 29-Jun-2026 29-Jun-2026 29-Jun-2026 29-Jun-2026 29-Jun-2026 29-Jun-2026 29-Jun-2026 29-Jun-2026 29-Jun-2026 29-Jun-2026 29-Jun-2026 29-Jun-2026 30-Jun-2026 01-Jul-2026 01-Jul-2026 01-Jul-2026 01-Jul-2026 06-Jul-2026 06-Jul-2026 06-Jul-2026 08-Jul-2026 08-Jul-2026 08-Jul-2026 09-Jul-2026 09-Jul-2026 09-Jul-2026 09-Jul-2026 09-Jul-2026 10-Jul-2026 10-Jul-2026 10-Jul-2026 10-Jul-2026 10-Jul-2026 10-Jul-2026 10-Jul-2026 10-Jul-2026 14-Jul-2026 14-Jul-2026 14-Jul-2026 14-Jul-2026 15-Jul-2026 15-Jul-2026 15-Jul-2026 15-Jul-2026 16-Jul-2026 16-Jul-2026 20-Jul-2026 20-Jul-2026 20-Jul-2026 20-Jul-2026 20-Jul-2026 20-Jul-2026 21-Jul-2026 22-Jul-2026 22-Jul-2026 23-Jul-2026 23-Jul-2026 24-Jul-2026 24-Jul-2026 24-Jul-2026 24-Jul-2026
Nature of Change(6) BUY BUY BUY BUY BUY BUY BUY SELL BUY SELL BUY BUY SELL BUY BUY BUY BUY SELL BUY BUY SELL SELL SELL SELL SELL BUY SELL SELL SELL BUY SELL BUY BUY SELL SELL SELL SELL BUY SELL SELL SELL BUY SELL SELL SELL SELL SELL SELL SELL BUY SELL BUY SELL SELL SELL BUY SELL SELL SELL BUY SELL SELL BUY SELL SELL BUY BUY SELL
Person whose relevant interest changed Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management
Consideration given in relation to change(7) 26.62 USD 26.67 USD 26.55 USD 26.62 USD 26.67 USD 26.68 USD 26.70 USD 26.59 USD 26.67 USD 26.69 USD 26.67 USD 26.70 USD 26.70 USD 26.70 USD 26.62 USD 26.62 USD 26.70 USD 26.61 USD 26.67 USD 30.15 USD 29.32 USD 29.37 USD 29.32 USD 29.37 USD 28.63 USD 28.91 USD 28.52 USD 23.97 USD 24.03 USD 23.95 USD 23.88 USD 23.91 USD 23.93 USD 23.88 USD 23.93 USD 24.33 USD 24.60 USD 24.60 USD 24.84 USD 24.55 USD 24.56 USD 24.70 USD 24.71 USD 25.27 USD 25.32 USD 25.30 USD 25.29 USD 24.64 USD 24.56 USD 24.64 USD 24.39 USD 23.28 USD 23.31 USD 22.38 USD 22.32 USD 22.59 USD 22.49 USD 22.49 USD 22.49 USD 24.37 USD 23.89 USD 23.79 USD 21.81 USD 21.72 USD 21.65 USD 21.50 USD 21.71 USD 21.50 USD
External Use Authorized
Class ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR
Number of securities Person's votes affected affected 76 760 19 190 19 190 19 190 19 190 36 360 19 190 (13) (130) 54 540 (17) (170) 19 190 19 190 (13) (130) 19 190 19 190 19 190 91 910 (13) (130) 19 190 230 2,300 (13) (130) (14) (140) (13) (130) (14) (140) (11) (110) 17 170 (16) (160) (14) (140) (53) (530) 19 190 (20) (200) 21 210 21 210 (14) (140) (29) (290) (1,300) (130) (164) (1,640) 563 5,630 (40) (400) (14) (140) (22) (220) 21 210 (13) (130) (24) (240) (24) (240) (145) (1,450) (35) (350) (16) (160) (190) (19) 43 430 (13) (130) 20 200 (29) (290) (18) (180) (16) (160) 22 220 (102) (1,020) (16) (160) (16) (160) 22 220 (16) (160) (42) (420) 21 210 (16) (160) (16) (160) 23 230 23 230 (21) (210)
Annexure A
Date of change 24-Jul-2026 28-Jul-2026 28-Jul-2026 28-Jul-2026 28-Jul-2026 28-Jul-2026 28-Jul-2026 28-Jul-2026 28-Jul-2026 29-Jul-2026 29-Jul-2026 29-Jul-2026 29-Jul-2026 30-Jul-2026 30-Jul-2026 30-Jul-2026 30-Jul-2026 30-Jul-2026 30-Jul-2026 30-Jul-2026 30-Jul-2026 30-Jul-2026 31-Jul-2026 31-Jul-2026 31-Jul-2026 31-Jul-2026 31-Jul-2026 31-Jul-2026 31-Jul-2026 03-Aug-2026 03-Aug-2026 04-Aug-2026 04-Aug-2026 05-Aug-2026 06-Aug-2026 07-Aug-2026 10-Aug-2026 10-Aug-2026 11-Aug-2026 17-Aug-2026 17-Aug-2026 17-Aug-2026 20-Aug-2026 21-Aug-2026 24-Aug-2026 24-Aug-2026 24-Aug-2026 24-Aug-2026 27-Aug-2026 27-Aug-2026 31-Aug-2026 31-Aug-2026 31-Aug-2026 31-Aug-2026 31-Aug-2026 31-Aug-2026 01-Sep-2026 02-Sep-2026 03-Sep-2026 03-Sep-2026 03-Sep-2026 03-Sep-2026 03-Sep-2026 04-Sep-2026 08-Sep-2026 08-Sep-2026 09-Sep-2026 09-Sep-2026
Nature of Change(6) SELL SELL BUY SELL BUY SELL BUY BUY SELL BUY SELL BUY BUY SELL SELL SELL SELL SELL SELL SELL SELL SELL BUY SELL SELL SELL BUY SELL SELL SELL SELL SELL SELL BUY SELL SELL SELL SELL SELL BUY BUY BUY BUY SELL SELL SELL SELL SELL SELL BUY BUY SELL SELL SELL BUY BUY BUY SELL BUY BUY BUY BUY BUY BUY BUY SELL BUY BUY
Person whose relevant interest changed Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management
Consideration given in relation to change(7) 21.47 USD 22.11 USD 22.35 USD 22.16 USD 22.13 USD 22.11 USD 22.11 USD 22.18 USD 22.16 USD 20.57 USD 20.56 USD 20.57 USD 20.57 USD 21.47 USD 21.55 USD 21.55 USD 21.47 USD 21.47 USD 21.45 USD 21.47 USD 21.47 USD 21.55 USD 21.08 USD 20.96 USD 21.01 USD 21.01 USD 21.08 USD 21.01 USD 20.98 USD 21.59 USD 21.59 USD 23.82 USD 23.82 USD 23.81 USD 23.58 USD 24.92 USD 25.80 USD 25.71 USD 25.61 USD 24.60 USD 24.41 USD 24.47 USD 20.58 USD 22.31 USD 21.44 USD 21.49 USD 21.46 USD 21.60 USD 22.30 USD 21.57 USD 21.98 USD 22.01 USD 21.76 USD 22.00 USD 21.63 USD 22.02 USD 21.24 USD 21.21 USD 21.74 USD 21.66 USD 21.70 USD 21.72 USD 21.59 USD 21.65 USD 22.69 USD 22.69 USD 21.70 USD 22.19 USD
External Use Authorized
Class ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR
Number of securities Person's votes affected affected (29) (290) (18) (180) 20 200 (19) (190) 30 300 (190) (19) 22 220 22 220 (22) (220) 25 250 (19) (190) 23 230 260 26 (19) (190) (19) (190) (19) (190) (19) (190) (19) (190) (190) (19) (19) (190) (19) (190) (190) (19) 23 230 (21) (210) (76) (760) (36) (360) 230 23 (19) (190) (19) (190) (190) (19) (230) (2,300) (18) (180) (180) (18) 76 760 (17) (170) (19) (190) (54) (540) (91) (910) (16) (160) 22 220 79 790 339 3,390 300 30 (22) (220) (17) (170) (230) (23) (21) (210) (22) (220) (200) (20) 24 240 24 240 (23) (230) (21) (210) (22) (220) 24 240 24 240 23 230 (21) (210) 23 230 23 230 23 230 23 230 23 230 23 230 23 230 (25) (250) 22 220 22 220
Annexure A
Date of change 10-Sep-2026 10-Sep-2026 10-Sep-2026 10-Sep-2026 10-Sep-2026 11-Sep-2026 11-Sep-2026 11-Sep-2026 11-Sep-2026 11-Sep-2026 11-Sep-2026 11-Sep-2026 11-Sep-2026 11-Sep-2026 14-Sep-2026 15-Sep-2026 15-Sep-2026 15-Sep-2026 15-Sep-2026 16-Sep-2026 16-Sep-2026 16-Sep-2026 16-Sep-2026
Nature of Change(6) SELL BUY BUY BUY SELL SELL BUY BUY BUY SELL BUY SELL BUY BUY SELL BUY BUY BUY BUY BUY SELL BUY BUY DELIVER
Person whose relevant interest changed Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management Vanguard Personalized Indexing Management
Consideration given in relation to change(7) 19.38 USD 19.34 USD 19.38 USD 19.36 USD 19.43 USD 18.71 USD 18.69 USD 19.20 USD 18.72 USD 18.73 USD 18.69 USD 19.08 USD 18.78 USD 18.74 USD 18.30 USD 17.84 USD 17.84 USD 18.09 USD 18.12 USD 19.24 USD 19.25 USD 19.31 USD 19.31 USD
This is Annexure A of 6 pages referred to in Form 603, Notice of initial substantial holder.
Signature: Name: Shawn Acker Capacity: Compliance Manager Date:
23-Sep-2026
External Use Authorized
Class ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR ADR
Number of securities Person's votes affected affected (563) (5,630) 23 230 50 500 23 230 (64) (640) (280) (28) 26 260 26 260 40 400 (25) (250) 26 260 (35) (350) 730 73 590 5,900 (22) (220) 57 570 42 420 73 730 43,600 4,360 36 360 (120) (1,200) 760 76 48 480 (79) (790)
Advancing titanium beyond batch production: GenX™ has validated continuous HAMR™ processing, advancing beyond the batch model used in conventional Kroll titanium production. Major operating gains support the potential for lower unit costs, higher titanium throughput, and a modular capital-efficient expansion pathway
Verified oxygen results: All valid product samples met the relevant oxygen benchmark: ASTM Grade 5 for angular powder and the more stringent Grade 23 specification for spherical titanium powder
Six times throughput volume: Total throughput for the GenX™ furnace was six times the volume of the batch HAMR™ system, on a like-for-like run time basis
Lower energy intensity: Power consumption reduced by more than 75% versus batch HAMR™ processing
Substantially lower measured input use: More than 45% less magnesium and over 60% less hydrogen required per kilogram of titanium powder, relative to batch HAMR™
Further efficiency potential: Operational data highlights potential for far lower capex intensity (installed capital per ton of capacity) and the potential for significantly lower labor unit costs
Next stage in Q4 2026: IperionX will continue to optimize the current GenX™ furnace; integrate the continuous furnace into a full titanium powder production line; and advance technoeconomic and engineering work for the first industrial-scale GenX™ production line
IperionX Limited (NASDAQ: IPX, ASX: IPX) (IperionX) is pleased to announce that GenX™, its next-generation continuous HAMR™ titanium production platform, has been successfully validated through the first four production campaigns, completed on the commercial-scale GenX™ system at IperionX’s Virginia R&D facility. GenX™ validation opens a pathway to a step change in titanium production economics. Moving beyond the batch model used in conventional Kroll titanium production, continuous processing offers the potential for higher throughput, significantly lower unit costs, improved equipment utilization and reduced processing time. Successful testing demonstrates low-oxygen titanium powder production The GenX™ system processed more than 500 kg of titanium powder across four separate continuous runs totaling 41 hours, at an average rate of approximately 12 kg per hour. Product from each run was collected separately, with samples randomly selected from different locations for oxygen analysis. Measure
Angular powder
Spherical powder
Starting oxygen
0.250% - 0.323%
0.215%
Product oxygen range
0.104% - 0.144%
0.072% - 0.084%
Average product oxygen
0.126%
0.078%
Relevant oxygen specification Runs and combined duration
Grade 5: 0.200%
/
Grade 23: 0.130%
2 runs / 18 hours
2 runs / 23 hours
7
8
Analyzed samples
Seven of the eight angular powder samples collected met the Grade 5 oxygen limit applicable to Ti-6Al-4V plate and bar under ASTM B265 and B348. Four of the eight also met the more stringent Grade 23 oxygen limit. One sample collected during an interrupted furnace run did not complete the HAMR™ cycle and was excluded from the validation assessment. IperionX anticipates that minor process refinements will enable angular powder to meet the Grade 23
Virginia
Tennessee
Utah
1092 Confroy Drive
279 West Main Street
1782 W 2300 S
South Boston, VA 24592
Camden, TN 38320
West Valley City, UT 84119
IperionX Limited ABN 84 618 935 372
oxygen limit. All spherical titanium powder samples met the Grade 23 oxygen limit and therefore also satisfied the Grade 5 oxygen specifications. GenX™ continuous processing – potential to materially shift the titanium cost curve The patented HAMR™ process is IperionX’s hydrogen-enabled, low-temperature process for low-oxygen titanium powder, currently in operation on a batch basis in Virginia. GenX™ applies that process continuously, eliminating the repeated furnace heat-up, cool-down, loading and unloading time inherent in batch cycles. Measured GenX™ data has firmly established the potential to materially reduce the cost base for HAMR™ titanium production. Operating measure
Measured GenX result
Comparison basis (batch HAMR)1
Magnesium consumption
45% lower
Per kg
Hydrogen consumption
60% lower
Per kg
Power consumption
75% lower
Per kg
6 times throughput
Like-for-like run time
Processing time
- Actual operating data based upon current batch HAMR operations
All comparisons are measured results against the batch HAMR™ reference; power use was measured directly on the GenX™ system. Magnesium is HAMR’s largest reagent cost, and lower use also reduces the by-product requiring downstream leaching and handling, which will be evaluated and quantified in further production campaigns. Continuous GenX™ operation is expected to improve equipment utilization, eliminate ancillary process steps and support expansion through replicated and scaled-up production lines. Operational data highlights the potential for far lower installed capital per ton of annual capacity, and IperionX estimates significant potential labor cost savings. Engineering the next stage During Q4 2026, IperionX will continue to run and optimize the GenX™ furnace, integrate the current furnace into a full powder production line; and conduct technoeconomic and engineering evaluation for the first industrial-scale GenX™ production line. GenX™ remains a high capacity, low cost development platform but is not required to achieve low cost production for the existing 200 tpa production ramp or planned expansions in Virginia. Similar industrial scale furnace types in service are achieving throughputs measured in 1000s of tons per annum per unit. GenX™ also complements continuous HSPT™ development, supporting a pathway from continuous titanium powder production to finished titanium components. U.S. Army Task Order 2, awarded on August 31, 2026 under IperionX's US$99 million SBIR Phase III contract, funds a continuous HSPT™ development furnace and industrialscale continuous HSPT™ and dehydrogenation capacity in Virginia. IperionX CEO Taso Arima said: “Achieving continuous primary titanium production has long been the ultimate aspiration for the titanium industry. IperionX’s GenX™ process is a continuous titanium production platform that is more efficient to operate and easier to scale. These first results exceeded our expectations: more than 500 kilograms of recycled titanium powder processed across four separate runs, with every sample meeting its relevant oxygen specification. Substantially lower magnesium, hydrogen and power consumption at steady state, together with processing throughput increasing by six times, give us a strong basis for industrial development. Our next step is the engineering and economic evaluation of the first industrial-scale GenX™ production line. We aim to establish a scalable platform for expansion that lowers production costs and brings titanium within reach of a broader range of applications.” This announcement has been authorized for release by the CEO and Managing Director.
604
Page 1 of 6
Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder
To Company Name/Scheme ACN/ARSN/ABN
IPERIONX LTD 84 618 935 372
- Details of substantial holder (1) Name
JPMorgan Chase & Co. and its affiliates
ACN/ARSN (if applicable)
NA
There was a change in the interests of the substantial holder on
01/September/2026
The previous notice was given to the company on
10/August/2026
The previous notice was dated
06/August/2026
- Previous and present voting power The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:
Class of securities (4)
Previous notice Person’s votes
Ordinary
19,561,173
Present notice Voting power (5)
Person’s votes
5.40%
24,126,965
Voting power (5) 6.66%
- Changes in relevant interests Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows: Date of change
See Appendix
Person whose relevant interest Nature of change (6) changed
Consideration given Class and number of Person's in relation to securities affected votes change (7) affected
JPMORGAN CHASE BANK, N.A.
Securities on Loan as Agent Lender
See Appendix
3,154,208 (Ordinary)
3,154,208 (Ordinary)
See Appendix
JPMORGAN ASSET MANAGEMENT (UK) LIMITED
In its capacity as investment manager or in various other related capacities
See Appendix
235 (Ordinary)
235 (Ordinary)
See Appendix
J.P. MORGAN SECURITIES PLC
Holder of securities subject to an obligation to return under a securities lending agreement
See Appendix
160,000 (Ordinary)
160,000 (Ordinary)
604
Page 2 of 6
See Appendix
J.P. MORGAN SECURITIES PLC
Purchase and sales of securities in its capacity as Principal/Proprietary
See Appendix
192 (Ordinary)
192 (Ordinary)
See Appendix
J.P. MORGAN SECURITIES PLC
Rehypothecation of client securities under a Prime Brokerage Agreement
See Appendix
131,171 (Ordinary)
131,171 (Ordinary)
See Appendix
J.P. MORGAN SECURITIES LLC
Holder of securities subject to an obligation to return under a securities lending agreement
See Appendix
2,000 (Ordinary)
2,000 (Ordinary)
See Appendix
J.P. MORGAN SECURITIES LLC
Purchase and sales of securities in its capacity as Principal/Proprietary
See Appendix
16,620 (Ordinary)
16,620 (Ordinary)
See Appendix
J.P. MORGAN SECURITIES LLC
Rehypothecation of client securities under a Prime Brokerage Agreement
See Appendix
356,705 (Ordinary)
356,705 (Ordinary)
See Appendix
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
Purchase and sales of securities in its capacity as Principal/Proprietary
See Appendix
836,043 (Ordinary)
836,043 (Ordinary)
See Appendix
J.P. MORGAN PRIME INC.
Rehypothecation of client securities under a Prime Brokerage Agreement
See Appendix
208,200 (Ordinary)
208,200 (Ordinary)
- Present relevant interests Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows: Holder of relevant interest
Registered holder of securities
JPMORGAN CHASE BANK, N.A.
JPM Nominees Australia Pty Limited
Person entitled to be registered as holder (8)
Various Borrowers under the Securities Lending Agreement
Nature of relevant interest (6)
Class and number of securities
Person's votes
Securities on Loan as Agent Lender
11,601,589 (Ordinary)
11,601,589 (Ordinary)
604
Page 3 of 6
JPMORGAN ASSET MANAGEMENT (UK) LIMITED
Citibank, N.A., Hong Kong Branch
Various Clients and Custodians
In its capacity as investment manager or in various other related capacities
104,121 (Ordinary)
104,121 (Ordinary)
JPMORGAN ASSET MANAGEMENT (UK) LIMITED
BNP Paribas (Sydney Branch)
Various Clients and Custodians
In its capacity as investment manager or in various other related capacities
262,982 (Ordinary)
262,982 (Ordinary)
J.P. MORGAN SECURITIES PLC
JPM Nominees Australia Pty Limited
JPM Nominees Australia Pty Limited
Holder of securities subject to an obligation to return under a securities lending agreement
971,702 (Ordinary)
971,702 (Ordinary)
J.P. MORGAN SECURITIES PLC
JPM Nominees Australia Pty Limited
J.P. MORGAN SECURITIES PLC
Purchase and sales of securities in its capacity as Principal/Proprietary
156,763 (Ordinary)
156,763 (Ordinary)
J.P. MORGAN SECURITIES LLC
Citi Australia
Various Clients and Custodians
Rehypothecation of client securities under a Prime Brokerage Agreement
993,465 (Ordinary)
993,465 (Ordinary)
J.P. MORGAN SECURITIES LLC
Citi Australia
Citi Australia
Holder of securities subject to an obligation to return under a securities lending agreement
3,024,000 (Ordinary)
3,024,000 (Ordinary)
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
Ecapital Nominees Pty Ltd
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
Purchase and sales of securities in its capacity as Principal/Proprietary
3,028,353 (Ordinary)
3,028,353 (Ordinary)
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
Ecapital Nominees Pty Ltd
Ecapital Nominees Pty Ltd
Holder of securities subject to an obligation to return under a securities lending agreement
2,250,000 (Ordinary)
2,250,000 (Ordinary)
604
Page 4 of 6
J.P. MORGAN PRIME INC.
Citi Australia
Various Clients and Custodians
Rehypothecation of client securities under a Prime Brokerage Agreement
1,723,450 (Ordinary)
1,723,450 (Ordinary)
J.P. MORGAN INVESTMENT MANAGEMENT INC.
Not Available
Various Clients and Custodians
In its capacity as investment manager or in various other related capacities
10,540 (Ordinary)
10,540 (Ordinary)
- Changes in association The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows: Name and ACN/ARSN (if applicable)
Nature of association
J.P. MORGAN SECURITIES LLC
Subsidiary of JPMorgan Chase & Co.
J.P. MORGAN SECURITIES PLC
Subsidiary of JPMorgan Chase & Co.
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
Subsidiary of JPMorgan Chase & Co.
JPMORGAN CHASE BANK, N.A.
Subsidiary of JPMorgan Chase & Co.
J.P. MORGAN PRIME INC.
Subsidiary of JPMorgan Chase & Co
JPMORGAN ASSET MANAGEMENT (UK) LIMITED
Subsidiary of JPMorgan Chase & Co.
- Addresses The addresses of persons named in this form are as follows: Name
Address
JPMorgan Chase & Co.
270 Park Avenue, New York, New York, NY, 10017, United States
J.P. MORGAN SECURITIES AUSTRALIA LIMITED
LEVEL 18, 83-85 CASTLEREAGH STREET, SYDNEY, NSW 2000, Australia
J.P. MORGAN SECURITIES LLC
270 Park Avenue, New York, New York, NY, 10017, United States
J.P. MORGAN SECURITIES PLC
25 Bank Street, Canary Wharf, London, E14 5JP, England
JPMORGAN CHASE BANK, N.A.
1111 Polaris Parkway, Columbus, Delaware, OH, 43240, United States
J.P. MORGAN PRIME INC.
270 Park Avenue, New York, New York, NY, 10017, United States
604
Page 5 of 6
J.P. MORGAN INVESTMENT MANAGEMENT INC.
270 Park Avenue, New York, New York, NY, 10017, United States
JPMORGAN ASSET MANAGEMENT (UK) LIMITED
60 Victoria Embankment, London, EC4Y0JP, England
Signature print name sign here
Vasim Pathan
Capacity Date
Compliance Officer 03/September/2026
604
Page 6 of 6
DIRECTIONS (1)
If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 6 of the form.
(2)
See the definition of "associate" in section 9 of the Corporations Act 2001.
(3)
See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
(4)
The voting shares of a company constitute one class unless divided into separate classes.
(5)
The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.
(6)
Include details of: (a)
any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
(b)
any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).
See the definition of "relevant agreement" in section 9 of the Corporations Act 2001. (7)
Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
(8)
If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown".
(9)
Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.
TRADES FOR RELEVANT PERIOD Transaction Date Balance at start of relevant period 7-Aug-26 7-Aug-26 7-Aug-26 7-Aug-26 7-Aug-26 7-Aug-26 7-Aug-26 7-Aug-26 7-Aug-26 7-Aug-26 7-Aug-26 7-Aug-26 7-Aug-26 7-Aug-26 7-Aug-26 7-Aug-26 7-Aug-26 7-Aug-26 7-Aug-26 7-Aug-26 7-Aug-26 7-Aug-26 7-Aug-26 10-Aug-26 10-Aug-26 10-Aug-26 10-Aug-26 10-Aug-26 10-Aug-26 10-Aug-26 10-Aug-26 11-Aug-26 11-Aug-26 11-Aug-26 11-Aug-26 11-Aug-26 11-Aug-26 11-Aug-26 11-Aug-26 11-Aug-26 11-Aug-26 11-Aug-26 11-Aug-26 11-Aug-26 11-Aug-26 11-Aug-26 12-Aug-26 12-Aug-26 12-Aug-26 12-Aug-26 12-Aug-26 12-Aug-26 12-Aug-26 12-Aug-26 12-Aug-26 12-Aug-26 12-Aug-26 12-Aug-26 12-Aug-26 12-Aug-26 12-Aug-26 12-Aug-26 13-Aug-26 13-Aug-26 13-Aug-26 13-Aug-26 13-Aug-26 13-Aug-26 13-Aug-26 13-Aug-26 13-Aug-26 13-Aug-26 13-Aug-26 13-Aug-26 13-Aug-26 13-Aug-26 13-Aug-26 13-Aug-26 14-Aug-26 14-Aug-26 14-Aug-26 14-Aug-26 14-Aug-26 14-Aug-26 14-Aug-26 14-Aug-26 14-Aug-26 14-Aug-26 14-Aug-26 14-Aug-26 14-Aug-26 14-Aug-26 14-Aug-26 14-Aug-26 14-Aug-26 14-Aug-26 14-Aug-26 14-Aug-26 17-Aug-26 17-Aug-26 17-Aug-26 17-Aug-26 17-Aug-26 17-Aug-26 17-Aug-26 17-Aug-26 17-Aug-26 17-Aug-26 17-Aug-26 17-Aug-26 17-Aug-26 17-Aug-26 17-Aug-26 18-Aug-26 18-Aug-26 18-Aug-26 18-Aug-26 18-Aug-26 18-Aug-26 18-Aug-26 18-Aug-26 18-Aug-26 18-Aug-26
Appendix Entity
Product Type
Type of Transaction
J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC JPMORGAN ASSET MANAGEMENT (UK) LIMITED JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC JPMORGAN ASSET MANAGEMENT (UK) LIMITED JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED
Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity
Adjustment Sell Buy Sell Buy Buy Buy Buy Buy Buy Sell Borrow Return Borrow Buy Sell Borrow Borrow Borrow Return Borrow Return Borrow Borrow Borrow Borrow Return Buy Buy Sell Buy Buy Buy Buy Borrow Return Buy Buy Sell Sell Sell Buy Borrow Sell BUy Sell Sell Buy Borrow Borrow Return Borrow Return Buy Sell Buy Buy Buy Sell Sell Sell Sell Buy Buy Sell Borrow Borrow Borrow Borrow Sell Buy Sell Buy Buy Buy Sell Buy Sell Sell Buy Sell Borrow Return Buy Borrow Borrow Sell Sell Buy Sell Buy Buy Buy Sell Sell Sell Sell Sell Sell Sell Sell Borrow Borrow Borrow Borrow Borrow Return Sell Buy Buy Sell Buy Sell Sell Buy Buy Sell Buy Borrow Borrow Borrow Borrow Return Buy Sell Sell Sell Buy Sell Sell Buy Buy Sell
Quantity 19,561,173 (366) (19) 3,029 (19,553) 4,930 49,717 1,979 1,514 219 675 (42,008) (12,000) 11,000 2,820 (4,290) 5,000 71,000 (241,000) (112,250) 31 382 30 (45,818) 51,424 68 (14,107) 22,003 1,976 3,946 127,986 (791,703) 49,765 4,363 (19,650) (5) (4,082) 11,986 2,000 (520) 520 (220) (11,830) 7,860 10,000 (10,446) (29,854) 2,783 (10) 38,276 283 5,922 (17,950) (1,312) (14,930) (3,070) 4,660 7,170 (7,625) 5,000 62,000 97,470 108,000 (843) 42,420 (15,384) 2,149 1,976 1,009 (25) 180 (8,017) (3) 1,914 (1,701) (31,000) 3,070 30,000 8,575 (400) (909) 2,725 (9,686) 2,838 51,338 1,053 (3,948) (3,949) (4,341) (3,222) (3,222) (2,845) (2,242) (4,350) 5,000 10,000 16,793 38,416 (20,028) (7,386) 44,836 794 (13,162) 1,209 (771) (410) 51 127 (610) 4,350 60,000 20,000 8,482 (85,198) 327 (1,289) (10,956) (6) 6 (71) (8,424) 42,735 178 (8,283)
Price (AUD) 3.44 3.44 3.39 3.44 3.39 3.44 3.44 3.44 3.41 3.44 3.55 3.55 3.52 3.49 3.52 3.54 3.60 3.60 3.60 3.73 3.63 3.71 3.77 3.60 3.72 3.63 3.63 3.58 3.58 3.63 3.58 3.58 3.60 3.58 3.58 3.60 3.72 3.51 3.50 3.56 3.50 3.58 3.51 3.46 3.46 3.51 3.51 3.51 3.48 3.46 3.46 3.46 3.46 3.58 3.40 3.29 3.29 3.40 3.28 3.30 3.28 3.40 3.29 3.29 3.29 3.29 3.29 3.46 3.46 3.33 3.54 3.51 3.45 3.54 3.54 3.29 3.29 3.54 3.54 3.46 3.43 3.28 3.54 3.28 3.28 3.28 3.28 3.29 3.35 3.50 3.37
Consideration $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $
65.36 10,419.76 66,262.50 16,943.39 168,690.13 6,807.76 5,208.16 753.36 2,301.93 144,507.52 10,014.18 15,230.51 180,911.74 237.34 49,605.49 77,932.23 7,113.60 14,205.60 460,749.60 185,761.90 15,838.96 72,889.73 18.83 14,695.20 44,587.92 1,889.53 1,889.53 787.43 42,299.97 28,531.80 9,963.14 35.80 137,758.46 1,013.67 21,200.76 64,557.70 4,880.64 52,471.03 10,737.39 16,588.78 25,077.22 27,297.50 2,958.93 146,617.01 53,178.44 7,542.99 6,931.27 3,541.59 87.00 622.80 27,738.82 10.38 6,622.44 6,089.58 10,446.21 1,316.00 2,990.61 9,265.74 31,777.25 9,374.49 168,189.86 3,580.20 12,988.92 12,992.21 14,281.89 10,600.38 10,600.38 9,843.70 7,757.32 14,473.06 26,146.44 157,479.99 2,742.99 46,593.48 4,280.20 2,536.59 1,348.90 180.54 449.58 2,107.65 14,922.84 1,072.56 4,563.06 35,935.68 19.68 19.68 232.88 27,746.66 143,141.95 623.05 27,930.82
1/3
TRADES FOR RELEVANT PERIOD 18-Aug-26 18-Aug-26 18-Aug-26 18-Aug-26 18-Aug-26 18-Aug-26 18-Aug-26 18-Aug-26 19-Aug-26 19-Aug-26 19-Aug-26 19-Aug-26 19-Aug-26 19-Aug-26 19-Aug-26 19-Aug-26 19-Aug-26 19-Aug-26 19-Aug-26 19-Aug-26 19-Aug-26 19-Aug-26 19-Aug-26 19-Aug-26 19-Aug-26 19-Aug-26 19-Aug-26 19-Aug-26 20-Aug-26 20-Aug-26 20-Aug-26 20-Aug-26 20-Aug-26 20-Aug-26 20-Aug-26 20-Aug-26 20-Aug-26 20-Aug-26 20-Aug-26 20-Aug-26 20-Aug-26 20-Aug-26 21-Aug-26 21-Aug-26 21-Aug-26 21-Aug-26 21-Aug-26 21-Aug-26 21-Aug-26 21-Aug-26 21-Aug-26 21-Aug-26 21-Aug-26 21-Aug-26 21-Aug-26 21-Aug-26 24-Aug-26 24-Aug-26 24-Aug-26 24-Aug-26 24-Aug-26 24-Aug-26 24-Aug-26 24-Aug-26 24-Aug-26 24-Aug-26 24-Aug-26 24-Aug-26 24-Aug-26 24-Aug-26 25-Aug-26 25-Aug-26 25-Aug-26 25-Aug-26 25-Aug-26 25-Aug-26 25-Aug-26 25-Aug-26 25-Aug-26 25-Aug-26 25-Aug-26 25-Aug-26 25-Aug-26 25-Aug-26 25-Aug-26 25-Aug-26 25-Aug-26 25-Aug-26 25-Aug-26 26-Aug-26 26-Aug-26 26-Aug-26 26-Aug-26 26-Aug-26 26-Aug-26 26-Aug-26 26-Aug-26 26-Aug-26 26-Aug-26 26-Aug-26 26-Aug-26 26-Aug-26 26-Aug-26 26-Aug-26 27-Aug-26 27-Aug-26 27-Aug-26 27-Aug-26 27-Aug-26 27-Aug-26 27-Aug-26 27-Aug-26 27-Aug-26 27-Aug-26 27-Aug-26 28-Aug-26 28-Aug-26 28-Aug-26 28-Aug-26 28-Aug-26 28-Aug-26 28-Aug-26 28-Aug-26 28-Aug-26 28-Aug-26 28-Aug-26
J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A.
Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity - Depository Receipt Equity Equity Equity
Sell Sell Buy Sell Borrow Borrow Return Borrow Borrow Return Sell Buy Buy Buy Sell Buy Buy Sell Sell Borrow Return Borrow Return Borrow Return Buy Borrow Borrow Borrow Return Borrow Return Borrow Return Borrow Return Borrow Buy Sell Buy Buy Buy Buy Buy Sell Buy Sell Sell Borrow Borrow Borrow Buy Buy Buy Buy Buy Sell Sell Sell Sell Sell Sell Sell Borrow Borrow Return Buy Sell Buy Sell Sell Buy Sell Borrow Return Buy Buy Borrow Borrow Return Borrow Return Borrow Return Borrow Sell Sell Buy Sell Buy Sell Sell Buy Sell Borrow Return Borrow Borrow Borrow Borrow Borrow Return Borrow Return Borrow Return Borrow Return Buy Sell Buy Buy Sell Buy Buy Sell Borrow Return Borrow Return Borrow Borrow Borrow Return Borrow Borrow Buy Sell Buy Buy Sell Sell Borrow Return Borrow Borrow Borrow Return Borrow Buy Buy Buy Buy Buy Sell Borrow Return Borrow Borrow Borrow Return Borrow Return
(23) (1,967) 610 (3,950) 15,000 (10,000) 6,080 (21,979) (14,075) 13,819 56,104 4,202 (129) 44 23,364 (44) (389) (19,000) (50,000) (39,000) 3,950 15,000 21,800 (16,793) (5,571) (32,758) (389,884) 328,198 3,751 (32,949) 7,554 6,581 2,632 86 71,696 (1,975) 140 (86) (1,903) 90,000 20,160 3,128,526 395 23,945 55 13,675 5,923 (20,683) (10) (3,177) (55) (3,713) (260,528) (9,830) 42,000 (2) 77,937 (17,190) 20,475 (183) (24,243) 2,122 (630) (32,000) 5,130 4,700 110,700 (34,722) (6) (419,179) 160,000 (2) (10,214) 50,489 (4,034) 11,155 (1,009) (2,723) 150 (1,642) (42,000) 44,000 10,000 9,682 95,000 (3,286) (4) (243,788) (9,700) 2,174 (264) 12,330 10,960 (1,975) 46,103 1,234 (1,234) (78,000) (85,285) 57,000 30,619 (61,332) 69,000 9,700 50,834 (13,840) 22,669 879 (29,837) (727) (43,000) 45,000 897 (30,873) 7 323 36,190 17,767 65,800 6,178 (5,863) (1,000) 125,000 29,000 (40,301) (25,847)
3.54 3.54 3.15 3.14 3.02 3.02 3.03 3.10 3.10 3.03 3.02 3.28 3.28 3.01 3.12 2.89 2.98 3.12 3.12 3.09 2.98 2.89 2.89 3.02 3.02 2.89 2.91 2.88 2.90 2.89 2.89 2.89 2.89 2.89 2.89 2.89 3.14 3.16 3.17 3.16 3.17 3.18 3.16 2.89 3.04 3.04 3.18 3.05 3.03 3.05 3.04 3.05 3.05 3.08 3.18 3.06 3.14 3.10 3.09 3.06 3.07 3.06 3.06 2.96 2.93 2.96 2.93 2.93 3.06 3.05 3.04 3.05 3.04 3.05 3.05
Appendix $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $
81.42 6,963.18 1,922.12 12,399.17 42,506.50 41,733.38 170,183.35 13,032.71 400.16 133.32 70,559.28 144.32 1,275.92 11,902.59 11,703.12 95,222.61 22,500.78 20,532.72 8,211.84 265.74 213,319.90 5,707.75 404.60 259.72 5,747.06 1,141.55 69,632.85 158.40 39,711.61 17,117.47 59,773.87 28.90 9,181.53 158.95 10,730.57 752,925.92 30,845.07 246,030.59 54,531.30 64,601.10 579.20 77,092.74 6,708.90 1,820.70 15,576.53 14,270.89 6.36 31,152.70 153,026.25 12,319.51 33,856.77 3,077.45 8,305.15 462.04 5,221.56 6,652.44 828.96 38,243.62 33,829.16 6,043.50 141,629.48 3,776.34 3,776.04 150,330.22 40,552.25 67,110.42 2,575.68 87,422.41 2,224.62 985.15 110,117.23 54,189.35 200,087.86 18,836.89 17,882.15
2/3
TRADES FOR RELEVANT PERIOD 28-Aug-26 31-Aug-26 31-Aug-26 31-Aug-26 31-Aug-26 31-Aug-26 31-Aug-26 31-Aug-26 31-Aug-26 31-Aug-26 31-Aug-26 31-Aug-26 31-Aug-26 31-Aug-26 31-Aug-26 31-Aug-26 31-Aug-26 31-Aug-26 31-Aug-26 31-Aug-26 31-Aug-26 1-Sep-26 1-Sep-26 1-Sep-26 1-Sep-26 1-Sep-26 1-Sep-26 1-Sep-26 1-Sep-26 1-Sep-26 1-Sep-26 1-Sep-26 1-Sep-26 1-Sep-26 1-Sep-26 1-Sep-26 Balance at end of relevant period
JPMORGAN CHASE BANK, N.A. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. J.P. MORGAN PRIME INC. J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC J.P. MORGAN SECURITIES PLC J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES AUSTRALIA LIMITED J.P. MORGAN SECURITIES LLC JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A. JPMORGAN CHASE BANK, N.A.
Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity Equity Equity Equity Equity Equity Equity Equity Equity Equity - Depository Receipt Equity Equity Equity Equity
Borrow Buy Buy Buy Buy Buy Sell Sell Borrow Borrow Borrow Borrow Borrow Borrow Return Borrow Return Borrow Return Borrow Return Borrow Return Borrow Return Borrow Borrow On-Lend Adjustment On-Lend On-Lend Return Buy Sell Buy Buy Buy Buy Borrow Borrow Borrow Borrow Borrow
1 727 904 7,250 77,823 147 (4,683) (525) 9,000 45,000 22,917 30 13,822 (214,580) (19) (7,663) (382) (30) (41,900) 20 298,000 208,200 103,138 356,705 (131,171) 8,310 (527) 15,793 64,774 438 95 109,000 52,400 7,600 72,051 1,030,000 24,126,965
2.98 2.97 2.98 2.98 2.98 3.05 2.98 3.05 2.90 3.10 3.07 3.10 3.10
Appendix $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $
2,166.46 2,685.10 21,588.70 231,830.28 438.09 14,283.15 1,564.50 25,370.42 1,528.30 48,958.30 198,758.95 1,355.67 294.52
3/3
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX. Date:
03-Sep-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant interests: Schedule
01-Sep-2026
Type of agreement
Global Master Securities Lending Agreement (“GMSLA”)
Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and BARCLAYS CAPITAL SECURITIES LIMITED ( “Borrower”) Settlement Date: 02-Jun-2025 29-Jan-2026 30-Jan-2026 10-Apr-2026 16-Jun-2026
Transfer date
Holder of voting rights Are there any restriction on voting rights If yes, detail Scheduled return date (if any) Does the borrower have the right to return early?
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA. None Yes
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX. Date:
03-Sep-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant interests: Schedule
01-Sep-2026
Type of agreement
Master Securities Lending Agreement (“MSLA”)
Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Barclays Capital, Inc. ( “Borrower”)
Transfer date
Settlement Date 07-Aug-2026 18-Aug-2026
Holder of voting rights Are there any restriction on voting rights If yes, detail Scheduled return date (if any) Does the borrower have the right to return early?
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out as per the rights of the borrower as stated in the MSLA. None Yes
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
03-Sep-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 01-Sep-2026 interests: Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and BNP Paribas Financial Markets (Borrower)
Transfer date
Settlement Date 14-Aug-2026 17-Aug-2026 19-Aug-2026 20-Aug-2026 25-Aug-2026 27-Aug-2026 28-Aug-2026 31-Aug-2026 01-Sep-2026 02-Sep-2026 03-Sep-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX. Date:
03-Sep-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant interests: Schedule
01-Sep-2026
Type of agreement
Master Securities Lending Agreement (“MSLA”)
Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Bofa Securities, Inc. ( “Borrower”)
Transfer date
Settlement date 07-Aug-2026 11-Aug-2026 21-Aug-2026 26-Aug-2026 28-Aug-2026
Holder of voting rights Are there any restriction on voting rights If yes, detail Scheduled return date (if any) Does the borrower have the right to return early?
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out as per the rights of the borrower as stated in the MSLA. None Yes
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
03-Sep-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 01-Sep-2026 interests: Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Citigroup Global Markets Limited (Borrower)
Transfer date
Settlement Date 10-Aug-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
03-Sep-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 01-Sep-2026 interests: Schedule Type of agreement Australian Master Securities Lending Agreement (“AMSLA”) Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Macquarie Bank Limited(Borrower)
Transfer date
Settlement Date 31-Aug-2026 02-Sep-2026 03-Sep-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4.3 of the standard form AMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender’s instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
03-Sep-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 01-Sep-2026 interests: Schedule Type of agreement Australian Master Securities Lending Agreement (“AMSLA”) Parties to agreement
Transfer date
Holder of voting rights Are there any restriction on voting rights
If yes, detail
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Merrill Lynch Equities (Australia) Limited(Borrower) Settlement Date 05-Jun-2026 13-Jul-2026 12-Aug-2026 25-Aug-2026 Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4.3 of the standard form AMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender’s instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
03-Sep-2026
Company’s name: IPERIONX LTD ISIN:
AU0000208910
Date of change of relevant interests:
01-Sep-2026
Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Merrill Lynch International(Borrower)
Transfer date
Settlement Date 09-Jun-2026 16-Jun-2026 26-Jun-2026 14-Jul-2026 15-Jul-2026 17-Jul-2026 21-Jul-2026 22-Jul-2026 23-Jul-2026 24-Jul-2026 29-Jul-2026 30-Jul-2026 31-Jul-2026 03-Aug-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions.
Will the securities be returned on Yes settlement?
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
03-Sep-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 01-Sep-2026 interests: Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
Transfer date
Holder of voting rights Are there any restriction on voting rights
If yes, detail
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Morgan Stanley & Co. International PLC (Borrower) Settlement Date 30-Oct-2025 14-Jul-2026 15-Jul-2026 14-Aug-2026 17-Aug-2026 18-Aug-2026 20-Aug-2026 21-Aug-2026 24-Aug-2026 03-Sep-2026 Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
03-Sep-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 01-Sep-2026 interests: Schedule Type of agreement Australian Master Securities Lending Agreement (“AMSLA”) Parties to agreement
Transfer date
Holder of voting rights Are there any restriction on voting rights
If yes, detail
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and Morgan Stanley Australia Securities Limited (Borrower) Settlement Date 31-Oct-2025 05-Nov-2025 18-Mar-2026 10-Jul-2026 15-Jul-2026 21-Jul-2026 Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4.3 of the standard form AMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender’s instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX.
Date:
03-Sep-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of relevant 01-Sep-2026 interests: Schedule Type of agreement Global Master Securities Lending Agreement ("GMSLA") Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and UBS AG London Branch (Borrower)
Transfer date
Settlement Date 28-Aug-2026 31-Aug-2026 01-Sep-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 6.6 of the standard form GMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the If yes, detail lender's instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender's instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending arrangement disclosed under the substantial shareholding notice filed with ASX. Date:
03-Sep-2026
Company’s name:
IPERIONX LTD
ISIN:
AU0000208910
Date of change of 01-Sep-2026 relevant interests: Schedule Type of agreement Australian Master Securities Lending Agreement (“AMSLA”) Parties to agreement
JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) and UBS Securities Australia Ltd (Borrower)
Transfer date
Settlement Date 18-Jun-2026 25-Jun-2026 26-Jun-2026 29-Jun-2026 16-Jul-2026 27-Aug-2026 01-Sep-2026
Holder of voting rights Are there any restriction on voting rights
If yes, detail
Borrower Yes The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4.3 of the standard form AMSLA.
Scheduled return None date (if any) Does the borrower have the right to Yes return early? Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s If yes, detail instructions. Does the lender have the right to Yes recall early?
If yes, detail
Will the securities be returned on settlement? If yes, detail any exceptions Statement
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions. Yes No exceptions If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX. Date:
03-Sep-2026
Company’s name:
IPERIONX LTD
ISIN: Date of change of relevant interests: Schedule
AU0000208910
Type of agreement Parties to agreement
Australian Master Securities Lending Agreement ("AMSLA")
01-Sep-2026
JPMorgan Chase Bank, N.A. (acting as agent) ("lender"), J.P. Morgan Securities Australia Limited ('borrower')
Transfer date
Settlement Date 20-Mar-2026 28-Apr-2026
Holder of voting rights
Borrower
Are there any restriction on voting Yes rights
If yes, detail
The borrower undertakes to use its best endeavours to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavours to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4.3 of the standard form AMSLA.
Scheduled return date (if any)
None
Does the borrower have the right to return early?
Yes
If yes, detail
Borrower has right to return all and any securities or equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities on any business day by giving such notice as agreed by the parties. The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exception
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX. Date:
03-Sep-2026
Company’s name:
IPERIONX LTD
ISIN: Date of change of relevant interests: Schedule
AU0000208910
Type of agreement
Global Master Securities Lending Agreement ("GMSLA")
Parties to agreement Transfer date Holder of voting rights Are there any restriction on voting rights If yes, detail
01-Sep-2026
State Street Bank and Trust Company ("lender") and J.P. Morgan Securities Australia Limited ("borrower") Settlement Date 23-Feb-2026 07-Jul-2026 Borrower Yes The borrower shall have no obligation to arrange for voting rights to be exercised in accordance with the instructions of the other party, unless otherwise agreed between the parties.
Scheduled return date (if None any) Does the borrower have the right to return early?
Yes
If yes, detail
Borrower has the right to terminate a loan and redeliver all and any equivalent securities due and outstanding to the lender in accordance with lender's instructions and lender shall accept such redelivery.
Does the lender have the Yes right to recall early? Lender has right to recall all or any equivalent securities on any business day by giving such notice as If yes, detail agreed by the parties. The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions. Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX.
Date: Company’s name: ISIN: Date of change of relevant interests: Schedule Type of agreement
03-Sep-2026 IPERIONX LTD AU0000208910
01-Sep-2026 Institutional Account Agreement
Parties to agreement
JP Morgan Securities LLC for itself and as agent and trustee for the other J.P. Morgan Entities and VANGUARD GROUP INC (AS AGT),CHARLES SCHWAB & CO., INC,STATE STREET BANK AND TRUST CO (AS AGENT),INTERACTIVE BROKERS LLC (herein referred to as “JPMS”). “ J.P. Morgan Entities” means, as the context may require or permit, any and all of JPMSL, JPMorgan Chase Bank, N.A., J.P. Morgan Securities LLC., J.P. Morgan Markets Limited, J.P. Morgan Securities Australia Limited, J.P. Morgan Securities (Asia Pacific) Limited, J.P. Morgan Securities Japan Co., Ltd and J.P. Morgan Prime Nominees Limited and any additional entity notified to the Company from time to time.
Transfer date
Settlement Date 25-Jun-2026 30-Jun-2026 17-Jul-2026 30-Jul-2026 31-Jul-2026 03-Aug-2026 05-Aug-2026 06-Aug-2026 07-Aug-2026 11-Aug-2026 25-Aug-2026 27-Aug-2026 28-Aug-2026 31-Aug-2026 01-Sep-2026
Holder of voting rights
JPMS is the holder of the voting rights from the time at which it exercises its right to borrow. Notwithstanding this, please note that the Company has the right to recall equivalent securities if it wishes to exercise its voting rights in respect of the securities.
Are there any restriction on voting Yes rights JPMS will not be able to exercise voting rights in circumstances where the Company has recalled If yes, detail equivalent securities from JPMS before the voting rights have been exercised. In these circumstances, JPMS must return the securities to the Company and the Company holds the voting rights. Scheduled return N/A. There is no term to the loan of securities. date (if any) Does the borrower have the right to Yes. return early? If yes, detail
JPMS has the right to return all and any securities or equivalent securities early at any time.
Does the lender have the right to recall early?
Yes.
If yes, detail
The Company has the right to recall all or any equivalent securities on demand.
Will the securities be returned on settlement?
Yes. Settlement of the loan will occur when JPMS returns equivalent securities to the Company. There is no term to the loan of securities.
If yes, detail any exceptions Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX. Date:
03-Sep-2026
Company’s name:
IPERIONX LTD
ISIN: Date of change of relevant interests: Schedule
AU0000208910
Type of agreement
Global Master Securities Lending Agreement ("GMSLA")
Parties to agreement
BANK JULIUS BAER & CO. AG vs JPMS PLC
Transfer date
Settlement Date 01-Jul-2026 02-Jul-2026 06-Jul-2026 09-Jul-2026 13-Jul-2026
Holder of voting rights
01-Sep-2026
Borrower
Are there any Yes restriction on voting rights If yes, detail Scheduled return date (if any) Does the borrower have the right to return early?
If yes, detail
Does the lender have the right to recall early?
If yes, detail
The borrower shall have no obligation to arrange for voting rights to be exercised in accordance with the instructions of the other party, unless otherwise agreed between the parties. None
Yes
Borrower has the right to terminate a loan and redeliver all and any equivalent securities due and outstanding to the lender in accordance with lender's instructions and lender shall accept such redelivery on a business day if notice of redelivery has been given within the standard market settlement period.
Yes
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time provided notification is given by the lender within standard market settlement period for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered. The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX.
Date: Company’s name:
03-Sep-2026
ISIN: Date of change of relevant interests: Schedule
AU0000208910
Type of agreement
IPERIONX LTD
01-Sep-2026 Overseas Securities Lender's Agreement ("OSLA")
Parties to agreement
J.P. Morgan Securities Plc ("borrower") and Citibank N.A. acting as Agent ("lender")
Transfer date
Settlement Date 07-Aug-2026
Holder of voting rights Borrower Are there any restriction on voting rights
Yes
If yes, detail
The borrower undertakes to use its best endeavours to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavours to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4(B)(vi) of the standard form OSLA.
Scheduled return date None (if any) Does the borrower have the right to return early?
Yes
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered. The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX. Date:
03-Sep-2026
Company’s name:
IPERIONX LTD
ISIN: Date of change of relevant interests:
AU0000208910
01-Sep-2026
Schedule Type of agreement Parties to agreement
Transfer date
Overseas Securities Lender’s Agreement (“OSLA”) JPMorgan Chase Bank, N.A. (acting as agent) (“lender”) J.P. Morgan Securities plc (“borrower”) Settlement Date 19-Mar-2026 30-Mar-2026 09-Apr-2026 27-Aug-2026
Holder of voting rights
Borrower
Are there any restriction on voting rights
Yes
If yes, detail
The borrower undertakes to use its best endeavors to arrange for the voting rights to be exercised in accordance with the instructions of the lender, provided that the lender uses its best endeavors to notify the borrower of its instructions in writing no later than 7 business days prior to the date upon which such votes are exercisable or as otherwise agreed between the parties. This undertaking is set out in clause 4(B)(vi) of the standard form OSLA.
Scheduled return date (if any)
None
Does the borrower have the right to Yes return early?
If yes, detail
Borrower has right to return all and any equivalent securities early at any time in accordance with the lender’s instructions.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered (and where there is a difference between the settlement time for sales and purchases on the relevant exchange or clearing organisation, the standard settlement time shall be the shorter of the two times). The borrower must return the securities not later than the expiry of such notice in accordance with the lender’s instructions.
Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
Appendix: Prescribed information pursuant to securities lending transaction disclosed under the substantial shareholding notice filed with ASX.
Date: Company’s name:
03-Sep-2026
ISIN: Date of change of relevant interests: Schedule
AU0000208910
Type of agreement
IPERIONX LTD
01-Sep-2026
Global Master Securities Lending Agreement ("GMSLA")
Parties to agreement
J.P. Morgan Securities plc ("borrower") and State St Bank and Trust Company as agent ("lender")
Transfer date
Settlement Date 29-Jul-2026
Holder of voting rights
Borrower
Are there any restriction on voting Yes rights
If yes, detail
The borrower shall have no obligation to arrange for voting rights to be exercised in accordance with the instructions of the other party, unless otherwise agreed between the parties.
Scheduled return date (if any)
None
Does the borrower have the right to return early?
Yes
If yes, detail
Borrower has the right to terminate a loan and redeliver all and any equivalent securities due and outstanding to the lender in accordance with lender's instructions and lender shall accept such redelivery.
Does the lender have the right to recall early?
Yes
If yes, detail
Lender has right to recall all or any equivalent securities at any time by giving notice on any business day of not less than the standard settlement time for such equivalent securities on the exchange or in the clearing organisation through which the relevant borrowed securities were originally delivered. The borrower must return the
securities not later than the expiry of such notice in accordance with the lender’s instructions. Will the securities be returned on settlement?
Yes
If yes, detail any exceptions
No exceptions
Statement
If requested by the company to whom the prescribed form must be given, or if requested by ASIC, a copy of the agreement will be given to that company or ASIC.
PRESS RELEASE | NASDAQ: IPX | ASX: IPX
August 31, 2026
IPERIONX SECURES SECOND U.S. ARMY TASK ORDER TO ACCELERATE INDUSTRIAL-SCALE AMERICAN TITANIUM PRODUCTION Highlights: Second U.S. Army task order under SBIR Phase III contract: Task Order 2 issued under IperionX’s existing US$99 million SBIR Phase III contract for Low-Cost, Domestic Titanium for Defense Applications. US$11.5 million obligated, up to US$25.4 million potential value: Current funding fully covers three priority industrialization work packages and provides an initial allotment to a fourth. Unexercised and unfunded options could increase Task Order 2’s value to a maximum of US$25.4 million. Industrial-scale American titanium capacity: The program advances integrated titanium powder-to-finishedcomponent operations, with continuous HSPT™ and dehydride furnace capacity, together with equipment that will bring titanium fastener finishing fully in-house at IperionX’s Virginia facility. Continuous titanium powder-to-part manufacturing platform: Continuous HSPT™ processing is the downstream complement to GenX™, IperionX’s next-generation continuous HAMR™ titanium production platform. Together, the technologies are designed to increase throughput and reduce unit costs from titanium powder through to finished titanium components for the U.S. defense sector. Expanded U.S. defense manufacturing capability: Manufacturing program for titanium track pins, bolts and fasteners for defense applications, with inspection and acceptance planned at Detroit Arsenal and Army Research Laboratory’s Aberdeen Proving Ground. Potential expansion into aerospace and refractory alloys: Future option line items could extend IperionX’s patented technologies into an aerospace-grade titanium component program with a leading global aerospace and defense supplier, C103 alloy scrap recycling for a large advanced materials company, and spherical niobium and C103 powder development with Global Advanced Metals. IperionX Limited (NASDAQ: IPX; ASX: IPX) (IperionX or the Company) announces that the U.S. Army has awarded Task Order 2 under the Small Business Innovation Research (SBIR) Phase III Indefinite Delivery, Indefinite Quantity (IDIQ) contract for Low-Cost, Domestic Titanium for Defense Applications. IperionX’s SBIR Phase III IDIQ contract enables qualifying U.S. Government agencies to place project-specific orders collectively capped at US$99 million (refer to details in the release dated June 5, 2025 “IperionX Awarded U.S. DoD SBIR Contract for up to US$99M”). Task Orders 1 and 2 have an aggregate stated value of approximately US$19.8 million, with US$79.2 million remaining available under the IDIQ contract ceiling. Task Order W911QX26FA097 is firm-fixed-price and has a stated base value of US$18.5 million. Of this amount, US$11.5 million is currently funded and obligated. A further US$6.9 million of unexercised and unfunded options could increase the maximum potential task order value to US$25.4 million if exercised and funded at the U.S. Government’s discretion. The SBIR funding supports equipment and manufacturing systems to expand IperionX’s domestic titanium powderto-part manufacturing capacity. The program will increase titanium component-processing capability, bring critical manufacturing steps in-house and support shorter lead times, providing the potential to lower acquisition and production costs for U.S. defense applications. CEO Commentary “This second U.S. Army task order represents an important step in scaling IperionX’s titanium powder-to-part manufacturing platform. The SBIR Phase III award aims to advance continuous and industrial-scale HSPT™ and dehydride capacity and bring titanium fastener finishing fully in-house at our Virginia titanium manufacturing facility. Virginia
Tennessee
Utah
1092 Confroy Drive
279 West Main Street
1782 W 2300 S
South Boston, VA 24592
Camden, TN 38320
West Valley City, UT 84119
IperionX Limited ABN 84 618 935 372
This award aligns with GenX™, our next-generation continuous HAMR™ production platform, which together will provide an integrated American titanium manufacturing system. The program will expand our capacity to manufacture titanium track pins, bolts and fasteners for the U.S. Army, shorten production lead times and strengthen the domestic titanium manufacturing capabilities required to support U.S. defense supply chains.”
— Taso Arima, IperionX CEO
Expanding American titanium powder-to-part manufacturing capacity IperionX’s titanium manufacturing platform integrates two proprietary technologies. HAMR™ converts titanium scrap or mineral feedstocks into low-oxygen titanium powder. HSPT™ then consolidates that powder into near-netshape components with a wrought-like microstructure and high-performance mechanical attributes. Task Order 2 will expand downstream conversion capacity required to transform larger volumes of titanium powder into qualified finished components. The three fully funded work packages support continuous HSPT™ furnace development, centerless grinding and thread-rolling equipment for in-house fastener production, and industrialscale continuous HSPT™ and dehydrogenation furnaces. Refer to Appendix A with details of tasks and Appendix B for the terms of the Task Order. The funded SBIR Phase III program is designed to increase manufacturing throughput and flexibility while reducing reliance on external finishing suppliers. Bringing fastener finishing in-house will give IperionX greater control over cost and production schedules and establish a more complete titanium powder-to-finished-component capability at its Virginia facility. The program includes production-scale titanium track pins, bolts and fasteners for U.S. Army ground-combat applications, with inspection and acceptance planned at Detroit Arsenal. Accelerating commercial scale-up and strengthening the U.S. defense industrial base IperionX’s customer programs range across defense, aerospace, automotive and consumer electronics, from material and component qualification through funded prototyping and initial low-rate orders. Finished componentconversion capacity is currently a key constraint in advancing these programs toward potential higher-volume supply arrangements. The new HSPT™ and dehydrogenation capacity is expected to increase both the number and volume of components IperionX can process. Internalizing fastener finishing is also expected to shorten lead times, improve manufacturing control and retain more value within IperionX’s integrated powder-to-part production platform. The new capabilities will provide a scalable manufacturing backbone serving both U.S. defense requirements and IperionX’s commercial growth strategy. For the defense industrial base, it will expand domestic capacity for titanium track pins, bolts, fasteners and other mission-critical components, while improving supply-chain resilience and potential surge capacity. The same equipment, workforce and operating expertise can support the scale-up of titanium products for aerospace and other advanced manufacturing markets. By integrating advanced titanium processing and finished-component manufacturing in Virginia, Task Order 2 is expected to accelerate IperionX’s commercial scale-up and enhance American industrial capability for strategically important titanium components. Continuous manufacturing across the platform IperionX is advancing a transition from batch to continuous processing at both ends of its titanium manufacturing platform. GenX™, IperionX’s next-generation HAMR™ development platform, targets continuous production of low-oxygen titanium powder. Task Order 2 separately supports the development of continuous HSPT™ processing and industrial-scale dehydrogenation capacity for converting HAMR™ powder into titanium near-net-shape components. Connecting continuous powder production with continuous downstream titanium component manufacturing is designed to increase throughput, improve production consistency and progressively reduce unit costs as manufacturing volumes scale.
2
Potential expansion into aerospace and refractory metals The SBIR Phase III Task Order 2 includes four option line items totaling US$6.9 million, subject to U.S. Government exercise, additional funding, technical development and customer qualification. If exercised and funded, the options would support: • an integrated binder-jet and HSPT™ demonstration for an aerospace-grade titanium component with a leading global aerospace and defense supplier; • recycling C103 alloy scrap for a large advanced materials company into high-purity powder suitable for additive manufacturing or remelting; and • niobium reduction, powder spheroidization and scaled production of spherical niobium and C103 powders with Global Advanced Metals. C103 is a niobium-hafnium-titanium refractory alloy designed for sustained operation in high-temperature environments, including space and defense propulsion systems. Its use in additive manufacturing and powder metallurgy depends on reliable access to tightly specified low-oxygen powder feedstock. The funding options could position IperionX’s patented technologies to establish an integrated domestic capability spanning C103 scrap recycling, niobium reduction, deoxygenation and powder spheroidization. End-to-end U.S. Government support for a secure domestic titanium supply chain The SBIR Phase III Task Order 2 adds industrial-scale titanium component manufacturing to a broader portfolio of previously announced U.S. Government programs supporting IperionX’s development of an integrated American titanium supply chain. Collectively, these separate initiatives span strategic feedstock, titanium metal and powder production, workforce and industrial-base development, and finished-component manufacturing. Previously announced support includes: • US$59.8 million of fully obligated reimbursable funding under the Defense Production Act Title III and Industrial Base Analysis and Sustainment (IBAS) programs, supporting the expansion of domestic titanium production capabilities; • approximately 290 metric tons of high-quality titanium alloy scrap transferred at no cost, providing IperionX with a strategic domestic feedstock for recycled titanium production; and • the initial US$1.3 million U.S. Army task order under the SBIR Phase III contract, which commenced the development of low-cost, American-made titanium components for defense applications. Task Order 2 extends this engagement further downstream by funding equipment and manufacturing systems that convert titanium powder into production-scale finished components. The progression from strategic feedstock and primary metal production through to qualified defense components reinforces IperionX’s role in rebuilding a secure, vertically integrated and competitive U.S. titanium supply chain. This announcement has been authorized for release by the CEO and Managing Director.
August 31, 2026
Array
Share This Article
SOUTH BOSTON, Va., Aug. 31, 2026 (GLOBE NEWSWIRE) — IperionX Limited (IperionX) (NASDAQ: IPX, ASX: IPX) IperionX Limited announces that the U.S. Army has awarded Task Order 2 under the Small Business Innovation Research (SBIR) Phase III Indefinite Delivery, Indefinite Quantity (IDIQ) contract for Low-Cost, Domestic Titanium for Defense Applications.
IperionX’s SBIR Phase III IDIQ contract enables qualifying U.S. Government agencies to place project-specific orders collectively capped at US$99 million (refer to details in the release dated June 5, 2025 “IperionX Awarded U.S. DoD SBIR Contract for up to US$99M”). Task Orders 1 and 2 have an aggregate stated value of approximately US$19.8 million, with US$79.2 million remaining available under the IDIQ contract ceiling.
Task Order W911QX26FA097 is firm-fixed-price and has a stated base value of US$18.5 million. Of this amount, US$11.5 million is currently funded and obligated. A further US$6.9 million of unexercised and unfunded options could increase the maximum potential task order value to US$25.4 million if exercised and funded at the U.S. Government’s discretion.
The SBIR funding supports equipment and manufacturing systems to expand IperionX’s domestic titanium powder-to-part manufacturing capacity. The program will increase titanium component-processing capability, bring critical manufacturing steps in-house and support shorter lead times, providing the potential to lower acquisition and production costs for U.S. defense applications.
Highlights:
-
**Second U.S. Army task order under SBIR Phase III contract:**Task Order 2 issued under IperionX’s existing US$99 million SBIR Phase III contract for Low-Cost, Domestic Titanium for Defense Applications.
-
**US$11.5 million obligated, up to US$25.4 million potential value:**Current funding fully covers three priority industrialization work packages and provides an initial allotment to a fourth. Unexercised and unfunded options could increase Task Order 2’s value to a maximum of US$25.4 million.
-
**Industrial-scale American titanium capacity:**The program advances integrated titanium powder-to-finished-component operations, with continuous HSPT™ and dehydride furnace capacity, together with equipment that will bring titanium fastener finishing fully in-house at IperionX’s Virginia facility.
-
Continuous titanium powder-to-part manufacturing platform: Continuous HSPT™ processing is the downstream complement to GenX™, IperionX’s next-generation continuous HAMR™ titanium production platform. Together, the technologies are designed to increase throughput and reduce unit costs from titanium powder through to finished titanium components for the U.S. defense sector.
-
**Expanded U.S. defense manufacturing capability:**Manufacturing program for titanium track pins, bolts and fasteners for defense applications, with inspection and acceptance planned at Detroit Arsenal and Army Research Laboratory’s Aberdeen Proving Ground.
-
**Potential expansion into aerospace and refractory alloys:**Future option line items could extend IperionX’s patented technologies into an aerospace-grade titanium component program with a leading global aerospace and defense supplier, C103 alloy scrap recycling for a large advanced materials company, and spherical niobium and C103 powder development with Global Advanced Metals.
CEO Commentary
“This second U.S. Army task order represents an important step in scaling IperionX’s titanium powder-to-part manufacturing platform. The SBIR Phase III award aims to advance continuous and industrial-scale HSPT™ and dehydride capacity and bring titanium fastener finishing fully in-house at our Virginia titanium manufacturing facility.
This award aligns with GenX™, our next-generation continuous HAMR™ production platform, which together will provide an integrated American titanium manufacturing system. The program will expand our capacity to manufacture titanium track pins, bolts and fasteners for the U.S. Army, shorten production lead times and strengthen the domestic titanium manufacturing capabilities required to support U.S. defense supply chains.”
**–**Taso Arima, IperionX CEO
Full announcement: (link)
604 Page 1 18-Aug-2026
Form 604 Corporations Act 2001 Section 671B
Notice of change of interests of substantial holder To Company Name/Scheme IPERIONX LIMITED ACN/ARSN
618 935 372
- Details of substantial holder (1) Name
State Street Corporation and subsidiaries named in paragraph 6 to this form
ACN/ARSN (if applicable) There was a change in the interests of the substantial holder on
14/08/2026
The previous notice was given to the company on
06/08/2026
The previous notice was dated
04/08/2026
- Previous and present voting power The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows: Previous notice
Class of securities (4)
Present notice
Person’s votes
Voting power (5)
24,151,564
Ordinary
6.67%
Person’s votes
Voting power (5)
27,793,172
7.67%
- Changes in relevant interests Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows: Date of change
Person whose relevant interest changed
Consideration given in relation to change (7)
Nature of change (6)
Class and number of securities affected
Person's votes affected
Annexure A, B & C
4.Present relevant interests Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows: Holder of relevant interest
Registered holder of securities
Person entitled to be registered as holder (8)
STATE STREET GLOBAL ADVISORS EUROPE LIMITED
State Street Bank n/a and Trust Co
STATE STREET GLOBAL ADVISORS EUROPE LIMITED
Citibank NA
n/a
THE REGENTS OF THE REGENTS OF STATE STREET BANK AND THE UNIVERSITY OF THE UNIVERSITY OF TRUST COMPANY CALIFORNIA CALIFORNIA
STATE OF ALASKA - STATE OF ALASKA STATE STREET BANK AND ALASKA RETIREMENT ALASKA RETIREMENT TRUST COMPANY MANAGEMENT BOARD MANAGEMENT BOARD
AWARE SUPER PTY AWARE SUPER PTY STATE STREET BANK AND LTD AS TRUSTEE OF LTD AS TRUSTEE OF TRUST COMPANY THE AWARE SUPER THE AWARE SUPER
STATE STREET BANK AND VANECK ETF FUNDS TRUST COMPANY
VANECK ETF FUNDS
STATE STREET BANK AND TIAA - CREF TRUST COMPANY
TIAA - CREF
STATE STREET BANK AND NATIXIS TRUST COMPANY
NATIXIS
STATE STREET BANK AND THE MORGAN STANLEY GROUP TRUST COMPANY
THE MORGAN STANLEY GROUP
Nature of relevant interest (6) Power to control the exercise of a right to vote attached to securities and/or the power to dispose of securities as investment manager or trustee Power to control the exercise of a right to vote attached to securities and/or the power to dispose of securities as investment manager or trustee For Lent securities:Relevant interest under section 608(8A) being the holder of securities subject to an obligation to return under a securities lending agreement.State Street Bank and Trust Company has lent the securities and retains a relevant interest For Lent securities:Relevant interest under section 608(8A) being the holder of securities subject to an obligation to return under a securities lending agreement.State Street Bank and Trust Company has lent the securities and retains a relevant interest For Lent securities:Relevant interest under section 608(8A) being the holder of securities subject to an obligation to return under a securities lending agreement.State Street Bank and Trust Company has lent the securities and retains a relevant interest For Lent securities:Relevant interest under section 608(8A) being the holder of securities subject to an obligation to return under a securities lending agreement.State Street Bank and Trust Company has lent the securities and retains a relevant interest For Lent securities:Relevant interest under section 608(8A) being the holder of securities subject to an obligation to return under a securities lending agreement.State Street Bank and Trust Company has lent the securities and retains a relevant interest For collateral securities:Relevant interest under section 608(8A) being the right, as lender, to dispose of shares transferred to secure a securities loan For collateral securities:Relevant interest under section 608(8A) being the right, as lender, to dispose of shares transferred to secure a securities loan
Class and number of securities
Person's votes
68,010
Ordinary
68,010
41,523
Ordinary
41,523
84,746
Ordinary
84,746
7,944
Ordinary
7,944
2,784,210
Ordinary
2,784,210
687,186
Ordinary
687,186
151,830
Ordinary
151,830
1,871,420
Ordinary
1,871,420
68,290
Ordinary
68,290
604 Page 2 18-Aug-2026
For Lent securities:Relevant interest under POLICE AND POLICE AND section 608(8A) being the holder of securities FIREMENS subject to an obligation to return under a STATE STREET BANK AND FIREMENS RETIREMENT SYSTEM RETIREMENT SYSTEM securities lending agreement.State Street Bank TRUST COMPANY OF NEW JERSEY OF NEW JERSEY and Trust Company has lent the securities and retains a relevant interest
93,306
Ordinary
93,306
STATE STREET BANK AND UNKNOWN TRUST COMPANY
For borrowed securities:Relevant interest under section 608(1) being the holder of STATE STREET BANK securities subject to an obligation to return AND TRUST COMPANY under a securities lending agreement.STATE STREET BANK AND TRUST COMPANY has on-lent the securities and retains a relevant interest
161,161
Ordinary
161,161
STATE STREET BANK AND THE BANK OF AMERICA GROUP TRUST COMPANY
THE BANK OF AMERICA GROUP
13
Ordinary
13
1,682,808
Ordinary
1,682,808
50,291
Ordinary
50,291
562,957
Ordinary
562,957
157,014
Ordinary
157,014
519,223
Ordinary
519,223
1,566,660
Ordinary
1,566,660
14,318
Ordinary
14,318
131,641
Ordinary
131,641
64,322
Ordinary
64,322
104,515
Ordinary
104,515
123,939
Ordinary
123,939
175,621
Ordinary
175,621
145,653
Ordinary
145,653
184,368
Ordinary
184,368
264,705
Ordinary
264,705
1,638,964
Ordinary
1,638,964
114,988
Ordinary
114,988
STATE STREET BANK AND THE GOLDMAN SACHS THE GOLDMAN SACHS GROUP GROUP TRUST COMPANY
STATE STREET BANK AND SSGA SPDR ETFS EUROPE II PLC TRUST COMPANY
SSGA SPDR ETFS EUROPE II PLC
STATE STREET BANK AND SSGA TRUST COMPANY
SSGA
STATE STREET BANK AND SSUTM AUTHORISED SSUTM AUTHORISED UNIT TRUST SCHEME UNIT TRUST SCHEME TRUST COMPANY
BRIGHTER SUPER STATE STREET BANK AND TRUSTEE AS TRUSTEE FOR TRUST COMPANY BRIGHTER SUPER
BRIGHTER SUPER TRUSTEE AS TRUSTEE FOR BRIGHTER SUPER
STATE STREET BANK AND THE ING GROUP TRUST COMPANY
THE ING GROUP
STATE STREET BANK AND SSGA SPDR ETFS EUROPE I PLC TRUST COMPANY
SSGA SPDR ETFS EUROPE I PLC
STATE STREET BANK AND ALPS ETF TRUST TRUST COMPANY
ALPS ETF TRUST
MERCER GLOBAL INVESTMENTS STATE STREET BANK AND MANAGEMENT TRUST COMPANY LIMITED - MERCER QIF FUND PLC
MERCER GLOBAL INVESTMENTS MANAGEMENT LIMITED - MERCER QIF FUND PLC
STATE STREET BANK AND SSGA FUNDS TRUST COMPANY
SSGA FUNDS
STATE STREET BANK AND WA STATE INVESTMENT BOARD TRUST COMPANY
WA STATE INVESTMENT BOARD
TEACHER TEACHER STATE STREET BANK AND RETIREMENT SYSTEM RETIREMENT SYSTEM TRUST COMPANY OF TEXAS OF TEXAS
STATE STREET BANK AND SSGA SPDR INDEX SHARE FUNDS TRUST COMPANY
SSGA SPDR INDEX SHARE FUNDS
FEDERAL FEDERAL STATE STREET BANK AND RETIREMENT THRIFT RETIREMENT THRIFT TRUST COMPANY INVESTMENT BOARD INVESTMENT BOARD
STATE STREET BANK AND CALSTRS TRUST COMPANY
CALSTRS
STATE STREET GLOBAL ADVISORS TRUST COMPANY
State Street Bank n/a and Trust Co
STATE STREET GLOBAL ADVISORS TRUST COMPANY
Bank of New York Mellon
n/a
For collateral securities:Relevant interest under section 608(8A) being the right, as lender, to dispose of shares transferred to secure a securities loan For collateral securities:Relevant interest under section 608(8A) being the right, as lender, to dispose of shares transferred to secure a securities loan For Lent securities:Relevant interest under section 608(8A) being the holder of securities subject to an obligation to return under a securities lending agreement.State Street Bank and Trust Company has lent the securities and retains a relevant interest For Lent securities:Relevant interest under section 608(8A) being the holder of securities subject to an obligation to return under a securities lending agreement.State Street Bank and Trust Company has lent the securities and retains a relevant interest For Lent securities:Relevant interest under section 608(8A) being the holder of securities subject to an obligation to return under a securities lending agreement.State Street Bank and Trust Company has lent the securities and retains a relevant interest For Lent securities:Relevant interest under section 608(8A) being the holder of securities subject to an obligation to return under a securities lending agreement.State Street Bank and Trust Company has lent the securities and retains a relevant interest For collateral securities:Relevant interest under section 608(8A) being the right, as lender, to dispose of shares transferred to secure a securities loan For Lent securities:Relevant interest under section 608(8A) being the holder of securities subject to an obligation to return under a securities lending agreement.State Street Bank and Trust Company has lent the securities and retains a relevant interest For Lent securities:Relevant interest under section 608(8A) being the holder of securities subject to an obligation to return under a securities lending agreement.State Street Bank and Trust Company has lent the securities and retains a relevant interest For Lent securities:Relevant interest under section 608(8A) being the holder of securities subject to an obligation to return under a securities lending agreement.State Street Bank and Trust Company has lent the securities and retains a relevant interest For Lent securities:Relevant interest under section 608(8A) being the holder of securities subject to an obligation to return under a securities lending agreement.State Street Bank and Trust Company has lent the securities and retains a relevant interest For Lent securities:Relevant interest under section 608(8A) being the holder of securities subject to an obligation to return under a securities lending agreement.State Street Bank and Trust Company has lent the securities and retains a relevant interest For Lent securities:Relevant interest under section 608(8A) being the holder of securities subject to an obligation to return under a securities lending agreement.State Street Bank and Trust Company has lent the securities and retains a relevant interest For Lent securities:Relevant interest under section 608(8A) being the holder of securities subject to an obligation to return under a securities lending agreement.State Street Bank and Trust Company has lent the securities and retains a relevant interest For Lent securities:Relevant interest under section 608(8A) being the holder of securities subject to an obligation to return under a securities lending agreement.State Street Bank and Trust Company has lent the securities and retains a relevant interest For Lent securities:Relevant interest under section 608(8A) being the holder of securities subject to an obligation to return under a securities lending agreement.State Street Bank and Trust Company has lent the securities and retains a relevant interest Power to control the exercise of a right to vote attached to securities and/or the power to dispose of securities as investment manager or trustee Power to control the exercise of a right to vote attached to securities and/or the power to dispose of securities as investment manager or trustee
604 Page 3 18-Aug-2026
STATE STREET GLOBAL ADVISORS TRUST COMPANY
Northern Trust Company
SSGA FUNDS MANAGEMENT, INC.
State Street Bank n/a and Trust Co
STATE STREET GLOBAL ADVISORS LIMITED
State Street Bank n/a and Trust Co
STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED
JPMorgan AG
STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED
State Street Bank n/a and Trust Co
STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED
BNP Paribas
n/a
STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED
Citibank NA
n/a
STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED
Northern Trust Company
n/a
n/a
n/a
Power to control the exercise of a right to vote attached to securities and/or the power to dispose of securities as investment manager or trustee Power to control the exercise of a right to vote attached to securities and/or the power to dispose of securities as investment manager or trustee Power to control the exercise of a right to vote attached to securities and/or the power to dispose of securities as investment manager or trustee Power to control the exercise of a right to vote attached to securities and/or the power to dispose of securities as investment manager or trustee Power to control the exercise of a right to vote attached to securities and/or the power to dispose of securities as investment manager or trustee Power to control the exercise of a right to vote attached to securities and/or the power to dispose of securities as investment manager or trustee Power to control the exercise of a right to vote attached to securities and/or the power to dispose of securities as investment manager or trustee Power to control the exercise of a right to vote attached to securities and/or the power to dispose of securities as investment manager or trustee
13,126
Ordinary
13,126
263,336
Ordinary
263,336
211,037
Ordinary
211,037
1,312,121
Ordinary
1,312,121
11,177,391
Ordinary
11,177,391
77,225
Ordinary
77,225
1,019,133
Ordinary
1,019,133
198,177
Ordinary
198,177
- Changes in association The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows: Nature of association
Name and ACN/ARSN (if applicable) STATE STREET BANK AND TRUST COMPANY
Subsidiary of State Street Corporation
STATE STREET GLOBAL ADVISORS EUROPE LIMITED
Subsidiary of State Street Corporation
SSGA FUNDS MANAGEMENT, INC.
Subsidiary of State Street Corporation
STATE STREET GLOBAL ADVISORS TRUST COMPANY
Subsidiary of State Street Corporation
STATE STREET GLOBAL ADVISORS LIMITED
Subsidiary of State Street Corporation
STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED
Subsidiary of State Street Corporation
- Addresses The addresses of persons named in this form are as follows: Address
Name STATE STREET BANK AND TRUST COMPANY
ONE CONGRESS STREET, SUITE 1,
BOSTON MA 02114, UNITED STATES
STATE STREET GLOBAL ADVISORS EUROPE LIMITED
78 SIR JOHN ROGERSON’S QUAY, DUBLIN 2, IRELAND
SSGA FUNDS MANAGEMENT, INC.
1 CONGRESS STREET, BOSTON MA 02114, UNITED STATES
STATE STREET GLOBAL ADVISORS TRUST COMPANY
1 CONGRESS STREET, BOSTON MA 02114, UNITED STATES
STATE STREET GLOBAL ADVISORS LIMITED
20
STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED
LEVEL 15, 420 GEORGE STREET, SYDNEY NSW 2000, AUSTRALIA
CHURCHILL PLACE, LONDON, ENGLAND, E14 5HJ, UNITED KINGDOM
Signature print name
sign here
Alok Maheshwary
capacity
Authorised signatory
date
18/08/2026
604 Page 4 18-Aug-2026
DIRECTIONS (1)
If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and ADDRESSES of members is clearly set out in paragraph 6 of the form.
(2) See the definition of "associate" in section 9 of the Corporations Act 2001. (3) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001. (4) The voting shares of a company constitute one class unless divided into separate classes. (5) The person's votes divided by the total votes in the body corporate or scheme multiplied by 100. (6) Include details of: (a)
any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
(b)
any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).
See the definition of "relevant agreement" in section 9 of the Corporations Act 2001. (7) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired. (8) If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown". (9) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.
604 Page 5 18-Aug-2026
Annexure A This is Annexure A referred to in Form 604, Notice of change of interest of substantial holder
Alok Maheshwary
Dated the
Authorised signatory
Consideration given in relation to change
Class and number of securities affected
18/08/2026
Person's votes affected
Date of change
Person whose relevant interest changed
Nature of change
05/08/2026
STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED
Transfer in
3.41
1,645
Ordinary
1,645
05/08/2026
STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED
Transfer out
3.41
-1,416
Ordinary
-1,416
05/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
40,795
Ordinary
40,795
05/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
25,900
Ordinary
25,900
05/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
95,700
Ordinary
95,700
05/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
20,400
Ordinary
20,400
05/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
7,100
Ordinary
7,100
05/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
-44,492
Ordinary
-44,492
05/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-1,519
Ordinary
-1,519
05/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-2,586
Ordinary
-2,586
05/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-767
Ordinary
-767
05/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-160,805
Ordinary
-160,805
05/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-430
Ordinary
-430
05/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-14,772
Ordinary
-14,772
05/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-60
Ordinary
-60
05/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-346,630
Ordinary
-346,630
05/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-4,152
Ordinary
-4,152
05/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-15,876
Ordinary
-15,876
05/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-3,764
Ordinary
-3,764
05/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
-1,000
Ordinary
-1,000
05/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
-13
Ordinary
-13
05/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
-4,300
Ordinary
-4,300
05/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
-5,000
Ordinary
-5,000
05/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
-261
Ordinary
-261
05/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
27
Ordinary
27
06/08/2026
STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED
Transfer in
3.40
1,617
Ordinary
1,617
06/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
13
Ordinary
13
06/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
21,465
Ordinary
21,465
06/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
-17,900
Ordinary
-17,900
06/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
5,100
Ordinary
5,100
06/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
12,600
Ordinary
12,600
06/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
-98
Ordinary
-98
06/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
600
Ordinary
600
06/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
-35,360
Ordinary
-35,360
06/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-1,694
Ordinary
-1,694
604 Page 6 18-Aug-2026
06/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-3,236
Ordinary
-3,236
06/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-864
Ordinary
-864
06/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-185,529
Ordinary
-185,529
06/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-478
Ordinary
-478
06/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-17,773
Ordinary
-17,773
06/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-78
Ordinary
-78
06/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-389,662
Ordinary
-389,662
06/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-5,450
Ordinary
-5,450
06/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-18,203
Ordinary
-18,203
06/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-4,177
Ordinary
-4,177
06/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
19,600
Ordinary
19,600
06/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
-18,887
Ordinary
-18,887
06/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
-900
Ordinary
-900
06/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
-187
Ordinary
-187
07/08/2026
STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED
Transfer in
3.44
354
Ordinary
354
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-13
Ordinary
-13
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
8,269
Ordinary
8,269
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
10,559
Ordinary
10,559
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
3,300
Ordinary
3,300
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
-55,200
Ordinary
-55,200
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
-300
Ordinary
-300
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
100,000
Ordinary
100,000
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
100,000
Ordinary
100,000
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
37,308
Ordinary
37,308
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
-37,308
Ordinary
-37,308
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-1,546
Ordinary
-1,546
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-2,950
Ordinary
-2,950
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-788
Ordinary
-788
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-169,243
Ordinary
-169,243
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-436
Ordinary
-436
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
1,594,478
Ordinary
1,594,478
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
36
Ordinary
36
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-16,197
Ordinary
-16,197
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-71
Ordinary
-71
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-355,427
Ordinary
-355,427
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-4,954
Ordinary
-4,954
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-16,542
Ordinary
-16,542
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-3,870
Ordinary
-3,870
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
-19,600
Ordinary
-19,600
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
19,419
Ordinary
19,419
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
-25,950
Ordinary
-25,950
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
25,950
Ordinary
25,950
604 Page 7 18-Aug-2026
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
-114,904
Ordinary
-114,904
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
114,904
Ordinary
114,904
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
-181
Ordinary
-181
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-27
Ordinary
-27
07/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
27
Ordinary
27
10/08/2026
STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED
Transfer in
3.60
354
Ordinary
354
10/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
13
Ordinary
13
10/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
56,998
Ordinary
56,998
10/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
5,710
Ordinary
5,710
10/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
1,500
Ordinary
1,500
10/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
9,100
Ordinary
9,100
10/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
-4,000
Ordinary
-4,000
10/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
-33,488
Ordinary
-33,488
10/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-6,454
Ordinary
-6,454
10/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
400
Ordinary
400
10/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
323
Ordinary
323
11/08/2026
STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED
Transfer out
3.72
-705
Ordinary
-705
11/08/2026
STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED
Transfer out
3.72
-1,416
Ordinary
-1,416
11/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-56,998
Ordinary
-56,998
11/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
6,400
Ordinary
6,400
11/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
4,000
Ordinary
4,000
11/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-20,900
Ordinary
-20,900
11/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
-97,000
Ordinary
-97,000
11/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
40,572
Ordinary
40,572
11/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
178
Ordinary
178
11/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
888,692
Ordinary
888,692
11/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
12,298
Ordinary
12,298
11/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
41,387
Ordinary
41,387
11/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
9,533
Ordinary
9,533
11/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
3,867
Ordinary
3,867
11/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
7,427
Ordinary
7,427
11/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
1,985
Ordinary
1,985
11/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
422,940
Ordinary
422,940
11/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
620
Ordinary
620
11/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
1,092
Ordinary
1,092
11/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
-200
Ordinary
-200
11/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
-82
Ordinary
-82
11/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
-205
Ordinary
-205
11/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-27
Ordinary
-27
12/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
20,419
Ordinary
20,419
12/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
31,200
Ordinary
31,200
604 Page 8 18-Aug-2026
12/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
5,000
Ordinary
5,000
12/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
-1,400
Ordinary
-1,400
12/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
131,670
Ordinary
131,670
12/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
-8,330
Ordinary
-8,330
12/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
-28,330
Ordinary
-28,330
12/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
-90,997
Ordinary
-90,997
12/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-1,488
Ordinary
-1,488
12/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-40,572
Ordinary
-40,572
12/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-178
Ordinary
-178
12/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-888,692
Ordinary
-888,692
12/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-12,298
Ordinary
-12,298
12/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-41,387
Ordinary
-41,387
12/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-9,533
Ordinary
-9,533
12/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-3,867
Ordinary
-3,867
12/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-7,427
Ordinary
-7,427
12/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-1,985
Ordinary
-1,985
12/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-422,940
Ordinary
-422,940
12/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-1,092
Ordinary
-1,092
12/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
-200
Ordinary
-200
12/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
1,100
Ordinary
1,100
12/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
-86
Ordinary
-86
12/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
-286
Ordinary
-286
12/08/2026
STATE STREET GLOBAL ADVISORS TRUST COMPANY
Transfer out
3.58
-22,792
Ordinary
-22,792
13/08/2026
STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED
Transfer out
3.46
-1,770
Ordinary
-1,770
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
60,345
Ordinary
60,345
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
6,754
Ordinary
6,754
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
-300
Ordinary
-300
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
-4,500
Ordinary
-4,500
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
84,746
Ordinary
84,746
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
3,872
Ordinary
3,872
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
6,240
Ordinary
6,240
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
11,070
Ordinary
11,070
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
19,488
Ordinary
19,488
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
3,572
Ordinary
3,572
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
13,310
Ordinary
13,310
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
973,052
Ordinary
973,052
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-6,392
Ordinary
-6,392
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
3,383
Ordinary
3,383
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
19,268
Ordinary
19,268
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
301
Ordinary
301
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
145,949
Ordinary
145,949
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
21,073
Ordinary
21,073
604 Page 9 18-Aug-2026
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
171,438
Ordinary
171,438
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
1,323
Ordinary
1,323
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
83,401
Ordinary
83,401
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
45,330
Ordinary
45,330
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
146,567
Ordinary
146,567
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
185,107
Ordinary
185,107
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
8,501
Ordinary
8,501
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
3,907
Ordinary
3,907
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
-6
Ordinary
-6
13/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
-406
Ordinary
-406
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-15,535
Ordinary
-15,535
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-60,345
Ordinary
-60,345
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-385
Ordinary
-385
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-612
Ordinary
-612
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
12,374
Ordinary
12,374
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
5,058
Ordinary
5,058
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-694
Ordinary
-694
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
9,728
Ordinary
9,728
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-1,863
Ordinary
-1,863
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
8,824
Ordinary
8,824
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
2,598
Ordinary
2,598
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-341
Ordinary
-341
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-1,266
Ordinary
-1,266
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
553,687
Ordinary
553,687
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-94,768
Ordinary
-94,768
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
1,169,944
Ordinary
1,169,944
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
1,427
Ordinary
1,427
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-325
Ordinary
-325
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
193,123
Ordinary
193,123
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-1,854
Ordinary
-1,854
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
145,007
Ordinary
145,007
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-29
Ordinary
-29
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-14,535
Ordinary
-14,535
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-2,047
Ordinary
-2,047
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
37,301
Ordinary
37,301
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
53,103
Ordinary
53,103
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-16,604
Ordinary
-16,604
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
233
Ordinary
233
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-126
Ordinary
-126
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
1,162,841
Ordinary
1,162,841
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-7,476
Ordinary
-7,476
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
16,138
Ordinary
16,138
604 Page 10 18-Aug-2026
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-4,271
Ordinary
-4,271
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
54,129
Ordinary
54,129
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-14,065
Ordinary
-14,065
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-20,871
Ordinary
-20,871
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-824
Ordinary
-824
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
88
Ordinary
88
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-385
Ordinary
-385
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
12,478
Ordinary
12,478
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-1,580,765
Ordinary
-1,580,765
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Collateral received
n/a
-35
Ordinary
-35
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
-1,100
Ordinary
-1,100
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
1,100
Ordinary
1,100
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
-19,419
Ordinary
-19,419
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
19,419
Ordinary
19,419
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
-25,776
Ordinary
-25,776
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
25,738
Ordinary
25,738
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
-114,904
Ordinary
-114,904
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Borrow - for stock borrows
n/a
114,904
Ordinary
114,904
14/08/2026
STATE STREET BANK AND TRUST COMPANY
Lend - for stock lend
n/a
-438
Ordinary
-438
604 Page 11 18-Aug-2026
Annexure B This is Annexure B referred to in Form 604, Notice of change of interest of substantial holder
Alok Maheshwary
Dated the
Authorised signatory
18/08/2026
State Street Bank and Trust Company will, if requested by the company or responsible entity to whom this form must be given under the Corporations Act 2001 (Cth) or if requested by the Australian Securities and Investment Commission (ASIC), provide a copy of the master securities lending agreement/s and security agreement/s referred to below to the company, responsible entity or ASIC. Part A: For relevant interests arising out of lending securities - State Street Bank and Trust Company acquires relevant interest as lender of the securities under securities lending authorisation agreement, subject to obligation to return under the agreement. (State Street Bank and Trust Company has lent the securities and retains relevant interest as per Part B of this Annexure.)
Type of agreement:
Parties to agreement: Holder of voting rights Are there any restrictions on voting rights? If yes, in what detail? Date on which the securities were (or are) expected to be delivered to the borrower or its nominee (ie borrow date): Scheduled date (if any) when the securities are expected to be returned to the lender or its nominee (ie return date) Does the borrower have the right to return the securities early? [Yes/No] If yes, in which circumstances? Does the lender have the right to recall the securities early (ie before the scheduled return date)? [Yes/No] If yes, in which circumstances?
Securities Lending Authorisation Agreement/ Global Master Securities Lending Agreement/ Securities Loan Agreement. A pro forma copy of the agreement will be given if requested by the ASIC or the company or responsible entity to whom the prescribed report is given. (1) State Street Bank and Trust Company (2) Counterparty / entities details to be shared, as and when requested. BORROWER (1) No (2) Yes. (Borrower has the right to vote, but may on-lend securities) (1) Only if instructed to by the borrower (2) As determined by the owner of the securities The dates on which the securities were delivered by State Street Bank and Trust Company as borrower are set out in Annexure A to this notice No scheduled return date No scheduled return date. Borrower can return securities or equivalent securities at any time subject to giving notice Borrower can return securities or equivalent securities at any time subject to giving notice No scheduled return date. Lender can require return of securities or equivalent securities at any time subject to giving notice Lender can require return of securities or equivalent securities at any time subject to giving notice
Are there circumstances in which the borrower will not be required to return the securities on settlement? [Yes/No]
No
If yes, in which circumstances?
n/a
Part B: For relevant interests arising out of lending securities - State Street Bank and Trust Company acquires a relevant interest in securities through taking a security interest (“title transfer”) over the securities as collateral to secure a securities loan. (See Part A of this Annexure for securities loan details.)
Type of agreement:
Parties to agreement: Holder of voting rights Are there any restrictions on voting rights? If yes, in what detail? Date on which the securities were (or are) expected to be delivered to the borrower or its nominee (ie borrow date): Scheduled date (if any) when the securities are expected to be returned to the lender or its nominee (ie return date) Does the borrower have the right to return the securities early? [Yes/No] If yes, in which circumstances?
Global Master Securities Lending Agreement Securities Lending Authorisation Agreement If requested, a pro forma copy of the agreement will be given to the ASIC or the company or responsible entity to whom the prescribed report was given. (1) State Street Bank and Trust Company (2) Counterparty / entities details to be shared, as and when requested. LENDER (1) Yes, but only if the borrower defaults and ownership is enforce; (2) Yes (1) Only if the borrower defaults and ownership is enforced; The dates on which the securities were transferred, as indicated in Annexure A to this notice No scheduled return date. Securities collateral is returned on termination of related securities loan At any time subject to returning the borrowed securities or equivalent securities or providing alternative collateral At any time subject to returning the borrowed securities or equivalent securities or providing alternative collateral
Does the lender have the right to recall the securities early (ie before the scheduled return date)? [Yes/No]
No, assuming the borrower returns the borrowed securities or equivalent securities
If yes, in which circumstances?
n/a (lender must return securities collateral if the borrower returns the borrowed securities or equivalent securities)
604 Page 12 18-Aug-2026
Annexure C This is Annexure C referred to in Form 604, Notice of change of interest of substantial holder
Alok Maheshwary
Dated the
Authorised signatory
18/08/2026
State Street Bank and Trust Company will, if requested by the company or responsible entity to whom this form must be given under the Corporations Act 2001 (Cth) or if requested by the Australian Securities and Investment Commission (ASIC), provide a copy of the master securities lending agreement/s and security agreement/s referred to below to the company, responsible entity or ASIC. Part A: For relevant interests arising out of lending securities - State Street Bank and Trust Company acquires relevant interest as borrower of the securities under securities lending agreement, subject to obligation to return under the agreement. (State Street Bank and Trust Company has on-lent the securities and retains relevant interest as per Part A of this Annexure.)
Type of agreement:
Parties to agreement: Holder of voting rights Are there any restrictions on voting rights?
If yes, in what detail?
Global Master Securities Lending Agreement/Master Securities Loan Agreement/Securities Loan Agreement. If requested, a pro forma copy of the agreement will be given to the ASIC or the company or responsible entity to whom the prescribed report was given. (1) State Street Bank and Trust Company (2) Counterparty / entities details to be shared, as and when requested. BORROWER (1) Yes (if the borrower is the registered holder. However the securities are on-lent by the borrower as per Part B of this Annexure) (2) No, not during term of securities loan (1) Only if the borrower is the registered holder. However the securities are on-lent by the borrower as per Part B of this Annexure (2) n/a
Date on which the securities were (or are) expected to be delivered to the borrower or its nominee (ie borrow date):
The dates on which the securities were delivered to State Street Bank and Trust Company as borrower are set out in Annexure A to this notice
Scheduled date (if any) when the securities are expected to be returned to the lender or its nominee (ie return date)
No scheduled return date
Does the borrower have the right to return the securities early? [Yes/No] If yes, in which circumstances? Does the lender have the right to recall the securities early (ie before the scheduled return date)? [Yes/No] If yes, in which circumstances? Are there circumstances in which the borrower will not be required to return the securities on settlement? [Yes/No] If yes, in which circumstances?
No scheduled return date. Borrower can return securities or equivalent securities at any time subject to giving notice Borrower can return securities or equivalent securities at any time subject to giving notice No scheduled return date. Lender can require return of securities or equivalent securities at any time subject to giving notice Lender can require return of securities or equivalent securities at any time subject to giving notice No n/a
Part B: For relevant interests arising out of lending securities - State Street Bank and Trust Company lends the securities under securities lending agreement, and retains relevant interest through the right to recall the securities or equivalent securities.
Type of agreement: Parties to agreement: Holder of voting rights Are there any restrictions on voting rights?
If yes, in what detail? Date on which the securities were (or are) expected to be delivered to the borrower or its nominee (ie borrow date): Scheduled date (if any) when the securities are expected to be returned to the lender or its nominee (ie return date) Does the borrower have the right to return the securities early? [Yes/No] If yes, in which circumstances? Does the lender have the right to recall the securities early (ie before the scheduled return date)? [Yes/No] If yes, in which circumstances?
Global Master Securities Lending Agreement/Master Securities Loan Agreement. If requested, a pro forma copy of the agreement will be given to the ASIC or the company or responsible entity to whom the prescribed report was given. (1) State Street Bank and Trust Company (2) Counterparty / entities details to be shared, as and when requested. LENDER (1) Yes, but only if the lender recalls the loan and exercises its right to become the registered holder (2) Yes (while registered holder) (1) Only if the lender recalls the loan and exercises its right to become the registered holder (2) Borrower may exercise voting rights (while registered holder) The dates on which the securities were delivered to the borrower are set out in Annexure A to this notice No scheduled return date No scheduled return date. Borrower can return securities or equivalent securities at any time subject to giving notice Borrower can return securities or equivalent securities at any time subject to giving notice No scheduled return date. Lender can require return of securities or equivalent securities at any time subject to giving notice Lender can require return of securities or equivalent securities at any time subject to giving notice
Are there circumstances in which the borrower will not be required to return the securities on settlement? [Yes/No]
No
If yes, in which circumstances?
n/a
604 Page 13 18-Aug-2026
Part C: For relevant interests arising out of lending securities - State Street Bank and Trust Company acquires a relevant interest in securities through taking a security interest (“pledge”) over the securities as collateral to secure a securities loan. (See Part B of this Annexure for securities loan details.)
Type of agreement:
Parties to agreement: Holder of voting rights Are there any restrictions on voting rights? If yes, in what detail?
Global Master Securities Lending Agreement Security Agreement: If requested, a pro forma copy of the agreement will be given to the ASIC or the company or responsible entity to whom the prescribed report was given. (1) State Street Bank and Trust Company (2) Counterparty / entities details to be shared, as and when requested. LENDER (1) Yes, but only if the borrower defaults and pledge is enforced (1) Only if the borrower defaults and pledge is enforced (2) In accordance with ordinary rights as registered holder, either directly or through nominee holder
Date on which the securities were (or are) expected to be delivered to the borrower or its nominee (ie borrow date):
The dates on which the securities were pledged, as indicated in Annexure A to this notice
Scheduled date (if any) when the securities are expected to be returned to the lender or its nominee (ie return date)
No scheduled release date. Securities are released from pledge on termination of related securities loan No scheduled release date. Securities are released from pledge on termination of related securities loan or the provision of alternative collateral At any time subject to returning the borrowed securities or equivalent securities or providing alternative collateral
Does the borrower have the right to return the securities early? [Yes/No] If yes, in which circumstances? Does the lender have the right to recall the securities early (ie before the scheduled return date)? [Yes/No]
No, assuming the borrower returns the borrowed securities or equivalent securities
If yes, in which circumstances?
n/a (lender must release pledged securities if the borrower returns the borrowed securities or equivalent securities)
Highlights
■ Proposed U.S. redomiciliation: IperionX intends to redomicile its ultimate parent company to Texas, subject to shareholder, court, regulatory and other customary approvals, to align the Company’s legal and capital-markets structure with its integrated U.S. manufacturing, critical minerals and technology operations.
■ Simplified Nasdaq structure: Subject to final structuring and exchange approvals, common stock in the new U.S. parent is expected to be listed directly on Nasdaq, replacing IperionX’s existing ADS structure.
■ Continuity of operations and strategy: The proposed redomiciliation is not expected to change IperionX’s underlying assets, operations or strategic priorities.
■ Building a fully American titanium supply chain: IperionX is developing an integrated U.S. platform extending from domestic titanium minerals and recycled titanium feedstocks through low-cost titanium metal production to advanced manufactured products and components.
■ Board strengthened for industrial scale-up: Michael J.
IperionX Limited (Nasdaq: IPX | ASX: IPX) is pleased to present its quarterly report for the period ended June 30, 2026. Highlights during and subsequent to the end of the quarter include:
Operations – Titanium powder production
• Virginia operations continued on a 24/7 production schedule during the quarter, with HAMR™ systems in ramp-up and production focused on supporting customer qualification, engineered product programs and direct powder requirements.
• HAMR™ powder production continues to consistently meet or exceed grade 5 quality parameters, and has confirmed the ability to successfully commercialize HAMR™ as a breakthrough process for the production of primary titanium metal.
• Production volumes during the quarter were temporarily reduced by furnace downtime and maintenance, with operations subsequently returning to regular ramp-up cadence. The downtime did not affect the availability of titanium powder for downstream production activities.
• IperionX continues to target a run-rate production capacity of approximately 200 tpa of titanium powder by the end of CY2026, subject to completion of ramp-up and operating optimization activities.
South Boston, VA, July 7, 2026 - IperionX Limited (“IperionX” or the “Company”) (Nasdaq:IPX; ASX:IPX) today announced the pricing of an underwritten public offering of 2,275,000 of its American Depositary Shares (“ADSs”), with each ADS representing 10 of its ordinary shares (“Public Offering”), at a price per ADS to the public of $21.98, for aggregate gross proceeds of approximately $50 million, before deducting underwriting discounts, commission and estimated offering expenses payable by the Company. The Public Offering was led by U.S. institutional investors and is expected to close on July 9, 2026, subject to customary closing conditions.
Proceeds from the Public Offering will be used to continue the commercialization and scale-up of certain of our titanium and metal alloy production technologies, including continued scale-up and expansion of the Company’s Titanium Manufacturing Campus in Virginia and associated titanium metal research and development activities, continued development of the Camden-Titan Project in Tennessee, and for general corporate purposes.
Cantor is acting as sole book-running manager for the Public Offering. Roth Capital Partners and B.
Camden surface stockpiles return exceptional grades up to 23% THM — more than 8x higher grade than the Titan Project average — positioning IperionX to accelerate strategic titanium, zircon, and heavy rare earth feedstocks to the U.S. defense and advanced technology sectors
INVESTMENT HIGHLIGHTS
■ Transformational asset integration & strategic scale: IperionX has successfully completed the acquisition of the Camden critical mineral, heavy rare earths, and infrastructure assets. Highly synergistic with the adjacent Titan Project in Tennessee, this acquisition materially consolidates and expands IperionX’s landholding across the Big Sandy Critical Minerals Province.
■ Ultra-high-grade surface stockpiles: Decades of historical high-purity silica sand operations have effectively pre-processed the heavy critical mineral fractions. This has generated approximately 70 acres of at-surface, ultra-high-grade critical mineral stockpiles, uniquely enriched in titanium, zircon, and high-value rare earth minerals.
■ Exceptional stockpile assay results (up to 10x uplift): Grab samples from the surface stockpiles returned outstanding Total Heavy Minerals (THM) grading up to 21.5%.
Funding supports domestic production of ballistic-grade titanium plate and large-format military titanium components at IperionX’s Titanium Manufacturing Campus
■ IperionX awarded up to US$6.6 million by the Office of the Secretary of War – Submarine Workforce and Industrial Base program (OSW‑SWIB)
■ The award forms part of a larger, multi-organization program to scale production of high-performance titanium alloy products, including ballistic-grade titanium plate, for land and maritime defense platforms
■ Funding will support expanded manufacturing capability for large-format military titanium components at IperionX’s Titanium Manufacturing Campus in Virginia, strengthening U.S. capacity for mission-critical titanium products and critical-material supply chains
■ IperionX will collaborate with the George H.W. Bush Combat Development Complex (BCDC) and the U.S. Army Combat Capabilities Development Command (DEVCOM) Army Research Laboratory (ARL) to accelerate product scale-up, validation, and transition pathways for defense and strategic industrial applications
■ Alongside the OSW-SWIB award, IperionX has received an additional purchase order from the U.S.
Covia asset acquisition consolidates the Big Sandy Critical Minerals Province in Tennessee, adding mineral rights, at-surface stockpiled pre-processed minerals, pre-stripped horizons and established infrastructure to strengthen IperionX's U.S. minerals-to-metals platform HIGHLIGHTS ◾ Strategic acquisition adjacent to Titan Project: IperionX to acquire key Camden mineral, mining and infrastructure assets from Covia Solutions LLC (Covia), located adjacent to IperionX's Titan Critical Minerals Project (Titan) in Tennessee, for US$3 million ◾ Consolidates a U.S. critical minerals province: The Camden assets (Camden) have the potential to be synergistic with Titan by adding feedstock optionality and reduced development complexity ◾ Established infrastructure advantage: The assets include mineral rights, existing stockpiles, mining and processing equipment, rail spur, approximately 1,400 acres of owned property and approximately 1,400 acres of leased property, with access to established power, water and gas infrastructure ◾ Potential for heavy rare earth minerals: Camden is located in the McNairy Formation geological system which has been proven to be rich in monazite and xenotime…
In accordance with the requirements of Regulation S-K 1300 Modernization of Property Disclosures §229.1302(b)(4)(iv)
Report Description
Report titled “[Titan Project - Technical Report Summary on Feasibility Study]”
Titan Project
On or about June 4, 2026
Statement
I, Etienne Raffaillac, of Mineral Technologies Pty Ltd confirm that:
1) In connection with any filings under the U.S. Securities Act of 1933 (as amended, the “Securities Act”) or U.S. Exchange Act of 1934 (as amended, the “Exchange Act”) report and any amendment, supplement, or exhibit thereto, Etienne Raffaillac consents to:
a) The filing and use of the Technical Report Summary titled “[Titan Project - Technical Report Summary on Feasibility Study]” (the “TRS”) with an effective date on or about June 4, 2026;
b) The use of my name in connection with the TRS, including identification of such person as an expert or Qualified Person (as defined in Subpart 1300 of Regulation S-K promulgated by the Securities and Exchange Commission); and
c) The use of the information derived, summarized, quoted or reference from the TRS, or portions thereof, that were prepared by me, that I supervised the preparation of and/or that
A vertically integrated minerals-to-metals platform in the U.S. 4 Proprietary titanium manufacturing technologies, underpinned with secure Tennessee critical minerals reserves TITANIUM METAL OPERATIONS Titanium manufacturing • powder • parts Re-shoring end-to-end titanium metal production to the U.S. TITAN CRITICAL MINERAL DEVELOPMENT Titanium • zircon + hafnium • rare earths ‘Shovel-ready’ critical mineral project with key permits in place Scaling U.S. titanium powder and advanced manufacturing in Virginia HAMR™ process: Titanium from mineral or scrap feedstocks HSPT™ process for ‘forged’ near-net-shape titanium parts Focused on defense, aerospace & advanced manufacturing industries 100%-owned U.S. Critical Minerals Project in Tennessee High-value titanium, zircon & heavy rare earth critical mineral reserves in a premier U.S. jurisdiction Shovel-ready with established infrastructure, DFS defined and key permits in place Strategic focus: Long-term domestic critical minerals feedstock for defense, aerospace, robotics supply chains
Titan DFS: strong economics, strategic products and shovel-ready 5 Leading U.S.
U.S. Government supported Definitive Feasibility Study delivers US$813 million after-tax NPV8, 39% IRR and US$1.9 billion after-tax free cash flow from an initial 14-year mine plan producing heavy rare earth concentrate, titanium minerals and zircon in Tennessee, U.S.A.
IperionX Limited (NASDAQ: IPX, ASX: IPX) (IperionX or Company) is pleased to announce the results of the Definitive Feasibility Study (DFS or Study) for the Company’s 100%-owned Titan Critical Minerals Project (Titan or Project), located near Camden, Tennessee, United States.
The DFS confirms Titan as a large-scale, technically robust and high-return critical minerals project designed to produce titanium, zircon and a heavy rare earth concentrate from a single domestic resource in the United States. The Study underpins an initial 14-year mine plan based entirely on Proved and Probable Ore Reserves, with no Inferred Mineral Resources included in the Production Target.
U.S. Army DEVCOM GVSC and independent WMTR testing demonstrate high-strength steel-benchmark performance for IperionX Ti-6Al-4V fasteners, supporting U.S. defense industrial-base resilience and lightweighting initiatives
HIGHLIGHTS
■ Independent, third-party product-level validation: Testing completed by the U.S. Army Combat Capabilities Development Command (DEVCOM) Ground Vehicle Systems Center (GVSC) and Westmoreland Mechanical Testing & Research (WMTR) validates the performance of IperionX titanium fasteners manufactured with advanced patented titanium technologies
■ Torque-to-yield performance above Grade 8 steel: IperionX 3/4-10 x 3.0-inch titanium Ti-6Al-4V fasteners demonstrated yield torque of 563 to 615 ft-lbf in U.S. Army DEVCOM GVSC testing, compared with approximately 480 to 502 ft-lbf for SAE Grade 8 steel fasteners.
■ Commissioned advanced 300-ton, six-axis SACMI powder metallurgy press at IperionX’s Titanium Manufacturing Campus in South Boston, Virginia
■ Triples IperionX’s existing powder metallurgy capacity and materially expands the range of high-value titanium powder-to-product components that can be manufactured in the United States
■ Significantly enhances product flexibility and production repeatability, enabling more complex near-net-shape titanium components including fasteners, gears, brackets, actuators and other high-value defense, aerospace and industrial parts
■ High-productivity titanium manufacturing platform capable of up to 24 pressing cycles per minute, equivalent to approximately 11 million single-cavity parts per year under operating assumptions, with higher part rates achievable using multi-cavity tooling for simpler components
■ Designed to integrate with additional HSPT™ furnace capacity expected to arrive in June, supporting customer qualification, low-rate initial production and the scale-up of titanium component manufacturing in Virginia
IperionX Limited (NASDAQ: IPX, ASX: IPX) (IperionX) is pleased to announce the successful completion of site acceptance and
Investor Presentation On April 27, 2026, IperionX Limited posted a corporate presentation on its website. The presentation may be obtained at https://iperionx.com/investor-center/reports-presentations/.
Title:
Chief Financial Officer
IperionX Limited (Nasdaq | ASX: IPX) is pleased to present its quarterly report for the period ended March 31, 2026. Highlights during and subsequent to the end of the quarter include:
Operations – Titanium powder production
• Virginia operations transitioned to a 24/7 production schedule during the quarter, marking the move from commissioning into continuous operations
• All HAMR™ powder production systems have been commissioned and are now in ramp-up, with IperionX targeting run-rate production of ~200 tpa of titanium powder by end-CY2026
• HAMR™ powder production increased during the quarter, reaching ~4.2 metric tons in March, equivalent to approximately 50 tpa annualized. This represents the early-stage ramp rate, and throughput is expected to build as product mix shifts toward higher-volume angular powders and powder-to-part manufacturing
• Development of GenX™, IperionX’s next-generation continuous HAMR™ platform, advanced during the quarter.
IperionX Limited (NASDAQ: IPX, ASX: IPX) advises that a General Meeting of Shareholders was held today, March 19, 2026, at 11.00am (AEDT).
The resolutions voted on were in accordance with the Notice of General Meeting previously advised to the Australian Securities Exchange (“ASX”).
All resolutions were decided on and carried by way of a poll.
In accordance with Section 251AA of the Corporations Act 2001 and ASX Listing Rule 3.13.2, the details of the poll and the proxies received in respect of each resolution are set out in the attached summary.
This announcement has been authorized for release by the Company Secretary.
Virginia
Tennessee
Utah
1092 Confroy Drive
279 West Main Street
1782 W 2300 S
South Boston, VA 24592 Camden, TN 38320
West Valley City, UT 84119
IperionX Limited ABN 84 618 935 372
IperionX Limited
General Meeting
March 19, 2026
Resolution
Number of Proxy Votes
Number of Votes cast on the Poll
Result
For
Against
Abstain
Proxy’s Discretion
For
Against
Abstain
1. Issue of Options to Mr.
PERTH WA 6000
Response to ASX Price Query
IperionX Limited (NASDAQ: IPX, ASX: IPX) (IperionX) provides this response in relation to ASX’s letter dated 16 March 2026 regarding a change in the price of IPX’s securities from a high of $6.93 on 12 March 2026 to an intraday low of $4.58 today.
In response to the questions detailed in ASX’s letter the Company advises as follows:
1.
Is IPX aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
No.
2.
If the answer to question 1 is “yes”
Not applicable.
3.
If the answer to question 1 is “no”, is there any other explanation that IPX may have for the recent trading in its securities?
The Company is not aware of any reason or information which could be an explanation for the manner of trading in the Company’s securities over the period.
The Company notes that its half year report was released last week, and it has received requests from stakeholders for further information relating to the funding mechanics of its U.S. Department of War grants, provided below:
1.
IperionX Limited (NASDAQ: IPX, ASX: IPX) (IperionX) advises the appointment of Ms. Louisa Martino as Company Secretary, effective February 16, 2026.
Ms. Martino has over 15 years of experience providing company secretarial and corporate advisory services to a number of listed entities. Her extensive experience includes assisting with corporate compliance and capital raisings, as well as previous employment at a major accounting firm in Perth, London and Sydney where she provided corporate advisory services and performed due diligence reviews. Louisa has a Bachelor of Commerce from the University of Western Australia, is a member of Chartered Accountants Australia and New Zealand, a member of the Chartered Institute for Securities & Investment (CISI) (formerly FINSIA) and a Fellow of the Governance Institute of Australia (FGIA).
As part of this change, Mr. Gregory Swan will step down from his role as Company Secretary, effective February 16, 2026. The Board thanks Mr. Swan for his valuable contributions to the Company over the duration of his appointment.
For the purposes of ASX Listing Rule 12.6, Ms.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding IperionX Limited
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.